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1. Cobalt-Catalyzed Reactions with Functionalized Zinc Reagents 
Transition-metal catalyzed C-C bond forming reactions have considerably shaped the landscape of modern 
synthetic organic chemistry. Their success culminated in 2003 by awarding Richard Heck, Ei-ichi Negishi 
and Akira Suzuki the Nobel prize in chemistry.1 Although the discovery of transition-metal-promoted C-C 
bond formation reactions can be dated back to the end of the 19th century,2 the constant need for highly 
active but also cheap catalytic systems is more relevant than ever. Metal complexes based on palladium 
salts are the most common catalysts for these transformations. Their broad reaction scope and exceptional 
high catalytic activity led to numerous applications in academia but also industry.3 However, major 
drawbacks of palladium-based catalysis are the need of often sophisticated and costly ligands as well as 
the high price of the metal itself.3 Thus, the search for viable alternatives is of huge importance for the 
chemical community. In this context, cobalt salts are of great interest, since their relatively high abundance 
makes them rather inexpensive catalysts.4 The low price combined with a high catalytic activity have 
triggered research towards the usage of cobalt catalysts for several transformations.5  
 
 
                                                          
1 The Nobel Prize in Chemistry 2010. NobelPrize.org. Nobel Media AB 2020. Wed. 11 Mar 2020. 
<https://www.nobelprize.org/prizes/chemistry/2010/summary/>. 
2 a) C. Glaser, Ber. Dtsch. Chem. Ges. 1869, 2, 422-424; b) C. Glaser, Ann. Chem. Pharm. 1870, 154, 137-171; c) A. 
Baeyer, Ber. Dtsch. Chem. Ges. 1882, 15, 50-56; d) F. Ullmann, J. Bielecki, Ber. Dtsch. Chem. Ges. 1901, 34, 2174-2185; 
e) C. C. C. Johansson Seechurn, M. O. Kitching, T. J. Colacot, V. Snieckus, Angew. Chem. Int. Ed. 2012, 51, 5062-5085. 
3 a) Cross-Coupling Reactions: A Practical Guide, (Ed.: N. Miyaura), Springer, Heidelberg, 2002; b) Metal-Catalyzed 
Cross-Coupling Reactions, Second Edition (Eds.: A. de Meijere, F. Diederich), Wiley-VCH, Weinheim, 2004; c) Modern 
Drug Synthesis (Eds.: J. J. Li, D. S. Johnson), John Wiley & Sons, Hoboken, 2010; d) A. Biffis, P. Centomo, A. Del Zotto, 
M. Zecca, Chem. Rev. 2018, 118, 2249−2295. 
4 a) H. Pellissier, H. Clavier, Chem. Rev. 2014, 114, 2775-2823; b) X.‐G. Liu, C.‐J. Zhou, E. Lin, X.‐L. Han, S.‐S. Zhang, Q. 
Li, H. Wang, Angew. Chem. Int. Ed. 2018, 57, 13096-13100. 
5 a) H. Shinokubo, K. Oshima, Eur. J. Org. Chem. 2004, 2004, 2081-2091; b) W. Hess, J. Treutwein, G. Hilt, Synthesis 
2008, 22, 3537-3562; c) C. Gosmini, J.-M. Bégouin, A. Moncomble, Chem. Commun. 2008, 3221-3233; d) G. Cahiez, 
A. Moyeux, Chem. Rev. 2010, 110, 1435-1462; e) C. E. I. Knappke, S. Grupe, D. Gärtner, M. Corpet, C. Gosmini, A. J. 
von Wangelin, Chem. Eur. J. 2014, 20, 6828-6842; f) M. S. Hofmayer, J. M. Hammann, F. H. Lutter, P. Knochel, 
Synthesis 2017, 49, 3925-3930; g) Non-Noble Metal Catalysis (Eds.: R. J. M. Klein Gebbink, M.-E. Moret), Wile-VCH, 
Weinheim, 2019; f) C. Dorval, C. Gosmini, Low-valent Cobalt Complexes in C-X Coupling and Related Reactions in 





Whereas cobalt-catalyzed reactions using organomagnesium reagents have been widely reported,5 a 
growing interest in the application of organozinc reagents as reaction partners became apparent.5f,6 
Zinc organometallics provide some highly advantageous properties. In comparison to the rather ionic 
carbon-metal bond of lithium or magnesium organometallics the carbon-zinc bond has a more covalent 
character, thus enabling the tolerance of a plethora of sensitive functional groups.7 This, in turn, causes a 
comparably low reactivity with a range of electrophiles. However, the low lying p-orbitals of organozinc 
reagents enable a fast transmetalation to transition-metal catalysts, which opens the way for a variety of 
reactions due to the presence of empty d-orbitals at the transition-metal centre.7c Furthermore, the 
comparably low toxicity and constantly increasing commercial availability make zinc reagents a unique 
class of compounds.7 The following part outlines the most common methods for the preparation of 
functionalized organozinc reagents. 
  
                                                          
6 a) J.-M. Bégouin, C. Gosmini, J. Org. Chem. 2009, 74, 3221-3224; b) J. M. Hammann, D. Haas, P. Knochel, Angew. 
Chem. Int. Ed. 2015, 54, 4478-4481; c) D. Haas, J. M. Hammann, F. H. Lutter, P. Knochel, Angew. Chem. Int. Ed. 2016, 
55, 3809-3812; d) L. Thomas, F. H. Lutter, M. S. Hofmayer, K. Karaghiosoff, P. Knochel, Org. Lett. 2018, 20, 2441-2444; 
e) F. Liu, J. Zhong, Y. Zhou, Z. Gao, P. J. Walsh, W. Wang, S. Ma, S. Hou, S. Liu, M. Wang, M. Wang, Q. Bian, Chem. Eur. 
J. 2018, 24, 2059-2064. 
7 a) P. Knochel, R. D. Singer, Chem. Rev. 1993, 93, 2117-2188; b) P. Knochel, N. Millot, A. L. Rodriguez, C. E. Tucker, 
Preparation and Applications of Functionalized Organozinc Compounds in Organic Reactions, Vol. 58 (Ed.: L. E. 
Overman), Wiley, New York, 2001; c) P. Knochel, H. Leuser, L-Z. Gong, S. Perrone, F. F. Kneisel, Polyfunctional Zinc 
Organometallics for Organic Synthesis in Handbook of Functionalized Organometallics, (Ed.: P. Knochel), Wiley-VCH, 
Weinheim, 2005; d) P. Knochel, H. Leuser, L.-Z. Gong, S. Perrone, F. F. Kneisel, Functionalized Organozinc Compounds 
in Patai's Chemistry of Functional Groups: Functionalized Organozinc Compounds Part 1 (Eds.: Z. Rappoport, I. Marek), 
Wiley, Chichester, 2006; e) A. Sidduri, J. Tilley, N. Fotouhi, Synthesis 2014, 46, 430-444; f) D. Haas, J. M. Hammann, 
R. Greiner, P. Knochel, ACS Catal. 2016, 6, 1540-1552; g) A. D. Dilman, V. V. Levin, Tetrahedron Lett. 2016, 57, 3986-
3992; h) A. D. Benischke, M. Ellwart, M. R. Becker, P. Knochel, Synthesis 2016, 48, 1101-1107; i) F. H. Lutter, M. S. 
Hofmayer, J. M. Hammann, V. Malakhov, P. Knochel Generation and Trapping of Functionalized Aryl- and 






2. Preparation of Polyfunctional Organozinc Reagents 
2.1 Oxidative Insertion of Zinc Powder 
Organozinc reagents can be obtained via oxidative insertion of zinc powder into a carbon-halide bond. 
However, zinc dust is often covered by an oxide layer, which significantly hampers the reaction. Thus, in 
order to ensure a fast and complete insertion reaction, the surface of the metal has to be activated prior 
to use. Treatment of the metal powder with a combination of trimethylsilyl chloride and 1,2-
dibromoethane enables the preparation of various alkylzinc reagents from the corresponding iodides.7c 
Hence, the reaction of zinc with β-amino acid derivative 1 proceeded within 15 min affording the 
polyfunctional alkylzinc reagent 2, which underwent a subsequent cross-coupling leading to the alkylated 
arene 3 in 89% yield (Scheme 1). Using DMF as solvent for the generation of 2 was crucial to avoid β-
elimination of the amino group.8 
 
 
Scheme 1: Preparation of a chiral alkylzinc reagent and subsequent palladium-catalyzed cross-coupling. 
 
Alternatively, Riecke found that in situ reduction of ZnCl2 with alkaline metals produces highly active zinc 
(Riecke-zinc). This allows the formation of various zinc organometallics from alkyl iodides and even 
bromides. Also, (hetero)aryl halides are readily transformed into the corresponding zinc reagents.9 A 
convenient alternative is the activation of the zinc surface with lithium chloride, which enables the 
preparation of a variety of alkyl-, alkenyl-, aryl- and heteroarylzinc reagents.10 Mechanistic studies revealed 
that LiCl promotes the solubilization of surface-bound organometallic species, thus enabling the progress 
of the insertion reaction.11 Under these conditions, zinc powder inserted regioselectively into the carbon-
                                                          
8 C. S. Dexter, R. F. W. Jackson, J. Elliott, J. Org. Chem. 1999, 64, 7579-7585. 
9 a) R. D. Riecke, Science 1989, 246, 1260-1264; b) R. D. Rieke, M. V. Hanson, Tetrahedron 1997, 53, 1925-1956. 
10 A. Krasovskiy, V. Malakhov, A. Gavryushin, P. Knochel, Angew. Chem. Int. Ed. 2006, 45, 6040-6044. 
11 a) C. Feng, D. W. Cunningham, Q. T. Easter, S. A. Blum, J. Am. Chem. Soc. 2016, 138, 11156-11159; b) C. Feng, Q. T. 





iodine bond of the polyfunctional aryl tosylate 4 leading to the zinc reagent 5. A copper-catalyzed allylation 
afforded the polyfunctional arene 6 in 82% yield (Scheme 2).12 
 
 
Scheme 2: Regioselective zinc insertion and subsequent copper-catalyzed allylation. 
 
Later, it was found that the addition of indium salts further accelerates the insertion reaction. Thus, 
thiophenylzinc reagent 7 was prepared from the corresponding heterocyclic bromide 8 within 2 h in 74% 
yield. Subsequent acylation in the presence of a palladium catalyst led to the unsymmetrical ketone 9 in 
95% yield (Scheme 3).13  
 
 
Scheme 3: Zinc insertion in the presence of indium and lithium salts. 
 
Recently, a nickel-catalyzed generation of various arylzinc reagents from aryl sulfonates was reported. 
Tosylate 10 was treated with zinc powder in the presence of 1,2-dibromoethane, a nickel catalyst and 
diazadiene ligand 11 furnishing the corresponding arylzinc tosylate 12. Trapping reaction with iodine 
afforded aryl iodide 13 in 86% yield (Scheme 4).14 Mechanistically, the authors propose an initial reduction 
                                                          
12 N. Boudet, S. Sase, P. Sinha, C.-Y. Liu, A. Krasovskiy, P. Knochel, J. Am. Chem. Soc. 2007, 129, 12358-12359. 
13 A. D. Benischke, G. Le Corre, P. Knochel, Chem. Eur. J. 2017, 23, 778-782. 





of the Ni(II) catalyst leading to the corresponding Ni(0) complex, which undergoes an oxidative addition to 
the aryl tosylate. Subsequent in situ transmetalation affords the arylzinc tosylate. 
 
 
Scheme 4: Nickel-catalyzed zinc insertion into aryl sulfonates. 
 
2.2 Transmetalation 
Another approach towards organozinc reagents is their preparation via transmetalation. Lithium or 
magnesium organometallics undergo fast transmetalation with zinc salts, driven by the formation of a 
more covalent and thus thermodynamically more stable carbon-metal bond.7c For example, the 
asymmetric lithiation of N-boc pyrrolidine 14 in the presence of (−)-spartein and subsequent 
transmetalation with ZnCl2 afforded the chiral organozinc reagent 15. A palladium-catalyzed cross-




Scheme 5: Asymmetric lithiation of N-Boc pyrrolidine and subsequent cross-coupling of the corresponding zinc reagent. 
 
                                                          





Also, the reaction of magnesium metal with (hetero)aryl halides in the presence of ZnCl2 allowed the 
efficient preparation of various polyfunctional zinc organometallics.16 Later, this method was extended to 
functionalized alkylzinc reagents. Thus, the reaction of ethyl 6-bromohexanoate (17) with a mixture of 
magnesium and ZnCl2 provided 70% of alkylzinc reagent 18 within 2.5 h at 20 °C. Copper-catalyzed 
acylation led to ketone 19 in 70% yield (Scheme 6).17 Remarkably, the related reaction of zinc powder with 
17 in the presence of LiCl proceeded significantly slower furnishing 70% of reagent 18 after 70 h reaction 
time at 50 °C.17  
 
 
Scheme 6: Preparation of an alkylzinc reagent via magnesium insertion followed by in situ transmetalation with ZnCl2. [a] Salts are 
omitted for clarity. 
 
2.3 Halogen/Zinc-Exchange 
Furthermore, functionalized alkyl-, alkenyl-, aryl- and heteroarylzinc reagents can be prepared from the 
corresponding halides via halogen/zinc-exchange using diorganozinc reagents or zincates.18 In general, the 
rate of halogen/metal-exchange reactions is highly dependent on the nature of the carbon-metal bond 
present in the exchange reagent. The more ionic this bond the faster the exchange reaction. Due to the 
covalent character of the carbon-zinc bond an exchange reaction is comparably slow and requires more 
polar solvents or rather forcing reaction conditions.7i Thus, performing an iodine/zinc-exchange reaction 
using alkyl iodide 20 required treatment with an excess Et2Zn at 50 °C. The corresponding dialkylzinc 
reagent 21 was subsequently trapped with 2-cyclohexenone affording the alkylated cyclohexanone 22 in 
83% yield (Scheme 7).19 
                                                          
16 a) F. M. Piller, P. Appukkuttan, A. Gavryushin, M. Helm, P. Knochel, Angew. Chem. Int. Ed. 2008, 47, 6802-6806; b) 
F. M. Piller, A. Metzger, M. A. Schade, B. A. Haag, A. Gavryushin, P. Knochel, Chem. Eur. J. 2009, 15, 7192-7202. 
17 T. D. Blümke, F. M. Piller, P. Knochel, Chem. Commun. 2010, 46, 4082-4084. 
18 M. Balkenhohl, P. Knochel, Chem. Eur. J. 2020, DoI: 10.1002/chem.201904794. 






Scheme 7: Preparation of dialkylzinc reagents via iodine/zinc-exchange using Et2Zn. 
 
Alternatively, highly reactive alkylzincates enable the halogen/zinc-exchange of various aryl iodides. 
However, low reaction temperatures were required to allow the tolerance of sensitive functional groups 
under the reaction conditions.20 In 2004 a mild halogen/zinc-exchange reaction of various (hetero)aryl 
iodides using either iPr2Zn or sBu2Zn was reported displaying an exceptional functional group tolerance. 
The addition of Li(acac) was found to increase the reactivity of the exchange reagent due to in situ 
formation of zincates. Treating polyfunctional aryl iodide 23 with sBu2Zn in the presence of 10 mol% 
Li(acac) for 3 h at room temperature provided the diarylzinc reagent 24. Trapping reaction with Bu3SnCl 
afforded arylstannane 25 in 66% yield (Scheme 8).21 
 
 
Scheme 8: Li(acac)-catalyzed preparation of diorganozinc reagents via iodine/zinc-exchange. 
 
Recently, it was found that the complexation of sBu2Zn with two lithium alkoxides resulted in a highly 
reactive but yet selective exchange reagent, which enables the preparation of di(hetero)aryl zinc reagents 
from various electron-rich as well as -deficient halo arenes. Thus, iodo anitpyrine 26 underwent a fast 
iodine/zinc-exchange leading to 27 within 10 min. A copper-catalyzed allylation furnished the 
                                                          
20 a) Y. Kondo, N. Takazawa, C. Yamazaki, T. Sakamoto, J. Org. Chem. 1994, 59, 4717-4718; b) Y. Kondo, M. Fujinami, 
M. Uchiyama, T. Sakamoto, J. Chem. Soc., Perkin Trans. 1 1997, 799-800; c) Kondo, N. Takazawa, A. Yoshida, T. 
Sakamoto, J. Chem. Soc., Perkin Trans. 1 1995, 1207-1208. 





functionalized heterocycle 28 in 74% yield (Scheme 9). Remarkably, the bimetallic exchange reagent 
enabled the first halogen/zinc-exchange reaction using aryl bromides.22 
 
 
Scheme 9: Preparation of a diorganozinc reagent using sBu2Zn⋅2LiOR. 
 
2.4 Directed Metalation  
The directed metalation of arenes and heterocycles has proved to be a powerful tool for the selective 
functionalization of various scaffolds.7I,23 Especially, TMP-magnesium or -zinc bases found broad 
application in academic as well as industrial research.23b,c TMP2Zn⋅2MgCl2⋅2LiCl24 and TMPZnCl⋅LiCl25, 
which are prepared via transmetalation from the corresponding Mg- or Li-amide, are the most common 
reagents for the mild deprotonation of various sensitive substrates. The non-nucleophilic zinc amide 
TMP2Zn⋅2MgCl2⋅2LiCl enabled the selective metalation of 3-formylindole 29 affording the heteroarylzinc 
reagent 30 within 30 min at 25 °C. After a copper-catalyzed allylation, the functionalized indole 31 was 
obtained in 71% yield (Scheme 10).24 
 
 
                                                          
22 M. Balkenhohl, D. S. Ziegler, A. Desaintjean, L. J. Bole, A. R. Kennedy, E. Hevia, P. Knochel, Angew. Chem. Int. Ed. 
2019, 58, 12898-12902. 
23 a) V. Snieckus, Chem. Rev. 1990, 90, 879-933; b) B. Haag, M. Mosrin, H. Ila, V. Malakhov, P. Knochel, Angew. Chem. 
Int. Ed. 2011, 50, 9794-9824. b) M. Balkenhohl, P. Knochel, SynOpen 2018, 2, 78-95.  
24 S. H. Wunderlich, P. Knochel, Angew. Chem. Int. Ed. 2007, 46, 7685-7688. 






Scheme 10: Directed metalation of an indole derivative using TMP2Zn⋅2MgCl2⋅2LiCl. 
 
Interestingly, the regioselectivity of the metalation of chromone (32) can be adjusted by the composition 
of the metal amide used for the deprotonation. Thus, treating 32 with TMPZnCl⋅LiCl led to the metalation 
in 3-position (33), whereas TMP2Zn⋅2MgCl2⋅2LiCl afforded the corresponding diheteroarylzinc reagent 34 
in 2-position. This might be explained by the presence of the magnesium salt within the reaction mixture. 
MgCl2 is coordinated by the ketone moiety, thus blocking the preferential coordination-site for the zinc-
amide. Trapping the zinc reagents 33 and 34 with I2 afforded iodo-chromones 35 and 36 in 77 and 80% 
yield, respectively (Scheme 11).26 
 
 
Scheme 11: Regioselective metalation of chromone. 
 
Remarkably, a one-pot late-stage zincation/cross-coupling sequence was reported for the synthesis of the 
PI3K inhibitor GDC-0908 (37). Treating 1,2,4-triazole 38 with TMPZnCl⋅LiCl in the presence of a palladium 
catalyst and heteroaryl bromide 39 led to the formation of the corresponding cross-coupling product. 
Subsequent benzoyl deprotection afforded GDC-0908 (37) in 83% yield over two steps (Scheme 12).27 
 
                                                          
26 L. Klier, T. Bresser, T. A. Nigst, K. Karaghiosoff, P. Knochel, J. Am. Chem. Soc. 2012, 134, 13584-13587. 






Scheme 12: Synthesis of GDC-0908 (37) via a late stage zincation/cross-coupling sequence. 
 
Remarkably, organozinc reagents exhibit a high thermal stability enabling the zincation of less activated 
arenes using TMP2Zn⋅2MgCl2⋅2LiCl at elevated temperatures.7i,28 Therefore, N,N-diethylbenzamide (40) 
was treated with the zinc base for 5 h at 120 °C under microwave irradiation yielding 41 in more than 90% 
yield. Remarkably, performing the reaction in an oil bath at the same reaction conditions only afforded 
10-20% of the corresponding organozinc reagent 41. Zincated arene 41 was used in a subsequent 
palladium-catalyzed cross-coupling leading to the arylated benzamide 42 in 85% yield (Scheme 13).29  
 
 
Scheme 13: High-temperature zincation of N,N-diethylbenzamide. 
 
                                                          
28 a) L. Zhu, R. M. Wehmeyer, R. D. Rieke, J. Org. Chem. 1991, 56, 1445-1453; b) M. Mosrin, G. Monzon, T. Bresser, P. 
Knochel, Chem. Commun. 2009, 5615-5617. 





Besides the directed zincation of various arenes and heterocycles, TMP-zinc bases also allow for the 
metalation at benzylic30 or allylic31 positions and the deprotonation of functionalized alkenes.32 The 
metalation in α-position to several electron-withdrawing groups has also been reported.31,33 
Recently, Wang showed that α-metalated alkyl compounds bearing phosphonate, phosphine oxide, 
sulfonamide or sulfoxide groups undergo a copper-catalyzed cross-coupling with alkenyl iodonium salts. 
Thus, treating phosphonate 43 with TMPZnCl⋅LiCl afforded the zinc reagent 44, which led after copper-




Scheme 14: Metalation of an alkyl phosphonate. 
 
3. Cobalt Catalyzed Cross-Coupling Reactions with Organozinc Reagents  
The relatively high abundance and catalytic activity of cobalt salts combined with easy accessible and mild 
zinc organometallics led to a rising number of publications within this field.5f,6 In the following part, an 
overview on recent developments in cobalt catalyzed Negishi cross-couplings will be given. 
 
                                                          
30 a) S. Duez, A. K. Steib, S. M. Manolikakes, P. Knochel, Angew. Chem. Int. Ed. 2011, 50, 7686-7690; b) S. Duez, A. K. 
Steib, P. Knochel, Org. Lett. 2012, 14, 1951-1953; c) A. Castelló-Micó, P. Knochel, Synthesis 2018, 2, 155-169. 
31 S. Duez, S. Bernhardt, J. Heppekausen, F. F. Fleming, P. Knochel, Org. Lett. 2011, 13, 1690-1693. 
32 T. Bresser, P. Knochel, Angew. Chem. Int. Ed. 2011, 50, 1914-1917. 
33 a) I. Popov, S. Lindeman, O. Daugulis, J. Am. Chem. Soc. 2011, 133, 9286-9289; b) R. J. Mycka, S. Duez, S. Bernhardt, 
J. Heppekausen, P. Knochel, F. F. Fleming, J. Org. Chem. 2012, 77, 7671-7676; c) T. Knauber, J. Tucker, J. Org. Chem. 
2016, 81, 5636-5648; d) M. E. Dalziel, P. Chen, D. E. Carrera, H. Zhang, F. Gosselin, Org. Lett. 2017, 19, 3446-3449. 





3.1 Cobalt-Catalyzed Cross-Couplings of Sp2-Hybridized Organozinc Reagents 
In 2013, Inoue and co-worker developed a protocol for the cobalt-catalyzed arylation of ethyl 
bromodifluoroacetate (46). A catalytic system comprising 5 mol% CoCl2 and 6 mol% Me4DACH (Trans-
N,N,N′,N′-tetramethylcyclohexane-1,2-diamine, 47) enabled the coupling of functionalized arylzinc 
reagents. Thus, various arylated ethyl difluoroacetates such as 48 were obtained at room temperature 
within 18 h (Scheme 15).35  
 
 
Scheme 15: Cobalt-catalyzed cross-coupling of arylzinc reagents with bromo difluoroacetates. 
 
Furthermore, (hetero)aryl zinc reagents generated via directed deprotonation using 
TMP2Zn⋅2MgCl2⋅2LiCl24,36 as a metalation agent were efficiently coupled with various primary and 
secondary alkyl iodides or bromides. Thus, the conversion of ethyl 3-fluorobenzoate (49) to the 
corresponding diarylzinc derivative 50 using TMP2Zn⋅2MgCl2⋅2LiCl followed by the cross-coupling with the 
primary iodide 51 provided the alkylated benzoate 52 in 58% yield. Additionally, the coupling proceeded 
with high diastereoselectivity using the 1,2-disubstituted TBS protected iodohydrin 53 affording 54 in 68% 
yield and dr = 99:1 (Scheme 16).6b 
 
                                                          
35 K. Araki, M. Inoue, Tetrahedron 2013, 69, 3913-3918. 
36 a) M. Mosrin, P. Knochel, Chem. Eur. J. 2009, 15, 1468-1477; b) S. H. Wunderlich, C. J. Rohbogner, A. Unsinn, P. 






Scheme 16: Cobalt-catalyzed cross-coupling of diarylzinc 50 with primary and secondary alkyl iodides 51 and 53. 
 
An enantioselective cobalt-catalyzed Negishi cross-coupling was reported by Bian and co-workers. A 
variety of racemic α-bromo esters was coupled with functionalized (hetero)aryl zinc reagents using 
10 mol% CoI2 in combination with the tailored bisoxazolidine ligand 56. Remarkably, the protocol enabled 
the efficient coupling of sterically hindered ortho- arylzinc reagents with α-bromo esters for the first time. 
Thus, the method gives access to a variety of α-arylated chiral esters, such as 57-60 (Scheme 17).6e Later, 
this procedure was applied to the enantioselective synthesis of (S)-preclamol.37 
 
 
Scheme 17. Enantioselective cobalt-catalyzed cross-coupling of racemic α-bromo esters. 
                                                          





Recently, Wang et al. reported a cobalt-catalyzed decarboxylative cross-coupling of functionalized 
N-hydroxyphthalimide esters with diaryl-, dialkenyl- and dialkynylzinc reagents. No additional ligand was 
required to obtain various arylated, olefinated and alkynylated alkyl compounds such as 61-65 
(Scheme 18). Remarkably, the use of alkynylzinc pivalates instead of the corresponding dialkylzinc reagent 
led to improved coupling yields in some cases.4b 
 
 
Scheme 18: Cobalt-catalyzed decarboxylative cross-coupling. [a] The corresponding alkynylzinc pivalate was used. 
 
Furthermore, Gosmini described the coupling of substituted arylzinc reagents with 1-chloropyrimidine and 
2-chloropyrazine. Organometallic reagents were formed in situ from the corresponding halide in the 
presence of zinc powder and 10 mol% CoBr2. Subsequent addition of an N-heterocyclic halide to the 
reaction mixture led to products, such as 66 (Scheme 19).6a 
 
 
Scheme 19: Cobalt-catalyzed cross-coupling of 2-chloropyrazine 
 
Later, it was found that the addition of carboxylate salts, such as sodium formate or pivalate have 
beneficial effects on cobalt-catalyzed Csp2-Csp2 cross-couplings. These salts presumably act as ligands for 





ortho-activated halides or electron deficient N-heterocycles were coupled with aryl- or heteroarylzinc 
organometallics affording products 67-71 in 61-88% yield (Scheme 20).6c  
 
 
Scheme 20: Cobalt-catalyzed cross-coupling using sodium formate as additive. 
 
These findings led to the development of a cobalt-catalyzed cross-coupling using organozinc pivalates as 
reaction partners. This class of organometallics show a significantly enhanced stability towards moisture 
and air and can be stored as solids under argon at room temperature for several months.38 Remarkably, 
the use of these reagents considerably improved the yield of the coupling. Thus, the reaction of anisylzinc 
pivalate 72 with bromo benzonitrile 73 afforded the biaryl product 74 in 80% yield, whereas the 
corresponding arylzinc chloride 75 led to a significantly lower yield of 41% (Scheme 21). 39 
 
                                                          
38 a) S. Bernhardt, G. Manolikakes, T. Kunz, P. Knochel, Angew. Chem. Int. Ed. 2011, 50, 9205-9209; b) C. I. Stathakis, 
S. Bernhardt, V. Quint, P. Knochel, Angew. Chem. Int. Ed. 2012, 51, 9428-9432; c) J. R. Colombe, S. Bernhardt, C. 
Stathakis, S. L. Buchwald, P. Knochel, Org. Lett. 2013, 15, 5754-5757; d) C. I. Stathakis, S. M. Manolikakes, P. Knochel, 
Org. Lett. 2013, 15, 1302-1305; e) A. Hernán‐Gómez, E. Herd, E. Hevia, A. R. Kennedy, P. Knochel, K. Koszinowski, S. 
M. Manolikakes, R. E. Mulvey, C. Schnegelsberg, Angew. Chem. Int. Ed. 2014, 53, 2706-2710; f) S. M. Manolikakes, 
M. Ellwart, C. I. Stathakis, P. Knochel, Chem. Eur. J. 2014, 20, 12289-12297; g) M. Ellwart, P. Knochel, Angew. Chem. 
Int. Ed. 2015, 54, 10662-10665; h) Y.-H. Chen, M. Ellwart, V. Malakhov, P. Knochel, Synthesis 2017, 49, 3215-3223; i) 
Y. H. Chen, C. P. Tüllmann, M. Ellwart, P. Knochel, Angew. Chem. Int. Ed. 2017, 56, 9236-9239; j) Y.-H. Chen, M. Ellwart, 
G. Toupalas, Y. Ebe, P. Knochel, Angew. Chem. Int. Ed. 2017, 56, 4612-4616; k) C. P. Tüllmann, Y.-H. Chen, R. J. 
Schuster, P. Knochel, Org. Lett. 2018, 20, 4601-4605;  






Scheme 21: Comparison of arylzinc pivalates and arylzinc chlorides in cobalt-catalyzed cross-couplings. 
 
Furthermore, the combination of cobalt salts and organozinc pivalates expanded the scope of cobalt-
catalyzed Csp2-Csp2 cross-couplings. Thus, meta-substituted halo arenes, sterically hindered metal 
reagents and unactivated heterocyclic halides could be used leading to functionalized coupling products, 
such as 76-78. Also, alkenyl halides and bromo alkynes underwent cobalt-catalyzed cross-couplings with 
arylzinc pivalates leading to stilbene derivative 79 and the arylated alkyne 80 (Scheme 22).39 Later, a 
further extension of the scope and the scalability of the method was reported.5f 
 
 
Scheme 22: Cobalt-catalyzed cross-couplings using aryl- and heteroarylzinc pivalates. [a] reaction was carried out at −40 °C 
 
In addition, functionalized benzylzincs proved to be suitable organometallic reagents for cobalt-catalyzed 
couplings with various ortho- and para-activated aryl and heteroaryl halides giving access to di(hetero)aryl 
methane derivatives.40  
Electron-deficient as well as electron-rich arylzinc reagents could be coupled with a variety of 
functionalized bromo alkynes. Hence, the reaction of the zinc reagent generated from aryl bromide 81 
                                                          





with functionalized bromo alkyne 82 proceeded smoothly in the presence of 10 mol% CoBr2(phen) 
affording the arylated alkyne 83 in 91% yield (Scheme 23).41 
 
 
Scheme 23: Cobalt-catalyzed coupling of arylzinc reagents with bromoalkynes. 
 
3.2 Cobalt-Catalyzed Cross-Couplings of Sp-Hybridized Organozinc Reagents 
Alkynylzinc pivalates are a versatile class of organometallic reagents, which show a greatly enhanced 
stability towards air and moisture in comparison to the corresponding zinc halide derivatives.42 Cobalt 
catalysis allows their coupling with various aryl and heteroaryl halides in the presence of TMEDA. Thus, 
various pyridine, benzonitrile or benzophenone halides were alkynylated furnishing the products 84-86 in 
up to 95% yield. Furthermore, a steroid derived alkynylzinc pivalate was coupled with 
chlorobenzophenone providing the cross-coupling product 87 in 75% yield (Scheme 24).43  
 
 
Scheme 24: Cobalt-catalyzed cross-couplings of alkynylzinc pivalates with heteroaryl halides. 
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Furthermore, the use of a combination of CoCl2 and diamine ligand 47 allowed for the highly 
diastereoselective preparation of various alkynylated cycloalkyl compounds. Various 1,4-, 1,3- and 1,2-
substituted cycloalkyl halides underwent highly diastereoselective cross-couplings with alkynylzinc 
pivalates leading to highly functionalized anti-1,4-, syn-1,3-, or anti-1,2-disubstituted products, such as 88-
90 in 62-76% yield. Furthermore, the mild reaction conditions enabled the coupling of α-bromo gylcosides 
or steroid scaffolds bearing sensitive functionalities such as ketones, furnishing the coupling products 91 
and 92 (Scheme 25).6d 
 
 
Scheme 25: Diastereoselective cobalt-catalyzed cross-couplings between alkynylzinc pivalates and iodo cycloalkanes. 
 
3.3 Cobalt-Catalyzed Cross-Couplings of Sp3-Hybridized Organozinc Reagents 
In 1996, Knochel and Cahiez described the stereoselective alkylation of alkenyl halides.44 However, the 
reaction required a high catalyst loading and a huge excess of the corresponding dialkylzinc reagent. 
Recently, McNally developed a cobalt catalyzed alkylation of in situ formed N-heterocyclic phosphonium 
salts harnessing zinc organometallics. The reaction proceeded with a variety of functionalized 
N-heterocycles providing alkylated complex molecules, such as 93 (Scheme 26).45  
 
                                                          
44 H. Avedissian, L. Bérillon, G. Cahiez, P. Knochel, Tetrahedron 1998, 39, 6163-6166. 






Scheme 26: Cobalt-catalyzed alkylation of heteroaryl phosphonium salts. 
 
4. Cobalt-Catalyzed Acylation Reactions 
The reaction of an activated carbonyl group, such as an acyl halide, or thioesters with highly reactive 
organolithium or -magnesium reagents often proceeds unselectively leading to undesired side products 
due to enol formation or over addition to the newly formed ketone.46,47 However, less reactive 
organometallics, such as zinc reagents usually do not undergo this addition without further activation. 
Transition-metal catalyzed acylation reactions are a valuable alternative, since they ensure a high 
selectivity and enable the use of organozinc reagents, which allows the tolerance of various functional 
groups in both the metal reagent as well as the electrophile.46,47 Besides well-established procedures 
utilizing copper,7b,48 palladium49 or nickel50 catalysts, the use of cobalt salts has received growing attention. 
                                                          
46 R. K. Dieter Tetrahedron, 1999, 55, 4177-4236. 
47 D. A. Shirley, Synthesis of Ketones from Acid Halides and Organometallic Compounds of Magnesium, Zinc, and 
Cadmium in Organic Reactions, Vol. 8 (Ed.: R. Adams), Wiley, New York, 1954. 
48 a) J.-E. Dubois, Y. J. Bonzougou, J. Chem. Res. (M) 1978, 826-835; b) J. P. Gillet, R. Sauvêtre, J. F. Normant, Synthesis 
1982, 297-301; c) C. R. Johnson, D. S. Dhanoa, J. Org. Chem. 1987, 52, 1885-1888; d) L. Zhu, R. M. Wehmeyer, R.D. 
Rieke, J. Org. Chem. 1991, 56, 1445-1453; e) F. Langer, L. Schwink, A. Devasagayaraj, P.-Y. Chavant, P. Knochel, J. Org. 
Chem. 1996, 61, 8229-8243; f) R. K. Dieter, R. R. Sharma, W. Ryan, Tetrahedron Lett. 1997, 38, 783-786. 
49 a) T. Sato, K. Naruse, M. Enokiya, T. Fujisawa, Chem. Lett. 1981, 1135-1138; b) E. Nakamura, I. Kuwajima, 
Tetrahderon Lett. 1986, 27, 83-86; c) Y. Tamaru, H. Ochiai, T. Nakamura, Z.-I. Yoshida, Angew. Chem. Int. Ed. Engl. 
1987, 26, 1157-1158; d) M. M. Faul, L. L. Winneroski, Tetrahedron Lett. 1997, 38, 4749-4752; e) H. Tokuyama, S. 
Yokoshima, T. Yamashita, T. Fukuyama, Tetrahedron Lett. 1998, 39, 3189-3192; f) K. Kunchithapatham, C. C. Eichman, 
J. P. Stambuli, Chem. Commun. 2011, 47, 12679-12681; g) A. H. Cherney, S. E. Reisman, Tetrahedron, 2014, 70, 3259-
3265. 
50 a) M. Onaka, Y. Matsuoka, T. Mukaiyama, Chem. Lett. 1981, 10, 531-534; b) C. Cardellicchio, V. Fiandanese, G. 
Marchese, L. Ronzini, Tetrahedron Lett. 1985, 26, 3595-3598; c) C. Malanga, L. A. Aronica, L. Lardicci, Tetrahedron 
Lett. 1995, 36, 9185-9188; d) T. Shimizu, M. Seki, Tetrahedron Lett. 2002, 43, 1039-1042; e) Y. Zhang, T. Rovis, J. Am. 





In 1996, a cobalt-catalyzed acylation of dialkylzincs was reported using 10 mol% CoBr2 in a mixture of THF 
and NMP. Thus, the reaction of n-octanoyl chloride (94) with the bisalkylzinc reagent 95 afforded ketone 
96 in 78% yield. (Scheme 27).51 
 
 
Scheme 27: Cobalt-catalyzed acylation of a diorganozinc reagent. 
 
This method was extended to aryl- and heteroarylzinc reagents. Various aromatic ketones were obtained 
by the acylation of arylzinc reagents, which were prepared electrochemically using a zinc anode in the 
presence of ZnBr2 together with cobalt salt or via a cobalt catalyzed zinc insertion in acetonitrile from the 
corresponding aryl halide.52 Later, the use of carboxylic anhydrides as acylating agents was reported, which 
enabled the preparation of various unsymmetrical ketones in a preparatively simple one-pot procedure. 
Thus, after cobalt-catalyzed activation of the zinc dust, 4-bromoanisole (97) and acetic anhydride were 
added affording the ketone 98 in 81% yield (Scheme 28).53 
 
 
Scheme 28: Preparation of unsymmetrical ketones using a cobalt-catalyzed one-pot procedure. 
 
This cobalt-catalyzed formation of arylzinc reagents also enabled the synthesis of symmetrical (hetero)aryl 
ketones by using ethyl chloroformate, which acts as a carbon monoxide surrogate in the presence of 
13 mol% CoBr2 and a bipyridine ligand.54 
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Recently, Gosmini reported a cobalt catalyzed acylation utilizing various N-benzoyl glutarimides as 
electrophilic coupling partners leading to products such as 99 (Scheme 29). Remarkably, the reaction can 
be performed in a simple one-pot procedure and does not require precautions towards moisture and air.55 
 
 
Scheme 29: Cobalt-catalyzed acylation of arylzinc reagents using amide electrophiles.
                                                          






Transition-metal-catalyzed C-C bond forming reactions are indispensable tools in modern synthetic 
organic chemistry. Cobalt catalysts proved to be auspicious alternatives to commonly used palladium and 
nickel catalysts. As described before, various cobalt-catalyzed Negishi-type cross-couplings utilizing 
(hetero)aryl and alkynyl zinc reagents have been reported. However, the usage of alkylzinc reagents in 
these reactions is still barley investigated. Thus, a simple and cheap catalytic system based on cobalt salts 
for the cross-coupling of functionalized alkyl zinc reagents with various aryl and heteroaryl halides should 
be developed. Furthermore, the amenability of diastereomeric cross-couplings using secondary alkylzinc 
reagents should be examined (Scheme 30).56 
 
 
Scheme 30: Cobalt-catalyzed cross-coupling of alkylzinc reagents with (hetero)aryl halides. 
 
Moreover, the application of alkylzinc reagents in cross-couplings with other electrophilic coupling 
partners using a non-precious cobalt catalyst is highly desirable. Therefore, the development of a cobalt-
catalyzed Csp3-Csp3 cross-coupling utilizing functionalized alkylzinc reagents with various alkyl halides 
should be investigated (Scheme 31).  
 
 
Scheme 31: Cobalt-catalyzed cross-coupling of alkylzinc reagents with alkyl halides. 
 
A protocol developed by Fukuyama utilizes organothioester as efficient acylation agents of various zinc 
organometallics in the presence of a palladium catalyst. Especially, S-pyridyl esters can be readily prepared 
from the corresponding carboxylic acid without the need of harsh reaction conditions. This enables the 
                                                          
56 This project was developed in cooperation with Lucie Grokenberger, see: F. H. Lutter, L. Grokenberger, P. Spieß, J. 
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tolerance of various sensitive functional moieties including stereocenters, which are prone to 
racemization. Therefore, functionalized S-pyridyl esters should be tested for their suitability as acylating 
agents in a cobalt-catalyzed Fukuyama-type acylation using functionalized (hetero)arylzinc 
organometallics (Scheme 32).57 
 
 
Scheme 32: Cobalt-catalyzed acylation of S-pyridyl esters with organozinc reagents. 
 
The aim of the last part of this thesis was to develop a highly regioselective mono-functionalization of aryl 
azoles at the aryl moiety. These motifs are of great interest, since they appear as core structure in several 
blockbuster drugs. By now, a regioselective functionalization is enabled by transition-metal catalyzed C-H 
arylation. However, the need of often precious metal catalysts, the harsh reaction conditions and the 
predominant formation of the bis-functionalized arene significantly limits this methodology. Thus, the use 
of sterically hindered metal amides for a regioselective mono-metalation of the aryl moiety in presence of 
several possible metalation sites at the azole ring should be examined. The generated arylmetal reagents 
should be tested for their use in cross-couplings and other trapping sequences (Scheme 33).58 
 
 
Scheme 33: Regioselective metalation of aryl azoles using metal amide bases and subsequent trapping reactions.
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III. Results and Discussion 
1. Cobalt‐Catalyzed Cross‐Coupling of Functionalized Alkylzinc Reagents with 
(Hetero)Aryl Halides59 
1.1 Introduction 
The transition-metal-catalyzed construction of new C-C bonds is of utmost importance in modern organic 
chemistry, and finds wide application in academic and industrial processes.3c Especially, Negishi cross-
couplings are among the most versatile methods for the formation of carbon bonds to create highly 
functionalized scaffolds.7f Organozinc reagents represent an attractive class of organometallic reagents for 
cross-couplings, combining both, the low toxicity of zinc salts as well as a high functional group tolerance. 
Albeit, various examples of palladium-7f,60 or nickel-catalyzed7f,60e,61  Csp2-Csp3 cross-couplings using 
alkylzinc reagents have been reported, the search for cheaper and more abundant alternative catalytic 
systems is highly desirable. Cobalt-salts have been found to display several beneficial characteristics.5d,6a,62 
In comparison to palladium, cobalt is a fairly cheap metal and for many transformations no sophisticated 
ligands are required for an efficient catalysis. 5d,6a,62 Additionally, several reported protocols showed, that 
cobalt salts are especially well suited catalysts for various types of reactions utilizing organozinc reagents 
as nucleophilic coupling partners5d,6a,62 including acylations,52-55,63 cross-coupling reactions,6b-f,35,39,41,43-45,64 
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or aminations65. Using this beneficial combination, a cobalt-catalyzed cross-coupling of functionalized 
primary and secondary alkylzinc reagents with a variety of aryl, heteroaryl and alkynyl halides is reported. 
 
1.2 Optimization of the Reaction Conditions 
In a preliminary experiment, 6-chloronicotinonitrile (100a) was treated with (2-(1,3-dioxan-2-yl)ethyl)zinc 
chloride (101a) under various conditions (Table 1). 
Table 1: Optimization of the reaction conditions for the cross-coupling of 100a with alkylzinc reagent 101a. 
 
 
Entry Catalyst Ligand Yield of 102a [%][a] 
1 - - 0 
2 MnCl2 - 0 
3 CuCl2 - 0 
4 FeCl2 - 0 
5 CrCl2 - 0 
6 NiCl2 - 51 
7 CoCl2 - 52 
8 CoCl2 bipy[b] 66 
9 CoCl2 dtbbpy[c] 63 
10 CoCl2 neocuproine 65 
11 CoCl2 TMEDA 39 
12[d] CoCl2 bipy[b] 80 (75)[e] 
13[d] CoCl2[f] bipy[b] 82 
[a] Reactions were performed on a 0.25 mmol scale. Yields were determined by GC-analysis. Tetradecane (C14H30) was used as 
internal standard. [b] 2,2'-Bipyridine. [c] 4,4'-Di-tert-butyl-2,2'-dipyridyl. [d] 20 mol% of bipy was used. [e] Isolated yield of the 
reaction performed on a 1.00 mmol scale. [f] CoCl2 (99.99% purity) was used. 
                                                          
65 a) X. Qian, Z. Yu, A. Auffrant, C. Gosmini, Chem. Eur. J. 2013, 19, 6225-6229; b) Y.-H. Chen, S. Graßl, P. Knochel, 
Angew. Chem. Int. Ed. 2018, 57, 1108-1111; c) S. Graßl, Y.-H. Chen, C. Hamze, C. P. Tüllmann, P. Knochel, Org. Lett. 
2019, 21, 494-497. 




In the absence of a catalyst, the desired coupling product 102a could not be detected (entry 1). Various 
metal halides such as MnCl2, CuCl2, FeCl2 or CrCl2 were tested. However, no catalytic activity was observed 
for this cross-coupling (entries 2-5). As expected, NiCl2 was able to catalyze the reaction leading to 102a in 
51% yield (entry 6). However, CoCl2 also proved to be a suitable catalyst for this transformation affording 
the desired alkylated heterocycle 102a in 52% yield (entry 7). Various ligands were tested to further 
improve the reaction outcome (entries 8-12). Thus, using the unsubstituted 2,2'-bipyridine led to the best 
coupling yield of 66% (entry 8). Increasing the amount of ligand furnished 102a in 75% isolated yield 
(entry 12). Variation of the reaction solvent, the amounts of metal species or the catalyst loading did not 
further improve the yield.66 At this point it was verified that no other metal contaminants are responsible 
for this catalysis. Using CoCl2 (99.99% purity) in combination with a new stirring bar67 and reaction vessel 
afforded the pyridine derivative 102a in 82% yield (entry 13). 
 
1.3 Cobalt-Catalyzed Cross-Coupling of Primary Alkylzinc Reagents with N-Heterocyclic Halides 
With these results in hand the scope of this cross-coupling reaction was examined (Scheme 34). N-
heterocyclic halides of type 100 were coupled with various functionalized alkylzinc reagents of type 101. 
Thus, the reaction of 100a with (3-phenylpropyl)zinc chloride afforded 102b in 73% yield. Also, the 
corresponding bromopyridine was used leading to coupling products 102c and 102d in 62-75% yield. 
Several alkylzinc reagents bearing various functional groups were excellent substrates for this cross-
coupling. Zinc organometallics containing nitrile groups, masked amines, and acetates were successfully 
coupled furnishing the alkylated pyridines 102e-g in 66-87% yield. The reactions of zinc species derived 
from natural products such as (1R)-(−)-nopol and (S)-citronellol with ethyl 6-chloronicotinate afforded 
102h and 102i in 76-83% yield. Also, using 2-halonicotinic esters in combination with zinc reagents bearing 
a heterocyclic or an alkyne moiety coupled smoothly leading to 102j and 102k in 78-83% yield. 
Furthermore, other N-heterocyclic halides, such as quinoline, isoquinoline, quinazoline, and pyrimidine 
derivatives were successfully cross-coupled with various functionalized alkylzinc reagents furnishing 
products 102l-s in 58-95% yield. However, the reaction with less activated heterocyclic halides led to poor 
coupling results.68 
                                                          
66 For further details, see: V. Experimental Part, Table 10. 
67 E. O. Pentsak, D. B. Eremin, E. G. Gordeev, V. P. Ananikov, ACS Catal. 2019, 9, 3070-3081. 
68 For unsuccessful substrates see: V. Experimental Part, Scheme 57. 





Scheme 34: Compounds of type 102 obtained by the Co-catalyzed reaction of N-heterocyclic halides of type 100 with primary 
alkylzinc reagents of type 101. [a] Reactions were performed on a 0.5 mmol scale. Yields are determined from the purified and 
analytical pure product. [b] 20% CoCl2, 40% dtbbpy and 1.9 equiv of the corresponding alkylzinc reagent were used. 




1.4 Cobalt-Catalyzed Cross-Coupling of Primary and Secondary Alkylzinc Reagents with Electron-
Deficient Aryl Halides 
Next, this cobalt catalyzed cross-coupling was extended to various electron-deficient aryl halides as 
electrophilic coupling partners (Scheme 35). Thus, (2-(1,3-dioxan-2-yl)ethyl)zinc chloride (101a) was 
coupled with 4-bromo-2-fluorobenzonitrile and ethyl 4-iodobenzoate furnishing 102t-u in 66-82% yield. 
Benzophenone was successfully alkylated in ortho- and para-position, respectively, starting from the 
corresponding halide, leading to 102v and 102w in 70-85% yield. The cross-coupling of a zinc reagent 
containing an ester moiety with a functionalized chlorobenzophenone led to 102x in 73% yield. Also, 




Scheme 35: Compounds of type 102 obtained by the Co-catalyzed reaction of aryl halides of type 100 with alkylzinc reagents of 
type 101. [a] Reactions were performed on a 0.5 mmol scale. Yields are determined from the purified and analytical pure product. 
[b] 20% CoCl2, 40% dtbbpy and 1.9 equiv of the corresponding alkylzinc reagent were used. [c] Dtbbpy was used instead of bipy. 








1.5 Diastereoselective Cobalt-Catalyzed Cross-Coupling of Secondary Alkylzinc Reagents with Heteroaryl 
Halides 
Encouraged by the results with the secondary cyclopropylzinc reagent, the cross-coupling of various 
substituted six-membered cycloalkylzinc reagents was examined. In the past, several diastereoselective 
Csp3-Csp2 Negishi-type cross-couplings using palladium33b,69 and nickel salts70 have been reported. Also, a 
cobalt-catalyzed version applying diarylzinc reagents is known.6b However, this method only allows the 
coupling of 1,2-substituted cycloalkyl iodides with (hetero)aryl zinc reagents in a diastereoselective 
manner. To overcome this limitation, the problem was approached by using substituted cycloalkylzinc 
species with heteroaryl halides as coupling partners. Previous studies have shown that the carbon-zinc 
bond is prone for an easy epimerization in the presence of metal salts.69a-b Thus, a highly diastereoselective 
cross-coupling is only enabled by a fast transmetalation of the thermodynamically more stable alkylzinc 
species to the transition-metal catalyst.69a  
To evaluate the scope of a diastereoselective cross-coupling using substituted cyclohexylzinc reagents, 
2-methylcyclohexylzinc iodide was coupled with 6-bromonicotinonitrile. A short screening revealed that a 
catalytic system of 10% CoCl2 and 20% 4,4'-di-tert-butyl-2,2'-dipyridyl in acetonitrile led to the best yield 
and diastereomeric ratio.71 Hence, the coupling of various 1,3-, and 1,4-functionalized cycloalkylzinc 
reagents with N-heterocyclic bromides was examined (Scheme 36). The reaction of 6-bromonicotinonitrile 
with 3-methylcyclohexylzinc iodide led to the thermodynamically more stable cis-1,3-disubstituted 
cyclohexane 102aa in 80% yield and dr = 91:9. However, using the corresponding zinc reagent bearing the 
bulkier iso-propyl residue led to 102ab in 63% yield and an improved diastereomeric ratio of 96:4. 
Additionally, this zinc reagent was coupled with 2-bromopyrimidine furnishing 102ac (52% yield, 
dr = 94:672). Also, 1,4-substituted cyclohexylzinc reagents could be used in this protocol. Thus, the cross-
coupling of zinc reagents bearing an ester or a pyrrole substituent with a trifluoromethylated 
bromopyridine led to the corresponding trans-1,4-bifunctionalized cyclohexanes 102ad and 102ae in 51-
                                                          
69 a) T. Thaler, B. Haag, A. Gavryushin, K. Schober, E. Hartmann, R. M. Gschwind, H. Zipse, P. Mayer, P. Knochel, Nat. 
Chem. 2010, 2, 125-130; b) T. Thaler, L.-N. Guo, P. Mayer, P. Knochel, Angew. Chem. Int. Ed. 2011, 50, 2174-2177; c) 
S. Seel, T. Thaler, K. Takatsu, C. Zhang, H. Zipse, B. F. Straub, P. Mayer, P. Knochel, J. Am. Chem. Soc. 2011, 133, 4774-
4777; d) P. Knochel, C. Diène, Compt. Rend. Chim. 2011, 14, 842-850; e) K. Moriya, P. Knochel, Org. Lett. 2014, 16, 
924-927. 
70 a) H. Gong, M. R. Gagné, J. Am. Chem. Soc. 2008, 130, 12177-12183; b) H. Gong, R. Sinisi, M. R. Gagné, J. Am. Chem. 
Soc. 2007, 129, 1908-1909. 
71 For further details, see: V. Experimental Part, Table 11. 
72 The stereochemistry of 102ac was determined by NOESY-NMR, see: VI. Appendix, 1.1 2-(3-
Isopropylcyclohexyl)pyrimidine (102ac). 




54% yield (dr = 80:20-98:273). Bromopyrimidine derivatives were coupled with functionalized cyclohexyl 
reagents affording 102af-ah in 64-73% yield and diastereomeric ratios of up to 98:2.  
 
 
Scheme 36: Diastereoselective cobalt-catalyzed cross-coupling of heteroaromatic bromides of type 100 with 1,3- and 1,4-
substituted secondary alkylzinc reagents of type 101 leading to products of type 102. [a] Reactions were performed on a 0.5 mmol 
scale. Yields are determined from the purified and analytical pure product. The diastereomeric ratio (dr) was determined by GC 
analysis. The major diastereomer is shown. 
 
Remarkably, 2-bromopyrimidine could be coupled with complex alkylzinc reagents prepared from steroid 
and sesquiterpene derivatives (Scheme 37). The reaction of cholesterylzinc chloride 101b furnished 102ai 
in 78% yield and a diastereomeric ratio of 98:2. Also, the corresponding coupling using zinc reagent 101c 
derived from a reduced nootkaton derivative proceeded in a highly diastereoselective fashion leading to 
102aj in 52% yield (dr = 98:2). 
 
                                                          
73 The stereochemistry of 102ae was determined by crystal structure analysis, see: VI. Appendix, 3. Single Crystal X-
Ray Diffraction Studies. 





Scheme 37: Diastereoselective cobalt-catalyzed cross-coupling of 2-bromopyridine with zinc organometallics 101b and 101c 
derived from cholesterol and nootkatone derivatives. [a] Reactions were performed on a 0.5 mmol scale. Yields are determined 
from the purified and analytically pure product. The diastereomeric ratio (dr) was determined by GC analysis. The major 
diastereomer is shown. 
 
1.6 Cobalt-Catalyzed Cross-Coupling of Primary and Secondary Alkylzinc Reagents with Alkynyl Bromides 
Finally, this cobalt-catalyzed cross-coupling was further extended to alkynyl bromides (Scheme 38). 
(Bromoethynyl)-benzene (103a) reacted smoothly with (2-(1,3-dioxan-2-yl)ethyl)zinc chloride (101a) 
affording the alkylated alkyne 104a in 55% yield. Interestingly, the coupling of the TIPS protected alkyne 
103b with the 1,4-phenyl substituted cyclohexylzinc reagent 101d furnished the trans-1,4-alkynylated 










Scheme 38: Cobalt-catalyzed cross-coupling of alkynyl bromides with primary and secondary alkylzinc reagents. [a] Reactions were 
performed on a 0.5 mmol scale. Yields are determined from the purified and analytical pure product. [b] The diastereomeric ratio 
(dr) was determined by GC analysis. The major diastereomer is shown. 
 
1.7 Mechanistic Considerations 
To gain an insight into the reaction mechanism, radical-trapping experiments using 
2,2,6,6-tetramethylpiperidine 1-oxyl (TEMPO) were performed. Previous studies showed that TEMPO is 
able to significantly inhibit cobalt-catalyzed reactions, which might indicate the involvement of radical 
intermediates within the course of these reactions.63,74 Thus, to a standard coupling setup of 6-
chloronicotinonitrile (100a) with (2-(1,3-dioxan-2-yl)ethyl)zinc chloride (101a) 2.0 equiv of TEMPO were 
added.[9] However, the coupling product 102a was afforded in a similar yield, compared to the standard 
conditions without the radical trapping agent. This indicates that this new cobalt-catalyzed cross-coupling 
might not proceed via radical intermediates. 
  
                                                          
74 L. Nicolas, P. Angibaud, I. Stansfield, P. Bonnet, L. Meerpoel, S. Reymond, J. Cossy, Angew. Chem. Int. Ed. 2012, 51, 
11101-11104. 




2. Cobalt-Catalyzed Csp3-Csp3  Cross-Coupling of Functionalized Alkylzinc Reagents with 
Alkyl Iodides75 
2.1. Introduction 
Transition-metal catalyzed cross-coupling reactions are among the most powerful tools for the 
construction of complex structures. Over the past decades, significant progress has been made in the 
formation of new C-C bonds, which led to numerous applications in academic as well as in industrial 
research.3c The most common catalysts for performing cross-couplings are palladium and nickel salts.3b 
These Csp3-Csp3 cross-couplings are particularly difficult due to a hampered oxidative insertion of the 
transition-metal catalyst into the alkyl-X bond and the propensity of the subsequently formed alkyl-
transition metal species to undergo β-hydride elimination.60e,76 Especially, the use of mild organometallic 
reagents in these couplings, such as organozinc compounds, is still a challenge.76a Zinc organometallics 
display several beneficial properties, including a high functional group compatibility and the ability to 
undergo a fast transmetalation to a transition-metal catalyst.7,60e Additionally, a growing commercial 
availability of these reagents and the low toxicity of zinc salts make them an attractive class of metal 
reagents. 7,60e Various palladium and nickel catalyzed Csp3-Csp3 cross-couplings using zinc organometallics, 
including enantioselective versions have been reported by Organ77, Fu78, and others60e,70b,76a,76c-e,79 
However, the high price and the need of often sophisticated ligands triggered the search for cheaper and 
                                                          
75 Adapted with permission from (F. H. Lutter, L. Grokenberger, M. Benz, P. Knochel, Org. Lett. 2020, 22, 3028-3032). 
Copyright (2020) American Chemical Society. 
76 a) D. J. Cárdenas, Angew. Chem. Int. Ed. 2003, 42, 384-387; b) M. R. Netherton, G. C. Fu, Adv. Synth. Catal. 2004, 
346, 1525-1532; c) A. C. Frisch, M. Beller, Angew. Chem. Int. Ed. 2005, 44, 674-688; d) A. Rudolph, M. Lautens, Angew. 
Chem. Int. Ed. 2009, 48, 2656-2670; e) J. Choi, G. C. Fu, Science 2017, 356, eaaf7230. 
77 a) N. Hadei, E. A. B. Kantchev, C. J. O'Brien, M. G. Organ, J. Org. Chem. 2005, 70, 8503-8507; b) N. Hadei, E. A. B. 
Kantchev, C. J. O'Brie, M. G. Organ, Org. Lett. 2005, 7, 3805-3807; c) G. A. Chass, C. J. O'Brien, N. Hadei, E. A. B. 
Kantchev, W.-H. Mu, D.-C. Fang, A. C. Hopkinson, I. G. Csizmadia, M. G. Organ, Chem. Eur. J. 2009, 15, 4281-4288; d) 
G. T. Achonduh, N. Hadei, C. Valente, S. Avola, C. J. O'Brien, M. G. Organ, Chem. Commun. 2010, 46, 4109-4111; e) N. 
Hadei, G. T. Achonduh, C. Valente, C. J. O'Brien, M. G. Organ, Angew. Chem. Int. Ed. 2011, 50, 3896-3899; f) L. C. 
McCann, H. N. Hunter, J. A. C. Clyburne, M. G. Organ, Angew. Chem. Int. Ed. 2012, 51, 7024-7027. 
78 a) J. Zhou, G. C. Fu, J. Am. Chem. Soc. 2003, 125, 12527-12530; b) J. Zhou, G. C. Fu, J. Am. Chem. Soc. 2003, 125, 
14726-14727; c) F. O. Arp, G. C. Fu, J. Am. Chem. Soc. 2005, 127, 10482-10483; d) C. Fischer, G. C. Fu, J. Am. Chem. 
Soc. 2005, 127, 4594-4595; e) S. Son, G. C. Fu, J. Am. Chem. Soc. 2008, 130, 2756-2757; f) C. J. Cordier, R. J. Lundgren, 
G. C. Fu, J. Am. Chem. Soc. 2013, 135, 10946-10949; g) J. Schmidt, J. Choi, A. T. Liu, M. Slusarczyk, G. C. Fu, Science 
2016, 354, 1265-1269; h) X. Mu, Y. Shibata, Y. Makida, G. C. Fu, Angew. Chem. Int. Ed. 2017, 56, 5821-5824; i) G. M. 
Schwarzwalder, C. D. Matier, G. C. Fu, Angew. Chem. Int. Ed. 2019, 58, 3571-3574. 
79 a) C. E. Tucker, P. Knochel, J. Org. Chem. 1993, 58, 4781-4782; b) A. Devasagayaraj, T. Stüdemann, P. Knochel, 
Angew. Chem., Int. Ed. Engl. 1996, 34, 2723-2725; c) R. Giovannini, T. Stüdemann, G. Dussin, P. Knochel, Angew. 
Chem. Int. Ed. 1998, 37, 2387-2390; d) A. E. Jensen, P. Knochel, J. Org. Chem. 2002, 67, 79-85; e) A. Lei, X. Zhang, Org. 
Lett. 2002, 4, 2285-2288; f) C. F. Malosh, J. M. Ready, J. Am. Chem. Soc. 2004, 126, 10240-10241; g) V. B. Phapale, E. 
Buñuel, M. García-Iglesias, D. J. Cárdenas, Angew. Chem. Int. Ed. 2007, 46, 8790-8795. 




more abundant metal catalysts. Although iron80, cobalt81, and manganese82 salts have been found to 
catalyze the cross-coupling of alkyl halides with alkylmagnesium reagents there is no protocol utilizing 
alkylzinc organometallics as coupling reagents. However, this would be highly desirable thus enabling the 
tolerance of sensitive functional groups attached to the electrophile as well as in the organometallic 
reagent itself. 
In the following the first cobalt-catalyzed Negishi type Csp3-Csp3 cross-coupling of various primary 
dialkylzinc reagents with primary and secondary iodides is reported. 
 
2.2 Optimization of the Reaction Conditions 
In preliminary experiments the coupling of (3-iodopropyl)benzene (105a) with (2-(1,3-dioxan-2-
yl)ethyl)zinc chloride (101a) was investigated (Table 2). Without a metal catalyst no product formation of 
107a was observed (entry 1). Transition-metal chlorides such as CuCl2, FeCl2 or MnCl2 in combination with 
both, the mono-alkylzinc reagent 101a or the dialkylzinc species 106a did not catalyze the formation of 
107a (entries 2-4). However, CoCl2 showed catalytic activity, especially in combination with the dialkylzinc 
reagent 106a, furnishing the desired product 107a in 32% yield (entries 5). Switching to acetonitrile as 
solvent was beneficial leading to 39% yield of 107a (entry 6). Various ligands were tested to further 
improve the cross-coupling (entries 7-10). Me4DACH (47)6d,35,83 turned out to be superior to other ligands 
affording 107a in 50% yield (entry 10). Previous reports showed the beneficial effects of 






                                                          
80 a) K. G. Dongol, H. Koh, M. Sau, C. L. L. Chai, Adv. Synth. Catal. 2007, 349, 1015-1018; b) M. Guisán-Ceinos, F. Tato, 
E. Buñuel, P. Calle, D. J. Cárdenas, Chem. Sci. 2013, 4, 1098-1104. 
81 a) G. Cahiez, C. Chaboche, C. Duplais, A. Giulliani, A. Moyeux, Adv. Synth. Catal. 2008, 350, 1484-1488; b) C. 
Andersen, V. Ferey, M. Daumas, P. Bernardelli, A. Guérinot, J. Cossy, Org. Lett. 2019, 21, 2285-2289. 
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H. Ohmiya, H. Yorimitsu, K. Oshima, Synlett 2006, 2006, 3061-3064; c) W. M. Czaplik, M. Mayer, A. Jacobi von 
Wangelin, Synlett 2009, 2009, 2931-2934. 
84 M. Piber, A. E. Jensen, M. Rottländer, P. Knochel, Org. Lett. 1999, 1, 1323-1326. 




Table 2. Optimization of the reaction conditions for the cross-coupling of alkyl iodide (105a) with zinc reagents of type 101a or 
106a. 
 
Entry Catalyst Zinc Reagent Solvent Ligand Additive Yield of 107a [%][b] 
1 - 101a THF - - traces 
2 CuCl2 101a (106a) THF - - 1 (3)[c] 
3 FeCl2 101a (106a) THF - - 1 (2)[c] 
4 MnCl2 101a (106a) THF - - Traces (traces)[c] 
5 CoCl2 101a (106a) THF - - 11 (32)[c] 
6 CoCl2 106a MeCN - - 39 
7 CoCl2 106a MeCN neocuproine - 46 
8 CoCl2 106a MeCN PPh3[d] - 11 
9 CoCl2 106a MeCN TMEDA - 42 
10 CoCl2 106a MeCN Me4DACH (47) - 50 
11 CoCl2 106a MeCN Me4DACH (47) TBAB[e] 44 
12 CoCl2 106a MeCN Me4DACH (47) TBAI[e] 57 
13 CoCl2 106a MeCN Me4DACH (47) TBAI[f] 74 (72)[g] (78)[h] 
[a] MgX2.LiX (X = Cl or Br) is omitted for clarity. [b] Reactions were performed on a 0.25 mmol scale. Yields were determined by 
GC-analysis. Tetradecane (C14H30) was used as internal standard. [c] 106a was used. [d] 40 mol% of the ligand were used. [e] 
1.00 equiv. of the additive were used. [f] 2.25 equiv. of the additive were used. [g] Isolated yield. [h] CoCl2 of 99.99% purity and a 
new stirring bar were used 
 
A screening revealed, that 2.25 equiv of tetrabutylammonium iodide (TBAI) significantly increased the 
yield leading to the coupling product 107a in 72% (entries 11-13). Variation of the equivalents of the 
organozinc reagent, the cobalt source, or the amount of catalyst did not further improve the reaction 
yield.85 Additionally, it was verified that no metal contaminants are responsible for the catalysis. Thus, 
                                                          
85 For further details, see: V. Experimental Part, Table: 12. 
 




performing the reaction with CoCl2 (99.99% purity), a new stirring bar and reaction vessel furnished 107a 
in 78% yield (entry 13).67  
 
2.3 Cobalt-Catalyzed Cross-coupling of Bis(2-(1,3-dioxan-2-yl)ethyl)zinc with Primary and Secondary 
Alkyl Iodides 
With these results in hand the scope of this cross-coupling was examined (Scheme 39). Thus, dialkylzinc 
reagent 106a was coupled with primary alkyl iodides containing nitrile, aryl or heteroaryl moieties 
furnishing the corresponding products 107b-d in 61-67% yield. Switching to neocuproine as ligand enabled 
the use of various secondary alkyl iodides. The coupling with cyclohexyl iodide afforded the corresponding 
product 107e in 76% yield. Also, tetrahydropyranyl and piperidyl iodides underwent a smooth coupling 
with 106a. Thus, the corresponding products 107f-h were obtained in 58-74% yield. The coupling with 
secondary acyclic iodides bearing an aryl moiety or derived from β-ionone led to 107i-j in 72-77% yield. 
Various other secondary iodides containing alkyl, aryl or heteroaryl esters were suitable electrophiles for 
the coupling with the dialkylzinc reagent 106a furnishing 107k-n in 51-91% yield. Interestingly, TBS-
protected iodohydrin and a cyclic iodide derived from menthol could also be used for the coupling 
affording 107o-p in 65-67% yield and up to 89:11 dr. Furthermore, benzylic and allylic halides could be 
coupled under these conditions furnishing the expected products 107q-s in 60-98% yield.51  
 





Scheme 39. Products of type 107 obtained by the cobalt-catalyzed cross-coupling of alkyl iodides (105) with dialkylzinc species 
106a. [a] MgX2.LiX (X = Cl or Br) is omitted for clarity. [b] All reactions were performed on a 0.5 mmol scale. Isolated yields of 
analytically pure products. [c] Me4DACH (47) was used as a ligand. [d] Neocuproine was used as a ligand. [e] The diastereomeric 
ratio (dr) was determined by GC-analysis of the crude reaction mixture. The major diastereomer is shown. [f] Benzyl bromide was 
used as an electrophile. [g] Benzyl chloride was used as an electrophile. [h] Allyl bromide derivatives were used as electrophiles. 
 
 




2.4 Cobalt-Catalyzed Cross-coupling of Dialkylzincs with Primary and Secondary Alkyl Iodides 
Next, cross-couplings of various dialkylzinc reagents with secondary iodides were examined (Table 3). The 
reaction of iodotetrahydropyran 105b and piperidinyl iodide 105c with dialkylzinc reagent 106b led to the 
coupling products 107t-u in 66-71% yield. Also, di(4-chlorobutyl)zinc 106c underwent a cross-coupling with 
iodo piperidine 105d affording the alkylated heterocycle 107v 66% yield. At this point the scalability of the 
method was examined. Thus, the reaction of 106c with N-boc protected 4-iodo piperidine 105c was 
performed on a 5 mmol scale, leading to the 4-alkylated piperidine 107w in 58% yield. Zinc organometallics 
106d-f bearing sensitive functional groups such as acetates, carbamates and esters were conveniently 
prepared from the corresponding bromides performing a magnesium insertion in the presence of 
0.5 equiv ZnCl2.17 The reaction of the dialkylzinc 106d with cyclic and acyclic iodides afforded the products 
107x-y in 65-72% yield. The secondary iodide 105g was coupled with the Boc-protected 4-
piperidylalkylzinc 106e leading to the product 107z in 72% yield. Also, dialkylzinc reagent 106f bearing an 
ester function was coupled with various substituted secondary alkyl iodides affording 107aa-ac in 68-80% 
yield.  
 
Table 3: Products of type 107 obtained by the cobalt-catalyzed cross-coupling of secondary alkyl iodides of type 105 with dialkyl 
zincs of type 106. 
 




Table 3: continued 
 
[a] MgX2.LiX (X = Cl or Br) is omitted for clarity. [b] All reactions were performed on a 0.5 mmol scale. Isolated yield of analytically 
pure products.  
 
Additionally, primary alkyl iodides were coupled with various dialkylzinc reagents (Table 4). Thus, the 
coupling of di(3,3,3-trifluoropropyl)zinc (106g) with iodide 105a afforded the coupling product 107ad in 
75% yield. Moreover, primary alkyl iodides containing sensitive functionalities such as nitrile (105i) or ester 
groups (105j) could be coupled using cobalt-catalysis leading to the corresponding products 107ae-af in 
39% and 62%, respectively.  




Table 4. Products of type 107 obtained by the cobalt-catalyzed cross-coupling of primary alkyl iodides of type 105 with dialkyl 
zincs of type 106.  
 
[a] MgX2.LiX (X = Cl or Br) is omitted for clarity. [b] All reactions were performed on a 0.5 mmol scale. Isolated yield of analytically 
pure products.  
 
2.5 Mechanistic Considerations 
To shed some light on the reaction mechanism, experiments with radical-clock precursors 105k and 105l 
were performed (Scheme 40).80b,86 Thus, treatment of iodohydrine 105k with dialkylzinc reagent 106a in 
the presence of the cobalt catalyst only led to the cyclization product 107ag in 45% yield (dr = 90:10). 
Furthermore, the reaction with (iodomethyl)cyclopropane (105l) afforded the ring-opening product 107ah 
in 44% yield. These findings suggest the involvement of radical intermediates during the course of the 
reaction potentially formed via a stepwise one-electron oxidation of the cobalt catalyst to the alkyl 
iodide.83c,86b,87 
                                                          
86 a) H. Ohmiya, H. Yorimitsu, K. Oshima, Org. Lett. 2006, 8, 3093-3096; b) H. Someya, H. Ohmiya, H. Yorimitsu, K. 
Oshima, Org. Lett. 2007, 9, 1565-1567; b) T. Tsuji, H. Yorimitsu, K. Oshima, Angew. Chem. Int. Ed. 2002, 41, 4137- 
4139; c) K. Wakabayashi, H. Yorimitsu, K. Oshima, J. Am. Chem. Soc. 2001, 123, 5374-5375. 
87 a) H. Ohmiya, K. Wakabayashi, H. Yorimitsu, K. Oshima, Tetrahedron 2006, 62, 2207-2213; b) L. Gonnard, A. 
Guérinot, J. Cossy, Chem. Eur. J. 2015, 21, 12797-12803; c) F. Kreyenschmidt, S. E. Meurer, K. Koszinowski, Chem. Eur. 
J. 2019, 25, 5912-5921. 
 





Scheme 40. Mechanistic experiments using radical-clock precursors 105k and 105l. [a] 2MgX2.2LiX (X = Cl or Br) is omitted for 
clarity. [b] Reactions were performed on a 0.5 mmol scale. Isolated yield of analytically pure products. [c] The diastereomeric ratio 
(dr) was determined by GC analysis from the crude reaction mixture. The major diastereomer is shown. 
  




3. Cobalt-Catalyzed Acylation-Reactions of (Hetero)Arylzinc Pivalates with Thiopyridyl 
Ester Derivatives88 
3.1. Introduction 
The carbonyl group is a central functionality in organic chemistry and the performance of acylation 
reactions employing organometallic reagents represents a general access to various ketones.46,47 A major 
drawback of these reactions is the moderate chemoselectivity or the use of expensive catalysts. 46,47 Acid 
chlorides are the most common acylation reagents. 7a,7c,46,47,51,52,89 However, their preparation requires 
harsh conditions, thus lowering the functional group tolerance. In contrast, the use of thioesters is a 
valuable alternative since Fukuyama showed in pioneering work that these acylating reagents react readily 
with organozinc halides in the presence of a palladium catalyst.49e Additionally, Seki,50d Rovis,50e 
Fleischer,50f and others49f-g,50a-b,90 showed that these reactions can be performed using various transition-
metal catalysts. Recently, it was shown that organozinc pivalates (RZnOPiv) are an attractive class of zinc 
organometallics due to their enhanced air- and moisture stability and their excellent compatibility with 
various transition metal-catalyzed transformations.38,91 Especially, cobalt-catalyzed reactions have proved 
to be advantageous.5f,6d,39,43,62c,65b  
In the following a new cobalt-catalyzed acylation reaction of various saturated and unsaturated thioesters 
of type R1C(O)SPy (108) with aryl- and heteroarylzinc pivalates of type R2ZnOPiv (109), leading to a broad 
range of polyfunctional ketones of type 110 is reported. Although thioesters are readily available from the 
corresponding acid chlorides and thiols,92 the pyridyl thioesters 108 were prepared under exceedingly mild 
and neutral conditions from the corresponding carboxylic acid of type 111 using Mukaiyama’s method 
(Scheme 41).93 
 
                                                          
88 Adapted with permission from (F. H. Lutter, L. Grokenberger, M. S. Hofmayer, P. Knochel, Chem. Sci. 2019, 10, 
8241-8245). Copyright (2019) Royal Society of Chemistry. 
89 S.-H. Kim, R. D. Rieke, Tetrahedron Lett. 2011, 52, 1523-1526. 
90 a) W. Oppolzer, C. Darcel, P. Rochet, S. Rosset, J. De Brabander, Helv. Chim. Acta 1997, 80, 1319-1337; b) B. Li, R. 
A. Buzon, C. K. F. Chiu, S. T. Colgan, M. L. Jorgensen, N. Kasthurikrishnan, Tetrahedron Lett. 2004, 45, 6887-6890; c) 
R. Haraguchi, S.-G. Tanazawa, N. Tokunaga, S.-I. Fukuzawa, Org. Lett. 2017, 19, 1646-1649. 
91 M. S. Hofmayer, F. H. Lutter, L. Grokenberger, J. M. Hammann, P. Knochel, Org. Lett. 2019, 21, 36-39. 
92 B. P. Bandgar, P. E. More, V. T. Kamble, S. S. Sawant, Aust. J. Chem. 2008, 61, 1006-1010. 
93 a) T. Endo, S. Ikenaga, T. Mukaiyama, Bull. Chem. Soc. Jpn. 1970, 43, 2632-2633; b) T. Mukaiyama, M. Araki, H. 
Takei, J. Am. Chem. Soc. 1973, 95, 4763-4765; c) T. Hofmann, P. Schieberle, J. Agric. Food. Chem. 1998, 46, 616-619. 





Scheme 41: Preparation of thiopyridyl esters of type 108 from carboxylic acids 111 and cobalt-catalyzed acylation with organozinc 
pivalates 109, affording ketones of type 110. Py = 2-pyridyl. 
 
3.2 Optimization of the Reaction Conditions 
In preliminary experiments, S-(pyridin-2-yl)-cyclohexanecarbothioate (108a) was treated with 4-
(methoxyphenyl)zinc pivalate (72) under various conditions (Table 5). In the absence of a catalyst, ketone 
110a was obtained in only 9% yield (Table 5, entry 1). Although palladium and nickel are well-known metal 
catalysts for the Fukuyama acylation, the use of cheaper and more abundant catalysts is highly desirable. 
Whereas, MnCl2, CrCl2, FeCl2 or CuCl2 gave unsatisfying results (entries 2-5), CoCl2 proved to be an excellent 
catalyst for this transformation (entry 6). Its catalytic efficiency could be further improved by the addition 
of various ligands. After a short screening it became clear that 4,4'-di-tert-butyl-2,2'-dipyridyl (dtbbpy) 



















Table 5: Optimization of the reaction conditions for the acylation of thioester 108a with arylzinc pivalate 72. 
 
[a] Reactions were performed on a 0.5 mmol scale. Determined by GC-analysis. Tetradecane (C14H30) was used as internal 
standard. [b] 20% of the ligand was used. [c] 2,2'-Bipyridine. [d] 4,4'-Di-tert-butyl-2,2'-dipyridyl. [e] Isolated yield. [f] Reaction was 
performed on a 5 mmol scale. [g] CoCl2 (99.99% purity) was used. 
 
At this point, it was verified that no other metal contaminations are responsible for this catalysis. Thus, 
using CoCl2 (99.99% purity) together with a new stirring bar and reaction vessel led to 110a in 86% yield 
(entry 12).67 Furthermore, a screening showed that RC(O)SPy thioesters are superior to thioesters of type 
RC(O)SEt or RC(O)SPh.94  
 
3.3 Cobalt-Catalyzed Acylation of Alkylthiopyridyl Esters with (Hetero)Arylzinc Pivalates 
With the optimized conditions in hand, the scope of the acylation reaction was examined. In a typical 
experiment palmitic acid was treated with 2,2'-dipyridyl disulfide (1.1 equiv) and PPh3 (1.5 equiv) in 
                                                          
94 For further details, see: V. Experimental Part, Tables 13 and 14. 
Entry Catalyst Ligand Yield of 110a [%][a] 
1 - - 9 
2 MnCl2 - traces 
3 CrCl2 - traces 
4 FeCl2 - 50 
5 CuCl2 - 29 
6 CoCl2 - 67 
7 CoCl2 PPh3[b] 63 
8 CoCl2 TMEDA 64 
9 CoCl2 neocuproine 49 
10 CoCl2 bipy[c] 71 
11 CoCl2 dtbbpy[d] 90 (88)[e] (87)[f] 
12 CoCl2[g] dtbbpy[d] 86 




acetonitrile (0.3 M) under reflux for 3 h. Short purification using flash column chromatography afforded 
108b in 98% yield. Zinc pivalate 109a was prepared by treating 1-bromo-3,4-(methylene-dioxy)benzene 
with Mg (1.2 equiv) and anhydrous LiCl (1.2 equiv) for 2 h at 0 °C leading to the corresponding 
arylmagnesium derivative (91% yield).95 Transmetalation with Zn(OPiv)2 (1.0 equiv) afforded the zinc 
organometallic 109a in 93% yield.95 The thioester 108b was treated with 3,4-(methylene-dioxy)-1-
phenylzinc pivalate (109a) in the presence of 10 % CoCl2 and 10% dtbbpy in THF (25 °C, 4 h) furnishing, 
after standard workup and chromatographic purification the ketone 110b in 90% yield (Table 6, entry 1).  
According to this procedure various ketones of type 110 were prepared. Hence, the heterocyclic 
indolylzinc pivalate (109b) was acylated with palmitic S-pyridyl thioate (108b) furnishing ketone 110c in 
74% yield (entry 2). Additionally, secondary thioesters derived from cyclobutane- (108c) and 
cyclohexanecarboxylic acid (108a) were employed to this acylation procedure leading to the 
corresponding ketones (110d-g) in 60-95% yield (entries 3-6). Tertiary S-pyridyl esters 108d and 108e 
derived from 1-adamantanecarboxylic acid and the lipid regulating drug gemfibrozil96 reacted smoothly 

















                                                          
95 A. Krasovskiy and P. Knochel, Synthesis, 2006, 890-891. 
96 P. A. Todd, A. Ward, Drugs 1988, 36, 314-339. 













Table 6: continued 
 
[a] The reactions were performed on a 0.5 mmol scale [b] Isolated yield of the S-pyridyl ester prepared from the corresponding 
carboxylic acid, PySSPy (1.1 equiv), PPh3 (1.5 equiv), MeCN, reflux, 3 h. [c] Isolated yield. [d] Prepared using iPrMgCl⋅LiCl 
(1.1 equiv), THF, -20 °C, 2 h. 
 
3.4 Cobalt-Catalyzed Acylation of (Hetero)Arylthiopyridyl Esters with (Hetero)Arylzinc Pivalates 
Furthermore, the acylation reaction was extended to aryl- and heteroaryl-S-pyridyl esters (Table 7). Thus, 
(4-(ethoxycarbonyl)-phenyl)zinc pivalate (109j) prepared via I/Mg-exchange using iPrMgCl⋅LiCl followed 
by transmetalation with Zn(OPiv)238f was readily acylated with S-pyridyl ester 108f affording the 
benzophenone 110l in 71% yield (entry 1). Also, 2-benzothiophenylzinc pivalate 109k generated via 
directed metalation of benzothiophene using TMPMgCl⋅LiCl and subsequent transmetalation with 
Zn(OPiv)238f underwent a cobalt catalyzed acylation reaction with 108f leading to the ketone 110m in 68% 
yield (entry 2). Various substituted aryl thioesters and ferrocenyl derivatives reacted successfully with 
functionalized (hetero)arylzinc pivalates affording the diaryl ketones 110n-r in 81-96% yield (entries 3-7). 
Additionally, 4-trifluoromethoxyphenylzinc pivalate (109n) was acylated using quinoline thioester 108j 
furnishing ketone 110s in 68% yield (entry 8).97  
 
                                                          
97 For unsuccessful acylation reactions with (hetero)arylzinc pivalates including several electron poor N-heterocyclic 
and sterically hindered organozinc reagents, see: V. Experimental Part, Scheme 58. 












Table 7: continued 
 
[a] The reactions were performed on a 0.5 mmol scale [b] Isolated yield of the S-pyridyl ester prepared from the corresponding 
carboxylic acid, PySSPy (1.1 equiv), PPh3 (1.5 equiv), MeCN, reflux, 3 h [c] Isolated yield [d] Prepared using iPrMgCl⋅LiCl (1.1 equiv), 
THF, -40 °C, 2 h. [e] Prepared using TMPMgCl⋅LiCl (1.0 equiv), THF, 0 °C, 3 h. [f] TMEDA was used instead of dtbbpy. 
 
3.5 Cobalt-Catalyzed Acylation of α-Chiral S-Pyridyl Esters s with Arylzinc Pivalates 
The synthesis of α-chiral ketones is of great interest49e,49g,50e,90a.98 but often challenging under basic 
conditions due to epimerization. Also, reactions under pH-neutral conditions have been reported by 
Liebeskind et al. for the synthesis of highly enantiopure peptidyl ketones.99 We also tested the applicability 
of this cobalt-catalyzed acylation to the synthesis of optically enriched α-chiral ketones. Using α-chiral S-
pyridyl esters at 0 °C afforded several α-chiral ketones with high stereoretention (Table 8). Thus, S-pyridyl 
ester 108k prepared from N-Boc protected (S)-proline was treated with arylzinc reagents 72 and 109a 
leading to the corresponding α-chiral ketones 110t-u in 72-82% yield and >99% ee (entries 1-2). 
Furthermore, thioester 108l derived from enantiopure (S)-ibuprofen reacted smoothly with the 
functionalized arylzinc pivalates 109o and 109m leading to the products 110v-w in 71-89% yield and 94-
97% ee (entries 3-4). Also, arylzinc pivlalates 109p and 109q bearing an amide or dimethylamino 
                                                          
98 a) G. T. Crisp, T. P. Bubner, Synth. Commun. 1990, 20, 1665-1670; b) G. Cahiez, E. Metais, Tetrahedron Lett. 1995, 
36, 6449-6452; c) T. Fukuyama, H. Tokuyama, Aldrichimica Acta 2004, 37, 100-101; d) A. H. Cherney, N. T. Kadunce, 
S. E. Reisman, J. Am. Chem. Soc. 2013, 135, 7442-7445; e) R. Oost, A. Misale, N. Maulide, Angew. Chem. Int. Ed. 2016, 
55, 4587-4590. 
99 a) H. Li, H. Yang, L. S. Liebeskind, Org. Lett. 2008, 10, 4375-4378; b) L. S. Liebeskind, H. Yang, H. Li, Angew. Chem. 
Int. Ed. 2009, 48, 1417-1421. 




functionality were acylated using optically pure S-(pyridin-2-yl)-(S)-2-methylbutanethioate furnishing the 
α-chiral ketones 110x-y in 69-84% yield and 95-98% ee (entries 5-6). 
 
Table 8: Preparation of α-chiral ketones 110 by acylation of thiopyridyl esters 108 with (hetero)arylzinc pivalates 109.[a]  
 
 




Table 8: continued 
 
[a] The reactions were performed on a 0.5 mmol scale and at 0 °C instead of 25 °C. [b] Isolated yield of the S-pyridyl ester prepared 
from the corresponding carboxylic acid, PySSPy (1.0 equiv), PPh3 (1.0 equiv), MeCN, 0 °C to 25 °C, 16 h. [c] Isolated yield. [d] 
Prepared using iPrMgCl⋅LiCl (1.1 equiv), THF, 0 °C, 2 h. 
 
3.6 Mechanistic Considerations 
To gain insights into the reaction mechanism, radical trapping experiments were carried out. Thus, to a 
standard acylation setup of the developed protocol using S-pyridyl ester 108a and organozinc pivalate 72 
various amounts of the radical trapping agent 2,2,6,6-tetramethylpiperidinyloxyl (TEMPO) were added 
(Scheme 42). With 10% of the trapping reagent a decrease of the yield by 19% was observed for the 
acylation product 110a. However, using 1.5 equiv of TEMPO the product formation is almost completely 
suppressed. This may indicate the involvement of radical intermediates within this acylation reaction.100  
 
 
Scheme 42: Cobalt-catalyzed acylation reaction in the presence of various amounts of TEMPO. [a] Tetradecane (C14H30) was used 
as internal standard. 
 
                                                          
100 For further details, see: V. Experimental Part, Table 15. 




3.7 Application of the Cobalt-Catalyzed Acylation Reaction to Synthesis of Fenofibrate 
The utility of this acylation was demonstrated in the synthesis of the anitlipedemic drug fenofibrate101 
(110z, Scheme 43). Alkylation of 4-iodophenol (112) with isopropyl 2-bromo-2-methyl-propanoate (113) 
affords the corresponding iodo-aryl ether 114 in 70% yield. 114 was treated with Mg, LiCl and Zn(OPiv)2 
generating the arylzinc pivalate 109r in 72% yield.38a Using the new cobalt-catalyzed acylation procedure, 
fenofibrate (110z) was obtained in 65% yield. 
 
 
Scheme 43: Synthesis of fenofibrate (110z) using the Co-catalyzed acylation. 
                                                          
101 G. M. Keating, K. F. Croom, Drugs 2007, 67, 121-153. 




4. Mild and Regioselective Magnesiation and Functionalization of Aryl Azoles as a 
Powerful Tool for the Synthesis of Pharmaceutically Relevant Targets 
4.1 Introduction 
Aryl azoles are widely spread scaffolds in biologically active compounds. N-aryl azoles are present in 
various blockbuster drugs, such as rimonabant,102 celecoxib103 and apixaban104 (Figure 1). The synthesis 
and future derivatization of such compounds is therefore of high importance. 
 
 
Figure 1: Biologically active compounds containing an aryl azole motif. 
 
A commonly used ortho-functionalization of the aryl ring in these scaffolds involves transition metal 
catalyzed C-H arylations.105,106 However, these reactions usually require harsh conditions and often 
                                                          
102 S. Henness, D. M. Robinson, K. A. Lyseng-Williamson, Drugs 2006, 66, 2109-2119. 
103 T. D. Penning, J. J. Talley, S. R. Bertenshaw, J. S. Carter, P. W. Collins, S. Docter, M. J. Graneto, L. F. Lee, J. W. 
Malecha, J. M. Miyashiro, R. S. Rogers, D. J. Rogier, S. S. Yu, G. D. Anderson, E. G. Burton, J. N. Cogburn, S. A. Gregory, 
C. M. Koboldt, W. E. Perkins, K. Seibert, A. W. Veenhuizen, Y. Y. Zhang, P. C. Isakson, J. Med. Chem. 1997, 40, 1347-
1365. 
104 D. J. P. Pinto, M. J. Orwat, S. Koch, K. A. Rossi, R. S. Alexander, A. Smallwood, P. C. Wong, A. R. Rendina, J. M. 
Luettgen, R. M. Knabb, K. He, B. Xin, R. R. Wexler, P. Y. S. Lam, J. Med. Chem. 2007, 50, 5339-5356. 
105 For selected reviews on C-H activation: a) D. Alberico, M. E. Scott, M. Lautens, Chem. Rev. 2007, 107, 174-238; b) 
L. Ackermann, Synlett 2007, 2007, 507-526; c) P. B. Arockiam, C. Bruneau, P. H. Dixneuf, Chem. Rev. 2012, 112, 5879-
5918; d) N. Kuhl, N. Schröder, F. Glorius, Adv. Synth. Catal. 2014, 356, 1443-1460; e) Y. Yang, J. Lan, J. You, Chem. Rev. 
2017, 117, 8787-8863; f) P. Gandeepan, T. Müller, D. Zell, G. Cera, S. Warratz, L. Ackermann, Chem. Rev. 2019, 119, 
2192-2452. 
106 a) F. Kakiuchi, M. Matsumoto, K. Tsuchiya, K. Igi, T. Hayamizu, N. Chatani, S. Murai, J. Organomet. Chem. 2003, 
686, 134-144; b) S. Oi, E. Aizawa, Y. Ogino, Y. Inoue, J. Org. Chem. 2005, 70, 3113-3119; c) L. Ackermann, A. 
Althammer, R. Born, Synlett 2007, 2007, 2833-2836; d) S. Oi, H. Sasamoto, R. Funayama, Y. Inoue, Chem. Lett. 2008, 
37, 994-995; e) M. Simonetti, D. M. Cannas, X. Just-Baringo, I. J. Vitorica-Yrezabal, I. Larrosa, Nat. Chem. 2018, 10, 
724-731; f) L. Ackermann, A. Althammer, R. Born, Tetrahedron 2008, 64, 6115-6124; g) S. H. Kwak, N. Gulia, O. 
Daugulis, J. Org. Chem. 2018, 83, 5844-5850; h) S. Oi, H. Sato, S. Sugawara, Y. Inoue, Org. Lett. 2008, 10, 1823-1826; 
i) L. Ackermann, R. Born, R. Vicente, ChemSusChem 2009, 2, 546-549; j) C. J. Teskey, S. M. A. Sohel, D. L. Bunting, S. 
G. Modha, M. F. Greaney, Angew. Chem. Int. Ed. 2017, 56, 5263-5266. 




predominantly lead to a double arylated product, which severely limits this methodology.105a,105c,106a-g,107 
An alternative for the selective functionalization of aryl azoles may be the directed deprotonation with a 
sterically hindered metal amide base. Especially, magnesium- and zinc-derived TMP-bases have proved to 
be powerful and selective reagents for the functionalization of various (hetero)arenes.7i,23b-c,108 However, 
a regioselective metalation of aryl rings linked to azole-heterocycles is especially challenging, due to the 
competitive metalation of the N-heterocycle itself. A potential approach to achieve a highly regioselective 
metalation at the aryl ring is the avoidance of coordinating solvents such as THF, which competes in a 
selective complexation of the base with the nitrogen atom of the azole ring.109 Thus, the use of hindered 
magnesium amides in hydrocarbons or related solvents should be beneficial. In the past, Hagadorn 
showed, that TMP2Zn is an excellent base for the α-zincation of various carbonyl compounds and the 
metalation of pyridine-N-oxide in toluene.110 Furthermore, Mulvey and co-workers reported several mixed 
bimetallic amide bases, which were used for metalation reactions in non-coordinating hydrocarbon 
solvents.111  
In the following a highly selective and broadly applicable magnesiation of various aryl azoles in toluene 
and subsequent cross-couplings and electrophilic quench reactions is reported. 
4.2 Optimization of the Metalation Conditions 
In preliminary experiments, the selective magnesiation of N-aryl-1,2,3-triazole 115a using various metal 
amide bases was investigated (Table 9). As expected, the use of strong bases like TMPLi did not lead to the 
                                                          
107 a) O. Daugulis, V. G. Zaitsev, Angew. Chem. Int. Ed. 2005, 44, 4046-4048; b) S. Oi, R. Funayama, T. Hattori, Y. Inoue, 
Tetrahedron 2008, 64, 6051-6059. 
108 For recent publications on directed metalation using TMP-metal bases, see a) D. S. Ziegler, R. Greiner, H. Lumpe, 
L. Kqiku, K. Karaghiosoff, P. Knochel, Org. Lett. 2017, 19, 5760-5763; b) M. Balkenhohl, R. Greiner, I. S. Makarov, B. 
Heinz, K. Karaghiosoff, H. Zipse, P. Knochel, Chem. Eur. J. 2017, 23, 13046-13050; c) S. B. Boga, M. Christensen, N. 
Perrotto, S. W. Krska, S. Dreher, M. T. Tudge, E. R. Ashley, M. Poirier, M. Reibarkh, Y. Liu, E. Streckfuss, L.-C. Campeau, 
R. T. Ruck, I. W. Davies, P. Vachal, React. Chem. Eng. 2017, 2, 446-450; d) M. Balkenhohl, B. Salgues, T. Hirai, K. 
Karaghiosoff, P. Knochel, Org. Lett. 2018, 20, 3114-3118; e) M. Balkenhohl, H. Jangra, T. Lenz, M. Ebeling, H. Zipse, K. 
Karaghiosoff, P. Knochel, Angew. Chem. Int. Ed. 2019, 58, 9244-9247. 
109 M. C. Whisler, S. MacNeil, V. Snieckus, P. Beak, Angew. Chem. Int. Ed. 2004, 43, 2206-2225. 
110 a) M. L. Hlavinka, J. R. Hagadorn, Organometallics 2007, 26, 4105-4108; b) M. L. Hlavinka, J. R. Hagadorn, 
Tetrahedron Lett. 2006, 47, 5049-5053. 
111 a) V. L. Blair, L. M. Carrella, W. Clegg, B. Conway, R. W. Harrington, L. M. Hogg, J. Klett, R. E. Mulvey, E. Rentschler, 
L. Russo, Angew. Chem. Int. Ed. 2008, 47, 6208-6211; b) A. J. Martínez-Martínez, S. Justice, B. J. Fleming, A. R. 
Kennedy, I. D. H. Oswald, C. T. O’Hara, Science Advances 2017, 3, e1700832; c) A. J. Martínez-Martínez, D. R. 
Armstrong, B. Conway, B. J. Fleming, J. Klett, A. R. Kennedy, R. E. Mulvey, S. D. Robertson, C. T. O'Hara, Chemical 
Science 2014, 5, 771-781; d) R. E. Mulvey, Organometallics 2006, 25, 1060-1075; e) A. J. Martínez-Martínez, A. R. 
Kennedy, R. E. Mulvey, C. T. O’Hara, Science 2014, 346, 834; f) S. D. Robertson, M. Uzelac, R. E. Mulvey, Chem. Rev. 
2019, 119, 8332-8405; g) M. A. Stevens, F. H. Hashim, E. S. H. Gwee, E. I. Izgorodina, R. E. Mulvey, V. L. Blair, Chemistry-
A European Journal 2018, 24, 15669-15677; h) M. Á. Fuentes, A. Zabala, A. R. Kennedy, R. E. Mulvey, Chemistry-A 
European Journal 2016, 22, 14968-14978. 




desired aryllithium reagent A, but exclusively afforded the unwanted metalation at the 1,2,3-triazole ring 
(B, entry 1). Similarly, mixtures of A and B were obtained with TMPMgCl⋅LiCl or TMP2Mg in THF112 (entries 
2-3). As mentioned above, it was anticipated that the use of the highly coordinating solvent THF hampers 
a selective coordination at the N(2)-atom. However, TMP2Mg in toluene proved to be too reactive, leading 
to extensive decomposition of the staring material 115a (entry 4).  
 
Table 9: Screening of the metalation of 115a 
 
Entry Base Equiv Solvent Time Temp A[a] B[a] 
1 TMPLi 1.2 THF 0.5 -78 °C 0% 99% 
2 TMPMgCl·LiCl 1.2 THF 1 rt 39% 19% 
3 TMP2Mg 1.2 THF 1 rt 67% 23% 
4 TMP2Mg 1.2 toluene 1 rt decomposition 
5 TMPMgBu 1.0 toluene 1 rt 81% 3% 
6 TMPMgBu 1.0 THF 1 rt 78% 32%[b] 
7 iPr2NMgBu 1.0 toluene 1 rt 67% 3% 
8 Cy2NMgBu 1.0 toluene 1 rt 65% 2% 
[a] Metalation yields were determined from D2O quenched reaction aliquots and subsequent 1H-NMR analysis.113 [b] including 
bis-metalated species.  
 
Therefore, the attention was turned to TMPMgBu114, which was conveniently prepared by treating TMP-
H with commercially available Bu2Mg in hexane (25 °C, 48 h) affording a clear 0.74-0.81 M solution (94-98% 
yield, Scheme 44). An analysis of iodolyzed samples of the reagent revealed, that the reagent contains 60% 
                                                          
112 a) P. E. Eaton, C. H. Lee, Y. Xiong, J. Am. Chem. Soc. 1989, 111, 8016-8018; b) P. E. Eaton, Y. Xiong, R. Gilardi, J. Am. 
Chem. Soc. 1993, 115, 10195-10202; c) T. Ooi, Y. Uematsu, K. Maruoka, J. Org. Chem. 2003, 68, 4576-4578. 
113 For further details, see: V. Experimental Part, 5.2 Preparation of Organometallic Reagents and Metalation 
Optimization. 
114 a) E. Hevia, A. R. Kennedy, R. E. Mulvey, S. Weatherstone, Angew. Chem. Int. Ed. 2004, 43, 1709-1712; b) B. 
Conway, E. Hevia, A. R. Kennedy, R. E. Mulvey, S. Weatherstone, Dalton Trans. 2005, 1532-1544. 




n-butylmagnesium and 40% sec-butylmagnesium species. This metal amide proved to be highly selective 
affording the desired metalated 1,2,3-triazole A within 1 h (A:B = 81%:3%, entry 5). The choice of the 
solvent was crucial in this experiment, since performing the metalation with TMPMgBu in THF provides a 
mixture of A:B including double metalated product (entry 6). Other alkyl magnesium amides, such as 
iPr2NMgBu or Cy2NMgBu did not improve the reaction outcome (entries 7-8).115  
 
 
Scheme 44: Preparation and composition of TMPMgBu. [a] Yields and composition was determined by GC-analysis of iodolyzed 
aliquots using undecane (C11H24) as internal standard by comparison with a calibration curve of various amounts of the respective 
molecule and undecane. 
 
4.3 Metalation of Functionalized Aryl Triazoles 
With these results in hand, the scope of the metalation reaction was examined. Thus, various substituted 
aryl triazoles were successfully deprotonated using TMPMgBu (Scheme 45). The metalation of the 
electron-deficient 1-(4-fluorophenyl)-4-(trimethylsilyl)-1H-1,2,3-triazole (115b) proceeded within 1 h 
leading to 86% of the organomagnesium reagent 116b. The unsubstituted phenyl derivative 115c was 
metalated in 4 h affording 72% of the desired metal reagent 116c. The electron-rich 1-(p-tolyl)-4-
(trimethylsilyl)-1H-1,2,3-triazole (115d) required a prolonged metalation time of 6 h furnishing 116d in 
68% yield. Interestingly, the metalation of a 4-methoxy aryl triazole 115e proceeded significantly faster 
(4 h) leading to 116e in 77% yield. This might be explained by the electron-pushing property of the 
methoxy group, which leads to an increased electron density in the triazole moiety, thus facilitating a 
coordination of the TMPMgBu base.116 The metalation of the corresponding meta-methoxy derivative 115f 
and the ortho-fluoro triazole 115g afforded 116f and 116g in 70% and 80% yield, respectively. However, 
                                                          
115 For further details, see: V. Experimental Part, Table 16. 
116 D. W. Slocum, E. A. Maulden, P. E. Whitley, T. K. Reinscheld, C. S. Jackson, J. B. Maddox, Eur. J. Org. Chem. 2017, 
2017, 6882-6884. 




using 4-butyl-1-(4-fluorophenyl)-1H-1,2,3-triazole only afforded mixtures of metalation at the arene and 
the triazole.117  
 
 
Scheme 45: Metalation of various aryl triazole derivatives of type 115. [a] Metalation yields were determined by 1H-NMR analysis 
of D2O-quenched reaction aliquots. Metalation time in brackets;113 [b] Metalation ratio in [%] determined by 1H-NMR analysis of 
D2O-quenched reaction aliquots.113 
 
4.4 Palladium-Catalyzed Cross-Coupling of Arylzinc Reagents derived from Aryl Triazoles  
Next, the applicability of the arylmetal species 116a-g in palladium-catalyzed Negishi-cross-couplings was 
examined (Scheme 46). After transmetalation with ZnCl2, the resulting arylzinc reagent was coupled with 
a (hetero)aryl bromide using 1% PdCl2(dppf). The coupling reactions proceeded smoothly with several 
electron-rich and -deficient aryl bromides furnishing the corresponding products 117a118-e in 75-87% yield. 
Remarkably, the reaction with the sterically demanding 2-bromo naphthalene led to 117f in 74% yield. 
Also, various fluorinated aryl bromides containing a trifluoromethoxy-, pentafluorosulfinyl-, 
trifluoromethyl-, or fluoro-substituent were coupled with various arylzinc reagents affording the desired 
products 117g-j in 70-95% yield. Furthermore, a range of heteroaryl bromides, such as pyridyl-, pyrimidyl-, 
                                                          
117 For unsuccessful substrates see: V. Experimental Part, Scheme 59. 
118 The structure of 117a was confirmed by NOESY-NMR, see, VI. Appendix, 1.2 1-(5-Chloro-4'-methoxy-[1,1'-
biphenyl]-2-yl)-4-(trimethylsilyl)-1H-1,2,3-triazole (117a). 




indolyl-, and various thienyl- and furyl bromides could be used as coupling partners leading to the 
corresponding products 117k-r in 62-96% yield.  
 
 
Scheme 46: Palladium-catalyzed cross-coupling of magnesium reagents of type 116. [c] All yields refer to isolated analytically pure 
compounds; [d] Reaction performed on 5 mmol scale. 




4.5 Metalation of Functionalized Aryl Azoles 
The metalation was extended to other aryl azoles (Scheme 47). Treating 1-(4-chlorophenyl)-3,5-dimethyl-
1H-pyrazole (118a) with TMPMgBu (1.0 equiv) for 1 h afforded 119a in 82% yield. Also, the unsubstituted 
aryl pyrazole 118b was selectively metalated at the aryl moiety leading to the magnesium reagent 119b 
(78% yield). Remarkably, no competitive metalation of the azole ring was observed in any case. 
Furthermore, 2,5-diphenyl-1,3,4-oxadiazole (118c) underwent a selective mono-magnesiation affording 
119c in 76% yield after 2 h metalation time. The metalation of phenyl oxazoline 118d proceeded within 
1 h leading to the metalated substrate 119d (77% yield).  
 
 
Scheme 47: Metalation of various aryl azole derivatives. [a] Metalation yields were determined by 1H-NMR analysis of D2O-
quenched reaction aliquots. Metalation time in brackets;113 [b] No metalation at the heterocycle was observed. 113  
 
4.6 Palladium-Catalyzed Cross-Coupling of Arylzinc reagents derived from Aryl Azoles  
Negishi cross-couplings were performed with metal reagents 119a-d after transmetalation to the 
corresponding arylzincs (Scheme 48). Negishi-cross-couplings starting from reagent 119a afforded the 
compounds 120a-b in 68-95% yield. Substrates containing a 3,5-dimethyl pyrazole group are of special 
interest, since an oxidative removal via ozonolysis affords the corresponding aniline.106g Also, the 
unsubstituted N-aryl pyrazole magnesium reagent 119b was coupled with functionalized aryl bromides 




bearing a tosyl or nitrile group leading to the products 120c and 120d119 in 88-89% yield. The reaction of 
119c with phenyl bromide furnished 2-(1,1'-biphenyl-2-yl)-5-phenyl-1,3,4-oxadiazole (120e) in 80% yield, 
which is a valuable precursor for the synthesis of organic electroluminescent compounds.120 Furthermore, 
a more electron-deficient derivative was synthesized following this procedure leading to 120f in 75% yield. 
Finally, the cross-coupling of 119d led to the corresponding products 120g and 120h121 in 91-96% yield.  
 
 
Scheme 48: Palladium-catalyzed cross-coupling of N-aryl azoles with (hetero)aryl bromides. [c] All yields refer to isolated yields of 
analytically pure compounds.  
 
4.7 Electrophilic Trapping Reactions  
The versatility of the new method was shown by performing various trapping reactions of arylmagnesium 
reagent 116a with several commonly used electrophiles (Scheme 49). Thus, a reaction with I2 afforded 
                                                          
119 The structure of 120d was confirmed by crystal structure analysis, see: VI. Appendix, 3. Single Crystal X-Ray 
Diffraction Studies. 
120 J. Feldmann, K. D. Dobbs, T. C. Gehret, C. D. McLaren, Y. Wang, US 20150236278 A1, 2015. 
121 The structure of 120h was confirmed by crystal structure analysis, see: VI. Appendix, 3. Single Crystal X-Ray 
Diffraction Studies. 




121a in 98% yield. Addition reactions of 116a to benzaldehyde or MeSSO2Me led to the corresponding 
alcohol 121b122 or the thioether 121c in 75-86% yield. Also, a transmetalation with CuCN⋅2LiCl and 
subsequent reaction with benzoyl chloride or an allyl bromide derivative proceeded smoothly furnishing 
the products 121d-e in 62-77% yield.  
 
 
Scheme 49: Trapping of magnesium reagent 116a with various electrophiles. [a] Metalation yields were determined by 1H-NMR 
analysis of D2O-quenched reaction aliquots; 113 [b] All yields refer to isolated yields of analytically pure compounds; [c] I2 (4.3 
equiv); [d] Benzaldehyde (2.5 equiv); [e] MeSSO2Me (2.5 equiv); [f] Transmetalation with CuCN⋅2LiCl (3.0 equiv), then benzoyl 
chloride (2.5 equiv); [g] Transmetalation with CuCN⋅2LiCl (3.0 equiv), then ethyl 2-(bromomethyl) acrylate (2.5 equiv). 
 
4.8 Late-Stage Modifications  
Demonstrating the synthetic utility of the cross-coupling products, various late-stage modifications were 
performed (Scheme 50). Thus, a fluoride mediated desilylation of 117g afforded triazole 122 in 91% yield. 
Treating 117g with TMPMgBu for 2 h in toluene led to the arylmagnesium reagent 123 in 80% yield. After 
transmetalation with ZnCl2 a palladium-catalyzed cross-coupling with 5-bromo-N-methyl indole furnished 
the bis-arylated triazole 124 in 88% yield. Furthermore, the reaction of 117g with 1,3-dibromo-5,5-
dimethylhydantoin (DBDMH) led to the corresponding bromide 125 in 93% yield. A subsequent palladium-
                                                          
122 The structure of 121b was confirmed by crystal structure analysis, see: VI. Appendix, 3. Single Crystal X-Ray 
Diffraction Studies. 




catalyzed Suzuki-cross-coupling of bromide 125 with an aryl boronic acid allows for the smooth 
functionalization of the triazole moiety, affording 126123 in 86% yield. 
 
 
Scheme 50: Late-stage functionalization of 117g. [a] Metalation yields was determined by 1H-NMR analysis of D2O-quenched 
reaction aliquots; 113 All other yields refer to isolated yields of analytically pure compounds. 
 
                                                          







The first part of this thesis was focused on the development of new cobalt-catalyzed reactions using 
functionalized zinc organometallics. A cobalt-catalyzed alkylation of various aryl and heteroaryl halides 
with functionalized primary and secondary alkylzinc reagents was developed. The catalytic system 
comprising an abundant cobalt catalyst and a bipyridyl ligand allowed the mild alkylation of several 
N-heterocyclic halides, such as pyridines, pyrimidines, (iso)quinolines and quinazolines, but also aryl 
halides bearing ester, nitrile or ketone moieties. 1,3- and 1,4-disubstituted cyclohexylzinc reagents 
including complex scaffolds derived from cholesterol or nootkatone were coupled with N-heterocyclic 
halides affording the corresponding products in high diasteroselectivities of up to 98:2 (Scheme 51). 
Furthermore, primary and secondary alkylzinc reagents were successfully coupled with alkynyl halides.  
 
 







Moreover, a cobalt-catalyzed Csp3-Csp3 cross-coupling of functionalized dialkylzinc reagents with various 
primary and secondary alkyl iodides was developed. Dialkylzinc reagents bearing sensitive functionalities, 
were readily prepared via magnesium insertion in the presence of 0.5 equiv ZnCl2. With 1,2-disubstituted 
cyclohexyl iodides the cross-coupling proceeded in a diastereoselective fashion affording the 
corresponding coupling-products with diastereoselectivities up to 89:11. Furthermore, the catalytic 
system allowed the smooth coupling of benzylic and allylic halides (Scheme 52). Mechanistic investigations 
















Also, a cobalt-catalyzed Fukuyama-type acylation of organo S-pyridyl esters with (hetero)aryl zinc pivalates 
was developed. The reaction proceeded with a variety of primary, secondary and tertiary alkyl, benzyl and 
(hetero)aryl S-pyridyl esters, which were readily prepared starting directly from the corresponding 
carboxylic acids under mild reaction conditions. This method avoids the preparation of a transient acyl 
chloride thus enabling a smooth synthesis of polyfunctional ketones. Furthermore, this cobalt-catalyzed 
acylation allow for the synthesis of several optically enriched α-chiral ketones from the corresponding 
enantiopure S-pyridyl esters with very high stereoretention (94% to >99% ee). Additionally, the 
antilipidemic drug fenofibrate was synthesized in a short sequence (Scheme 53). 
 
 











The second part of this thesis dealt with the development of a highly regioselective magnesiation of 
arylazoles using the mixed magnesium amide TMPMgBu. This base allows for the selective deprotonation 
of the aryl moiety circumventing the deprotonation of the more acidic sites at the N-heterocycle. The key 
for a high regioselectivity was the replacement of THF by the non-coordinating hydrocabons toluene and 
hexane as reaction solvents. The metalation proceeds with excellent regioselectivity at various substituted 
aryl 1,2,3-triazoles, pyrazoles, oxadiazoles and oxazolines affording, after transmetalation with ZnCl2 and 
subsequent palladium catalyzed cross-coupling, several mono-arylated N-aryl azoles in high yields 
(Scheme 54). Furthermore, the arylmagnesium reagent was trapped with various electrophiles including 
iodine, thiomethylsulfonate and benzoyl chloride affording functionalized N-aryl azoles  
 
 
Scheme 54: Regioselective magnesiation of various N-aryl azoles and subsequent palladium-catalyzed cross-coupling. 
 
Finally, the versatility of the resulting scaffolds was shown by performing late-stage modifications. Thus, a 
second metalation and subsequent cross-coupling afforded the difunctionalized N-aryl triazole. 
Furthermore, transformation of the TMS-moiety into a bromide followed by Suzuki-cross-coupling enabled 













V. Experimental Part 
1. General Considerations 
All reactions were carried out with magnetic stirring and in dry glassware under an argon atmosphere 
using Schlenk technique. Syringes used to transfer solvents or reagents were purged with argon three 
times prior to use. 
1.1 Solvents 
DCM was predried over CaCl2 and distilled from CaH2.  
DME was predried over CaCl2 and distilled from sodium benzophenone ketyl under argon atmosphere. 
DMF was refluxed over CaH2 (14 h), distilled from CaH2 and stored over 4 Å MS under argon atmosphere. 
DMPU was predried over CaH2 (4 h) and distilled.  
MeCN was purchased from Acros (99.9+% extra dry) 
THF was purchased from Acros (99.5% extra dry, stored over molecular sieve, stabilized) 
Toluene was continuously refluxed and freshly distilled from sodium under nitrogen. 
 
Solvents for column chromatography were distilled prior to use. 
 
1.2 Reagents 
Preparation of ZnCl2 solution in THF (1 M) 
In a dry and and argon flushed Schlenk-flask ZnCl2 (40.9 g, 300 mmol) was dried under high vacuum at 
150 °C for 4 h. After cooling to 25 °C, anhydrous THF was added until a total volume of 300 mL was 
reached. The suspension was left stirring overnight at 25 °C and after 12 h the salts had completely 
dissolved. The stirring was stopped and the solution was left for some hours to become completely clear. 








Preparation of Zn(OPiv)2124 
A dry, tared, 500 mL round-bottomed flask equipped with a magnetic stirring bar and a septum is charged 
with toluene (250 mL, 0.2 m). Pivalic acid (12.5 mL, 11.3 g, 110 mmol, 2.2 equiv) is added to form a colorless 
solution. Zinc oxide (4.07 g, 50 mmol, 1.0 equiv) is added in 1 g portions at 25 °C over 15 min to form a 
colorless suspension. The flask was equipped with a Dean-Stark apparatus (10 mL) wrapped in aluminum 
foil and topped with a reflux condenser (20 cm) and the suspension is stirred under nitrogen at reflux in 
an oil bath for 16 h. A viscous colorless suspension was obtained after 12 h. After cooling to 25 °C, the 
mixture is concentrated by rotary evaporation (50 °C/50 mmHg). The remaining pivalic acid and water 
were removed in vacuo from the reaction mixture using a vacuum line (0.1 mmHg) and a liquid nitrogen 
cold trap (1000 mL). The white solid was warmed to 100 °C in an oil bath and dried for at least 6 h. Zinc 
pivalate (13.1–13.2 g, 48.9–49.7 mmol, 98–99% yield), is obtained as a puffy amorphous white solid. 
 
CuCN·2LiCl solution in THF (1.0 M)125 
LiCl (8.40 g, 200 mmol) and CuCN (8.96 g, 100 mmol) were dried in a Schlenk-flask under high vacuum at 
150 °C for 4 h. After cooling to 25 °C, dry THF was added until a total volume of 100 mL was reached. The 
suspension was left stirring overnight at room temperature until all salts had completely dissolved. The 
solution was stored under argon upon use.  
 
Preparation of iPrMgCl·LiCl126 
Magnesium turnings (2.67 g, 110 mmol) and anhydrous LiCl (4.66 g, 100 mmol) were placed in an argon-
flushed flask and THF (50 mL) was added. A solution of iPrCl (9.13 mL, 100 mmol) in THF (50 mL) was slowly 
added at 25 °C. The reaction starts within a few minutes. After addition, the reaction mixture was stirred 
for 12 h at 25 °C. The grey solution of iPrMgCl·LiCl was cannulated to another flask under argon and 
removed in this way from excess of magnesium. A yield of ca. 95-98% of iPrMgCl·LiCl is obtained. 
 
TMPH, Cy2NH and iPr2NH were distilled from CaH2 under argon prior to use. 
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125 P. Knochel, M. C. P. Yeh, S. C. Berk, J. Talbert, J. Org. Chem. 1988, 53, 2390-2392. 





Preparation of TMPLi 
nBuLi (4 mL, 10 mmol, 2.5 M in hexane) was slowly added to a solution of TMPH (1.7 mL, 10 mmol) in THF 
(10 mL) at −40 °C and stirred for 30 min at −40 °C. 
 
Preparation of TMPMgCl⋅LiCl127 
A dry and argon-flushed 250-mL Schlenk-flask, equipped with a magnetic stirring bar and a septum, was 
charged with freshly titrated iPrMgCl·LiCl (100 mL, 1.2 m in THF, 120 mmol). TMPH (17.8 g, 126 mmol, 1.05 
equiv) was added dropwise at 25 °C. The reaction mixture was stirred at 25 °C until gas evolution ceased 
(ca. 24 h).  
 
Preparation of TMP2Mg 
In a dry and argon-flushed Schlenk-flask, equipped with a magnetic stirring bar and rubber septum, TMPH 
(1.69 ml, 10.00 mmol, 2.00 equiv) was placed and Bu2Mg (7.04 ml, 5.00 mmol, 1.00 equiv, 0.71 M in 
hexane) was added at 0 °C. The mixture was stirred for 48 h at room temperature resulting in a pale yellow 
solution.  
 
Preparation of Cy2NMgBu 
In a dry and argon-flushed Schlenk-flask, equipped with a magnetic stirring bar and rubber septum, 
dicyclohexylamine (1.99 ml, 10.00 mmol, 2.00 equiv) was placed and Bu2Mg (7.04 ml, 5.00 mmol, 1.00 
equiv, 0.71 M in hexane) was added at 0 °C. The mixture was stirred for 48 h at room temperature resulting 
in a pale yellow solution.  
 
Preparation of iPr2NMgBu 
In a dry and argon-flushed Schlenk-flask, equipped with a magnetic stirring bar and rubber septum, 
diisopropylamine (1.41 ml, 10.00 mmol, 2.00 equiv) was placed and Bu2Mg (7.04 ml, 5.00 mmol, 1.00 
equiv, 0.71 M in hexane) was added at 0 °C. The mixture was stirred for 48 h at room temperature resulting 
in a pale yellow solution.  
 
 
                                                          





Preparation of TMPMgBu 
In a dry and argon-flushed Schlenk-flask, equipped with a magnetic stirring bar and rubber septum, TMPH 
(1.18 ml, 7.00 mmol, 1.00 equiv) was placed and Bu2Mg (9.86 ml, 7.00 mmol, 1.00 equiv, 0.71 M in hexane) 
was added at 0 °C. The mixture was stirred for 48 h at room temperature resulting in a pale yellow solution. 
The yield was determined to be 94-98% yield (0.74-0.81 M). 
 
Preparation of the reagent TMP2Zn·2MgCl2·2LiCl24 
A dry and A flame-dried and argon-flushed Schlenk-flask, equipped with a magnetic stirring bar and rubber 
septum, was charged with a solution of TMPMgCl·LiCl (4.35 mL, 5 mmol, 1.00 equiv) and cooled to 0 °C. 
Then, ZnCl2 (2.5 mL, 2.5 mmol, 0.50 equiv) was and the mixture was stirred for 2 h at 0 °C. 
 
The content of organometallic reagent was determined either by the method of Paquette128 using iPrOH 
and 1,10-phen as indicator (organolithium reagents) or the method of Knochel95 using I2 in THF 
(organomagnesium and -zinc reagents). 
 
TMP-Bases were titrated against benzoic acid using 4-(phenylazo)diphenylamine as indicator in THF. 
 
Bu2Mg was titrated against I2 in a 0.5 M solution of LiCl in THF. 
 
1.3 Chromatography 
Flash column chromatography was performed using silica gel 60 (0.040–0.063 mm, 230–400 mesh ASTM) 
from Merck. 
 
Thin layer chromatography was performed using aluminum plates covered with SiO2 (Merck 60, F-254). 
The chromatograms were visualized by UV detection at 254 nm and/or by staining of the TLC-plate with 
one of the solutions given below followed by heating with a heat gun: 
 
- KMnO4 stain: KMnO4 (3.0 g), K2CO3 (20 g), 5% NaOH solution (5.00 mL), water (300 mL). 
- PMA stain: Dissolve 10 g PMA in 100 mL absolute ethanol. 
                                                          





1.4 Analytical Data 
NMR spectra were recorded on Bruker Avance III HD 400 MHz, WH 400 and Bruker AMX 600 instruments. 
Chemical shifts () are reported in parts per million (ppm) relative to the residual solvent peak of CHCl3 ( 
H = 7.26,  C = 77.0), d6-DMSO ( H = 2.50,  C = 39.52) or d6-benzene ( H = 7.16,  C = 128.06). For the 
characterization of the observed signal multiplicities the following abbreviations were used: s (singlet), d 
(doublet), t (triplet), q (quartet), quint (quintet), sept (septet), m (multiplet), br (broad). 
 
Mass spectra and high resolution mass spectra (HRMS) were recorded on a Finnigan MAT 95Q (EI) or a 
Thermo Finnigan LTQ FT instrument (ESI). Electron impact ionization (EI) was conducted with an electron 
energy of 70 eV. Electrospray ionization (ESI) was conducted with an IonMax ion-source equipped with an 
ESI head. It was performed with a voltage of 4 kV at the spray capillary tube, a heating filament 
temperature of 250 °C and a nitrogen flow of 25 units. 
 
Gas Chromatography (GC) was performed with machines of the types Hewlett-Packard 6890 or 5890 
Series II (Hewlett Packard, 5% phenylmethylpolysiloxane; column length: 15 m, diameter: 0.25 mm; film 
thickness: 0.25 m). For the combination of gas chromatography with mass spectroscopic detection, a GC-
MS from Hewlett Packard of type 6890/MSD 5973 was used. 
 
Infrared spectra (IR) were recorded from 4500 cm-1 to 650 cm-1 on a Perkin Elmer Spectrum BX-59343 
instrument. For detection a Smiths Detection Dura SamplIR II Diamond ATR sensor was used. The 
absorption bands (𝜈) are reported in wave numbers (cm-1). 
 
Melting points (m.p.) were measured using a Büchi B-540 apparatus and are uncorrected. 
 
Single Crystal X-Ray Diffraction Studies. Single crystals of the corresponding compounds, suitable for X-
ray diffraction, were obtained by slow evaporation of a DCM, CDCl3 or EtOAc solution. The crystals were 
introduced into perfluorinated oil and a suitable single crystal was carefully mounted on the top of a thin 
glass wire. Data collection was performed with an Oxford Xcalibur 3 diffractometer equipped with a 
Spellman generator (50 kV, 40 mA) and a Kappa CCD detector, operating with Mo-Kα radiation 
(λ = 0.71071 Å). Data collection and data reduction were performed with the CrysAlisPro software.129 
Absorption correction using the multiscan method129 was applied. The structures were solved with 
                                                          





SHELXS-97130, refined with SHELXL-97131 and finally checked using PLATON132. Details for data collection 
and structure refinement are summarized in the appendix section. The single crystal structures are shown 
in DIAMOND109 representation.133  
 
Enantiomeric excess (ee). The enantiomeric excess of optical enriched compounds was determined via 
chiral HPLC analysis on a Shimadzu Prominence 20A HPLC system. For developing a chiral resolution 
method, different chiral normal phase columns were tested with n-heptane and iPrOH as mobile phase 




 values of chiral products were measured in CHCl3 at 20 °C using a wavelength 
λ = 589 nm and a 1 dm cuvette on a Anton Paar MCP 200 instrument. The sample concentration was 
0.01 g/mL and the values are reported in °⋅ml⋅dm-1⋅g-1. 
  
                                                          
130 Sheldrick, G. M. (1997) SHELXS-97: Program for Crystal Structure Solution, University of Göttingen, Germany. 
131 Sheldrick, G. M. (1997) SHELXL-97: Program for the Refinement of Crystal Structures, University of Göttingen, 
Germany. 
132 Spek, A. L. (1999) PLATON: A Multipurpose Crystallographic Tool, Utrecht University, Utrecht, The Netherlands. 





2. Cobalt‐Catalyzed Cross‐Coupling of Functionalized Alkylzinc Reagents with 
(Hetero)Aryl Halides 
2.1 Optimization of the Reaction Conditions 




Cobalt salt CoCl2 
[mol%] 






GC-Yield[a] of 102a 
[%] 
1 CoCl2 10 1.5 THF 0 80 
2 CoBr2 10 1.5 THF 0 78 
3 Co(acac)2 10 1.5 THF 0 79 
4 Co(acac)3 10 1.5 THF 0 71 
5 CoCl2 2.5[b] 1.5 THF 0 51 
6 CoCl2 5.0[c] 1.5 THF 0 73 
7 CoCl2 20[d] 1.5 THF 0 12 
8 CoCl2 10 1.2 THF 0 62 
9 CoCl2 10 1.7 THF 0 81 
10 CoCl2 10 1.5 toluene 0 56 
11 CoCl2 10 1.5 MeCN 0 79 
12 CoCl2 10 1.5 Et2O 0 79 
13 CoCl2 10 1.5 tBuOMe 0 76 
14 CoCl2 10 1.5 THF -10 65 
15 CoCl2 10 1.5 THF 25 50 









Table 11: Further optimization of the reaction conditions for the Diastereoselective formation of 102aa. 
 
Entry catalyst Ligand [mol%] T[°C] solvent dr GC-Yield[a] of 102aa [%] 
1 CoCl2 - 25 THF 40:60 13 
2 CoCl2 neocuproine 25 THF 69:31 6 
3 CoCl2 bipy 25 THF 91:9 33 
4 CoCl2 bipy 0 THF 91:9 24 
5 CoCl2 dtbbpy 25 THF 90:10 28 
6 CoCl2 bipy 25 MeCN 79:21 81 
8 CoCl2 dtbbpy 25 MeCN 91:9 85 
9 NiCl2 dtbbpy 25 THF 88:12 19 
10 NiCl2 dtbbpy 25 MeCN 88:12 29 
11 NiCl2(PPh3)2 - 25 THF 80:20 70 
12 NiCl2(PPh3)2 - 25 MeCN 79:21 76 
[a] Tetradecane (C14H30) was used as internal standard.  
 
2.2 Mechanistic Experiments 
 






To gain an insight into the reaction mechanism, radical-trapping experiments using 2,2,6,6-
tetramethylpiperidine 1-oxyl (TEMPO) were performed. To a standard coupling setup of 6-
chloronicotinonitrile (100a) with (2-(1,3-dioxan-2-yl)ethyl)zinc chloride (101a) various amounts of TEMPO 
were added (entry 2-4). However, the coupling product 102a was obtained in a similar yield, compared to 
the standard conditions without the radical trapping agent. This indicates that the developed cobalt-
catalyzed cross-coupling might not proceed via radical intermediates. 
 
2.3 Selected Unsuccessful Substrates 
 
Scheme 57: Selected unsuccessful substrates for the cobalt-catalyzed cross-coupling. 
 
2.4 Preparation of Starting Materials 
(1R,5S)-2-(2-bromoethyl)-6,6-dimethylbicyclo[3.1.1]hept-2-ene134 
 
The title compound was prepared according to literature procedure from (1R)-(−)-nopol (6.7 mL, 40 mmol) 
affording (1R,5S)-2-(2-bromoethyl)-6,6-dimethylbicyclo[3.1.1]hept-2-ene as pale yellow oil (8.25 g, 
36.0 mmol, 90 %). The analytical data is in full consistency with the data reported in the literature. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 5.32 (tq, J = 2.9, 1.5 Hz, 1H), 3.36 (td, J = 7.7, 3.8 Hz, 2H), 2.56 – 2.48 
(m, 2H), 2.37 (dt, J = 8.6, 5.6 Hz, 1H), 2.31 – 2.15 (m, 2H), 2.09 (ttd, J = 5.8, 2.8, 1.3 Hz, 1H), 2.01 (td, J = 5.6, 
1.5 Hz, 1H), 1.27 (s, 3H), 1.17 (d, J = 8.6 Hz, 1H), 0.83 (s, 3H). 
 
                                                          







The title compound was prepared according to literature procedure from (4-(trimethylsilyl)-3-butyn-1-ol 
(3.00 g, 21 mmol), affording (4-bromobut-1-yn-1-yl)trimethylsilane as a colorless liquid (3.10 g, 16.0 mmol, 
76 %). The analytical data is in full consistency with the data reported in the literature. 




The title compound was prepared according to literature procedure from 3-bromopropylammonium 
bromide (5.00 g, 22.8 mmol) affording 1-(3-bromopropyl)-2,5-dimethyl-1H-pyrrole as a yellow oil (2.50 g, 
11.6 mmol, 54 %). The analytical data is in full consistency with the data reported in the literature. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 5.77 (s, 2 H), 3.95 – 3.88 (m, 2 H,), 3.42 (m, 2 H), 2.24 (s, 6 H), 




The title compound was prepared according to literature procedure from 2-(thiophen-3-yl)ethan-1-ol 
(2.56 g, 20 mmol), affording 3-(2-bromoethyl)thiophene as a colorless liquid (2.75 g, 14.4 mmol, 72 %). 
The analytical data is in full consistency with the data reported in the literature. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.29 (dd, J = 4.9, 2.9 Hz, 1H), 7.07 (d, J = 2.9 Hz, 1H), 6.98 (d, J = 4.9 Hz, 





                                                          
135 H. M. Wisniewska, E. C. Swift, E. R. Jarvo, J. Am. Chem. Soc. 2013, 135, 9083–9090. 
136 S. P. Bruekelman, S. E. Leach, G. D. Meakins, M. D. Tirel, J. Chem. Soc. Perkin Trans. 1 1984, 2801–2807. 





Preparation of cyclohexyl Iodides TP1138 
A dry round bottom flask equipped with a magnetic stirring bar was charged with I2 (1.20 equiv) which was 
dissolved in CH2Cl2 (0.5 m) and cooled to 0 °C. PPh3 (1.10 equiv) was carefully added at this temperature. 
The resulting suspension was stirred for 1.5 h. Then, N-methylimidazole (1.25 equiv) was added. After 
10 min of stirring, the respective cyclohexanol (1.00 equiv) was added. The reaction mixture was stirred 
for another 4 h, was allowed to warm to rt and stirred overnight. The reaction mixture was quenched with 
sat. aqueous Na2S2O3 solution. The phases were separated and the aqueous layer was extracted 3x with 
CH2Cl2. The combined organic layers were washed with brine and dried over Na2SO4. The solvents were 





1-Iodo-3-methylcyclohexane was prepared according to TP1 from 3-methylcyclohexanol (4.56 g, 40 mmol) 
and was obtained as a pale pink oil (6.05 g, 27 mmol, 68% yield). The analytical data is in full consistency 
with the data reported in the literature. 78h 
1H-NMR (400 MHz, CDCl3, ppm): δ = 4.91 – 4.79 (m, 1H), 4.15 (tt, J = 12.3, 4.0 Hz, 0.5H), 2.40 (ttq, J = 10.9, 




1-Iodo-3-isopropylcyclohexane was prepared according to TP1 from 3-isopropylcyclohexanol (12.1 g, 
85 mmol), which was prepared according to literature procedure139 and was obtained as a colorless oil 
(15.1 g, 60 mmol, 70%) The analytical data is in full consistency with the data reported in the literature. 69a 
1H-NMR (400 MHz, CDCl3, ppm): δ = 4.93 (qt, J = 3.3, 2.0 Hz, 1H), 2.05 (ddtt, J = 14.5, 10.5, 3.5, 1.8 Hz, 2H), 
1.81– 1.58 (m, 5H), 1.53 – 1.38 (m, 2H), 1.29 (ddd, J = 14.4, 11.0, 3.4 Hz, 1H), 1.13 – 1.00 (m, 1H), 0.87 (s, 
4H), 0.85 (s, 3H). 
 
                                                          
138 G. L. Lange, C. Gottardo, Synth. Commun. 1990, 20, 1473-1479. 
139 T. Thaler, B. Haag, A. Gavryushin, K. Schober, E. Hartmann, R. M. Gschwind, H. Zipse, P. Mayer, P. Knochel Nat. 







Ethyl 4-iodocyclohexane-1-carboxylate was prepared according to TP1 from ethyl 4-hydroxycyclohexane-
1-carboxylate (2.15 g, 12.5 mmol) and was obtained as a colorless oil (2.39 g, 8.5 mmol, 68% yield). The 
analytical data is in full consistency with the data reported in the literature.140 
1H-NMR (400 MHz, CDCl3, ppm): δ = 5.66 (s, 1H), 4.14 – 3.96 (m, 2H), 2.54 – 2.42 (m, 2H), 2.41 – 2.28 (m, 




1-(4-Iodocyclohexyl)-1H-pyrrole was prepared according to TP1 from 4-(1H-pyrrol-1-yl)cyclohexan-1-ol 
(6.60 g, 40.0 mmol), which was prepared according to literature procedure141 from 4-aminocyclohexan-1-
ol. 1-(4-iodocyclohexyl)-1H-pyrrole and was obtained as colorless crystals (6.08 g, 22.1 mmol, 55% yield). 
Purification: ihexane:ethyl acetate = 95:5. 
m.p.: 51.0 – 52.7 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 6.81 (t, J = 2.1 Hz, 2H), 6.20 (t, J = 2.1 Hz, 2H), 4.90 – 4.80 (m, 1H), 
3.92 (tt, J = 11.7, 3.9 Hz, 1H), 2.38 – 2.13 (m, 4H), 2.11 – 1.95 (m, 2H), 1.82 – 1.65 (m, 2H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 118.6, 107.8, 57.6, 35.8, 33.2, 30.6. 
FT-IR (ATR, cm-1): 𝜈 = 2945, 2934, 2832, 1490, 1438, 1428, 1410, 1346, 1392, 1276, 1258, 1238, 1214, 
1188, 1160, 1088, 1068, 1054, 1021, 1005, 961, 904, 875, 864, 820, 772, 723, 712, 697. 
MS (EI, 70 eV): m/z (%) = 275 (31), 149 (11), 148 (100), 120 (11), 118 (16), 106 (10), 81 (31), 80 (17), 79 
(27), 68 (16). 






                                                          
140 K. Moriya and P. Knochel Org Lett. 2014, 16, 924-927. 







1-Iodo-4-(trifluoromethyl)cyclohexane was prepared according to TP1 from ethyl 4-
(trifluoromethyl)cyclohexan-1-ol (1.00 g, 6.00 mmol) and was obtained as a colorless oil (750 mg, 
2.74 mmol, 46% yield). The analytical data is in full consistency with the data reported in the literature. 78h 
1H-NMR (400 MHz, CDCl3, ppm): δ = 4.74 (p, J = 3.4 Hz, 1H), 2.17 – 2.06 (m, 2H), 2.05 – 1.89 (m, 1H), 1.90 




(4-Iodocyclohexyl)benzene was prepared according to TP1 from (4-hydroxycyclohexyl)benzene (3.5 g, 
20.0 mmol) and was obtained as colorless crystals (5.31g, 18.6 mmol, 90%). The analytical data is in full 
consistency with the data reported in the literature. 78h 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.37 – 6.99 (m, 5H), 2.49 (dddd, J = 15.4, 11.8, 7.5, 3.6 Hz, 1H), 2.11 




(+)-Nootkatone (20.0 mmol, 4.40 g) and Pd/C (10%, 700 mg) were suspended in EtOAc (35 mL) in a 250 mL 
round-bottom flask charged with a stirring bar. A H2 balloon was attached to the flask was stirred for 72 h 
until full reduction of the olefinic double bonds was detected according to GC-MS and NMR analysis of a 
crude reaction aliquot. The reaction mixture was filtered through a short silica plug using EtOAc as eluent. 
After solvent evaporation the obtained pale yellow oil was dissolved in MeOH (50 mL), cooled to 0 °C, 
NaBH4 was added portion wise and the reaction mixture was stirred overnight. The reaction mixture was 
quenched with HCl (1.00 m) and extracted with DCM. After solvent evaporation the crude product was 
purified by a short silica column (9:1 hexanes/EtOAc), affording the corresponding alcohol as a colorless 
oil. (1S,2S,4aS,8aS)-6-Iodo-2-isopropyl-1,8a-dimethyldecahydronaphthalene was prepared according to 
TP1 from the corresponding alcohol and was obtained as pink oil (14.8 mmol, 4.95 g, 75% over 3 steps). 





1H-NMR (400 MHz, CDCl3, ppm): δ = 4.88 (tt, J = 4.0, 2.1 Hz, 1H), 1.72 (ddt, J = 13.8, 10.3, 3.2 Hz, 2H), 1.67– 
1.54 (m, 4H), 1.40 – 1.10 (m, 6H), 0.98 (ddt, J = 14.3, 12.3, 5.2 Hz, 1H), 0.79 (dd, J = 6.8, 4.3 Hz, 6H), 0.75 




The title compound was prepared according to literature procedure from ethynylbenzene (306 mg, 
3.00 mmol), affording (bromoethynyl)benzene as a pale yellow liquid (467 mg, 2.58 mmol, 86%). The 
analytical data is in full consistency with the data reported in the literature. 




The title compound was prepared according to literature procedure from ethynyltriisopropylsilane 
(546 mg, 3.00 mmol), affording (bromoethynyl)triisopropylsilane as a colorless oil (734 mg, 2.80 mmol, 
93%). The analytical data is in full consistency with the data reported in the literature. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 1.07 (s, 21H). 
  
                                                          





2.5 Preparation of Organometallic Reagents 
Preparation of alkylzinc reagents via magnesium insertion and subsequent transmetalation (TP2):16a 
Dry LiCl (1.2 equiv.) was placed in a dry and argon flushed 50 mL Schlenk-tube equipped with a magnetic 
stirring bar and a septum and was dried over 5 min at 300 °C under high vacuum (0.1 mbar). Magnesium 
turnings (1.2 equiv.) were added followed by dry THF (1.00 m solution relating to the aryl halide) and the 
respective alkyl bromide (1.0 equiv.). After the exothermic reaction started, the mixture was cooled with 
an ice bath. To monitor the progress of the insertion reaction, reaction aliquots quenched with iodine were 
analyzed as water-quenched samples by GC-analysis. When the insertion was completed, the 
concentrations of the magnesium reagent were determined via titration of a small aliquot with I2 (50 mg 
in 2 mL THF). A ZnCl2 solution (1.00 m in THF, 1.0 equiv.) was added at 0 °C and stirred at ambient 
temperature for 15 min affording the corresponding alkylzinc chloride. 
 
Preparation of alkylzinc halides via zinc insertion (TP3): 10,69b 
Dry LiCl (1.5 equiv.) was placed in a dry and argon flushed 25 mL Schlenk-tube equipped with a magnetic 
stirring bar and a septum, was dried over 5 min at 300 °C under high vacuum (0.1 mbar). Zn powder (3.0 
equiv.) was added under argon and the heterogeneous mixture of Zn and LiCl was dried one more time at 
300 °C for 5 min under high vacuum. The reaction flask was evacuated and refilled with argon three times. 
THF (1.00 m solution relating to the alkyl iodide) and 1,2-dibromoethane (0.05 equiv.) were added. The 
mixture was then gently heated in order to activate the Zn surface. TMSCl (0.05 equiv.) was added and the 
reaction mixture was again gently heated. 
The respective primary alkyl bromide or cyclohexyl iodide (1.0 equiv.) was added neat at rt in one portion. 
The resulting reaction mixture was stirred until full consumption of the alkyl halide, in case of the primary 
alkyl bromides the insertion reaction was stirred at 50°C. To monitor the progress of the insertion reaction, 
reaction aliquots quenched with iodine and quenched with sat. aqueous. NH4Cl were analyzed by GC-
analysis. When the insertion was completed the solution was then filtered from the remaining Zn powder 
via syringe filter (30 mm with 0.45 μm glass fiber membrane) and transferred to a dry argon flushed 
Schlenk-tube. The concentrations of all cyclohexylzinc reagents were determined via titration of a small 







2.6 Cobalt-Catalyzed Cross-Coupling of Polyfunctional Alkylzinc Reagents with (Hetero)Aryl Halides 
Cobalt-catalyzed acylation of arylzinc pivalates with thiopyridyl esters (TP4):  
A dry and argon flushed Schlenk-tube, equipped with a magnetic stir bar and a septum was charged with 
dry CoCl2 (6.5 mg, 0.05 mmol, 10 mol%), which was dried at 300 °C under high vacuum prior to use.  
A) For primary alkylzinc spezies: 
Bipyridine (17 mg, 0.1 mmol, 20 mol%) the respective (hetero)aryl halide (0.5 mmol, 1.0 equiv.) and dry 
THF (1.0 mL) were added. The reaction mixture was cooled to 0 °C with an ice bath and a solution of the 
appropriate alkylzinc halide (0.75 mmol, 1.5 equiv.) was added via syringe. 
B) For secondary alkylzinc spezies: 
4,4'-Di-tert-butyl-2,2'-bipyridine (27 mg, 0.1, 20 mol), the respective (hetero)aryl halide (0.5 mmol, 1.0 
equiv.) and dry MeCN (1.0 mL) were added (for the synthesis of 102x and 102y the reaction was performed 
in THF). The appropriate alkylzinc halide (0.75 mmol, 1.5 equiv.) was added via syringe at room 
temperature.  
In both cases the reaction was stirred for 16 h at room temperature. The solvent was removed and the 





Following TP4-A 6-chloronicotinonitrile (1a, 138 mg, 1.00 mmol, 1.0 equiv.) was coupled with (2-(1,3-
dioxan-2-yl)ethyl)zinc chloride (2a, 1.50 mmol, 1.5 equiv.) prepared according to TP2 from the 
corresponding bromide.  
Isolated yield: 163 mg, 0.75 mmol, 75%, white solid. 
Purification: pentane:ethyl acetate = 7:3. 
m.p.: 100.1 – 102.7 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.73 (dd, J = 2.2, 0.9 Hz, 1H), 7.78 (dd, J = 8.1, 2.2 Hz, 1H), 7.38 – 6.90 
(m, 1H), 4.50 (t, J = 5.0 Hz, 1H), 4.03 (ddt, J = 10.5, 4.9, 1.4 Hz, 2H), 3.80 – 3.52 (m, 2H), 3.00 – 2.76 (m, 2H), 
2.18 – 1.89 (m, 3H), 1.28 (dtt, J = 13.5, 2.6, 1.4 Hz, 1H). 






FT-IR (ATR, cm-1): 𝜈 = 2966, 2934, 2865, 227, 1979, 1596, 156, 1492, 1474, 1453, 1424, 1381, 1318, 1290, 
1266, 1241, 1191, 1138, 1121, 1070, 1040, 1029, 998, 952, 943, 926, 888, 865, 856, 834, 758, 668. 
MS (EI, 70 eV): m/z (%) = 217 (12), 159 (49), 143 (13), 132 (25), 131 (96), 118 (31), 101 (20), 87 (100). 




Following TP4-A 6-chloronicotinonitrile (1a, 69 mg, 0.50 mmol, 1.0 equiv.) was coupled with (3-
phenylpropyl)zinc chloride (0.75 mmol, 1.5 equiv.) prepared according to TP2 from the corresponding 
bromide.  
Isolated yield: 81 mg, 0.36 mmol, 73%, white solid. 
Purification: i-hexane:ethyl acetate = 8:2. 
m.p.: 62.3 – 64.1 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.87 – 8.74 (m, 1H), 7.84 (dd, J = 8.1, 2.2 Hz, 1H), 7.33 – 7.19 (m, 3H), 
7.20 – 7.16 (m, 3H), 2.96 – 2.83 (m, 2H), 2.69 (t, J = 7.6 Hz, 2H), 2.09 (p, J = 7.7 Hz, 2H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 166.8, 152.3, 141.6, 139.4, 128.6, 128.6, 126.1, 123.0, 117.1, 107.3, 
38.2, 35.5, 30.9. 
FT-IR (ATR, cm-1): 𝜈 = 3045, 3021, 2946, 2922, 2858, 2229, 1594, 1553, 1495, 1484, 1452, 1387, 1316, 
1289, 1204, 1187, 1156, 1129, 1076, 1043, 1027, 1017, 934, 914, 868, 849, 827, 750, 700, 677. 
MS (EI, 70 eV): m/z (%) = 223 (1), 131 (3), 119 (8), 118 (100), 117 (1), 91 (5). 




Following TP4-A 6-bromonicotinonitrile (92 mg, 0.50 mmol, 1.0 equiv.) was coupled with (2-((1R,4R)-5,5-
dimethylbicyclo[2.1.1]hex-2-en-2-yl)ethyl)zinc chloride (0.75 mmol, 1.5 equiv.) prepared according to TP2 
from the corresponding bromide.  
Isolated yield: 98 mg, 0.39 mmol, 78%, red crystals. 
Purification: i-hexane:ethyl acetate = 9:1. 





1H-NMR (400 MHz, CDCl3, ppm): δ = 8.79 (dd, J = 2.2, 0.9 Hz, 1H), 7.85 (dd, J = 8.1, 2.2 Hz, 1H), 7.30 – 7.26 
(m, 1H), 5.23 (tp, J = 3.0, 1.4 Hz, 1H), 2.98 – 2.86 (m, 2H), 2.44 – 2.31 (m, 3H), 2.30 – 2.12 (m, 3H), 2.11 – 
2.02 (m, 2H), 1.27 (s, 3H), 1.10 (d, J = 8.5 Hz, 1H), 0.80 (s, 3H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 166.8, 152.1, 146.8, 139.5, 123.0, 117.2, 117.1, 107.3, 45.9, 40.8, 4.1, 
36.6, 36.4, 31.7, 31.7, 26.4, 21.3. 
FT-IR (ATR, cm-1): 𝜈 = 2975 , 2925, 2834, 2231, 1595, 1554, 1482, 1447, 1382, 1364, 1338, 1304, 1264, 
1202, 1119, 1098, 1025, 1003, 936, 886, 862, 838, 806, 725. 
MS (EI, 70 eV): m/z (%) = 252 (5), 251 (6), 237 (7), 223 (7), 211 (5), 209 (52), 207 (7), 184 (13), 183 
(100), 181 (7). 
HR-MS (EI, 70eV): [C17H19N2], calcd.: 251.1548; found: 251.1539.  
Optical rotation: [α]D




Following TP4-A 6-bromonicotinonitrile (92 mg 0.50 mmol, 1.0 equiv.) was coupled with (4-
(trimethylsilyl)but-3-yn-1-yl)zinc chloride (0.75 mmol, 1.5 equiv.) prepared according to TP2 from the 
corresponding bromide.  
Isolated yield: 71 mg, 0.31 mmol, 62%, yellow solid. 
Purification: i-hexane:ethyl acetate = 8:2. 
m.p.: 70.0 – 71.2 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.81 (dd, J = 2.3, 0.9 Hz, 1H), 7.87 (dd, J = 8.1, 2.2 Hz, 1H), 7.35 (dd, 
J = 8.1, 1.0 Hz, 1H), 3.05 (t, J = 7.2 Hz, 2H), 2.67 (t, J = 7.2 Hz, 2H), 0.09 (s, 9H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 164.6, 152.3, 139.2, 123.5, 117.0, 107.8, 105.3, 86.4, 37.4, 19.7, 0.1. 
FT-IR (ATR, cm-1): 𝜈 = 2925, 2231, 2172, 1591, 1551, 1482, 1434, 1384, 1242, 1048, 1025, 999, 843, 757, 
699. 
MS (EI, 70 eV): m/z (%) = 229 (3), 228 (11), 227 (93), 213 (59), 157 (12), 156 (11), 155 (100). 











Following TP4-A using CoCl2 (13 mg, 0.1 mmol, 20 mol%) and bipyridine (31 mg, 0.2 mmol, 40 mol%), 2-
bromo-5-(trifluoromethyl)pyridine (113 mg, 0.50 mmol, 1.0 equiv.) was coupled with (3-cyanopropyl)zinc 
bromide (0.95 mmol, 1.9 equiv.) prepared according to TP3 from the corresponding bromide.  
Isolated yield: 93 mg, 0.43 mmol, 87%, colorless oil. 
Purification: i-hexane:ethyl acetate = 7:3 to 6:4. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.92 – 8.73 (m, 1H), 7.86 (dd, J = 8.2, 2.4 Hz, 1H), 7.32 (d, J = 8.1 Hz, 
1H), 3.03 (t, J = 7.4 Hz, 2H), 2.44 (t, J = 7.1 Hz, 2H), 2.17 (p, J = 7.2 Hz, 2H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 8.92 – 8.73 (m, 1H), 7.86 (dd, J = 8.2, 2.4 Hz, 1H), 7.32 (d, J = 8.1 Hz, 
1H), 3.03 (t, J = 7.4 Hz, 2H), 2.44 (t, J = 7.1 Hz, 2H), 2.17 (p, J = 7.2 Hz, 2H). 
FT-IR (ATR, cm-1): 𝜈 = 2940, 2247, 1608, 1574, 1496, 1430, 1396, 1325, 1166, 1121, 1079, 1017, 940, 854, 
750. 
MS (EI, 70 eV): m/z (%) = 175 (4), 174 (41), 161 (100), 147 (5), 146 (5), 141 (3), 126 (3). 




Following TP4-A 2-bromo-5-(trifluoromethyl)pyridine (113 mg, 0.50 mmol, 1.0 equiv.) was coupled with 
(3-(2,5-dimethyl-1H-pyrrol-1-yl)propyl)zinc chloride (0.75 mmol, 1.5 equiv.) prepared according to TP2 
from the corresponding bromide.  
Isolated yield: 107 mg, 0.38 mmol, 76%, brown oil. 
Purification: i-hexane:ethyl acetate = 8:2. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.80 (dt, J = 2.0, 1.0 Hz, 1H), 7.89 – 7.80 (m, 1H), 7.28 (d, J = 8.2 Hz, 
1H), 5.76 (s, 2H), 3.88 – 3.77 (m, 2H), 2.92 (t, J = 7.7 Hz, 2H), 2.20 (s, 6H), 2.18 – 2.04 (m, 2H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 164.8, 146.1 (q, J = 4.1 Hz), 133.7 (q, J = 3.5 Hz), 127.4, 124.5 (q, J = 
33.0 Hz), 123.6 (q, J = 272.0 Hz), 122.6, 105.3, 43.0, 35.2, 30.1, 12.5. 
FT-IR (ATR, cm-1): 𝜈 = 2933, 2575, 1608, 1573, 1395, 1332, 1161, 1128, 1081, 1017, 853, 750. 
MS (EI, 70 eV): m/z (%) = 282 (42), 189 (11), 188 (100), 187 (43), 186 (25), 178 (9), 174 





HR-MS (EI, 70eV): [C15H17F3N2], calcd.: 282.1344; found: 282.1335. 
 
Ethyl 6-(4-acetoxybutyl)nicotinate (102g) 
 
Following TP4-A using CoCl2 (13 mg, 0.1 mmol, 20 mol%) and bipyridine (31 mg, 0.2 mmol, 40 mol%), ethyl 
6-chloronicotinate (93 mg, 0.50 mmol, 1.0 equiv.) was coupled with (4-acetoxybutyl)zinc bromide 
(0.95 mmol, 1.9 equiv.) prepared according to TP3 from the corresponding bromide.  
Isolated yield: 87 mg, 0.33 mmol, 66%, colorless oil. 
Purification: i-hexane:ethyl acetate = 1:1. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 9.13 (dd, J = 2.3, 0.9 Hz, 1H), 8.20 (dd, J = 8.1, 2.2 Hz, 1H), 7.25 – 7.20 
(m, 1H), 4.40 (q, J = 7.1 Hz, 2H), 4.08 (t, J = 6.5 Hz, 2H), 2.96 – 2.83 (m, 2H), 2.03 (s, 3H), 1.89 – 1.77 (m, 
2H), 1.76 – 1.63 (m, 2H), 1.40 (t, J = 7.1 Hz, 3H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 171.3, 166.3, 165.6, 150.7, 137.6, 124.1, 122.5, 64.3, 6.4, 38.1, 28.4, 
26.1, 21.2, 14.4. 
FT-IR (ATR, cm-1): 𝜈 = 2955, 1718, 1598, 1568, 1464, 1385, 1366, 1278, 1234, 1173, 1112, 1026, 855, 763. 
MS (EI, 70 eV): m/z (%) = 206 (33), 192 (23), 178 (100), 165 (72), 164 (45), 150 (40), 137 (87). 
HR-MS (EI, 70eV): [C14H20NO4], calcd.: 266.1387; found: 266.1383 [M++H].  
 
Ethyl 6-(2-((1R,4R)-5,5-dimethylbicyclo[2.1.1]hex-2-en-2-yl)ethyl)nicotinate (102h) 
 
Following TP4-A ethyl 6-chloronicotinate (93 mg, 0.50 mmol, 1.0 equiv.) was coupled with (2-((1R,4R)-5,5-
dimethylbicyclo[2.1.1]hex-2-en-2-yl)ethyl)zinc chloride (0.75 mmol, 1.5 equiv.) prepared according to TP2 
from the corresponding bromide.  
Isolated yield: 108 mg, 0.36 mmol, 72%, yellow oil. 
Purification: i-hexane:ethyl acetate = 9:1. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 9.12 (dd, J = 2.3, 0.8 Hz, 1H), 8.22 (dd, J = 8.1, 2.2 Hz, 1H), 7.29 – 7.22 
(m, 1H), 5.23 (tt, J = 3.0, 1.5 Hz, 1H), 4.39 (q, J = 7.1 Hz, 2H), 2.99 – 2.89 (m, 2H), 2.45 – 2.30 (m, 3H), 2.28 
– 2.10 (m, 2H), 2.10 – 2.01 (m, 2H), 1.40 (t, J = 7.1 Hz, 3H), 1.26 (s, 3H), 1.11 (d, J = 8.5 Hz, 1H), 0.80 (s, 3H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 166.4, 165.4, 150.0, 147.1, 138.0, 124.2, 122.8, 117.0, 61.5, 45.8, 





FT-IR (ATR, cm-1): 𝜈 = 2982, 2913, 2831, 1678, 1619, 1600, 1563, 1504, 1468, 1427, 1381, 1364, 1312, 
1319, 1264, 1220, 1140, 1115, 1082, 1016, 954, 886, 869, 824, 782, 753. 
MS (EI, 70 eV): m/z (%) = 299 (10), 298 (10), 284 (15), 270 (20), 258 (13), 256 (31), 231 (13), 230 (100), 
228 (36), 216 (15), 204 (12), 203 (11), 202 (84), 188 (13), 174 (11), 165 (60), 150 (10), 137 (62), 91 (12). 
HR-MS (EI, 70eV): [C19H25NO2], calcd.: 299.1885; found: 299.1885.  
Optical rotation: [α]D
20 = - 23 (c 1.35, CHCl3). 
 
Ethyl (S)-6-(3,7-dimethyloct-6-en-1-yl)nicotinate (102i) 
 
Following TP4-A ethyl 6-chloronicotinate (93 mg, 0.50 mmol, 1.0 equiv.) was coupled with (R)-(3,7-
dimethyloct-6-en-1-yl)zinc chloride (0.75 mmol, 1.5 equiv.) prepared according to TP2 from the 
corresponding bromide.  
Isolated yield: 120 mg, 0.42 mmol, 83%, colorless oil. 
Purification: i-hexane:ethyl acetate = 95:5. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 9.18 – 9.04 (m, 1H), 8.18 (dd, J = 8.1, 2.1 Hz, 1H), 7.22 (d, J = 8.1 Hz, 
1H), 5.15 – 5.01 (m, 1H), 4.39 (q, J = 7.1 Hz, 2H), 2.85 (qdd, J = 13.8, 10.1, 5.6 Hz, 2H), 2.10 – 1.84 (m, 2H), 
1.74 (ddq, J = 15.2, 9.6, 5.0, 4.5 Hz, 1H), 1.67 (s, 3H), 1.58 (s, 3H), 1.56 – 1.44 (m, 1H), 1.39 (t, J = 7.1 Hz, 
4H), 1.44 – 1.33 (m, 1H), 1.19 (dddd, J = 18.8, 11.6, 9.3, 4.3 Hz, 1H), 0.95 (d, J = 6.3 Hz, 3H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 167.5, 165.6, 150.6, 137.5, 131.4, 124.9, 123.9, 122.4, 61.4, 37.1, 
37.0, 36.3, 32.5, 25.9, 25.6, 19.6, 17.8, 14.4. 
FT-IR (ATR, cm-1): 𝜈 = 2961, 1719, 1598, 1568, 1462, 1380, 1368, 1276, 1173, 1112, 1027, 972, 856, 773, 
736. 
MS (EI, 70 eV): m/z (%) = 260 (4), 246 (31), 206 (7), 178 (37), 165 (100), 150 (17), 137 (40). 
HR-MS (EI, 70eV): [C16H22NO2], calcd.: 260.1651; found: 260.1647 [M+-Et].  
Optical rotation: [α]D











Ethyl 2-(2-(thiophen-3-yl)ethyl)nicotinate (102j) 
 
Following TP4-A ethyl 2-chloronicotinate (93 mg, 0.50 mmol, 1.0 equiv.) was coupled with (2-(thiophen-3-
yl)ethyl)zinc chloride (0.75 mmol, 1.5 equiv.) prepared according to TP2 from the corresponding bromide.  
Isolated yield: 111 mg, 0.42 mmol, 85%, pale yellow oil. 
Purification: i-hexane:ethyl acetate = 8:2. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.68 (dd, J = 4.9, 1.8 Hz, 1H), 8.27 – 8.18 (m, 1H), 7.32 – 7.27 (m, 1H), 
7.24 (dd, J = 4.9, 2.9 Hz, 1H), 7.04 – 6.95 (m, 2H), 4.38 (q, J = 7.1 Hz, 2H), 3.57 – 3.46 (m, 2H), 3.14 – 3.04 
(m, 2H), 1.39 (t, J = 7.1 Hz, 3H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 165.9, 161.7, 150.6, 141.6, 139.8, 128.4, 126.4, 125.3, 121.5, 120.7, 
61.7, 30.4, 27.1, 14.3. 
FT-IR (ATR, cm-1): 𝜈 = 2982, 2118, 1714.2, 1587, 1568, 1439, 1389, 1366, 1277, 1249, 1198, 1171, 1125, 
1080, 1062, 1018, 934, 858, 840, 828, 779, 741, 686, 664. 
MS (EI, 70 eV): m/z (%) = 262 (12), 261 (62), 233 (18), 232 (100), 215 (14), 213 (23), 187 (18), 186 (2), 
97 (92), 79 (15), 57 (13), 53 (23), 45 (16), 43 (17). 
HR-MS (EI, 70eV): [C12H10NO2S], calcd.: 232.0423; found: 232.0414 [M+-Et].  
 
Methyl 2-(4-(trimethylsilyl)but-3-yn-1-yl)nicotinate (102k) 
 
Following TP4-A methyl 2-chloronicotinate (93 mg, 0.50 mmol, 1.0 equiv.) was coupled with with (4-
(trimethylsilyl)but-3-yn-1-yl)zinc chloride (0.75 mmol, 1.5 equiv.) prepared according to TP2 from the 
corresponding bromide.  
Isolated yield: 108 mg, 0.41 mmol, 83%, yellow oil 
Purification: i-hexane:ethyl acetate = 8:2. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.69 – 8.62 (m, 1H), 8.23 – 8.13 (m, 1H), 7.25 – 7.22 (m, 1H), 3.93 (s, 
3H), 3.44 (t, J = 7.6 Hz, 2H), 2.70 (t, J = 7.6 Hz, 2H), 0.10 (d, J = 1.0 Hz, 9H). 






FT-IR (ATR, cm-1): 𝜈 = 2955, 2175, 1726, 1584, 1569, 1431, 1279, 1248, 1190, 1132, 1082, 1066, 1042, 
1000, 964, 886, 838, 758, 698, 664. 
MS (EI, 70 eV): m/z (%) = 261 (13), 260 (100), 246 (63), 216 (19), 214 (15), 188 (74), 186 (11), 156 (11), 142 
(18). 




Following TP4-A 2-bromoquinoline (104 mg, 0.50 mmol, 1.0 equiv.) was coupled with (2-(1,3-dioxan-2-
yl)ethyl)zinc chloride (101a, 0.75 mmol, 1.5 equiv.) prepared according to TP2 from the corresponding 
bromide.  
Isolated yield: 115 mg, 0.47 mmol, 95%, colorless crystals. 
m.p.: 54.8 – 56.7 °C 
Purification: i-hexane:ethyl acetate = 7:3. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.03 (dd, J = 8.5, 1.8 Hz, 2H), 7.79 – 7.73 (m, 1H), 7.70 – 7.61 (m, 1H), 
7.46 (t, J = 7.7 Hz, 1H), 7.28 (d, J = 8.4 Hz, 1H), 4.59 (t, J = 5.2 Hz, 1H), 4.10 (dd, J = 11.4, 4.9 Hz, 2H), 3.73 
(td, J = 12.4, 2.5 Hz, 2H), 3.14 – 3.00 (m, 2H), 2.23 – 1.98 (m, 3H), 1.31 (ddt, J = 13.6, 3.1, 1.5 Hz, 1H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 162.0, 148.0, 136.3, 129.4, 129.0, 127.5, 126.8, 125.8, 121.6, 101.6, 
67.0, 34.8, 33.5, 25.9. 
FT-IR (ATR, cm-1): 𝜈 = 2971, 2922, 2856, 1732, 1618, 1601, 1563, 1505, 1469, 1444, 1426, 1407, 1380, 
1292, 1247, 1213, 1198, 1144, 1082, 1055, 1044, 998, 964, 942, 922, 905, 886, 850, 822, 788, 766, 741. 
MS (EI, 70 eV): m/z (%) = 242 (2), 158 (12), 156 (51), 144 (11), 143 (100), 128 (12). 




Following TP4-A 2-bromoquinoline (104 mg, 0.50 mmol, 1.0 equiv.) or 2-chloroquinoline (82 mg, 
0.50 mmol, 1.0 equiv) were coupled with (3-(2,5-dimethyl-1H-pyrrol-1-yl)propyl)zinc chloride (0.75 mmol, 
1.5 equiv.) prepared according to TP2 from the corresponding bromide.  





  using 2-chloroquinoline 108 mg, 0.41 mmol, 82%, yellow oil. 
Purification: i-hexane:ethyl acetate = 8:2. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.10 (t, J = 10.2 Hz, 2H), 7.81 (d, J = 8.1 Hz, 1H), 7.72 (t, J = 7.7 Hz, 1H), 
7.52 (t, J = 7.5 Hz, 1H), 7.30 (d, J = 8.4 Hz, 1H), 5.76 (s, 2H), 3.93 – 3.81 (m, 2H), 3.06 (t, J = 7.6 Hz, 2H), 2.22 
(s, 8H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 161.1, 136.8, 129.8, 128.5, 127.6, 127.4, 126.8, 126.1, 121.2, 121.2, 
105.1, 43.2, 35.9, 30.3, 12.5. 
FT-IR (ATR, cm-1): 𝜈 = 2932, 1619, 1600, 152, 1518, 1503, 1426, 1407, 1370, 1298, 1140, 1115, 1017, 974, 
873, 826, 781, 743. 
MS (EI, 70 eV): m/z (%) = 264 (5), 170 (24), 169 (19), 168 (13), 157 (12), 156 (100), 143 (54), 128 (12). 




Following TP4-A 2-bromoquinoline (104 mg, 0.50 mmol, 1.0 equiv.) was coupled with (2-((1R,4R)-5,5-
dimethylbicyclo[2.1.1]hex-2-en-2-yl)ethyl)zinc chloride (0.75 mmol, 1.5 equiv.) prepared according to TP2 
from the corresponding bromide.  
Isolated yield: 103 mg, 0.37 mmol, 75%, yellow oil. 
Purification: i-hexane:ethyl acetate = 95:5. 
1H-NMR (400 MHz, CDCl3, ppm): δ =  8.09 (d, J = 8.4 Hz, 2H), 7.78 (dd, J = 8.2, 1.4 Hz, 1H), 7.69 (ddd, J = 
8.3, 6.9, 1.5 Hz, 1H), 7.50 (ddd, J = 8.0, 6.8, 1.2 Hz, 1H), 7.32 (d, J = 8.4 Hz, 1H), 5.29 (tt, J = 3.0, 1.5 Hz, 1H), 
3.13 – 3.00 (m, 2H), 2.47 (ddq, J = 10.0, 6.4, 1.8 Hz, 2H), 2.38 (dt, J = 8.5, 5.6 Hz, 1H), 2.29 – 2.18 (m, 2H), 
2.15 (td, J = 5.6, 1.5 Hz, 1H), 2.08 (ttd, J = 5.8, 2.8, 1.2 Hz, 1H), 1.28 (s, 3H), 1.16 (d, J = 8.5 Hz, 1H), 0.84 (s, 
3H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 162.7, 147.5, 136.9, 129.8, 128.5, 127.6, 126.9, 126.1, 126.1, 121.5, 
116.8, 45.9, 40.9, 38.2, 37.0, 37.0, 31.8, 31.4, 26.4, 21.4. 
FT-IR (ATR, cm-1): 𝜈 = 2914.5, 1601.4, 1503.9, 1427.4, 1364.6, 1219.8, 904.6, 830.1, 731.6. 
MS (EI, 70 eV): m/z (%) = 277 (5), 276 (9), 262 (5), 236 (8), 234 (18), 209 (15), 208 (97), 206 (8) 194 (13), 
193 (8), 180 (15), 167 (8), 156 (12), 144 (11), 143 (100), 142 (6), 128 (8). 
HR-MS (EI, 70eV): [C20H22N], calcd.: 276.1752; ; found: 276.1748.  
Optical rotation: [α]D








Following TP4-A using CoCl2 (13 mg, 0.1 mmol, 20 mol%) and bipyridine (31 mg, 0.2 mmol, 40 mol%), 2-
chloro-4-methylquinoline (89 mg, 0.50 mmol, 1.0 equiv.) was coupled with (3-cyanopropyl)zinc bromide 
(0.95 mmol, 1.9 equiv.) prepared according to TP3 from the corresponding bromide.  
Isolated yield: 73 mg, 0.35 mmol, 70%, brown oil. 
Purification: i-hexane:ethyl acetate = 7:3. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.07 – 8.00 (m, 1H), 7.97 (dd, J = 8.4, 1.4 Hz, 1H), 7.70 (ddd, J = 8.4, 
6.8, 1.4 Hz, 1H), 7.53 (ddd, J = 8.3, 6.9, 1.3 Hz, 1H), 7.15 (d, J = 1.2 Hz, 1H), 3.08 (t, J = 7.4 Hz, 2H), 2.69 (d, 
J = 0.9 Hz, 3H), 2.48 (t, J = 7.2 Hz, 2H), 2.32 – 2.15 (m, 2H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 159.7, 147.8, 145.1, 129.5, 129.5, 127.1, 126.0, 123.8, 122.3, 119.81, 
37.1, 25.0, 18.9, 16.9.  
FT-IR (ATR, cm-1): 𝜈 = 2931, 2246, 1602, 1562, 1508, 1448, 1412, 1380, 1346, 1159, 1123, 1026, 953, 878, 
865, 757. 
MS (EI, 70 eV): m/z (%) = 210 (3), 170 (24), 158 (12), 157 (100), 156 (10), 142 (7), 115 (18). 
HR-MS (EI, 70eV): [C14H14N2], calcd.: 210.1157; found: 210.1151.  
 
4-(6-Chloroquinolin-2-yl)butyl acetate (102p) 
 
Following TP4-A using CoCl2 (13 mg, 0.1 mmol, 20 mol%) and bipyridine (31 mg, 0.2 mmol, 40 mol%), 2,6-
dichloroquinoline (99 mg, 0.50 mmol, 1.0 equiv.) was coupled with (4-acetoxybutyl)zinc bromide 
(0.95 mmol, 1.9 equiv.) prepared according to TP3 from the corresponding bromide.  
Isolated yield: 81 mg, 0.29 mmol, 58%, yellow oil. 
Purification: i-hexane:ethyl acetate = 7:3 to 6:4. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.97 (t, J = 8.5 Hz, 2H), 7.75 (d, J = 2.4 Hz, 1H), 7.61 (dd, J = 9.0, 2.4 Hz, 
1H), 7.31 (d, J = 8.5 Hz, 1H), 4.10 (t, J = 6.5 Hz, 2H), 3.08 – 2.91 (m, 2H), 2.03 (s, 3H), 1.96 – 1.82 (m, 2H), 
1.80 – 1.66 (m, 2H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 171.3, 162.7, 146.3, 135.6, 131.6, 130.5, 130.4, 127.4, 126.3, 122.3, 





FT-IR (ATR, cm-1): 𝜈 = 2933, 1733, 1599, 1558, 1490, 1462, 1388, 1365, 1303, 1237, 1188, 1118, 1073, 
1039, 959, 921, 876, 831, 745, 717, 683. 
MS (EI, 70 eV): m/z (%) = 234 (9), 220 (11), 218 (33), 204 (19), 192 (13), 190 (40), 179 (33), 178 (11), 177 
(100), 176 (13), 142 (13), 150 (12). 




Following TP4-A 1-bromoisoquinoline (104 mg, 0.50 mmol, 1.0 equiv.) was coupled with (2-(thiophen-3-
yl)ethyl)zinc chloride (0.75 mmol, 1.5 equiv.) prepared according to TP2 from the corresponding bromide.  
Isolated yield: 73 mg, 0.31 mmol, 61%, brown oil. 
Purification: i-hexane:ethyl acetate = 9:1. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.46 (d, J = 5.9 Hz, 1H), 8.20 – 8.11 (m, 1H), 7.92 – 7.84 (m, 1H), 7.78 
– 7.70 (m, 1H), 7.64 (dddd, J = 9.9, 8.4, 5.0, 2.7 Hz, 2H), 7.29 – 7.23 (m, 1H), 7.07 – 7.01 (m, 2H), 3.76 – 3.65 
(m, 2H), 3.30 – 3.20 (m, 2H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 160.9, 136.8, 131.2, 128.4, 128.0, 128.0, 127.7, 127.0, 125.8, 125.8, 
125.6, 120.9, 120.4, 35.6, 30.2. 
FT-IR (ATR, cm-1): 𝜈 = 3050, 2922, 2854, 1622, 1586, 1562, 1536, 1502, 1444, 1410, 1386, 1357, 1239, 
1199, 1140, 1080, 1020, 979, 867, 822, 798, 774, 737, 684 
MS (EI, 70 eV): m/z (%) = 241 (5), 240 (18), 239 (100), 238 (70), 224 (20), 223 (8), 206 (14), 204 (9), 156 
(17), 129 (30), 114 (18), 97 (25). 




Following TP4-A 4-chloro-6,7-dimethoxyquinazoline (112 mg, 0.50 mmol, 1.0 equiv.) was coupled with 
but-3-en-1- 
ylzinc chloride (0.75 mmol, 1.5 equiv.) prepared according to TP2 from the corresponding bromide.  
Isolated yield: 73 mg, 0.30 mmol, 60%, green solid. 





m.p.: 66.9 – 69.1°C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 9.02 (s, 1H), 7.45 (s, 1H), 7.21 (s, 1H), 5.88 (ddt, J = 16.9, 10.2, 6.7 Hz, 
1H), 5.10 – 4.90 (m, 1H), 4.02 (d, J = 13.4 Hz, 6H), 3.38 – 3.25 (m, 2H), 2.64 (tdt, J = 7.9, 6.6, 1.4 Hz, 2H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 167.3, 156.2, 152.6, 150.6, 147.6, 137.3, 119.7, 115.9, 107.0, 101.9, 
56.7, 56.4, 33.8, 32.5. 
FT-IR (ATR, cm-1): 𝜈 = 3079, 2923, 1639, 1613, 1579, 1554, 1501, 1464, 1452, 1427, 1363, 1307, 1280, 
1264, 1230, 1207, 1190, 1173, 1126, 1014, 995, 972, 890, 852, 828, 788, 760.  
MS (EI, 70 eV): m/z (%) = 244 (61), 243 (89), 230 (13), 229 (100), 228 (10), 227 (10), 213 (12), 201 (13), 
199 (11), 198 (11), 197 (16), 185 (16). 




Following TP4-A 2-bromopyrimidine (80 mg, 0.50 mmol, 1.0 equiv.) was coupled with (2-(thiophen-3-
yl)ethyl)zinc chloride (0.75 mmol, 1.5 equiv.) prepared according to TP2 from the corresponding bromide.  
Isolated yield: 65 mg, 0.34 mmol, 70%, yellow oil. 
Purification: i-hexane:ethyl acetate = 8:2. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.69 (d, J = 4.9 Hz, 2H), 7.24 (dd, J = 4.6, 3.3 Hz, 1H), 7.16 (t, J = 4.9 Hz, 
1H), 7.01 – 6.95 (m, 2H), 3.37 – 3.26 (m, 2H), 3.20 (ddd, J = 8.3, 6.2, 1.1 Hz, 2H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 170.1, 157.1, 141.4, 128.3, 125.6, 120.8, 118.9, 39.9, 29.0. 
FT-IR (ATR, cm-1): 𝜈 = 1566, 1426, 1232, 907, 797, 731  
MS (EI, 70 eV): m/z (%) = 191 (11), 190 (100), 189 (36), 175 (12), 157 (16), 145 (7), 107 (9), 98 (5), 97 
(94), 84 (12), 80 (10), 53 (6), 45 (11). 














Following TP4-A 4-bromo-2-fluorobenzonitrile (100 mg, 0.50 mmol, 1.0 equiv.) was coupled with (2-(1,3-
dioxan-2-yl)ethyl)zinc chloride (101a, 0.75 mmol, 1.5 equiv.) prepared according to TP2 from the 
corresponding bromide.  
Isolated yield: 77 mg, 0.33 mmol, 66%, colorless oil. 
Purification:  i-hexane:ethyl acetate = 8:2. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.51 (dd, J = 7.9, 6.7 Hz, 1H), 7.11 – 7.00 (m, 2H), 4.50 (t, J = 5.0 Hz, 
1H), 4.10 (ddt, J = 10.6, 5.1, 1.4 Hz, 2H), 3.79 – 3.67 (m, 2H), 2.83 – 2.72 (m, 2H), 2.07 (dtt, J = 13.6, 12.5, 
5.0 Hz, 1H), 1.96 – 1.82 (m, 2H), 1.35 (dtt, J = 13.6, 2.7, 1.4 Hz, 1H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 163.3 (d, J = 258.6 Hz), 151.0 (d, J = 7.7 Hz), 133.4, 125.1 (d, J = 3.2 
Hz), 116.5 (d, J = 19.0 Hz), 114.4, 100.8 , 98.9 (d, J = 15.5 Hz), 67.0 , 35.8 , 30.2, 30.2, 25.8. 
FT-IR (ATR, cm-1): 𝜈 = 2965, 2936, 2863, 2232, 1980, 162, 1569, 1502, 1458, 1430, 1404, 1377, 1283, 1270, 
1260, 1248, 1236, 1220, 1190, 1145, 1129, 1113, 1081, 1046, 995, 962, 942, 925, 890, 850, 826, 7750, 744, 
729. 
MS (EI, 70 eV): m/z (%) = 235 (2), 234 (18), 176 (20), 148 (51), 135 (35), 134 (37), 114 813), 107 (11), 87 
(100). 
HR-MS (EI, 70eV): [C13H14FNO2], calcd.: 235.1009; found: 235.1003.  
 
Ethyl 4-(2-(1,3-dioxan-2-yl)ethyl)benzoate (102u) 
 
Following TP4-A using CoCl2 (13 mg, 0.1 mmol, 20 mol%) and bipyridine (31 mg, 0.2 mmol, 40 mol%), ethyl 
4-iodobenzoate (138 mg, 0.50 mmol, 1.0 equiv.) was coupled with (2-(1,3-dioxan-2-yl)ethyl)zinc chloride 
(101a, 0.95 mmol, 1.9 equiv.) prepared according to TP2 from the corresponding bromide.  
Isolated yield:108 mg, 0.41 mmol, 82%, colorless oil. 
Purification: i-hexane:ethyl acetate = 8:2. 
1H-NMR (400 MHz, CDCl3, ppm): δ =7.98 – 7.93 (m, 2H), 7.29 – 7.23 (m, 2H), 4.49 (t, J = 5.2 Hz, 1H), 4.36 
(q, J = 7.1 Hz, 2H), 4.11 (ddt, J = 10.6, 5.0, 1.4 Hz, 2H), 3.81 – 3.66 (m, 2H), 2.82 – 2.71 (m, 2H), 2.09 (dtt, J 





13C-NMR (100 MHz, CDCl3, ppm): δ = 166.8, 147.3, 129.8, 128.6, 128.3, 101.3, 67.0, 60.9, 36.4, 30.2, 25.9, 
14.50. 
FT-IR (ATR, cm-1): 𝜈 =2963, 2849, 1712, 1611, 1367, 1308, 1271, 1177, 1146, 1132, 1101, 1038, 1021, 997, 
972, 946, 926, 888, 852, 765, 705. 
MS (EI, 70 eV): m/z (%) =263 (18), 219 (58), 218 (25), 177 (22), 161 (23), 133 (44), 115 (30), 114 (94), 105 
(31), 103 (21), 91 (23), 87 (100). 




Following TP4-A (2-chlorophenyl)(phenyl)methanone (108 mg, 0.50 mmol, 1.0 equiv.) was coupled with 
(2-(1,3-dioxan-2-yl)ethyl)zinc chloride (101a, 0.75 mmol, 1.5 equiv.) prepared according to TP2 from the 
corresponding bromide.  
Isolated yield: 104 mg, 0.35 mmol, 70%, colorless oil. 
Purification: i-hexane:ethyl acetate = 8:2. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.82 – 7.75 (m, 2H), 7.61 – 7.54 (m, 1H), 7.48 – 7.39 (m, 3H), 7.35 (d, 
J = 7.7 Hz, 1H), 7.31 – 7.20 (m, 2H), 4.42 (t, J = 5.3 Hz, 1H), 4.11 – 3.97 (m, 2H), 3.67 (td, J = 12.4, 2.5 Hz, 
2H), 2.83 – 2.69 (m, 2H), 2.03 (qt, J = 12.8, 5.0 Hz, 1H), 1.93 – 1.79 (m, 2H), 1.40 – 1.21 (m, 1H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 198.4, 140.9, 138.5, 137.8, 133.1, 130.4, 130.2, 128.7, 128.4, 125.3, 
101.39, 66.8, 36.7, 27.6, 25.8. 
FT-IR (ATR, cm-1): 𝜈 = 2961, 2850, 1661, 1597, 1580, 1484, 1448, 1403, 1378, 1314, 1265, 1239, 1196, 
1178, 1145, 1132, 1104, 1078, 1048, 1028, 999, 970, 927, 886, 851, 801, 762, 700. 
MS (EI, 70 eV): m/z (%) = 296 (2), 278 (1), 237 (2), 221 (1), 220 (4). 














Following TP4-A (4-bromophenyl)(phenyl)methanone (131 mg, 0.50 mmol, 1.0 equiv.) was coupled with 
(2-(1,3-dioxan-2-yl)ethyl)zinc chloride (101a, 0.75 mmol, 1.5 equiv.) prepared according to TP2 from the 
corresponding bromide.  
Isolated yield: 126 mg, 0.43 mmol, 85%, colorless crystals. 
Purification: i-hexane:ethyl acetate = 8:2. 
m.p.: 68.6 – 70.5 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.81 – 7.77 (m, 2H), 7.74 (d, J = 7.9 Hz, 2H), 7.58 (td, J = 7.4, 1.6 Hz, 
1H), 7.52 – 7.41 (m, 2H), 7.30 (d, J = 8.0 Hz, 2H), 4.53 (t, J = 5.1 Hz, 1H), 4.19 – 4.06 (m, 2H), 3.85 – 3.68 (m, 
2H), 2.81 (dd, J = 9.3, 6.8 Hz, 2H), 2.20 – 2.01 (m, 1H), 2.01 – 1.86 (m, 2H), 1.35 (dq, J = 13.7, 1.9 Hz, 1H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 196.6, 147.1, 138.0, 135.4, 132.3, 130.5, 130.1, 128.5, 128.3, 101.3, 
67.0, 36.4, 30.3, 25.9. 
FT-IR (ATR, cm-1): 𝜈 = 2914, 2846, 2048, 1981, 1646, 1603, 1576, 1443, 1415, 1404, 1382, 1317, 1306, 
1278, 1238, 1186, 1143, 1131, 1077, 1040, 1000, 970, 940, 920, 886, 856, 786, 745, 699, 666. 
MS (EI, 70 eV): m/z (%) = 296 (14), 237 (27), 220 (16), 167 (16), 161 (14), 114 (100), 105 (44), 87 (95), 77 
(15). 
HR-MS (EI, 70eV): [C19H20O3], calcd.: 296.1412; found: 296.1407.  
 
Ethyl 4-(2-(4-fluorobenzoyl)phenyl)butanoate (102x) 
 
Following TP4-A using CoCl2 (13 mg, 0.1 mmol, 20 mol%) and bipyridine (31 mg, 0.2 mmol, 40 mol%), (2-
chlorophenyl)(4-fluorophenyl)methanone (117 mg, 0.50 mmol, 1.0 equiv.) was coupled with (4-ethoxy-4-
oxobutyl)zinc bromide (0.95 mmol, 1.9 equiv.) prepared according to TP3 from the corresponding 
bromide.  
Isolated yield: 115 mg, 0.37 mmol, 73%, pale yellow oil. 





1H-NMR (400 MHz, CDCl3, ppm): δ = 7.83 – 7.68 (m, 2H), 7.35 (dt, J = 7.7, 4.2 Hz, 1H), 7.26 (d, J = 7.5 Hz, 
1H), 7.23 – 7.15 (m, 2H), 7.10 – 6.98 (m, 2H), 3.99 (q, J = 7.1 Hz, 2H), 2.69 – 2.47 (m, 2H), 2.18 (t, J = 7.4 Hz, 
2H), 1.89 – 1.69 (m, 2H), 1.13 (t, J = 7.1 Hz, 3H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 196.99, 173.42, 165.98 (d, J = 255.4 Hz), 140.66, 138.32, 134.25 (d, 
J = 2.9 Hz), 132.97 (d, J = 9.3 Hz), 130.51 (d, J = 7.9 Hz), 128.59, 125.66, 115.87, 115.65, 60.41, 33.92, 32.55, 
26.86, 14.34. 
FT-IR (ATR, cm-1): 𝜈 = 2981, 1729, 1663, 1596, 1504, 1485, 1446, 1410, 1374, 1262, 1227, 1195, 1147, 
1096, 1035, 930, 852, 810, 750, 688. 
MS (EI, 70 eV): m/z (%) = 227 (25), 225 (249, 213 (32), 212 (100), 209 (10), 183 (15), 123 (23). 




Following TP4-B (4-bromophenyl)(phenyl)methanone (131 mg, 0.50 mmol, 1.0 equiv.) was coupled with 
cyclopropylzinc chloride (0.75 mmol, 1.5 equiv.) in THF prepared according to TP2 from the corresponding 
bromide.  
Isolated yield: 74 mg, 0.33 mmol, 67%, pale yellow oil. 
Purification: i-hexane:ethyl acetate = 95:5. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.82 – 7.74 (m, 2H), 7.74 – 7.67 (m, 2H), 7.60 – 7.51 (m, 1H), 7.51 – 
7.42 (m, 2H), 7.18 – 7.10 (m, 2H), 1.97 (tt, J = 8.3, 5.0 Hz, 1H), 1.12 – 1.02 (m, 2H), 0.84 – 0.74 (m, 2H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 196.4, 149.9, 138.1, 134.8, 132.2, 130.5, 130.0, 128.3, 125.3, 15.8, 
10.5. 
FT-IR (ATR, cm-1): 𝜈 = 3002, 2194, 1928, 1646, 1603, 1578, 1447, 1417, 1317, 1278, 1227, 1188, 1176, 
1150, 1109, 1072, 1049, 1024, 1000, 971, 958, 971, 937, 922, 893, 840, 817, 791, 758, 741, 700, 675.  
MS (EI, 70 eV): m/z (%) = 223 (18), 222 (69), 146 (10), 145 (100), 117 (9), 116 (8), 115 (28), 105 (49), 91 
(12), 76 (33), 57 (6), 43 (10). 











Following TP4-B (2-chlorophenyl)(4-chlorophenyl)methanone (126 mg, 0.50 mmol, 1.0 equiv.) was 
coupled with cyclopropylzinc chloride (0.75 mmol, 1.5 equiv.) in THF prepared according to TP2 from the 
corresponding bromide.  
Isolated yield: 85 mg, 0.34 mmol, 68%, pale yellow oil. 
Purification: i-hexane:ethyl acetate = 98:2. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.78 – 7.67 (m, 2H), 7.42 – 7.26 (m, 3H), 7.23 – 7.08 (m, 2H), 6.97 (dd, 
J = 7.9, 1.0 Hz, 1H), 1.81 (tt, J = 8.5, 5.2 Hz, 1H), 0.79 – 0.67 (m, 2H), 0.62 – 0.49 (m, 2H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 197.8, 142.1, 139.8, 139.4, 136.3, 131.6, 130.6, 128.9, 127.9, 125.4, 
125.4, 13.8, 9.2. 
FT-IR (ATR, cm-1): 𝜈 = 3067, 3004, 1924, 1664, 1584, 1571, 1484, 1457, 1445, 1399, 1300, 1257, 1221, 
1174, 1151, 1030, 1013, 951, 929, 897845, 822, 778, 752, 682, 656. 
MS (EI, 70 eV): m/z (%) = 241 (10), 230 (32), 229 (15), 228 (100), 193 (41), 178 (8), 165 (23), 115 (12). 




Following TP4-B 6-bromonicotinonitrile (91 mg, 0.50 mmol, 1.0 equiv.) was coupled with (3-
methylcyclohexyl)zinc iodide (0.75 mmol, 1.5 equiv.) prepared according to TP3 from the corresponding 
iodide.  
Isolated yield: 80 mg, 0.40 mmol, 80%, dr = 91:1, colorless oil. 
Purification: pentane:ethyl acetate = 95:5. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.79 (dd, J = 2.3, 0.9 Hz, 1H), 7.86 (dd, J = 8.2, 2.2 Hz, 1H), 7.29 – 7.24 
(m, 1H), 2.80 (tt, J = 12.0, 3.4 Hz, 1H), 1.98 – 1.79 (m, 3H), 1.75 (ddt, J = 12.9, 3.4, 1.8 Hz, 1H), 1.67 – 1.48 
(m, 1H), 1.43 (tdd, J = 9.6, 4.8, 2.9 Hz, 2H), 1.28 – 1.11 (m, 1H), 0.94 (d, J = 6.5 Hz, 3H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 170.9, 152.1, 139.6, 121.4, 117.2, 107.2, 46.9, 41.0, 34.6, 32.8, 32.2, 
26.2, 22.8. 





MS (EI, 70 eV): m/z (%) = 200 (39), 185 (54), 157 (100), 145 (32), 143 (30), 131 (84), 118 (44). 




Following TP4-B 6-bromonicotinonitrile (91 mg, 0.50 mmol, 1.0 equiv.) was coupled with (3-
isopropylcyclohexyl)zinc iodide (0.75 mmol, 1.5 equiv.) prepared according to TP3 from the corresponding 
iodide.  
Isolated yield: 72 mg, 0.32 mmol, 63%, dr = 96:4, colorless crystals. 
Purification: pentane:ethyl acetate = 95:5. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.80 (dd, J = 2.2, 0.9 Hz, 1H), 7.86 (dd, J = 8.2, 2.2 Hz, 1H), 7.28 (dd, 
J = 8.2, 0.9 Hz, 1H), 2.77 (tt, J = 11.6, 3.4 Hz, 1H), 2.01 – 1.86 (m, 3H), 1.77 (ddq, J = 11.5, 4.9, 1.5 Hz, 1H), 
1.56 – 1.36 (m, 3H), 1.31 – 1.19 (m, 2H), 1.02 (dddd, J = 15.0, 12.4, 8.9, 3.7 Hz, 1H), 0.88 (d, J = 3.3 Hz, 3H), 
0.87 (d, J = 3.3 Hz, 3H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 171.0, 152.0, 139.5, 121.4, 117.1, 107.1, 47.1, 43.9, 35.9, 33.0, 32.4, 
29.1, 26.3, 19.8, 19.7. 
FT-IR (ATR, cm-1): 𝜈 = 2927, 2854, 2231, 1592, 1478, 1462, 1447, 1384, 1368, 1023, 839. 
MS (EI, 70 eV): m/z (%) = 228 (4), 185 (100), 157 (23), 145 (36), 143 (18), 131 (42), 118 (23). 




Following TP4-B 2-bromopyrimidine (80 mg, 0.50 mmol, 1.0 equiv.) was coupled with (3-
isopropylcyclohexyl)zinc iodide (0.75 mmol, 1.5 equiv.) prepared according to TP3 from the corresponding 
iodide.  
Isolated yield: 53 mg, 0.26 mmol, 52%, dr = 94:6 colorless oil. 
The cis-configuration of the product 102ac was confirmed using 2D-NMR analysis, see: VI. Appendix, 1. 
Structure Determination using NMR-Experiments.) 





1H-NMR (400 MHz, CDCl3, ppm): δ = 8.66 (d, J = 4.9 Hz, 2H), 7.09 (t, J = 4.9 Hz, 1H), 2.88 (tt, J = 11.9, 3.5 Hz, 
1H), 1.98 (dddq, J = 10.8, 5.0, 3.4, 2.0 Hz, 2H), 1.90 (dp, J = 13.2, 3.2 Hz, 1H), 1.73 (dddd, J = 12.8, 4.8, 3.3, 
1.6 Hz, 1H), 1.56 (ddd, J = 13.3, 12.2, 3.5 Hz, 1H), 1.51 – 1.44 (m, 1H), 1.44 – 1.37 (m, 1H), 1.37 – 1.30 (m, 
1H), 1.30 – 1.21 (m, 1H), 1.03 (tdd, J = 12.6, 11.2, 3.7 Hz, 1H), ), 0.87 (d, J = 2.2 Hz, 3H), 0.86 (d, J = 2.2 Hz, 
3H) 
13C-NMR (100 MHz, CDCl3, ppm): δ = 174.9, 157.1, 118.6, 48.0, 44.0, 35.4, 33.1, 32.0, 29.3, 26.4, 19.9, 19.9. 
FT-IR (ATR, cm-1): 𝜈 = 2928, 2853, 1571, 1558, 1462, 1446, 1422, 1385, 1368, 799, 665. 
MS (EI, 70 eV): m/z (%) = 204 (32), 162 (100), 133 (24), 121 (26), 119 (27), 107 (29). 




Following TP4-B 2-bromo-5-(trifluoromethyl)pyridine (113 mg, 0.50 mmol, 1.0 equiv.) was coupled with 
(4-(ethoxycarbonyl)cyclohexyl)zinc iodide (0.75 mmol, 1.5 equiv.) prepared according to TP2 from the 
corresponding iodide.  
Isolated yield: 77 mg, 0.26 mmol, 51%, dr = 80:20, colorless oil. 
Purification: pentane:ethyl acetate = 9:1. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.72 (dq, J = 4.1, 2.5, 1.8 Hz, 1H), 7.77 (dd, J = 8.3, 2.6 Hz, 1H), 7.26 – 
7.18 (m, 1H), 4.17 – 4.01 (m, 2H), 2.71 (dddd, J = 28.0, 24.6, 11.4, 7.3 Hz, 1H), 2.37 – 2.23 (m, 1H), 2.23 – 
1.88 (m, 4H), 1.87 – 1.61 (m, 1H), 1.60 – 1.48 (m, 3H), 1.21 (td, J = 7.1, 1.8 Hz, 3H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 175.9, 169.50 (d, J = 1.8 Hz), 146.25 (q, J = 4.1 Hz), 133.69 (q, J = 
3.5 Hz)124.5 (q, J = 32.9 Hz), 123.8 (q, J = 272.0 Hz), 121.1, 60.4, 45.7, 42.9, 31.7, 28.9, 14.4. 
FT-IR (ATR, cm-1): 𝜈 = 2936, 2862, 1728, 1606, 1452, 1393, 1377, 1326, 1161, 1128, 1081, 1041, 1015, 904, 
842, 728. 
MS (EI, 70 eV): m/z (%) = 301 (14) 228 (100), 200 (48), 198 (30), 186 (30), 174 (53), 161 (259). 












Following TP4-B 2-bromo-5-(trifluoromethyl)pyridine (113 mg, 0.50 mmol, 1.0 equiv.) was coupled with 
(4-(1H-pyrrol-1-yl)cyclohexyl)zinc iodide (0.75 mmol, 1.5 equiv.) prepared according to TP3 from the 
corresponding iodide.  
Isolated yield: 79 mg, 0.27 mmol, 54%, dr = 98:2, colorless crystals. 
The trans-configuration of 102ae was confirmed using X-ray structure analysis, see: VI. Appendix, 3. Single 
Crystal X-Ray Diffraction Studies. 
Purification: pentane:ethyl acetate = 9:1. 
m.p.: 130.8 – 132.4 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.88 – 8.76 (m, 1H), 7.87 (dd, J = 8.2, 2.4 Hz, 1H), 7.32 (d, J = 8.2 Hz, 
1H), 6.78 (t, J = 2.1 Hz, 2H), 6.18 (t, J = 2.1 Hz, 2H), 4.05 – 3.90 (m, 1H), 2.88 (tt, J = 11.4, 3.6 Hz, 1H), 2.38 
– 2.25 (m, 2H), 2.14 (dt, J = 13.3, 2.7 Hz, 2H), 1.96 – 1.70 (m, 4H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 169.0 (d, J = 1.5 Hz), 146.4 (q, J = 4.1 Hz), 133.8 (q, J = 3.6 Hz), 123.8 
(q, J = 272.0 Hz), 124.6 (q, J = 32.9 Hz), 121.2, 118.6, 107.8, 58.1, 45.5, 34.3, 31.7.  
FT-IR (ATR, cm-1): 𝜈 = 2940, 2860, 1706, 1605, 1571, 1489, 1452, 1399, 1366, 1325, 1272, 1259, 1243, 
1197, 1161, 1128, 1097, 1079, 1013, 957, 907, 813, 766, 722, 674.  
MS (EI, 70 eV): m/z (%) = 295 (18), 294 (100), 165 (179, 118 8249, 212 (16), 200 (16), 198 (46), 186 (19), 
174 (46), 161 (19). 




Following TP4-B 2-bromopyrimidine (80 mg, 0.50 mmol, 1.0 equiv.) was coupled with (3-
(trifluoromethyl)cyclohexyl)zinc iodide (0.75 mmol, 1.5 equiv.) prepared according to TP3 from the 
corresponding iodide.  
Isolated yield: 84 mg, 0.37 mmol, 73%, dr = 98:2, colorless oil. 





1H-NMR (400 MHz, CDCl3, ppm): δ = 8.67 (d, J = 4.9 Hz, 2H), 7.13 (t, J = 4.9 Hz, 1H), 2.87 (tt, J = 12.2, 3.6 Hz, 
1H), 2.27 – 2.03 (m, 5H), 1.75 – 1.57 (m, 2H), 1.56 – 1.41 (m, 2H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 173.4, 157.1, 127.8 (q, J = 278.5 Hz), 118.8, 46.4, 41.4 (q, J = 26.5 Hz), 
30.1, 24.8 (q, J = 2.6 Hz). 
FT-IR (ATR, cm-1): 𝜈 = 2950, 2926, 2858, 1571, 1558, 1451, 1438, 1423, 1390, 1370, 1337, 1271, 1249, 
1220, 170, 1134, 1116, 1092, 1078, 1069, 1027, 1003, 988, 966, 902, 884, 848, 817, 805, 700. 
MS (EI, 70 eV): m/z (%) = 231 (12), 230 (100), 229 (32), 169 (27), 133 (64), 119 (83), 107 (80), 94 (56). 




Following TP4-B 2-bromopyrimidine (80 mg, 0.50 mmol, 1.0 equiv.) was coupled with (4-
phenylcyclohexyl)zinc iodide (0.75 mmol, 1.5 equiv.) prepared according to TP3 from the corresponding 
iodide.  
Isolated yield: 80 mg, 0.34 mmol, 67%, dr = 96:4, colorless crystals. 
Purification: pentane:ethyl acetate = 9:1. 
m.p.: 117.8 – 119.1 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.68 (d, J = 4.9 Hz, 2H), 7.36 – 7.22 (m, 4H), 7.22 – 7.15 (m, 1H), 7.12 
(t, J = 4.9 Hz, 1H), 2.97 (tt, J = 12.1, 3.6 Hz, 1H), 2.63 (tt, J = 12.1, 3.5 Hz, 1H), 2.18 (dtd, J = 15.1, 4.6, 4.2, 
2.2 Hz, 2H), 2.06 (dtd, J = 15.1, 4.9, 4.2, 2.4 Hz, 2H), 1.95 – 1.73 (m, 2H), 1.73 – 1.53 (m, 2H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 174.5, 157.1, 147.4, 128.5, 127.0, 126.1, 118.7, 47.2, 43.9, 34.0, 32.2. 
FT-IR (ATR, cm-1): 𝜈 = 2925, 2867, 1987, 1572, 1561, 1464, 1427, 1382, 1375, 1168, 1024, 960, 832, 798. 
MS (EI, 70 eV): m/z (%) = 238 (100), 133 (38), 121 (52), 119 (78), 115 (32), 107 898), 91 (38). 














Following TP4-B 2-bromo-4-(4-chlorophenyl)pyrimidine (135 mg, 0.50 mmol, 1.0 equiv.) was coupled with 
(4-(1H-pyrrol-1-yl)cyclohexyl)zinc iodide (0.75 mmol, 1.5 equiv.) prepared according to TP3 from the 
corresponding iodide.  
Isolated yield: 108 mg, 0.32 mmol, 64%, dr = 91:9, colorless crystals. 
Purification: pentane:ethyl acetate = 8:2. 
m.p.: 104.0 – 105.7 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.43 (d, J = 5.2 Hz, 1H), 7.92 – 7.85 (m, 2H), 7.34 – 7.28 (m, 2H), 6.77 
(d, J = 5.3 Hz, 1H), 6.73 (t, J = 2.1 Hz, 2H), 6.53 (t, J = 2.1 Hz, 2H), 3.61 (tt, J = 11.9, 3.9 Hz, 1H), 3.05 (tt, J = 
12.1, 3.6 Hz, 1H), 2.33 – 2.18 (m, 2H), 2.13 – 1.98 (m, 2H), 1.98 – 1.82 (m, 2H), 1.74 – 1.52 (m, 2H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 174.2, 162.2, 158.0, 137.2, 135.8, 129.3, 128.7, 118.5, 113.8, 108.3, 
58.1, 46.6, 34.4, 31.2. 
FT-IR (ATR, cm-1): 𝜈 = 2929, 2856, 1706, 1597, 1568, 1545, 1491, 1462, 1436, 1409, 1384, 1315, 1294, 
1274, 1259, 1089, 1065, 1013, 962, 907, 822, 801,774, 721.  
MS (EI, 70 eV): m/z (%) = 339 (39), 338 (27), 227 (100), 243 (229), 217 (59), 137 (26), 95 (24), 93 (27), 67 
8339, 43 (31), 40 (22). 













(0.75 mmol, 1.5 equiv.) prepared according to TP2 from the corresponding chloride.  
Isolated yield: 174 mg, 0.39 mmol, 78%, dr = 98:2, colorless crystals. 
Purification: pentane:ethyl acetate = 95:5. 
m.p.: 125.2 – 127.0 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.68 (d, J = 4.9 Hz, 2H), 7.12 (t, J = 4.9 Hz, 1H), 5.39 (dt, J = 5.3, 1.9 Hz, 
1H), 2.89 (ddt, J = 15.9, 8.8, 4.0 Hz, 1H), 2.66 (tq, J = 13.2, 2.6 Hz, 1H), 2.37 – 2.25 (m, 1H), 2.10 – 1.78 (m, 
7H), 1.65 – 1.44 (m, 8H), 1.44 – 1.19 (m, 6H), 1.21 – 0.95 (m, 8H), 0.92 (d, J = 6.5 Hz, 3H), 0.87 (d, J = 1.9 Hz, 
3H), 0.86 (d, J = 1.9 Hz, 3H), 0.69 (s, 3H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 174.1, 157.0, 142.3, 120.5, 118.6, 56.8, 56.2, 50.3, 48.8, 42.3, 39.8, 
39.5, 39.4, 37.8, 37.0, 36.2, 35.8, 32.0, 31.9, 28.3, 28.0, 24.3, 23.9, 22.9, 22.6, 21.0, 19.7, 18.7, 11.9. 
FT-IR (ATR, cm-1): 𝜈 = 2937, 2867, 1572, 1561, 1463, 1427, 1382, 1375, 1333, 1167, 1062, 1024, 960, 833, 
797, 670. 
MS (EI, 70 eV): m/z (%) = 448 (566), 107 (39), 94 (22), 89 (41), 55 (48), 42 (100), 41 (49). 
HR-MS (EI, 70eV): [C31H48N2], calcd.: 448.3817; found: 448.3820.  
Optical rotation: [α]D




Following TP4-B 2-bromopyrimidine (80 mg, 0.50 mmol, 1.0 equiv.) was coupled with ((4R,4aS,6R)-6-
isopropyl-4,4a-dimethyldecahydronaphthalen-2-yl)zinc iodide (0.75 mmol, 1.5 equiv.) prepared according 
to TP3 from the corresponding iodide.  
Isolated yield: 149 mg, 0.26 mmol, 52%, dr = 98:2 colorless oil. 
Purification: pentane:ethyl acetate = 9:1. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.66 (d, J = 4.9 Hz, 2H), 7.09 (t, J = 4.9 Hz, 1H), 3.02 (tt, J = 11.9, 4.7 Hz, 
1H), 1.80 – 1.52 (m, 6H), 1.46 – 1.13 (m, 6H), 0.96 (qd, J = 12.2, 5.1 Hz, 1H), 0.87 – 0.80 (m, 9H), 0.77 (s, 
3H), 0.66 (t, J = 12.4 Hz, 1H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 174.5, 157.1, 118.5, 47.8, 46.3, 43.3, 42.3, 39.0, 36.5, 36.1, 34.0, 33.3, 
30.0, 29.8, 29.0, 20.2, 19.7, 15.2, 11.8. 





MS (EI, 70 eV): m/z (%) = 287 (20), 286 (96), 243 (32), 159 (29), 147 (75), 145 (44), 135 (39), 133 (64), 131 
(34), 119 (67), 107 (100), 94 (64). 
HR-MS (EI, 70eV): [C19H30N2], calcd.: 286.2409; found: 286.2404.  
Optical rotation: [α]D




Following TP4-A (bromoethynyl)benzene (103a, 91 mg, 0.50 mmol, 1.0 equiv.) was coupled with (2-(1,3-
dioxan-2-yl)ethyl)zinc chloride (101a, 0.75 mmol, 1.5 equiv.) prepared according to TP2 from the 
corresponding bromide.  
Isolated yield: 59 mg, 0.28 mmol, 55%, colorless oil. 
Purification: pentane:ethyl acetate = 9:1. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.45 – 7.33 (m, 2H), 7.34 – 7.21 (m, 3H), 4.71 (t, J = 5.2 Hz, 1H), 4.12 
(ddt, J = 10.5, 5.0, 1.4 Hz, 2H), 3.90 – 3.69 (m, 2H), 2.51 (t, J = 7.3 Hz, 2H), 2.09 (dtt, J = 13.4, 12.4, 5.0 Hz, 
1H), 1.89 (td, J = 7.3, 5.2 Hz, 2H), 1.36 (dtt, J = 13.5, 2.7, 1.4 Hz, 1H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 131.7, 128.3, 127.7, 124.0, 101.0, 89.5, 80.8, 67.1, 34.3, 26.0, 14.4. 
FT-IR (ATR, cm-1): 𝜈 = 2965, 2851, 1598, 1490, 1469, 1442, 1430, 1406, 1379, 1286, 1243, 1218, 1202, 
1132, 1085, 1061, 1047, 1007, 971, 960, 936, 922, 882, 789, 755, 691. 
MS (EI, 70 eV): m/z (%) = 216 (9), 215 (22), 158 (14), 157 (35), 130 (22), 129 (100), 128 (58), 115 (53). 




Following TP4-B (bromoethynyl)triisopropylsilane (103b, 131 mg, 0.50 mmol, 1.0 equiv.) was coupled with 
(4-phenylcyclohexyl)zinc iodide (0.75 mmol, 1.5 equiv.) prepared according to TP3 from the corresponding 
iodide. 






1H-NMR (400 MHz, CDCl3, ppm): δ = 7.25 – 7.17 (m, 2H), 7.16 – 7.08 (m, 3H), 2.44 (tt, J = 11.6, 3.5 Hz, 1H), 
2.26 (tt, J = 11.7, 3.7 Hz, 1H), 2.13 – 1.99 (m, 2H), 1.83 (dt, J = 12.2, 2.5 Hz, 2H), 1.58 – 1.30 (m, 4H), 1.00 
(d, J = 5.1 Hz, 21H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 147.3, 128.5, 126.9, 126.2, 113.7, 79.3, 43.7, 33.8, 33.7, 30.5, 18.8, 
11.4. 
FT-IR (ATR, cm-1): 𝜈 = 2938, 2892, 2863, 2173, 1498, 1463, 1449, 1382, 1298, 1073, 1018, 882, 754, 697, 
686, 671, 657. 
MS (EI, 70 eV): m/z (%) = 298 (25), 297 (100), 269 (10), 241 (9), 227 (7), 120 (8), 91 (9), 59 (14). 






3. Cobalt-Catalyzed Csp3-Csp3  Cross-Coupling of Functionalized Alkylzinc Reagents with 
Alkyl Iodides 
3.1 Optimization of the Reaction Conditions 
Table 12: Further optimization of the reaction conditions.  
 
Entry Cobalt salt CoCl2 [mol%] Amount of 106a [equiv] GC-Yield[a] of 107a [%] 
1 CoCl2 20 0.75 74 
2 CoBr2 20 0.75 73 
3 Co(acac)2 20 0.75 74 
4 CoCl2 10 0.75 68 
5 CoCl2 30 0.75 77 
6 CoCl2 20 0.6 71 
7 CoCl2 20 0.85 76 







3.2 Preparation of Starting Materials 
(3-iodopropyl)benzene (105a)143 
 
The title compound was prepared according to literature procedure from (3-bromopropyl)benzene. The 
analytical data is in full consistency with the data reported in the literature.  
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.34 – 7.27 (m, 2H), 7.21 (td, J = 6.8, 1.6 Hz, 3H), 3.18 (t, J = 6.8 Hz, 




The title compound was prepared according to literature procedure from 1-(2-chloroethyl)-4-
methoxybenzene. The analytical data is in full consistency with the data reported in the literature. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.15 – 7.05 (m, 2H), 6.91 – 6.80 (m, 2H), 3.80 (s, 3H), 3.32 (t, J = 7.8 Hz, 




The title compound was prepared according to literature procedure from 6-hydroxy-2,2-
dimethylhexanenitrile. The analytical data is in full consistency with the data reported in the literature.  
1H-NMR (400 MHz, CDCl3, ppm): δ = 3.20 (t, J = 6.9 Hz, 2H), 1.91 – 1.81 (m, 2H), 1.66 – 1.49 (m, 4H), 1.35 
(s, 6H). 
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The title compound was prepared according to literature procedure from 2-(1H-indol-3-yl)ethan-1-ol. The 
analytical data is in full consistency with the data reported in the literature.  
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.99 (dt, J = 8.3, 0.9 Hz, 1H), 7.80 – 7.73 (m, 2H), 7.45 (dt, J = 6.5, 
1.0 Hz, 2H), 7.32 (ddd, J = 8.4, 7.3, 1.3 Hz, 1H), 7.25 (dd, J = 7.6, 1.1 Hz, 1H), 7.23 – 7.17 (m, 2H), 3.41 (t, J = 
7.5 Hz, 2H), 3.24 (t, J = 7.5 Hz, 2H), 2.32 (s, 3H). 
 
2-(4-Iodopiperidin-1-yl)pyrimidine (105d)  
 
The title compound was prepared from 1-(pyrimidin-2-yl)piperidin-4-ol, which was prepared according to 
literature procedure.146 
Triphenylphosphine (2.88 g, 11 mmol, 1.1 equiv) and imidazole (2.04 g, 30 mmol, 3.0 equiv) were 
dissolved in dichloromethane (33 mL, 0.3 M to the corresponding alcohol) and cooled to 0 °C. Iodine 
(2.79 g, 11 mmol, 1.1 equiv) was added over 15 min and 1-(pyrimidin-2-yl)piperidin-4-ol (1.79 g, 10 mmol, 
1.0 equiv) was added dropwise. The reaction mixture was allowed to warm to room temperature and was 
stirred overnight. Saturated aqueous sodium thiosulfate solution (30 mL) was added and the mixture was 
extracted with dichloromethane (3 x 20 mL). After solvent evaporation, the crude product was subjected 
to column chromatography with i-hexane and ethyl acetate (9:1) as eluent. 2-(4-Iodopiperidin-1-
yl)pyrimidine was obtained as a yellow oil (2.60 g, 9.0 mmol, 90% yield).  
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.30 (d, J = 4.7 Hz, 2H), 6.48 (t, J = 4.7 Hz, 1H), 4.55 (tt, J = 6.9, 5.1 Hz, 
1H), 4.13 – 4.04 (m, 2H), 3.63 (ddd, J = 13.7, 6.9, 4.7 Hz, 2H), 2.17 – 2.07 (m, 4H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 161.5, 157.9, 109.9, 44.3, 37.5, 28.7. 
FT-IR (ATR, cm-1): 𝜈 = 2947, 2850, 1582, 1545, 1491, 1443, 1390, 1356, 1304, 1271, 1258, 1218, 1165, 
1083, 1060, 1011, 993, 976, 842, 846, 794, 779, 672. 
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MS (EI, 70 eV): m/z (%) = 289 (6), 163 (10), 162 (100), 160 (6), 134 (29), 108 (69), 79 (6). 




The title compound was prepared according to literature procedure from 1-(4-fluorophenyl)propan-2-ol. 
The analytical data is in full consistency with the data reported in the literature. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.17 –7.12 (m, 2H), 7.04 –6.97 (m, 2H), 4.29 (h, J = 7.0, 1H), 3.22 (dd, 




Dihydro-β-ionone was reduced according to literature procedure148 by NaBH4, affording 4-(2,6,6-
trimethylcyclohex-1-en-1-yl)butan-2-ol. Triphenylphosphine (4.32 g, 16.5 mmol, 1.1 equiv) and imidazole 
(1.12 g, 16.5 mmol, 1.1 equiv) were dissolved in dichloromethane (50 mL, 0.3 M to the corresponding 
alcohol) and cooled to 0 °C. Iodine (4.19 g, 16.6 mmol, 1.1 equiv) was added over 15 min and 4-(2,6,6-
trimethylcyclohex-1-en-1-yl)butan-2-ol (2.94 g, 15 mmol, 1.0 equiv) was added dropwise. The reaction 
mixture was warmed to room temperature and stirred overnight. Saturated aqueous sodium thiosulfate 
solution (30 mL) was added and the mixture was extracted with dichloromethane (3 x 20 mL). After solvent 
evaporation, the crude product was subjected to column chromatography with ihexane as eluent. 2-(3-
Iodobutyl)-1,3,3-trimethylcyclohex-1-ene was obtained as a colorless oil (2.48 g, 8.1 mmol, 54% yield). 
1H-NMR (400 MHz, CDCl3, ppm): δ = 4.19 (dqd, J = 8.2, 6.9, 4.8 Hz, 1H), 2.20 (td, J = 12.9, 4.5 Hz, 1H), 2.03 
(td, J = 12.9, 4.5 Hz, 1H), 1.94 (d, J = 6.9 Hz, 3H), 1.92 – 1.87 (m, 2H), 1.87 – 1.79 (m, 1H), 1.66 (ddt, J = 12.3, 
9.8, 4.7 Hz, 1H), 1.59 (s, 3H), 1.58 – 1.50 (m, 2H), 1.44 – 1.37 (m, 2H), 0.99 (s, 6H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 136.0, 128.0, 43.0, 39.9, 35.2, 32.9, 31.3, 29.1, 29.0, 28.7, 28.7, 20.1, 
19.62. 
FT-IR (ATR, cm-1): 𝜈 = 2957, 2925, 2864, 1471, 1443, 1376, 1360, 1270, 1259, 1223, 1191, 1173, 1134, 
1111, 1080, 1040, 991, 973, 902, 861, 833, 747, 704. 
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MS (EI, 70 eV): m/z (%) = 291 (43), 163 (26), 137 (88), 123 (81), 121 (30), 109 (26), 107 (46), 95 (96), 93 
(40), 91 (31), 81 (100), 79 (29), 67 (28). 




Butane-1,3-diol (2.23 mL, 25.0 mmol, 1.0 equiv), 4-(dimethylamino)pyridine (0.60 g, 5.00 mmol, 0.2 equiv) 
and triethylamine (5.05 g, 50.0 mmol, 2.0 equiv) were dissolved in DCM (50 mL) and cooled to 0 °C. 
Isobutyryl chloride (2.92 g, 27.5 mmol, 1.1 equiv) was dissolved in DCM (8 mL) and was added slowly to 
the cooled solution. The reaction mixture was warmed to room temperature and stirred overnight. The 
solution was washed twice with saturated NaHCO3, the aqueous phase was extracted with DCM and the 
combined organic layers were dried over anhydrous Na2SO4. The solvent was evaporated and the crude 
product was purified via column chromatography using ihexane/EtOAc (7:3) to yield 3-hydroxybutyl 
isobutyrate (3.02 g, 18.8 mmol, 68%) as a colorless liquid. The analytical data is in full consistency with the 
data reported in the literature.149 
1H-NMR (400 MHz, CDCl3, ppm): δ = 4.45 – 4.25 (m, 1H), 4.11 (dt, J = 11.2, 5.6 Hz, 1H), 3.95 – 3.76 (m, 1H), 
2.53 (hd, J = 7.0, 1.8 Hz, 1H), 1.88 – 1.56 (m, 2H), 1.22 (dd, J = 6.3, 1.9 Hz, 3H), 1.19 – 1.12 (m, 6H). 
 
Iodine (5.28, 20.6 mmol, 1.1 equiv) was dissolved in DCM (120 mL, 0.2 M with respect to the corresponding 
alcohol) and then cooled to 0 °C. Triphenylphosphine (5.50 g, 20.6 mmol, 1.1 equiv) was added slowly. The 
mixture was stirred for 1 h and cooled to -20 °C. Imidazole (1.36 g, 20.6 mmol, 1.1 equiv) was added and 
the mixture was stirred for 10 min. Then, 3-hydroxybutyl isobutyrate (3.02 g, 18.8 mmol, 1.0 equiv) was 
added and the solution was stirred overnight. The reaction mixture was washed with saturated aqueous 
sodium thiosulfate solution, brine and dried over anhydrous Na2SO4. After evaporation of the solvent, the 
crude product was subjected to flash column chromatography using ihexane/EtOAc (8:2) to yield 3-
iodobutyl isobutyrate as a colorless liquid (3.13 g, 11.6 mmol, 62%). 
1H-NMR (400 MHz, CDCl3, ppm): δ = 4.24 (tdd, J = 9.3, 7.6, 5.0 Hz, 2H), 4.10 (ddd, J = 11.2, 7.9, 5.6 Hz, 1H), 
2.54 (dt, J = 14.0, 7.0 Hz, 1H), 2.12 (ddt, J = 14.7, 9.1, 5.3 Hz, 1H), 2.03 – 1.89 (m, 4H), 1.16 (dd, J = 7.0, 
1.5 Hz, 6H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 177.1, 64.1, 41.4, 34.1, 29.1, 24.4, 19.1, 19.1. 
                                                          





FT-IR (ATR, cm-1): 𝜈 = 3412, 2973, 1732, 1469, 1388, 1344, 1191, 1154, 1125, 1076, 1048, 1021, 982, 929, 
845, 794, 752. 
MS (EI, 70 eV): m/z (%) = 143 (55), 89 (100), 71 (17), 55 (36), 43 (26). 
HR-MS (EI, 70eV): [M+H+] Calcd for C8H16O2I+ 271.0189; Found: 271.0189. 
 
3-Iodobutyl 4-methoxybenzoate (105h)150 
 
The title compound was prepared according to literature procedure from 3-hydroxybutyl 4-
methoxybenzoate. The analytical data is in full consistency with the data reported in the literature. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.01 – 7.91 (m, 2H), 6.95 – 6.83 (m, 2H), 4.47 (dt, J = 11.2, 5.6 Hz, 1H), 
4.30 (ddt, J = 11.8, 6.8, 4.2 Hz, 2H), 3.83 (s, 3H), 2.23 (ddt, J = 14.6, 9.1, 5.4 Hz, 1H), 2.09 (dddd, J = 15.0, 




The title compound was prepared according to literature procedure from 3-hydroxybutyl furan-2-
carboxylate. The analytical data is in full consistency with the data reported in the literature. 
1H-NMR (400 MHz, CDCl3, ppm): δ 7.58 (dd, J = 1.8, 0.9 Hz, 1H), 7.18 (dd, J = 3.6, 0.9 Hz, 1H), 6.51 (dd, J = 
3.5, 1.7 Hz, 1H), 4.50 (dt, J = 11.2, 5.6 Hz, 1H), 4.42 – 4.22 (m, 2H), 2.23 (ddt, J = 14.7, 9.2, 5.4 Hz, 1H), 2.10 




The title compound was prepared according to literature procedure from ethyl 3-hydroxybutanoate. The 
analytical data is in full consistency with the data reported in the literature. 
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1H-NMR (400 MHz, CDCl3, ppm): δ = 4.45 (dp, J = 8.1, 6.8 Hz, 1H), 4.17 (qd, J = 7.1, 0.8 Hz, 2H), 2.99 (dd, 




The title compound was prepared according to literature procedure from cyclohexene and N-
iodosuccinimide. The analytical data is in full consistency with the data reported in the literature. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 4.09 – 3.98 (m, 1H), 3.80 – 3.68 (m, 1H), 2.47 – 2.31 (m, 1H), 2.11 – 
2.02 (m, 1H), 2.00 – 1.88 (m, 1H), 1.84 – 1.70 (m, 1H), 1.58 – 1.46 (m, 1H), 1.41 – 1.25 (m, 3H), 0.91 (s, 9H), 




The title compound was prepared according to literature procedure from (+)-menthol. The analytical data 
is in full consistency with the data reported in the literature. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 4.94 (p, J = 2.8 Hz, 1H), 2.38 (dtd, J = 14.5, 3.3, 2.2 Hz, 1H), 2.14 (tdd, 
J  = 11.6, 5.7, 3.2 Hz, 1H), 1.92 (ttd, J = 12.7, 3.5, 2.2 Hz, 2H), 1.58 – 1.36 (m, 3H), 1.15 – 1.01 (m, 10H), 0.00 




The title compound was prepared according to literature procedure from 4-(4-methoxyphenyl)butan-2-ol. 
The analytical data is in full consistency with the data reported in the literature. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.15 – 7.10 (m, 2H), 6.87 – 6.81 (m, 2H), 4.11 (dqd, J = 9.1, 6.8, 4.5 Hz, 
1H), 3.79 (s, 3H), 2.79 (ddd, J = 13.9, 8.8, 5.2 Hz, 1H), 2.64 (ddd, J = 13.8, 8.8, 7.0 Hz, 1H), 2.13 (dtd, J = 14.2, 
8.9, 5.2 Hz, 1H), 1.95 (d, J = 6.8 Hz, 3H), 1.84 (dddd, J = 14.6, 8.8, 7.1, 4.5 Hz, 1H). 
                                                          







The title compound was prepared according to literature procedure from 1,4-dioxaspiro[4.5]decan-8-ol. 
The analytical data is in full consistency with the data reported in the literature. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 4.47 – 4.36 (m, 1H), 4.01 – 3.87 (m, 4H), 2.13 (dtt, J = 15.7, 7.7, 4.2 Hz, 




The title compound was prepared according to literature procedure from 3,4-dihydro-2H-pyran N-
iodosuccinimide and prop-2-en-1-ol. The analytical data is in full consistency with the data reported in the 
literature. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 5.87 (dddd, J = 16.9, 10.3, 6.1, 5.2 Hz, 1H), 5.27 (dq, J = 17.2, 1.7 Hz, 
1H), 5.15 (dq, J = 10.4, 1.4 Hz, 1H), 4.62 (d, J = 5.3 Hz, 1H), 4.20 (ddt, J = 12.9, 5.3, 1.5 Hz, 1H), 4.05 (ddd, J 
= 8.1, 5.3, 4.3 Hz, 1H), 4.02 –3.94 (m, 1H), 3.94 –3.88 (m, 1H), 3.52 (ddd, J = 11.2, 7.4, 3.5 Hz, 1H), 2.32 
(ddt, J = 14.9, 7.8, 4.1 Hz, 1H), 1.96 (dtd, J = 14.0, 8.3, 4.0 Hz, 1H), 1.71 (dtt, J = 14.2, 7.3, 3.8 Hz, 1H), 1.61–
1.41 (m, 1H). 
 
3.3 Preparation of Organometallic Reagents 
Preparation of dialkylzinc reagents via magnesium insertion and subsequent transmetalation (TP1):16a 
Dry LiCl (1.20 equiv.) was placed in a dry and argon flushed 50 mL Schlenk-tube equipped with a magnetic 
stirring bar and a septum and was dried over 5 min at 300 °C with a heat gun under high vacuum. 
Magnesium turnings (1.20 equiv.) were added and the flask was evacuated and back-filled with argon 
three times. Dry THF (1.0 M solution with respect to the alkyl halide) was added and the respective alkyl 
bromide (1.00 equiv). After the exothermic reaction started, the mixture was cooled with an ice bath. To 
monitor the progress of the insertion reaction, reaction aliquots quenched with iodine were analyzed by 
GC-analysis. After completion of the insertion, the concentrations of the magnesium reagent were 
                                                          





determined via titration with iodine (50 mg in 2 mL THF).95 A ZnCl2 solution (1.00 m in THF, 0.50 equiv.) 
was added at 0 °C and stirred at 0 °C for 15 min affording the corresponding dialkylzinc reagent. 
 
Preparation of dialkylzinc reagents by magnesium insertion in the presence of ZnCl2 (TP2):17 
Dry LiCl (504 mg, 9.60 mmol, 1.50 equiv) was placed in a dry and argon flushed 50 mL Schlenk-tube 
equipped with a magnetic stirring bar and a septum and was dried over 5 min at 300 °C under high vacuum 
(0.1 mbar). Magnesium turnings (480 mg, 20.0 mmol, 2.50 equiv.) were added and the flask was 
evacuated and back-filled with argon three times. ZnCl2 solution (4.00 mL, 1.00 m in THF, 0.50 equiv) was 
added and the respective alkyl halide (8.00 mmol, 1.00 equiv.) dissolved in THF (20.0 mL) was added via 
syringe. To monitor the progress of the insertion reaction, reaction aliquots quenched with iodine were 
analyzed by GC-analysis. After completion of the insertion, the black solution was filtered via syringe filter 
(30 mm with 0.45 μm glass fiber membrane) and transferred to a dry argon flushed Schlenk-tube. After 
reducing the volume to half the amount under reduced pressure, the concentrations of the dialkylzinc 
reagents were determined via titration with iodine (50 mg in 2 mL THF). 95 
 
3.4 Cobalt-Catalyzed Csp3-Csp3 Cross-Coupling of Functionalized Alkylzinc Reagents with Alkyl Iodides 
Cobalt-Catalyzed Cross-Coupling of Functionalized Alkylzinc Reagents with Alkyl Iodides (TP3):  
A dry and argon flushed Schlenk-tube, equipped with a magnetic stir bar and a septum was charged with 
dry CoCl2 (13 mg, 0.100 mmol, 20 mol%), which was dried at 300 °C under high vacuum for 2 min prior to 
use.  
A) For coupling of primary alkyl iodides: 
Tetrabutylammonium iodide (TBAI, 416 mg, 1.13 mmol, 2.25 equiv) the respective primary alkyl iodide 
(0.50 mmol, 1.00 equiv), dry MeCN (1.0 mL) and Me4DACH (17 mg, 20 mol%) were added. Then a solution 
of the respective dialkylzinc reagent (0.375 mmol, 0.75 equiv.) was added via syringe at room 
temperature. 
 
B) For coupling of secondary alkyl iodides: 
Tetrabutylammonium iodide (TBAI, 416 mg, 1.13 mmol, 2.25 equiv) the respective secondary alkyl iodide 
(0.50 mmol, 1.00 equiv), neocuproine (21 mg, 20 mol%) and dry MeCN (1.0 mL) were added. Then a 






In both cases the reaction was stirred for 16 h at room temperature. The solvent was removed and the 





Following TP3-A (3-iodopropyl)benzene (105a, 123 mg, 0.50 mmol, 1.00 equiv.) was coupled with di(2-
(1,3-dioxan-2-yl)ethyl)zinc (106a, 0.375 mmol, 0.75 equiv.) prepared according to TP1 from the 
corresponding bromide.  
Isolated yield: 84 mg, 0.360 mmol, 72%, colorless oil. 
Purification: pentane:ethyl acetate = 9:1. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.23 – 7.15 (m, 2H), 7.10 (m, 3H), 4.43 (t, J = 5.2 Hz, 1H), 4.03 (ddt, J 
= 10.5, 5.0, 1.4 Hz, 2H), 3.68 (ddt, J = 12.4, 10.5, 2.0 Hz, 2H), 2.53 (dd, J = 8.7, 6.9 Hz, 2H), 2.00 (dtt, J = 13.5, 
12.5, 5.0 Hz, 1H), 1.63 – 1.47 (m, 4H), 1.43 – 1.20 (m, 5H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 142.9, 128.5, 128.3, 125.7, 102.5, 67.0, 35.9, 35.3, 31.5, 29.2, 26.0, 
23.9. 
FT-IR (ATR, cm-1): 𝜈 = 2927, 2851, 1734, 1603, 1495, 1454, 1430, 1403, 1377, 1283, 1239, 1216, 1144, 
1089, 1053, 1030, 995, 939, 925, 907, 892, 856, 796, 745, 697. 
MS (EI, 70 eV): m/z (%) = 233 (16), 158 (100), 143 (41), 130 (42), 129 (48), 117 (25), 104 (32), 91 (57), 87 
(86). 




Following TP3-A 6-iodo-2,2-dimethylhexanenitrile (105i, 134 mg, 0.50 mmol, 1.00 equiv.) was coupled 
with di(2-(1,3-dioxan-2-yl)ethyl)zinc (106a, 0.375 mmol, 0.75 equiv.) prepared according to TP1 from the 
corresponding bromide.  
Isolated yield: 80 mg, 0.335 mmol, 67%, pale yellow oil. 





1H-NMR (400 MHz, CDCl3, ppm): δ = 4.50 (t, J = 5.2 Hz, 1H), 4.09 (ddd, J = 12.0, 5.1, 1.5 Hz, 2H), 3.75 (tt, 
J = 10.6, 2.3 Hz, 2H), 2.07 (qt, J = 12.6, 5.0 Hz, 1H), 1.57 (dt, J = 8.8, 5.7 Hz, 2H), 1.47 (dd, J = 5.5, 3.3 Hz, 
3H), 1.41 – 1.34 (m, 6H), 1.32 (m, 8H) 
13C-NMR (100 MHz, CDCl3, ppm): δ = 125.4, 102.4, 67.0, 41.2, 35.3, 32.5, 29.6, 29.4, 26.8, 26.0, 25.3, 24.0. 
FT-IR (ATR, cm-1): 𝜈 = 2932, 2854, 1469, 1430, 1404, 1377, 1287, 1238, 1215, 1143, 1093, 1054, 997, 940, 
893, 859, 834, 796, 726. 
MS (EI, 70 eV): m/z (%) = 238 (12), 180 (5), 152 (4), 88 (5), 87 (100), 59 (9). 




Following TP3-A 1-(2-iodoethyl)-4-methoxybenzene (131 mg, 0.50 mmol, 1.00 equiv.) was coupled with 
di(2-(1,3-dioxan-2-yl)ethyl)zinc (106a, 0.375 mmol, 0.75 equiv.) prepared according to TP1 from the 
corresponding bromide.  
Isolated yield: 76 mg, 0.304 mmol, 61 %, colorless oil. 
Purification: pentane:ethyl acetate = 9:1. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.14 – 7.04 (m, 2H), 6.88 – 6.77 (m, 2H), 4.50 (t, J = 5.2 Hz, 1H), 4.09 
(ddt, J = 10.5, 5.0, 1.4 Hz, 2H), 3.78 (s, 3H), 3.76 – 3.71 (m, 2H), 2.60 – 2.51 (m, 2H), 2.07 (dtt, J = 13.5, 12.5, 
5.0 Hz, 1H), 1.67 – 1.53 (m, 4H), 1.48 – 1.37 (m, 2H), 1.33 (dtt, J = 13.4, 2.6, 1.4 Hz, 1H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 157.7, 134.8, 129.4, 113.8, 102.4, 67.0, 55.4, 35.3, 35.1, 31.8, 26.0, 
23.8. 
FT-IR (ATR, cm-1): 𝜈 = 2927, 2851, 1611, 1583, 1511, 1464, 1441, 1403, 1377, 1299, 1241, 1176, 1143, 
1110, 1086, 1034, 992, 937, 893, 868, 830, 815, 749, 698. 
MS (EI, 70 eV): m/z (%) = 249 (4), 175 (13), 174 (100), 173 (30), 159 (32), 147 (37), 143 (51), 132 (10), 121 
(64), 91 (22), 87 (11). 












Following TP3-A 3-(2-iodoethyl)-1-tosyl-1H-indole (213 mg, 0.50 mmol, 1.00 equiv.) was coupled with di(2-
(1,3-dioxan-2-yl)ethyl)zinc (106a, 0.375 mmol, 0.75 equiv.) prepared according to TP1 from the 
corresponding bromide.  
Isolated yield: 130 mg, 0.315 mmol, 63 %, colorless oil. 
Purification: pentane:ethyl acetate = 8:2. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.89 (dt, J = 8.3, 0.9 Hz, 1H), 7.69 – 7.62 (m, 2H), 7.38 (dt, J = 7.8, 
0.9 Hz, 1H), 7.24 (d, J = 1.2 Hz, 1H), 7.23 – 7.19 (m, 1H), 7.16 – 7.08 (m, 3H), 4.45 (t, J = 5.1 Hz, 1H), 4.04 
(ddt, J = 10.6, 5.0, 1.3 Hz, 2H), 3.75 – 3.62 (m, 2H), 2.63 – 2.53 (m, 2H), 2.25 (s, 3H), 2.11 – 1.91 (m, 1H), 
1.68 – 1.51 (m, 4H), 1.47 – 1.33 (m, 2H), 1.27 (dtt, J = 13.5, 2.6, 1.4 Hz, 1H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 144.7, 135.5, 135.4, 131.3, 129.9, 126.9, 124.6, 123.5, 123.0, 122.7, 
119.6, 113.9, 102.3, 67.1, 35.0, 28.8, 26.0, 24.9, 23.9, 21.7. 
FT-IR (ATR, cm-1): 𝜈 = 2925, 2853, 1597, 1446, 1402, 1364, 1275, 1239, 1205, 1187, 1170, 1119, 1086, 
1050, 1018, 975, 937, 893, 868, 844, 812, 744, 702, 666. 
MS (EI, 70 eV): m/z (%) = 413 (7), 285 (19), 259 (17), 158 (100), 182 (16), 156 (43), 130 (23), 91 (17), 87 
(25). 




Following TP3-B iodocyclohexane (105 mg, 0.50 mmol, 1.00 equiv.) was coupled with di(2-(1,3-dioxan-2-
yl)ethyl)zinc (106a, 0.375 mmol, 0.75 equiv.) prepared according to TP1 from the corresponding bromide.  
Isolated yield: 75 mg, 0.381 mmol, 76%, pale yellow oil. 
Purification: pentane:ethyl acetate = 8:2. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 4.46 (t, J = 5.2 Hz, 1H), 4.14 – 4.02 (m, 2H), 3.74 (ddt, J = 12.3, 10.4, 
2.5 Hz, 2H), 2.06 (qt, J = 12.7, 5.0 Hz, 1H), 1.77 – 1.62 (m, 4H), 1.61 – 1.52 (m, 2H), 1.31 (dtt, J = 13.5, 2.6, 
1.4 Hz, 1H), 1.28 – 1.04 (m, 7H), 0.85 (qd, J = 13.7, 12.5, 3.6 Hz, 2H). 





FT-IR (ATR, cm-1): 𝜈 = 2920, 2847, 1448, 1403, 1376, 1237, 1144, 1098, 1074, 1054, 1001, 965, 1001, 965, 
941, 926, 893, 863, 840. 
MS (EI, 70 eV): m/z (%) = 197 (17), 121 (19), 93 (13), 87 (100), 81 (11), 79 (11), 59 (15). 




Following TP3-B 4-iodotetrahydro-2H-pyran (105b, 106 mg, 0.50 mmol, 1.00 equiv.) was coupled with 
di(2-(1,3-dioxan-2-yl)ethyl)zinc (106a, 0.375 mmol, 0.75 equiv.) prepared according to TP1 from the 
corresponding bromide.  
Isolated yield: 70 mg, 0.350 mmol, 70%, colorless oil. 
Purification: pentane:ethyl acetate = 8:2. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 4.50 (t, J = 5.1 Hz, 1H), 4.18 – 4.02 (m, 2H), 3.99 – 3.87 (m, 2H), 3.76 
(ddt, J = 12.3, 10.3, 2.4 Hz, 2H), 3.35 (td, J = 11.8, 2.1 Hz, 2H), 2.15 – 1.98 (m, 1H), 1.66 – 1.53 (m, 4H), 1.45 
(dtt, J = 17.1, 10.5, 3.6 Hz, 1H), 1.38 – 1.29 (m, 3H), 1.24 (ddd, J = 13.1, 11.2, 4.5 Hz, 2H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 102.6, 68.2, 67.1, 35.0, 33.2, 32.3, 31.1, 26.0. 
FT-IR (ATR, cm-1): 𝜈 = 2951, 2924, 2842, 1455, 1430, 1404, 1376, 1282, 1239, 1215, 1202, 1142, 1117, 
1094, 1074, 1041, 1010, 977, 942, 926, 908, 887, 860, 843, 813. 
MS (EI, 70 eV): m/z (%) = 199 (5), 123 (19), 96 (37), 87 (100), 59 (22).  
HR-MS (EI, 70eV): [M-H+] Calcd for C11H19O3+ 199.1329; Found: 199.1329.  
 
tert-Butyl 4-(2-(1,3-dioxan-2-yl)ethyl)piperidine-1-carboxylate (107g) 
 
Following TP3-B tert-butyl 4-iodopiperidine-1-carboxylate (105c, 156 mg, 0.50 mmol, 1.00 equiv.) was 
coupled with di(2-(1,3-dioxan-2-yl)ethyl)zinc (106a, 0.375 mmol, 0.75 equiv.) prepared according to TP1 
from the corresponding bromide.  
Isolated yield: 111 mg, 0.371 mmol, 74%, yellow oil. 





1H-NMR (400 MHz, CDCl3, ppm): δ = 4.49 (t, J = 5.1 Hz, 1H), 4.17 – 3.97 (m, 4H), 3.81 – 3.67 (m, 2H), 2.65 
(t, J = 12.4 Hz, 2H), 2.16 – 1.93 (m, 1H), 1.72 – 1.52 (m, 4H), 1.44 (d, J = 0.9 Hz, 9H), 1.39 – 1.26 (m, 4H), 
1.14 – 0.98 (m, 2H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 154.9, 102.4, 79.1, 66.9, 44.80 – 43.37 (br), 35.9, 32.4, 32.1, 30.6, 
28.5, 25.8. 
FT-IR (ATR, cm-1): 𝜈 = 2929, 2853, 1678, 1469, 1454, 1425, 1366, 1277, 1244, 1170, 1143, 1091, 1076, 
1010, 967, 909, 865, 770, 727. 
MS (EI, 70 eV): m/z (%) = 198 (33), 140 (40), 139 (19), 125 (30), 122 (46), 122 (60), 84 (19), 82 (100), 57 
(18). 




Following TP3-B 2-(4-iodopiperidin-1-yl)pyrimidine (105d, 145 mg, 0.50 mmol, 1.00 equiv.) was coupled 
with di(2-(1,3-dioxan-2-yl)ethyl)zinc (106a, 0.375 mmol, 0.75 equiv.) prepared according to TP1 from the 
corresponding bromide.  
Isolated yield: 80 mg, 0.289 mmol, 58%, pale yellow oil. 
Purification: pentane:ethyl acetate = 7:3. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.28 (d, J = 4.7 Hz, 2H), 6.43 (t, J = 4.7 Hz, 1H), 4.72 (dq, J = 13.4, 
2.2 Hz, 2H), 4.51 (t, J = 5.1 Hz, 1H), 4.15 – 4.02 (m, 2H), 3.76 (tt, J = 10.6, 2.4 Hz, 2H), 2.85 (td, J = 12.9, 2.7 
Hz, 2H), 2.18 – 1.99 (m, 1H), 1.84 – 1.71 (m, 2H), 1.70 – 1.57 (m, 2H), 1.50 (dtq, J = 14.8, 7.1, 3.5 Hz, 1H), 
1.44 – 1.29 (m, 3H), 1.16 (qd, J = 12.6, 4.4 Hz, 2H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 161.6, 157.7, 109.2, 102.5, 67.0, 44.1, 36.2, 32.5, 32.1, 30.7, 25.9. 
FT-IR (ATR, cm-1): 𝜈 = 2923, 2846, 1583, 1544, 1504, 1452, 1392, 1360, 1304, 1282, 1266, 1252, 1239, 
1218, 1201, 1181, 1142, 1110, 1074, 1044, 1002, 966, 943, 881, 852, 795, 777. 
MS (EI, 70 eV): m/z (%) = 277 (15), 218 (34), 200 (18), 176 (51), 163 (20), 160 (100), 134 (30), 122 (20), 108 
(38), 87. 









Following TP3-B 1-fluoro-4-(2-iodopropyl)benzene (132 mg, 0.50 mmol, 1.00 equiv.) was coupled with 
di(2-(1,3-dioxan-2-yl)ethyl)zinc (2b, 0.375 mmol, 0.75 equiv.) prepared according to TP1 from the 
corresponding bromide.  
Isolated yield: 91 mg, 0.361 mmol, 72%, brown oil. 
Purification: pentane:ethyl acetate = 9:1. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.13 – 7.03 (m, 2H), 6.99 – 6.90 (m, 2H), 4.48 (t, J = 5.2 Hz, 1H), 4.10 
(ddd, J = 11.8, 5.0, 1.5 Hz, 2H), 3.75 (td, J = 12.2, 2.5 Hz, 2H), 2.62 (dd, J = 13.5, 5.9 Hz, 1H), 2.32 (dd, J = 
13.5, 8.3 Hz, 1H), 2.07 (dtt, J = 13.4, 12.5, 5.0 Hz, 1H), 1.74 – 1.51 (m, 3H), 1.44 (ddt, J = 13.4, 11.5, 5.2 Hz, 
1H), 1.33 (dtt, J = 13.4, 2.7, 1.4 Hz, 1H), 1.29 – 1.17 (m, 1H), 0.83 (d, J = 6.6 Hz, 3H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 161.3 (d, J = 242.9 Hz), 137.1 (d, J = 3.3 Hz), 130.5 (d, J = 7.7 Hz), 114.9 
(d, J = 21.0 Hz), 102.7, 67.1, 42.8, 35.2, 33.1, 30.8, 26.0, 19.2. 
19F-NMR (376 MHz, CDCl3, ppm): δ = -117.95 (tt, J = 8.8, 5.4 Hz). 
FT-IR (ATR, cm-1): 𝜈 = 2956, 2926, 2851, 1600, 1509, 1460, 1431, 1404, 1378, 1283, 1220, 1145, 1103, 
1079, 1003, 935, 877, 846, 812, 763. 
MS (EI, 70 eV): m/z (%) = 176 (39), 161 (29), 149 (9), 147 (12), 146 (12), 136 (6), 135 (31), 133 (12), 122 
(10), 110 (12), 109 (100), 87 (47), 83 (17), 59 (14), 41 (12). 




Following TP3-B 2-(3-iodobutyl)-1,3,3-trimethylcyclohex-1-ene (105f, 153 mg, 0.50 mmol, 1.00 equiv.) was 
coupled with di(2-(1,3-dioxan-2-yl)ethyl)zinc (106a, 0.375 mmol, 0.75 equiv.) prepared according to TP1 
from the corresponding bromide.  
Isolated yield: 113 mg, 0.384 mmol, 77%, colorless oil 





1H-NMR (400 MHz, CDCl3, ppm): δ = 4.49 (t, J = 5.2 Hz, 1H), 4.17 – 4.02 (m, 2H), 3.76 (td, J = 12.3, 2.4 Hz, 
2H), 2.17 – 1.94 (m, 2H), 1.88 (m, 3H), 1.67 – 1.48 (m, 7H), 1.47 – 1.29 (m, 7H), 1.28 – 1.09 (m, 1H), 0.96 
(s, 6H), 0.90 (d, J = 6.0 Hz, 3H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 137.8, 126.5, 102.9, 67.1, 40.0, 37.5, 35.1, 34.1, 33.2, 32.9, 31.1, 28.8, 
28.8, 26.5, 26.0, 20.0, 19.7, 19.6. 
FT-IR (ATR, cm-1): 𝜈 = 2956, 2868, 1731, 1662, 1459, 1377, 1336, 1239, 1143, 1108, 1075, 998, 936, 880, 
848. 
MS (EI, 70 eV): m/z (%) = 218 (50), 162 (39), 147 (49), 123 (97), 121 (100), 119 (65), 107 (60), 95 (65), 81 
(100). 
HR-MS (EI, 70eV): [M-H+] Calcd for C19H33O2+ 293.2475; Found: 293.2474. 
 
5-(1,3-Dioxan-2-yl)-3-methylpentyl isobutyrate (107k) 
 
Following TP3-B 3-iodobutyl isobutyrate (135 mg, 0.50 mmol, 1.00 equiv.) was coupled with di(2-(1,3-
dioxan-2-yl)ethyl)zinc (106a, 0.375 mmol, 0.75 equiv.) prepared according to TP1 from the corresponding 
bromide.  
Isolated yield: 117 mg, 0.453 mmol, 91%, yellow oil. 
Purification: pentane:ethyl acetate = 8:2. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 4.49 (t, J = 5.1 Hz, 1H), 4.14 – 4.06 (m, 4H), 3.75 (ddt, J = 12.4, 10.4, 
2.4 Hz, 2H), 2.52 (hept, J = 7.0 Hz, 1H), 2.07 (dtt, J = 13.2, 12.3, 5.0 Hz, 1H), 1.73 – 1.46 (m, 4H), 1.47 – 1.38 
(m, 2H), 1.33 (dtt, J = 13.5, 2.7, 1.4 Hz, 1H), 1.24 (dddd, J = 13.2, 11.3, 7.7, 5.4 Hz, 1H), 1.15 (d, J = 7.0 Hz, 
6H), 0.90 (d, J = 6.5 Hz, 3H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 177.4, 102.7, 67.1, 62.8, 35.6, 34.2, 32.84, 31.0, 29.9, 26.0, 19.5, 19.2. 
FT-IR (ATR, cm-1): 𝜈 = 2960, 2930, 2852, 1733, 1470, 1432, 1404, 1379, 1346, 1259, 1241, 1193, 1147, 
1113, 1078, 1004, 929, 881, 850, 831. 
MS (EI, 70 eV): m/z (%) = 113 (6), 95 (7), 94 (6), 88 (5), 87 (100), 79 (5), 59 (8). 








5-(1,3-Dioxan-2-yl)-3-methylpentyl 4-methoxybenzoate (107l) 
 
Following TP3-B 3-iodobutyl 4-methoxybenzoate (105g, 167 mg, 0.50 mmol, 1.00 equiv.) was coupled with 
di(2-(1,3-dioxan-2-yl)ethyl)zinc (106a, 0.375 mmol, 0.75 equiv.) prepared according to TP1 from the 
corresponding bromide.  
Isolated yield: 108 mg, 0.335 mmol, 67%, yellow oil. 
Purification: pentane:ethyl acetate = 8:2. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.01 – 7.95 (m, 2H), 6.93 – 6.87 (m, 2H), 4.50 (t, J = 5.1 Hz, 1H), 4.32 
(ddd, J = 7.6, 6.5, 1.6 Hz, 2H), 4.09 (ddt, J = 10.5, 5.0, 1.4 Hz, 2H), 3.85 (s, 3H), 3.81 – 3.65 (m, 2H), 2.15 – 
1.99 (m, 1H), 1.79 (dtd, J = 12.5, 7.0, 4.9 Hz, 1H), 1.74 – 1.42 (m, 5H), 1.38 – 1.19 (m, 2H), 0.95 (d, J = 6.4 Hz, 
3H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 166.4, 163.2, 131.5, 122.9, 113.5, 102.5, 66.9, 63.1, 55.4, 35.5, 32.7, 
30.9, 29.9, 25.9, 19.4. 
FT-IR (ATR, cm-1): 𝜈 = 2957, 2928, 2848, 1708, 1606, 1582, 1512, 1460, 1420, 1404, 1379, 1316, 1274, 
1253, 1167, 1144, 1101, 1078, 1029, 1006, 938, 881, 848, 770, 697. 
MS (EI, 70 eV): m/z (%) = 153 (5), 152 (36), 136 (6), 135 (72), 113 (30), 92 (6), 88 (5), 87 (100), 77 (10), 59 
(8). 
HR-MS (EI, 70eV): [M-H+] Calcd for C18H25O5+ 321.1697; Found: 321.1682. 
 
5-(1,3-Dioxan-2-yl)-3-methylpentyl furan-2-carboxylate (107m) 
 
Following TP3-B 3-iodobutyl furan-2-carboxylate (147 mg, 0.50 mmol, 1.00 equiv.) was coupled with di(2-
(1,3-dioxan-2-yl)ethyl)zinc (106a, 0.375 mmol, 0.75 equiv.) prepared according to TP1 from the 
corresponding bromide.  
Isolated yield: 121 mg, 0.429 mmol, 86%, yellow oil. 





1H-NMR (400 MHz, CDCl3, ppm): δ = 7.57 (dd, J = 1.8, 0.9 Hz, 1H), 7.15 (dd, J = 3.5, 0.9 Hz, 1H), 6.50 (dd, 
J = 3.5, 1.7 Hz, 1H), 4.49 (t, J = 5.1 Hz, 1H), 4.33 (td, J = 6.6, 1.4 Hz, 2H), 4.09 (ddt, J = 10.5, 5.0, 1.4 Hz, 2H), 
3.82 – 3.69 (m, 2H), 2.16 – 1.99 (m, 1H), 1.85 – 1.73 (m, 1H), 1.73 – 1.42 (m, 5H), 1.38 – 1.27 (m, 1H), 1.26 
(tdd, J = 10.7, 6.6, 3.6 Hz, 1H), 0.94 (d, J = 6.3 Hz, 3H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 158.8, 146.2, 144.9, 117.7, 111.8, 102.5, 66.9, 63.4, 35.4, 32.7, 30.8, 
29.8, 25.8, 19.4. 
FT-IR (ATR, cm-1): 𝜈 = 2958, 2929, 2854, 1727, 1582, 1474, 1431, 1400, 1380, 1296, 1232, 1180, 1145, 
1117, 1077, 1011, 942, 884, 852, 813, 764. 
MS (EI, 70 eV): m/z (%) = 113 (17), 112 (5), 95 (29), 88 (5), 87 (100), 59 (9). 
HR-MS (EI, 70eV): [M-H+] Calcd for C15H21O5+ 281.1384; Found: 281.1375. 
 
Ethyl 5-(1,3-dioxan-2-yl)-3-methylpentanoate (107n) 
 
Following TP3-B ethyl 3-iodobutanoate (121 mg, 0.50 mmol, 1.00 equiv.) was coupled with di(2-(1,3-
dioxan-2-yl)ethyl)zinc (106a, 0.375 mmol, 0.75 equiv.) prepared according to TP1 from the corresponding 
bromide.  
Isolated yield: 59 mg, 0.256 mmol, 51%, yellow oil. 
Purification: pentane:ethyl acetate = 8:2. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 4.49 (t, J = 5.1 Hz, 1H), 4.15 – 4.06 (m, 4H), 3.75 (ddt, J = 12.4, 10.5, 
2.1 Hz, 2H), 2.30 (dd, J = 14.7, 5.7 Hz, 1H), 2.14 – 2.00 (m, 2H), 1.95 (qt, J = 7.9, 6.0 Hz, 1H), 1.70 – 1.51 (m, 
2H), 1.43 (ddt, J = 13.3, 11.0, 5.4 Hz, 1H), 1.38 – 1.25 (m, 2H), 1.25 (t, J = 7.1 Hz, 3H), 0.93 (d, J = 6.6 Hz, 
3H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 173.2, 102.4, 66.9, 60.1, 41.8, 32.7, 30.8, 30.2, 25.8, 19.5, 14.3. 
FT-IR (ATR, cm-1): 𝜈 = 2958, 2931, 2851, 1731, 1461, 1430, 1404, 1375, 1283, 1240, 1212, 1178, 1143, 
1108, 1095, 1074, 1031, 1003, 944, 929, 879, 849. 
MS (EI, 70 eV): m/z (%) = 115 (4), 88(5), 87 (100), 83 (7), 81 (16), 79 (7), 69 (15), 67 (7), 59 (10), 55 (10), 41 
(5). 









Following TP3-A tert-butyl((2-iodocyclohexyl)oxy)dimethylsilane (170 mg, 0.50 mmol, 1.00 equiv.) was 
coupled with di(2-(1,3-dioxan-2-yl)ethyl)zinc (106a, 0.375 mmol, 0.75 equiv.) prepared according to TP1 
from the corresponding bromide.  
Isolated yield: 107 mg, 0.326 mmol, 65%, dr = 86:14, pale yellow oil. 
Purification: pentane:ethyl acetate = 95:5 
1H-NMR (400 MHz, CDCl3, ppm): δ = 4.43 (dd, J = 5.8, 4.7 Hz, 1H), 4.05 (ddt, J = 10.6, 5.2, 1.4 Hz, 2H), 3.78 
– 3.67 (m, 2H), 3.17 (td, J = 9.2, 4.0 Hz, 1H), 2.03 (dtt, J = 13.5, 12.5, 4.9 Hz, 1H), 1.89 – 1.70 (m, 4H), 1.69 
– 1.51 (m, 3H), 1.44 (dddd, J = 13.5, 10.4, 5.5, 4.6 Hz, 1H), 1.34 – 1.26 (m, 1H), 1.26 – 1.10 (m, 4H), 1.11 – 
0.94 (m, 1H), 0.85 (s, 9H), 0.01 (s, 3H), -0.00 (s, 3H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 103.1, 75.3, 67.0, 44.9, 35.8, 32.6, 29.8, 26.7, 26.1, 26.0, 25.4, 24.8, 
18.3, -3.8, -4.6. 
FT-IR (ATR, cm-1): 𝜈 = 2927, 2854, 1737, 1471, 1462, 1448, 1403, 1377, 1360, 1249, 1205, 1145, 1120, 
1082, 1004, 954, 933, 878, 831, 814, 772, 666. 
MS (EI, 70 eV): m/z (%) = 287 (20), 211 (14), 139 (100), 133 (31), 121 (41), 105 (21), 95 (17), 87 821), 75 
(62), 73 (30). 




Following TP3-A (1S,2R,4R)-2-iodo-1-iso-propyl-4-methylcyclohexane (133 mg, 0.50 mmol, 1.00 equiv.) 
was coupled with di(2-(1,3-dioxan-2-yl)ethyl)zinc (106a, 0.375 mmol, 0.75 equiv.) prepared according to 
TP1 from the corresponding bromide.  
Isolated yield: 85 mg, 0.335 mmol, 67%, dr = 89:11, pale yellow oil. 
Purification: pentane:ethyl acetate = 9:1. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 4.46 (t, J = 4.9 Hz, 1H), 4.08 (ddt, J = 10.6, 5.0, 1.4 Hz, 2H), 3.73 (ddq, 
J = 12.4, 10.5, 2.1 Hz, 2H), 2.14 – 1.89 (m, 2H), 1.72 – 1.41 (m, 7H), 1.37 – 1.09 (m, 4H), 1.01 – 0.73 (m, 9H), 





13C-NMR (100 MHz, CDCl3, ppm): δ = 103.2, 67.0, 46.4, 41.3, 38.4, 35.5, 33.0, 31.6, 26.9, 26.4, 26.0, 24.4, 
22.9, 21.8, 15.4. 
FT-IR (ATR, cm-1): 𝜈 = 2954, 2917, 2844, 1737, 1455, 1402, 1376, 1283, 1239, 1216, 1144, 1129, 1103, 
1080, 1056, 1018, 997, 943, 927, 892, 870, 847. 
MS (EI, 70 eV): m/z (%) = 253 (6), 163 (59), 135 (100), 107 (25), 93 (24), 87 (77), 81 (18). 




Following TP3-B (bromomethyl)benzene (86 mg, 0.50 mmol, 1.0 equiv.) or (chloromethyl)benzene (63 mg, 
0.50 mmol, 1.00 equiv.) was coupled with di(2-(1,3-dioxan-2-yl)ethyl)zinc (106a, 0.375 mmol, 0.75 equiv.) 
prepared according to TP1 from the corresponding bromide.  
Isolated yield: 101 mg, 0.490 mmol, 98%, using (bromomethyl)benzene, 79 mg, 0.385 mmol, 77 %, using 
                         (chloromethyl)benzene, yellow oil. 
Purification: pentane:ethyl acetate = 9:1. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.22 – 7.14 (m, 2H), 7.13 – 7.06 (m, 3H), 4.45 (t, J = 5.0 Hz, 1H), 4.02 
(ddt, J = 10.5, 5.1, 1.4 Hz, 2H), 3.73 – 3.61 (m, 2H), 2.55 (t, J = 7.6 Hz, 2H), 1.99 (dtt, J = 13.5, 12.5, 5.0 Hz, 
1H), 1.72 – 1.53 (m, 4H), 1.26 (dtt, J = 13.5, 2.6, 1.4 Hz, 1H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 142.4, 128.6, 128.4, 125.8, 102.3, 67.0, 35.9, 35.0, 26.0, 26.0. 
FT-IR (ATR, cm-1): 𝜈 = 3026, 2955, 2925, 2850, 1603, 1496, 1454, 1430, 1404, 1378, 1283, 1242, 1217, 
1188, 1144, 1130, 1082, 1050, 1030, 1009, 988, 975, 941, 911, 892, 858, 807, 748, 733, 698. 
MS (EI, 70 eV): m/z (%) = 205 (5), 147 (5), 131 (7), 130 (67), 129 (13), 128 (10), 105 (22), 104 (100), 103 (7), 
100 (20), 91 (52), 87 (52), 78 (13), 77 (7), 65 (11), 59 (11), 58 (7). 
HR-MS (EI, 70eV): [M-H+] Calcd for C13H17O2+ 205.1223; Found: 205.1218. 
 
Ethyl (E)-6-(1,3-dioxan-2-yl)hex-2-enoate (107r) 
 
Following TP3-B ethyl (E)-4-bromobut-2-enoate (97 mg, 0.50 mmol, 1.00 equiv.) was coupled with di(2-
(1,3-dioxan-2-yl)ethyl)zinc (106a, 0.375 mmol, 0.75 equiv.) prepared according to TP1 from the 
corresponding bromide.  





Purification: pentane:ethyl acetate = 8:2. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 6.94 (dt, J = 15.6, 6.9 Hz, 1H), 5.81 (dt, J = 15.6, 1.6 Hz, 1H), 4.51 (t, 
J = 4.7 Hz, 1H), 4.16 (q, J = 7.2 Hz, 2H), 4.09 (ddt, J = 10.4, 5.0, 1.4 Hz, 2H), 3.80 – 3.67 (m, 2H), 2.21 (qd, J 
= 7.0, 1.6 Hz, 2H), 2.06 (dtt, J = 13.4, 12.4, 5.0 Hz, 1H), 1.65 – 1.50 (m, 4H), 1.33 (dtt, J = 13.5, 2.7, 1.4 Hz, 
1H), 1.27 (t, J = 7.2 Hz, 3H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 166.8, 148.9, 121.7, 102.0, 67.0, 60.3, 34.7, 32.1, 25.9, 22.5, 14.4. 
FT-IR (ATR, cm-1): 𝜈 = 2957, 2929, 2853, 2733, 2251, 1717, 1654, 1461, 1432, 1405, 1369, 1310, 1268, 
1242, 1200, 1177, 1146, 1096, 1084, 1046, 987, 914, 864, 850, 732. 
MS (EI, 70 eV): m/z (%) = 227 (5), 113 (12), 102 (5), 97 (7), 87 (100), 81 (18), 71 (11), 69 (12), 59 (23), 58 
(23), 57 (22), 55 (20), 43 (12), 43 (24), 41 (25). 




Following TP3-B 1-bromo-3-methylbut-2-ene (75 mg, 0.50 mmol, 1.00 equiv.) was coupled with di(2-(1,3-
dioxan-2-yl)ethyl)zinc (106a, 0.375 mmol, 0.75 equiv.) prepared according to TP1 from the corresponding 
bromide.  
Isolated yield: 55 mg, 0.299 mmol, 60%, yellow liquid. 
Purification: pentane:ethyl acetate = 9:1. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 5.10 (dddd, J = 8.8, 5.9, 3.0, 1.5 Hz, 1H), 4.51 (t, J = 5.2 Hz, 1H), 4.10 
(ddt, J = 10.5, 5.1, 1.4 Hz, 2H), 3.82 – 3.69 (m, 2H), 2.15 – 2.02 (m, 1H), 1.98 (q, J = 7.8, 7.3 Hz, 2H), 1.67 (d, 
J = 1.5 Hz, 3H), 1.62 – 1.55 (m, 5H), 1.47 – 1.37 (m, 2H), 1.33 (dtt, J = 13.4, 2.6, 1.4 Hz, 1H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 131.9, 124.4, 102.6, 67.1, 34.9, 27.9, 26.0, 25.9, 24.4, 17.8. 
FT-IR (ATR, cm-1): 𝜈 = 2956, 2925, 2850, 2731, 1457, 1432, 1404, 1378, 1286, 1243, 1217, 
1146, 1111, 1086, 1052, 990, 929, 893, 862, 826. 
MS (EI, 70 eV): m/z (%) = 113 (42), 100 (9), 93 (7), 91 (7), 87 (37), 83 (5),82 (79), 81 (6), 79 (8), 77 (5), 69 
(5), 68 (5), 67 (100), 65 (5), 59 (11), 55 (15),41 (13). 










Following TP3-B 4-iodotetrahydro-2H-pyran (105b, 106 mg, 0.50 mmol, 1.0 equiv.) was coupled with di(4-
fluorophenethyl)zinc (106b, 0.375 mmol, 0.75 equiv.) prepared according to TP1 from the corresponding 
bromide.  
Isolated yield: 74 mg, 0.356 mmol, 71%, colorless oil. 
Purification: pentane:ethyl acetate = 9:1. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.16 – 7.08 (m, 2H), 7.00 – 6.92 (m, 2H), 4.04 – 3.90 (m, 2H), 3.36 (td, 
J = 11.8, 2.0 Hz, 2H), 2.66 – 2.52 (m, 2H), 1.69 – 1.60 (m, 2H), 1.59 – 1.44 (m, 3H), 1.38 – 1.24 (m, 2H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 161.3 (d, J = 243.2 Hz), 138.2 (d, J = 3.2 Hz), 129.7 (d, J = 7.6 Hz), 115.2 
(d, J = 21.1 Hz), 68.2, 39.0, 34.6, 33.2, 32.0. 
19F-NMR (376 MHz, CDCl3, ppm): δ = -117.98 (tt, J = 8.8, 5.4 Hz). 
FT-IR (ATR, cm-1): 𝜈 = 2926, 2843, 1600, 1508, 1455, 1443, 1387, 1366, 1296, 1218, 1157, 1136, 1093, 
1014, 980, 904, 864, 846, 824, 767, 745, 705. 
MS (EI, 70 eV): m/z (%) = 208 (5), 161 (100), 147 (19), 146 (15), 135 (19), 122 (57), 109 (53). 
HR-MS (EI, 70eV): Calcd for C13H17FO 208.1263; Found: 208.1255. 
 
tert-Butyl 4-(4-fluorophenethyl)piperidine-1-carboxylate (107u) 
 
Following TP3-B tert-butyl 4-iodopiperidine-1-carboxylate (105c, 156 mg, 0.50 mmol, 1.00 equiv.) was 
coupled with di(4-fluorophenethyl)zinc (106b, 0.375 mmol, 0.75 equiv.) prepared according to TP1 from 
the corresponding bromide.  
Isolated yield: 101 mg, 0.329 mmol, 66%, colorless oil. 
Purification: pentane:ethyl acetate = 9:1. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.14 – 7.07 (m, 2H), 7.00 – 6.90 (m, 2H), 4.15 – 4.00 (m, 2H), 2.75 – 
2.52 (m, 4H), 1.78 – 1.63 (m, 2H), 1.60 – 1.49 (m, 2H), 1.45 (s, 10H), 1.12 (qd, J = 12.3, 4.3 Hz, 2H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 161.3 (d, J = 243.5 Hz), 155.0, 138.2 (d, J = 3.2 Hz), 129.7 (d, J = 7.7 Hz), 
115.2 (d, J = 21.1 Hz), 79.4, 44.1, 38.6, 35.6, 32.2, 32.2, 28.6. 





FT-IR (ATR, cm-1): 𝜈 = 2927, 2852, 1688, 1601, 1509, 1418, 1391, 1364, 1276, 1219, 1155, 1119, 1090, 
1015, 966, 932, 865, 824, 768, 705. 
MS (EI, 70 eV): m/z (%) = 251 (33), 129 (12), 109 (37), 85 (14), 57 (100), 41 (20). 




Following TP3-B 2-(4-iodopiperidin-1-yl)pyrimidine (105d, 145 mg, 0.50 mmol, 1.00 equiv.) was coupled 
with di(4-chlorobutyl)zinc (106c, 0.375 mmol, 0.75 equiv.) prepared from the corresponding bromide 
according to TP1 using 1.0 equiv magnesium turnings.  
Isolated yield: 83 mg, 0.328 mmol, 66%, colorless oil. 
Purification: pentane:ethyl acetate = 7:3. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.28 (d, J = 4.7 Hz, 2H), 6.42 (t, J = 4.7 Hz, 1H), 4.73 (ddt, J = 13.3, 4.3, 
1.9 Hz, 2H), 3.54 (t, J = 6.6 Hz, 2H), 2.92 – 2.73 (m, 2H), 1.85 – 1.70 (m, 4H), 1.59 – 1.41 (m, 3H), 1.33 – 1.22 
(m, 2H), 1.22 – 1.10 (m, 2H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 161.6, 157.8, 109.3, 45.2, 44.3, 36.3, 36.0, 32.9, 32.2, 24.1. 
FT-IR (ATR, cm-1): 𝜈 = 2920, 2845, 1583, 1543, 1502, 1455, 1445, 1392, 1360, 1304, 1241, 1218, 1176, 
1082, 1051, 973, 947, 795, 778, 734. 
MS (EI, 70 eV): m/z (%) = 253 (4), 238 (11), 219 (14), 218 (100), 134 (18), 122 (9), 108 (29). 
HR-MS (EI, 70eV): Calcd for C13H20ClN3 253.1346; Found: 253.1341. 
 
tert-Butyl 4-(4-chlorobutyl)piperidine-1-carboxylate (107w) 
 
Following TP3-B using CoCl2 (130 mg, 20 mol%), neocuproine (208 mg, 20 mol%), TBAI (4.16 g, 2.25 equiv) 
4-iodopiperidine-1-carboxylate (105c, 1.56 g 5.00 mmol, 1.00 equiv.) in MeCN (10 ml) with di(4-
chlorobutyl)zinc (106c, 3.75 mmol, 0.75 equiv.) prepared from the corresponding bromide according to 
TP1 using 1.0 equiv magnesium turnings.  
Isolated yield:  900 mg, (11% of the corresponding Iodide, due to nucleophilic substitution reaction with 
iodide in the reaction solution, which could not be separated by column chromatography, determined via 





Purification: pentane:ethyl acetate = 9:1. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 4.20 – 3.94 (m, 2H), 3.53 (td, J = 6.7, 1.2 Hz, 2H), 2.74 – 2.57 (m, 2H), 
1.85 – 1.70 (m, 2H), 1.69 – 1.57 (m, 3H), 1.45 (d, J = 1.2 Hz, 11H), 1.31 – 1.18 (m, 2H), 1.14 – 1.00 (m, 2H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 154.9, 79.2, 45.1, 44.0, 35.9, 35.7, 32.7, 32.1, 28.5, 23.9. 
FT-IR (ATR, cm-1): 𝜈 = 2975, 2929, 2849, 1687, 1447, 1419, 1364, 1276, 1235, 1153, 1120, 1087, 1009, 973, 
936, 866, 768, 735. 
MS (EI, 70 eV): m/z (%) = 275 (4), 221 (10), 220 (24), 219 (17), 218 (17), 202 (19), 184 (100), 174 (10), 140 
(44), 112 (13), 57 (61). 
HR-MS (EI, 70eV): Calcd for C14H26ClNO2 275.1652; Found: 275.1642. 
 
4-(Tetrahydro-2H-pyran-4-yl)butyl acetate (107x) 
 
Following TP3-B 4-iodotetrahydro-2H-pyran (105b, 106 mg, 0.50 mmol, 1.00 equiv.) was coupled with 
di(4-acetoxybutyl)zinc (106d, 0.375 mmol, 0.75 equiv.) prepared according to TP2 (3 h at room 
temperature) from the corresponding bromide.  
Isolated yield: 65 mg, 0.325 mmol, 65%, yellow oil. 
Purification: pentane:ethyl acetate = 95:5. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 4.03 (t, J = 6.7 Hz, 2H), 3.96 – 3.81 (m, 2H), 3.33 (td, J = 11.8, 2.0 Hz, 
2H), 2.02 (s, 3H), 1.64 – 1.52 (m, 4H), 1.51 – 1.39 (m, 1H), 1.39 – 1.29 (m, 2H), 1.24 (dtd, J = 12.5, 6.7, 
3.3 Hz, 4H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 171.3, 68.2, 64.6, 36.6, 35.0, 33.2, 28.8, 22.8, 21.1. 
FT-IR (ATR, cm-1): 𝜈 = 292, 2857, 1732, 1710, 1606, 1581, 1511, 1461, 1419, 1375, 1315, 1273, 1253, 1165, 
1100, 1028, 953, 847, 769, 696. 
MS (EI, 70 eV): m/z (%) = 199 (4), 96 (22), 87 (100), 83 (12), 59 (11). 












5-Methyl-7-(2,6,6-trimethylcyclohex-1-en-1-yl)heptyl acetate (107y) 
 
Following TP3-B 2-(3-iodobutyl)-1,3,3-trimethylcyclohex-1-ene (105f, 153 mg, 0.50 mmol, 1.00 equiv.) was 
coupled with di(4-acetoxybutyl)zinc (106d, 0.375 mmol, 0.75 equiv., 0.37 m) prepared according to TP2 
(3 h at room temperature) from the corresponding bromide. 
Isolated yield: 106 mg, 0.361 mmol, 72%, yellow oil. 
Purification: pentane:ethyl acetate = 95:5. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 4.05 (t, J = 6.7 Hz, 2H), 2.04 (s, 3H), 1.97 (dd, J = 12.8, 5.0 Hz, 1H), 1.94 
– 1.83 (m, 3H), 1.56 (s, 3H), 1.68 – 1.49 (m, 5H), 1.45 – 1.25 (m, 6H), 1.16 (dddd, J = 15.8, 10.8, 8.4, 5.2 Hz, 
2H), 0.97 (s, 6H), 0.89 (d, J = 6.2 Hz, 3H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 13C NMR (101 MHz, CDCl3) δ 171.36, 137.76, 126.51, 64.80, 39.97, 
37.47, 36.55, 35.05, 33.95, 32.86, 29.03, 28.79, 28.76, 26.40, 23.58, 21.16, 19.93, 19.69, 19.62. 
FT-IR (ATR, cm-1): 𝜈 = 2927, 2865, 1741, 1458, 1363, 1234, 1113, 1036, 974, 889, 735. 
MS (EI, 70 eV): m/z (%) = 149 (26), 123 (100), 109 (20), 95 (29), 81 (60). 
HR-MS (EI, 70eV): Calcd for C19H34O2 294.2559; Found: 294.2553. 
 
tert-Butyl 4-(5-(4-methoxyphenyl)-3-methylpentyl)piperidine-1-carboxylate (107z) 
 
Following TP3-B 1-(3-iodobutyl)-4-methoxybenzene (105g, 145 mg, 0.50 mmol, 1.00 equiv.) was coupled 
with di(2-(1-(tert-butoxycarbonyl)piperidin-4-yl)ethyl)zinc (106e, 0.375 mmol, 0.75 equiv., 0.26 m) 
prepared according to TP2 (4.5 h at room temperature) from the corresponding bromide. 
Isolated yield: 135 mg, 0.360 mmol, 72%, yellow oil. 
Purification: pentane:ethyl acetate = 95:5. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.12 – 7.05 (m, 2H), 6.86 – 6.78 (m, 2H), 4.06 (s, 2H), 3.78 (s, 3H), 2.76 
– 2.43 (m, 4H), 1.69 – 1.51 (m, 4H), 1.45 (s, 9H), 1.43 – 0.98 (m, 8H), 0.91 (d, J = 6.0 Hz, 3H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 157.7, 155.1, 135.2, 129.3, 113.8, 79.3, 55.4, 44.2 (br), 39.2, 36.4, 
33.9, 32.6, 32.6, , 32.5 (br), 28.6, 19.7. 
FT-IR (ATR, cm-1): 𝜈 = 2920, 2850, 1389, 1612, 1511, 1453, 1420, 1364, 1299, 1276, 1242, 1159, 1090, 





MS (EI, 70 eV): m/z (%) = 319 (24), 154 (25), 121 (100), 112 (16), 82 (14), 57 (71), 56 (14), 55 (11), 40 (20). 
HR-MS (EI, 70eV): Calcd for C23H37NO3 375.2773; Found: 375.2775. 
 
9-Ethoxy-3-methyl-9-oxononyl 4-methoxybenzoate (107aa) 
 
Following TP3-B 3-iodobutyl 4-methoxybenzoate (105h, 167 mg, 0.50 mmol, 1.00 equiv.) was coupled with 
di(6-ethoxy-6-oxohexyl)zinc (106f, 0.375 mmol, 0.75 equiv., 0.57 m) prepared according to TP2 (2 h at 
room temperature) from the corresponding bromide. 
Isolated yield: 119 mg, 0.340 mmol, 68%, colorless oil. 
Purification: pentane:ethyl acetate = 8:2. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.01 – 7.96 (m, 2H), 6.95 – 6.88 (m, 2H), 4.35 – 4.29 (m, 2H), 4.12 (q, 
J = 7.1 Hz, 2H), 3.86 (s, 3H), 2.28 (t, J = 7.5 Hz, 2H), 1.78 (dtd, J = 13.2, 7.1, 4.8 Hz, 1H), 1.68 – 1.48 (m, 5H), 
1.42 – 1.28 (m, 5H), 1.25 (t, J = 7.1 Hz, 3H), 0.94 (d, J = 6.4 Hz, 3H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 173.9, 166.5, 163.2, 131.5, 122.9, 113.6, 63.2, 60.2, 55.4, 36.8, 35.6, 
34.37, 30.0, 29.4, 26.6, 25.0, 19.6, 14.3. 
FT-IR (ATR, cm-1): 𝜈 = 2924, 2855, 1693, 1669, 1421, 1391, 1364, 1276, 1244, 1159, 1093, 1034, 964, 865, 
808, 768. 
MS (EI, 70 eV): m/z (%) = 350 (3), 153 (29), 152 (21), 152 (100), 135 (100). 
HR-MS (EI, 70eV): Calcd for C20H30O5 350.2093; Found: 350.2087.   
 
tert-Butyl 4-(6-ethoxy-6-oxohexyl)piperidine-1-carboxylate (107ab) 
 
Following TP3-B 4-iodopiperidine-1-carboxylate (105c, 156 mg 5.00 mmol, 1.00 equiv.) was coupled with 
di(6-ethoxy-6-oxohexyl)zinc (106f, 0.375 mmol, 0.75 equiv., 0.57 m) prepared according to TP2 (2 h at 
room temperature)  from the corresponding bromide. 
Isolated yield: 115 mg, 0.352 mmol, 70%, colorless oil. 
Purification: pentane:ethyl acetate = 9:1. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 4.12 (q, J = 7.1 Hz, 3H), 4.06 (s, 2H), 2.65 (t, J = 12.6 Hz, 2H), 2.28 (t, 
J = 7.5 Hz, 2H), 1.62 (dq, J = 7.1, 3.5, 3.1 Hz, 4H), 1.45 (s, 9H), 1.30 (tt, J = 4.2, 2.5 Hz, 4H), 1.25 (t, J = 7.1 Hz, 





13C-NMR (100 MHz, CDCl3, ppm): δ = 174.0, 155.1, 79.3, 60.3, 44.7 – 43.6 (br), 36.5, 36.1, 34.5, 32.3, 29.4, 
28.6, 26.4, 25.1, 14.4. 
FT-IR (ATR, cm-1): 𝜈 = 2976, 2927, 2853, 1734, 1690, 1447, 1419, 1391, 1364, 1276, 1243, 1153, 1123, 
1092, 1028, 963, 866, 809, 768, 729. 
MS (EI, 70 eV): m/z (%) = 254 (16), 226 (67), 212 (53), 182 (58), 140 (100), 112 (31), 98 (30), 84 (33). 
HR-MS (EI, 70eV): [M- Ot-Bu] Calcd for C14H24NO3• 254.1756; Found: 254.1752. 
 
Ethyl 6-(1,4-dioxaspiro[4.5]decan-8-yl)hexanoate (107ac) 
 
Following TP3-B 8-iodo-1,4-dioxaspiro[4.5]decane (105h, 119 mg, 0.50 mmol, 1.00 equiv.) was coupled 
with (6-ethoxy-6-oxohexyl)zinc (106f, 0.375 mmol, 0.75 equiv., 0.57 m) prepared according to TP2 (2 h at 
room temperature) from the corresponding bromide.  
Isolated yield: 114 mg, 0.401 mmol, 80%, colorless oil. 
Purification: pentane:ethyl acetate = 9:1. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 4.12 (q, J = 7.1 Hz, 2H), 3.93 (s, 4H), 2.28 (t, J = 7.5 Hz, 2H), 1.77 – 1.65 
(m, 4H), 1.61 (p, J = 7.4 Hz, 3H), 1.50 (td, J = 14.0, 13.1, 4.6 Hz, 2H), 1.35 – 1.14 (m, 13H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 174.1, 109.4, 64.3, 60.3, 36.4, 36.2, 34.7, 34.5, 30.3, 29.5, 27.0, 25.1, 
14.4. 
FT-IR (ATR, cm-1): 𝜈 = 2927, 2856, 1732, 1446, 1373, 1336, 1175, 1135, 1106, 1089, 1033, 928, 910, 859, 
766, 729, 662. 
MS (EI, 70 eV): m/z (%) =239 (10), 213 (23), 141 (7), 100 (5), 99 (100), 55 (12). 




Following TP3-B (3-iodopropyl)benzene (105a, 123 mg, 0.50 mmol, 1.00 equiv.) was coupled with di(3,3,3-
trifluoropropyl)zinc (106g, 0.375 mmol, 0.75 equiv., 0.36 m) prepared according to TP2 (1 h at room 
temperature) from the corresponding bromide. 






1H-NMR (400 MHz, CDCl3, ppm): δ = 7.33 – 7.24 (m, 3H), 7.22 – 7.14 (m, 3H), 2.62 (t, J = 7.7 Hz, 2H), 2.14 
– 1.97 (m, 2H), 1.72 – 1.51 (m, 5H), 1.41 (q, J = 8.3 Hz, 2H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 142.38, 128.51, 128.48, 131.54 – 123.08 (q, J = 276.3 Hz), 125.93, 
35.78, 33.81 (q, J = 28.4 Hz), 31.16, 28.42, 21.90 (q, J = 2.9 Hz). 
19F-NMR (376 MHz, CDCl3, ppm): δ = -66.51 (t, J = 11.1 Hz). 
FT-IR (ATR, cm-1): 𝜈 = 2956, 2873, 1496, 1454, 1385, 1335, 1254, 1175, 1135, 1033, 743, 697. 
MS (EI, 70 eV): m/z (%) = 217 (5), 216 (35), 105 (4), 92 (31), 91 (100), 78 (3). 




Following TP3-B 6-iodo-2,2-dimethylhexanenitrile (105i, 126 mg, 0.50 mmol, 1.00 equiv.) was coupled 
with di(cyclobutylmethyl)zinc (106h, 0.375 mmol, 0.75 equiv.) prepared according to TP1 from the 
corresponding bromide.  
Isolated yield: 60 mg, 0311 mmol, 62%, colorless oil. 
Purification: pentane. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 2.22 (hept, J = 7.6 Hz, 1H), 2.07 – 1.96 (m, 2H), 1.91 – 1.71 (m, 2H), 
1.63 – 1.40 (m, 7H), 1.40 – 1.35 (m, 1H), 1.33 (s, 6H), 1.33 – 1.14 (m, 4H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 125.5, 41.2, 37.1, 36.3, 32.6, 29.8, 28.5, 27.1, 26.8, 25.5, 18.6. 
FT-IR (ATR, cm-1): 𝜈 = 2971, 2927, 2855, 2234, 1693, 1469, 1391, 1368, 1079, 966, 802, 725. 
MS (EI, 70 eV): m/z (%) = 164 (28), 150 (100), 136 (36), 124 (28), 122 (70), 110 (33), 108 (100), 80 (38), 41 
(27). 




Following TP3-B ethyl 5-iodopentanoate (105j, 128 mg, 0.50 mmol, 1.00 equiv.) was coupled with di(4-
chlorobutyl)zinc (106c, 0.375 mmol, 0.75 equiv.) prepared from the corresponding bromide according to 
TP1 using 1.0 equiv magnesium turnings.  
Isolated yield: 55 mg, (17% of the corresponding Iodide, due to nucleophilic substitution reaction with 
iodide in the reaction solution, which couldn’t be separated by column chromatography, determined due 






1H-NMR (400 MHz, CDCl3, ppm): δ = 4.06 (q, J = 7.1 Hz, 2H), 3.46 (t, J = 6.7 Hz, 2H), 2.22 (t, J = 7.5 Hz, 2H), 
1.79 – 1.64 (m, 2H), 1.55 (p, J = 7.5 Hz, 2H), 1.41 – 1.29 (m, 2H), 1.24 (d, J = 2.6 Hz, 6H), 1.19 (t, J = 7.1 Hz, 
3H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 174.0, 60.3, 45.3, 34.5, 32.7, 29.2, 29.2, 28.8, 26.9, 25.1, 14.4. 
FT-IR (ATR, cm-1): 𝜈 = 2930, 2856, 1732, 1463, 1372, 1348, 1301, 1176, 1121, 1096, 1033, 859, 724. 
MS (EI, 70 eV): m/z (%) = 185 (16), 177 (17), 175 (41), 139 (19), 101 (39), 88 (100), 73 (16), 70 (15), 69 (22), 
61 (12), 60 (11), 55 (21). 




Following TP3-B 2-(allyloxy)-3-iodotetrahydro-2H-pyran (105k, 134 mg, 0.50 mmol, 1.00 equiv.) was 
coupled with di(2-(1,3-dioxan-2-yl)ethyl)zinc (106a, 0.375 mmol, 0.75 equiv.) prepared according to TP1 
from the corresponding bromide.  
Isolated yield: 58 mg, 0.227 mmol, 45%, dr = 9:1, colorless oil. 
Purification: pentane:ethyl acetate = 8:2. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 5.25 (d, J = 3.7 Hz, 1H, major), 4.96 (d, J = 3.6 Hz, 0.11H, minor), 4.48 
(t, J = 5.1 Hz, 1H, major), 4.26 (t, J = 8.3 Hz, 0.12H, minor), 4.07 (ddd, J = 12.1, 5.0, 1.5 Hz, 2H, major), 3.92 
(t, J = 8.0 Hz, 1H, major), 3.84 (dt, J = 11.7, 3.4 Hz, 0.13H, minor), 3.78 – 3.67 (m, 4H, major/minor), 3.64 – 
3.56 (m, 2H, major), 3.51 (t, J = 8.2 Hz, 0.11H, minor), 3.38 (td, J = 11.6, 2.3 Hz, 0.12H, minor), 2.37 – 2.21 
(m, 1H, major/minor), 2.04 (qt, J = 12.7, 5.0 Hz, 1H, major/minor), 1.92 (dtd, J = 12.0, 6.1, 3.7 Hz, 1H, 
major), 1.80 (dt, J = 8.6, 4.4 Hz, 0.34H, minor), 1.68 – 1.47 (m, 6H, major/minor), 1.44 – 1.18 (m, 7H, 
major/minor). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 102.2 (minor), 102.11 (major), 102.1 (major), 74.3 (minor), 70.1 
(major), 67.0 (major), 64.6 (minor), 61.0 (major), 44.2 (minor), 41.1 (major), 38.0 (minor), 36.5 (major), 
35.6 (minor), 35.4 (major), 32.9 (minor), 27.0 (major), 25.9 (major), 23.30 (major), 23.0 (minor), 22.7 
(major), 22.5 (minor), 20.8 (minor), 19.2 (major). 
FT-IR (ATR, cm-1): 𝜈 = 2925, 2853, 1461, 1437, 1403, 1377, 1279, 1243, 1216, 1201, 1141, 1111, 1081, 





MS (EI, 70 eV): m/z (%) = 180 (54), 179 (18), 151 (36), 125 (37), 113 (26), 93 (41), 87 (100), 59 (21). 




Following TP3-B (iodomethyl)cyclopropane (105l, 91 mg, 0.50 mmol, 1.00 equiv.) was coupled with di(2-
(1,3-dioxan-2-yl)ethyl)zinc (106a, 0.375 mmol, 0.75 equiv.) prepared according to TP1 from the 
corresponding bromide.  
 
Isolated yield: 37 mg, 0.218 mmol, 44%, colorless oil. 
Purification: pentane:ethyl acetate = 99:1. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 5.80 (ddt, J = 16.9, 10.2, 6.7 Hz, 1H), 4.99 (dq, J = 17.1, 1.7 Hz, 1H), 
4.93 (ddt, J = 10.2, 2.3, 1.2 Hz, 1H), 4.50 (t, J = 5.2 Hz, 1H), 4.09 (ddt, J = 10.6, 5.1, 1.4 Hz, 2H), 3.82 – 3.69 
(m, 2H), 2.07 (tdt, J = 12.6, 11.1, 5.0 Hz, 3H), 1.66 – 1.52 (m, 2H), 1.40 (td, J = 8.2, 7.3, 4.8 Hz, 4H), 1.33 (dtt, 
J = 13.5, 2.7, 1.4 Hz, 1H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 139.0, 114.5, 102.5, 67.0, 35.2, 33.8, 28.9, 26.0, 23.7. 
FT-IR (ATR, cm-1): 𝜈 = 2951, 2925, 2849, 1640, 1459, 1431, 1404, 1377, 1283, 1240, 1216, 1142, 1116, 
1086, 1053, 993, 936, 908, 868, 843. 
MS (EI, 70 eV): m/z (%) = 169 (15); 87 (100), 59 (15), 41 (7). 







4. Cobalt-Catalyzed Acylation-Reactions of (Hetero)Arylzinc Pivalates with Thiopyridyl 
Ester Derivatives 
4.1 Optimization of the Reaction Conditions 
Table 13: Screening of various thioesters for the cobalt-catalyzed acylation. 
 
Entry R = GC-Yield[a] [%] 







[a] Tetradecane (C14H30) was used as internal standard. 
Table 14: Optimization of the acylation conditions. 
 
Entry Cobalt salt CoCl2 [mol%] dtbbpy [mol%] Solvent 
Amount of 72  
[equiv] 
GC-Yield[a] [%] 
1 CoCl2 5 5 THF 1.9 81 
2 CoCl2 10 10 THF 1.9 90 
3 CoCl2 20 20 THF 1.9 92 
4 CoCl2 10 10 THF 1.5 85 
5 CoCl2 10 10 THF 2.5 87 
6 CoCl2 10 10 MeCN 1.9 89 






Table 14 continued. 
Entry Cobalt salt CoCl2 [mol%] dtbbpy [mol%] Solvent 
Amount of 72  
[equiv] 
GC-Yield[a] [%] 
9 CoCl2 10 10 2-MeTHF 1.9 87 
10 CoCl2 10 10 THF 1.9 80[b] 
11 CoCl2 10 10 THF 1.9 82[c] 
12 CoBr2 10 10 THF 1.9 86 
13 Co(acac)2 10 10 THF 1.9 86 
14 Co(acac)3 10 10 THF 1.9 84 
[a] Tetradecane (C14H30) was used as internal standard. [b] ArZnCl was used instead of ArZnOPiv. [c] The solid zinc pivalate 72 was 
weighed out on the bench and added to the reaction mixture under air. 
 
4.2 Mechanistic Experiments 
Table 15: Mechanistic experiments using cobalt salts of various oxidation states. 
 
[a] Tetradecane (C14H30) was used as internal standard. 





4.3 Unsuccessful Acylation Reactions with Several Heterocyclic and Sterically Hindered Organozinc 
Pivalates 
 
Scheme 58: Unsuccessful substrates for the cobalt-catalyzed acylation reaction. 
 
4.4 Preparation of Starting Materials 
Preparation of thiopyridyl esters (TP1):93a 
The corresponding carboxylic acid (1.0 equiv), PPh3 (1.5 equiv) and 2,2'-dipyridyl disulfide (1.1 equiv) were 
added to a round bottom flask equipped with a magnetic stirring bar. The mixture was dissolved in MeCN 
(0.3 M) and heated to reflux for 3 h. After solvent evaporation, the resulting thiopyridyl ester was purified 
by column chromatography (SiO2, ihexane/ethyl acetate) yielding the pure thioester. 
 
Preparation of α-chiral-thiopyridyl esters (TP2): 
The corresponding α-chiral-carboxylic acid (1.0 equiv), PPh3 (1.0 equiv) and 2,2'-dipyridyl disulfide 
(1.0 equiv) were added to a round bottom flask equipped with a magnetic stirring bar. The mixture was 
dissolved in MeCN (0.3 M), cooled to 0 °C and stirred for 16 h. After solvent evaporation, the resulting 










S-(Pyridin-2-yl) cyclohexanecarbothioate (108a) 
 
S-(Pyridin-2-yl) cyclohexanecarbothioate was prepared according to TP1 from cyclohexanecarboxylic acid 
(2.21 g, 10.00 mmol) and was obtained as a yellow solid (1.68 g, 7.60 mmol, 76% yield. The analytical data 
is in full consistency with the data reported in the literature.155 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.61 (dd, J = 5.2, 1.9 Hz, 1H), 7.71 (tt, J = 7.7, 1.4 Hz, 1H), 7.59 (d, J = 
7.9 Hz, 1H), 7.35 – 7.17 (m, 1H), 2.62 (tt, J = 11.4, 3.5 Hz, 1H), 2.08 – 1.96 (m, 2H), 1.81 (dt, J = 12.8, 3.4 Hz, 
2H), 1.67 (dt, J = 12.6, 3.6 Hz, 1H), 1.53 (qd, J = 12.0, 3.3 Hz, 2H), 1.40 – 1.12 (m, 3H). 
 
S-(Pyridin-2-yl) hexadecanethioate (108b) 
 
S-(Pyridin-2-yl) hexadecanethioate was prepared according to TP1 from palmitic acid (512 mg, 2.00 mmol) 
and was obtained as a yellow powder (684 mg, 1.96 mmol, 98% yield). 
Purification: ihexane:ethyl acetate = 8:2. 
m.p.: 62.0 – 63.8 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.66 – 8.58 (m, 1H), 7.73 (td, J = 7.7, 1.9 Hz, 1H), 7.61 (dd, J = 7.9, 
1.1 Hz, 1H), 7.33 – 7.26 (m, 1H), 2.69 (t, J = 7.5 Hz, 2H), 1.72 (p, J = 7.5 Hz, 2H), 1.25 (s, 24H), 0.87 (t, J = 6.7 
Hz, 3H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 196.8, 151.8, 150.5, 137.2, 130.3, 123.6, 44.4, 32.1, 29.9, 29.8, 29.8, 
29.8, 29.7, 29.6, 29.5, 29.4, 29.1, 25.6, 22.9, 14.3. 
FT-IR (ATR, cm-1): 𝜈 =2916, 2848, 1796, 1739, 1696, 1571, 1472, 1463, 1446, 1421, 1382, 1124, 1107, 1092, 
1061, 1049, 981, 945, 905, 762, 718. 
MS (EI, 70 eV): m/z (%) = 239 (9), 112 (32), 111 (100), 98 (16), 57 (11), 43 (25). 






                                                          





S-(pyridin-2-yl) cyclobutanecarbothioate (108c) 
 
S-(pyridin-2-yl) cyclobutanecarbothioate was prepared according to TP1 from cyclobutanecarboxylic acid 
(200 mg, 2.00 mmol) and was obtained as a yellow oil (305 mg, 1.58 mmol, 79%). 
Purification: ihexaner:ethyl acetate = 8:2. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.66 – 8.50 (m, 1H), 7.67 (td, J = 7.7, 1.9 Hz, 1H), 7.55 (dt, J = 8.0, 
1.1 Hz, 1H), 7.24 – 7.18 (m, 1H), 3.43 (pd, J = 8.5, 1.0 Hz, 1H), 2.45 – 2.27 (m, 2H), 2.20 (dtdd, J = 12.6, 8.3, 
4.2, 2.3 Hz, 2H), 2.02 – 1.72 (m, 2H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 198.4, 151.6, 150.4, 137.1, 130.2, 123.4, 47.0, 26.0, 18.00. 
FT-IR (ATR, cm-1): 𝜈 = 2986, 2944, 1698, 1572, 1562, 1448, 1420, 1334, 1280, 1245, 1186, 1139, 1105, 
1059, 1046, 988, 956, 885, 813, 763, 722, 677. 
MS (EI, 70 eV): m/z (%) = 258 (36), 211 (19), 136 (9) 135 (100), 77 (11). 




S-(pyridin-2-yl)-adamantane-1-carbothioate was prepared according to TP1 from adamantane-1-
carboxylic acid (360 mg, 2.00 mmol) and was obtained as a pale yellow powder (464 mg, 1.70 mmol, 85% 
yield). 
Purification: ihexane:ethyl acetate = 9:1  8:2. 
m.p.: 73.2 – 75.6 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.62 (dd, J = 5.0, 1.9 Hz, 1H), 7.71 (td, J = 7.7, 1.9 Hz, 1H), 7.55 (d, J = 
7.9 Hz, 1H), 7.35 – 7.17 (m, 1H), 2.09 (p, J = 3.1 Hz, 3H), 2.00 (d, J = 3.0 Hz, 6H), 1.83 – 1.63 (m, 6H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 203.5, 152.0, 150.5, 137.0, 131.1, 123.4, 49.6, 39.3, 36.5, 28.3. 
FT-IR (ATR, cm-1): 𝜈 =2909, 2848, 1689, 1572, 1562, 1449, 1421, 1342, 1280, 1250, 1188, 1138, 1116, 1102, 
1084, 1045, 986, 946, 918, 822, 795, 760, 742, 724, 671. 
MS (EI, 70 eV): m/z (%) = 273 (2), 244 (6), 136 (8), 135 (100), 93 (8), 79 (9). 







S-(Pyridin-2-yl) 3-(2,5-dimethylphenoxy)-2,2-dimethylpropanethioate (108e) 
 
S-(Pyridin-2-yl) 3-(2,5-dimethylphenoxy)-2,2-dimethylpropanethioate was prepared according to TP1 from 
3-(2,5-dimethylphenoxy)-2,2-dimethylpropanoic acid (444 mg, 2.00 mmol) and was obtained as a yellow 
oil (617 mg, 1.96 mmol, 98% yield). 
Purification: ihexane:ethyl acetate = 9:1  8:2. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.64 (ddd, J = 4.8, 2.0, 0.8 Hz, 1H), 7.73 (td, J = 7.7, 2.0 Hz, 1H), 7.53 
(dt, J  = 8.0, 1.0 Hz, 1H), 7.29 (ddd, J = 7.6, 4.8, 1.1 Hz, 1H), 7.00 (d, J = 7.4 Hz, 1H), 6.69 – 6.64 (m, 1H), 6.61 
(d, J = 1.5 Hz, 1H), 3.95 (t, J = 5.4 Hz, 2H), 2.31 (s, 3H), 2.19 (s, 3H), 1.91 – 1.79 (m, 4H), 1.36 (s, 6H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 203.6, 157.0, 151.9, 150.6, 137.1, 136.6, 131.0, 130.4, 123.7, 123.5, 
120.8, 112.0, 67.8, 50.6, 37.6, 25.4, 25.0, 21.6, 16.0. 
FT-IR (ATR, cm-1): 𝜈 = 2966, 2922, 1693, 1614, 1583, 1573, 1563, 1509, 1448, 1419, 1389, 1366, 1285, 
1263, 1156, 1129, 1044, 1000, 988, 931, 906, 803, 764, 724. 
MS (EI, 70 eV): m/z (%) = 258 (36), 211 (19), 136 (9) 135 (100), 77 (11). 
HR-MS (EI, 70eV): [C20H26NO2S], calcd.: 344.1679; found: 344.1678 [M++H]. 
 
S-(Pyridin-2-yl) benzothioate (108f) 
 
S-(Pyridin-2-yl) benzothioate was prepared according to TP1 from benzoic acid (1.22 g, 10.0 mmol) and 
was obtained as a yellow solid (1.81 g, 8.4 mmol, 84% yield). The analytical data was in full consistency 
with the data reported in the literature.156 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.72 – 8.62 (m, 1H), 8.08 – 7.97 (m, 2H), 7.79 (td, J = 7.7, 1.9 Hz, 1H), 






                                                          





S-(Pyridin-2-yl) 4-chlorobenzothioate (108g) 
 
S-(Pyridin-2-yl) 4-chlorobenzothioate was prepared according to TP1 from 4-chlorobenzoic acid (1.55 g, 
10.0 mmol) and was obtained as pale yellow needles (1.64 g, 6.6 mmol, 66 % yield). The analytical data 
was in full consistency with the data reported in the literature.157 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.68 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 8.03 – 7.92 (m, 2H), 7.79 (td, J = 
7.7, 1.9 Hz, 1H), 7.71 (dt, J = 7.9, 1.0 Hz, 1H), 7.51 – 7.41 (m, 2H), 7.34 (ddd, J = 7.6, 4.9, 1.2 Hz, 1H). 
 
S-(Pyridin-2-yl) 4-methoxybenzothioate (108h) 
 
S-(Pyridin-2-yl) 4-methoxybenzothioate was prepared according to TP1 from 4-methoxybenzoic acid 
(304 mg, 2.00 mmol) and was obtained as a yellow solid (338 mg, 1.38 mmol, 69% yield). The analytical 
data was in full consistency with the data reported in the literature.158 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.59 (ddt, J = 3.6, 2.6, 1.4 Hz, 1H), 7.93 (dd, J = 9.0, 2.2 Hz, 2H), 7.77 – 
7.59 (m, 2H), 7.25 (dtd, J = 6.8, 3.2, 1.6 Hz, 1H), 6.89 (dd, J = 9.1, 2.6 Hz, 2H), 3.81 (s, 3H). 
 
S-(Pyridin-2-yl) 4-methoxybenzothioate (108h’) 
 
S-(Pyridin-2-yl) 2-methoxybenzothioate was prepared according to TP1 from 2-methoxybenzoic acid 
(304 mg, 2.00 mmol) and was obtained as a yellow oil (470 mg, 1.92 mmol, 96% yield). The analytical data 
was in full consistency with the data reported in the literature.157 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.74 – 8.58 (m, 1H), 7.86 (dd, J = 8.0, 1.7 Hz, 1H), 7.80 – 7.70 (m, 2H), 
7.51 (ddd, J = 7.9, 7.0, 1.8 Hz, 1H), 7.30 (ddd, J = 6.7, 4.8, 1.9 Hz, 1H), 7.07 – 6.98 (m, 2H), 3.96 (s, 3H). 
 
 
                                                          
157 M. Ociepa, O. Baka, J. Nardodowiec, D. Gryko, Adv. Synth. Catal. 2017, 359, 3560-3565. 





S-(Pyridin-2-yl) ferrocenecarbothioate (108i) 
 
S-(Pyridin-2-yl) ferrocene was prepared according to TP1 from ferrocene monocarboxylic acid (460 mg, 
2.00 mmol) and was obtained as red crystals (588 mg, 1.82 mmol, 91% yield). 
Purification: ihexane:ethyl acetate = 9:1  8:2. 
m.p.: 84.6 – 86.8 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.64 (d, J = 5.1 Hz, 1H), 7.75 (d, J = 6.5 Hz, 2H), 7.28 (dd, J = 11.8, 
5.0 Hz, 1H), 4.94 (s, 2H), 4.55 (s, 2H), 4.31 (s, 5H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 190.9, 152.4, 150.4, 150.3, 137.0, 130.4, 123.3, 123.3, 123.3, 78.8, 
72.4, 72.4, 71.0, 70.8, 69.4, 69.3. 
FT-IR (ATR, cm-1): 𝜈 =2923, 1652, 1570, 1446, 1422, 1369, 1239, 1121, 1106, 1045, 1024, 1002, 986, 942, 
837, 810, 762, 721, 693. 
 
S-(Pyridin-2-yl) quinoline-2-carbothioate (108j) 
 
S-(Pyridin-2-yl) quinoline-2-carbothioate was prepared accordning to TP1 from quinoline-2-carboxylic acid 
(856 mg, 5.00 mmol) and was obtained as yellow crystals (998 mg, 3.75 mmol, 75%). 
Purification: ihexane:ethyl acetate = 9:1  8:2. 
m.p.: 142.8– 144.2 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.80 – 8.70 (m, 1H), 8.38 – 8.25 (m, 2H), 8.03 (d, J = 8.4 Hz, 1H), 7.90 
(dd, J = 8.2, 1.4 Hz, 1H), 7.87 – 7.73 (m, 3H), 7.69 (ddd, J = 8.2, 6.9, 1.2 Hz, 1H), 7.35 (ddd, J = 7.3, 4.8, 
1.4 Hz, 1H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 192.1, 152.5, 151.1, 150.6, 147.9, 137.8, 137.4, 131.0, 130.7, 130.6, 
130.5, 129.2, 127.9, 123.7, 117.3. 
FT-IR (ATR, cm-1): 𝜈 = 2926, 1682, 1668, 1572, 1561, 1502, 1461, 1448, 1419, 1378, 1305, 1279, 1263, 
1227, 1206, 1142, 1108, 1082, 1046, 988, 964, 912, 834, 792, 763, 738, 722,702. 
MS (EI, 70 eV): m/z (%) = 266 (3), 238 (19), 237 (40), 206 (40), 205 (23). 







tert-Butyl (S)-2-((pyridin-2-ylthio)carbonyl)pyrrolidine-1-carboxylate (108k) 
 
tert-Butyl (S)-2-((pyridin-2-ylthio)carbonyl)pyrrolidine-1-carboxylate was prepared according to TP2 from 
(tert-butoxycarbonyl)-L-proline (2.15 g, 10.0 mmol) and was obtained as a yellow solid (2.24 g, 7.3 mmol, 
73% yield). The analytical data is in full consistency with the data reported in the literature.93c 
1H-NMR (400 MHz, CDCl3, ppm, mixture of rotamers): δ = 8.61 (dd, J = 5.0, 2.0 Hz, 0.6 H), 8.60 – 8.56 (m, 
0.4 H), 7.72 (qd, J = 7.1, 6.5, 1.9 Hz, 1H), 7.65 (d, J = 7.9 Hz, 0.4 H), 7.55 (d, J = 7.9 Hz, 0.6 H), 7.26 (td, J = 
9.7, 8.7, 5.0 Hz, 1.1 H), 4.57 (dd, J = 8.3, 3.4 Hz, 0.4 H), 4.44 (dd, J = 8.8, 3.8 Hz, 0.6 H), 3.54 (dtdd, J = 37.3, 
18.1, 9.0, 6.1 Hz, 2H), 2.36 – 1.99 (m, 3H), 1.91 (pd, J = 7.6, 3.8 Hz, 1H), 1.48 (d, J = 7.1 Hz, 9H). 
Optical rotation: [α]D
20 = -118 (c 1.17, CHCl3). 
Chiral HPLC: >99% ee, AD-H column, heptane:iPrOH = 95:5, 1.5 mL/min, 30 °C. 
 
S-(Pyridin-2-yl) (S)-2-(4-isobutylphenyl)propanethioate (108l) 
 
(S)-2-(4-Isobutylphenyl)propanethioate was prepared according to TP2 at 0 °C from (S)-2-(4-
isobutylphenyl)-propanoic acid (412 mg, 2.00 mmol) and was obtained as a yellow oil (574 mg, 1.96 mmol, 
96% yield). 
Purification: ihexane:ethyl acetate = 9:1  8:2. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.80 (t, J = 1.8 Hz, 1H), 7.69 (dt, J = 7.6, 1.4 Hz, 1H), 7.34 (ddd, J = 7.8, 
2.0, 1.1 Hz, 1H), 7.32 – 7.23 (m, 1H), 7.20 – 7.14 (m, 2H), 7.09 – 7.02 (m, 2H), 4.01 (q, J = 7.1 Hz, 1H), 2.47 
(d, J  = 7.1 Hz, 2H), 1.86 (dp, J = 13.6, 6.8 Hz, 1H), 1.60 (d, J = 7.1 Hz, 3H), 0.91 (d, J = 6.7 Hz, 6H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 198.5, 151.8, 150.2, 141.3, 137.1, 136.2, 130.1, 129.6, 127.9, 123.4, 
54.2, 45.1, 30.2, 22.4, 18.4. 
FT-IR (ATR, cm-1): 𝜈 = 2954, 2928, 2868, 1706, 1573, 1563, 1511, 1448, 1420, 1368, 1240, 1217, 1183, 
1168, 1140, 121, 1097, 1084, 1066, 1045, 998, 988, 930, 847, 802, 763, 738, 724, 663. 
HR-MS (ESI, 70eV): [C18H22NOS], calcd.: 300.1417; found: 300.1416 [M++H]. 
Optical rotation: [α]D
20 = 104 (c 1.24, CHCl3). 







S-(Pyridin-2-yl) (S)-2-methylbutanethioate (108m) 
 
S-(Pyridin-2-yl) (S)-2-methylbutanethioate was prepared according to TP2 at 0 °C from (S)-2-
methylbutanoic acid (510 mg, 5 mmol) and was obtained as a yellow oil (950 mg, 4.87 mmol, 97% yield). 
Purification: ihexane:ethyl acetate = 9:1  8:2. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.61 (ddd, J = 5.1, 1.8, 0.9 Hz, 1H), 7.72 (td, J = 7.7, 1.9 Hz, 1H), 7.60 
(dt, J = 7.9, 1.0 Hz, 1H), 7.26 (ddd, J = 7.6, 4.7, 1.1 Hz, 1H), 2.70 (h, J = 6.9 Hz, 1H), 1.82 (dt, J = 13.7, 7.2 Hz, 
1H), 1.54 (tt, J = 14.4, 7.1 Hz, 1H), 1.25 (d, J = 6.9 Hz, 3H), 0.97 (t, J = 7.4 Hz, 3H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 200.8, 151.8, 150.4, 137.1, 130.3, 123.5, 50.6, 27.2, 17.1, 11.7. 
FT-IR (ATR, cm-1): 𝜈 = 2968, 2934, 2877, 1702, 1573, 15622, 1448, 1418, 1380, 1260, 1201, 1139, 1118, 
1084, 1045, 987, 967, 939, 829, 807, 762, 732, 719, 669, 670. 
MS (EI, 70 eV): m/z (%) = 196 (2), 166 (15), 139 (18), 134 (65), 112 (91), 111 (100), 67 (26). 
HR-MS (EI, 70eV): [C10H14NOS], calcd.: 196.0791; found: 196.0789 [M++H]. 
Optical rotation: [α]D
20 = 19 (c 1.20, CHCl3). 
Chiral HPLC: 98% ee, OD-H column, heptane:iPrOH = 98:2, 1.0 mL/min, 30 °C. 
 
4.5 Preparation of Organometallic Reagents 
Preparation of arylzinc pivalates by insertion (TP3):38f 
Magnesium turnings (1.2 equiv), dry LiCl (1.2 equiv) and dry THF (1.00 M solution relating to the aryl halide) 
were added to a dry and argon flushed Schlenk-tube equipped with a magnetic stirring bar and a septum. 
The tube was charged with the aromatic bromide (1.0 equiv). For controlling the following initial heat 
evolution of the insertion reaction, the Schlenk-tube was placed in an ice bath for cooling. To monitor the 
progress of the insertion reaction, reaction aliquots quenched with iodine and were analyzed as water-
quenched samples by GC-analysis. When the insertion was completed, solid Zn(OPiv)2 (1.0 equiv) was 
added in one portion at 0 °C and stirred at ambient temperature for 15 min.  
 
Preparation of arylzinc pivalates by halogen/magnesium exchange (TP4):38f 
A dry and argon flushed Schlenk-tube equipped with a magnetic stirring bar and a septum was charged 
with the corresponding aryl halide (1.00 mmol) in THF (0.50 M) Then, after stirring for 5 min at ambient 





dropwise. GC-analysis was used to monitor the progress of the halogen-magnesium exchange, by analysis 
of reaction aliquots quenched with I2. The reaction was completed within 60 min. Zn(OPiv)2 (1.0 equiv) 
was added in one portion at 0 °C and the mixture was slowly warmed to room temperature.  
 
4.6 Cobalt-Catalyzed Acylation-Reactions of (Hetero)arylzinc Pivalates with Organic Thiopyridylester 
derivatives  
Cobalt-catalyzed acylation of arylzinc pivalates with thiopyridyl esters (TP5): 
A dry and argon flushed Schlenk-tube equipped with a magnetic stirring bar and a septum was charged 
with CoCl2 (6.5 mg, 0.05 mmol, 0.10 equiv, dried in vacuo at 400 °C prior to use). Then, the ligand 4,4’-di-
tert-butyl-2,2’-dipyridyl (13.0 mg, 0.05 mmol, 0.10 equiv) and the corresponding thiopyridyl ester (108, 
0.50 mmol, 1.0 equiv) were added to the Schlenk-tube. The resulting mixture was dissolved in dry THF 
(1 mL). Then, the organozinc pivalate, synthesized via TP2 or TP3 (0.95 mmol, 1.9 equiv) was added and 
stirring was continued for 4 h, at 25 °C. For substance 110t-y the reaction was carried out at 0 °C. The 
reaction conversion was monitored by GC-analysis of water-quenched reaction aliquots (C14H30 was used 
as an internal standard). Upon consumption of the starting material, sat. aq. NH4Cl solution (10 mL) was 
added, the phases were separated and the aqueous phase was extracted with EtOAc (3 x 25 mL). The 
combined organic layers were dried over MgSO4. The solvents were evaporated and the residue was 
subjected to column chromatographical purification (pentane/ethyl acetate) on silica yielding the 




Following TP5 S-(pyridin-2-yl) cyclohexanecarbothioate (108a, 111 mg, 0.50 mmol, 1.0 equiv) was coupled 
with (4-(methoxy)phenylzinc pivalate (72, 0.95 mmol, 1.9 equiv) prepared according to TP3 from the 
corresponding bromide. The solution was stirred for 4 h and was worked-up as usual.  
Isolated yield: 96 mg, 0.44 mmol, 88%, colorless crystals. 
Purification: pentane:ethyl acetate = 99:1. 





1H-NMR (400 MHz, CDCl3, ppm): δ = 7.94 (d, J = 8.8 Hz, 2H), 6.93 (d, J = 8.9 Hz, 2H), 3.86 (s, 3H), 3.22 (tt, 
J = 11.5, 3.2 Hz, 1H), 1.85 (tdd, J = 11.7, 6.2, 3.0 Hz, 4H), 1.73 (dddt, J = 12.8, 5.0, 3.3, 1.7 Hz, 1H), 1.57 – 
1.38 (m, 3H), 1.36 – 1.19 (m, 2H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 202.6, 163.3, 130.6, 129.4, 113.8, 55.6, 45.4, 29.7, 26.1, 26.1. 
FT-IR (ATR, cm-1): 𝜈 = 3065, 3019, 2973, 2944, 2916, 2846, 1639, 1628, 1594, 1573, 1504, 1499, 1466, 
1454, 1442, 1416, 1405, 1302, 1296, 1284, 1256, 1224, 1182, 1175, 1148, 1116, 1094, 1064, 1028, 1013, 
967, 959, 949, 928, 856, 842, 828, 815, 789, 763, 682. 
FT-IR (ATR, cm-1): 𝜈 = 2923, 2851, 1658, 1598, 1571, 1505, 1458, 1420, 1370, 1334, 1313, 1299, 1251, 
1208, 1163, 1133, 1103, 1025, 972, 896, 844, 825, 791, 770, 742, 687. 
MS (EI, 70 eV): m/z (%) = 135 (100), 150 (13), 187 (8), 218 (6). 




Following TP5 S-(pyridin-2-yl) hexadecanethioate (108b, 175 mg, 0.50 mmol, 1.0 equiv) was coupled with 
(benzo[d][1,3]dioxol-5-yl)zinc pivalate (109a, 0.95 mmol, 1.9 equiv) prepared according to TP3 from the 
corresponding bromide. The solution was stirred for 4 h and was worked-up as usual.  
Isolated yield: 162 mg, 0.45 mmol, 90%, white solid. 
Purification: pentane:ethyl acetate = 100:2. 
m.p.: 73.5 – 75.3 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.56 (dd, J = 8.2, 1.7 Hz, 1H), 7.44 (d, J = 1.7 Hz, 1H), 6.84 (d, J = 8.1 Hz, 
1H), 6.04 (s, 2H), 2.87 (t, J = 7.5 Hz, 2H), 1.70 (p, J = 7.4 Hz, 2H), 1.25 (s, 26H), 0.88 (t, J = 6.7 Hz, 3H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 198.9, 151.7, 148.3, 132.1, 124.4, 108.1, 108.0, 101.9, 38.6, 32.1, 
29.9, 29.8, 29.8, 29.8, 29.8, 29.7, 29.7, 29.6, 29.6, 29.5, 24.8, 22.9, 14.3. 
FT-IR (ATR, cm-1): 𝜈 = 2961, 2952, 2914, 2868, 2847, 2774, 1675, 1604, 1497, 1488, 1472, 1462, 1444, 
1418, 1373, 1359, 1285, 1279, 1263, 1258, 1250, 1200, 1110, 1092, 1051, 1004, 990, 940, 900, 889, 824, 
811, 805, 780, 757, 742, 730, 719, 655. 
MS (EI, 70 eV): m/z (%) = 281 (21), 225 (8), 209 (8), 208 (10), 207 (84), 191 (16), 165 (10), 164 (100), 149 
(57), 121 (12), 44 (7). 








Following TP5 S-(pyridin-2-yl) hexadecanethioate (108b, 175 mg, 0.50 mmol, 1.0 equiv) was coupled with 
((1-methyl-1H-indol-5-yl)zinc pivalate (109b, 0.95 mmol, 1.9 equiv) prepared according to TP3 from the 
corresponding bromide. The solution was stirred for 4 h and was worked-up as usual.  
Isolated yield: 137 mg, 0.37 mmol, 74%, pale yellow crystals. 
Purification: pentane:ethyl acetate = 9:1. 
m.p.: 71.6 – 73.5 °C. 
1H-NMR (400 MHz, CDCl3, ppm): 8.31 (d, J = 1.6 Hz, 1H), 7.91 (dd, J = 8.7, 1.7 Hz, 1H), 7.34 (d, J = 8.7 Hz, 
1H), 7.11 (d, J = 3.2 Hz, 1H), 6.61 (d, J = 3.1 Hz, 1H), 3.82 (s, 3H), 3.03 (t, J = 7.5 Hz, 2H), 1.77 (p, J = 7.5 Hz, 
2H), 1.26 (s, 18H), 0.88 (t, J = 6.7 Hz, 3H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 200.9, 139.2, 130.4, 129.4, 128.0, 122.9, 121.9, 109.2, 103.1, 38.7, 
33.2, 32.1, 29.8, 29.8, 29.8, 29.7, 29.7, 29.6, 29.5, 25.1, 22.9, 14.3. 
FT-IR (ATR, cm-1): 𝜈 = 2948, 2920, 2848, 1657, 1606, 1556, 1513, 1464, 1450, 1212, 1412, 1368, 1343, 
1309, 1297, 1264, 1249, 1229, 1163, 1145, 1090, 968, 821, 803, 780, 766, 733, 724. 
MS (EI, 70 eV): m/z (%) = 130 (14), 158 (72), 173 (100), 174 (14), 369 (11). 
HR-MS (EI, 70eV): [C25H39NO], calcd.: 369.3032; found: 369.3037. 
 
Cyclobutyl(4-(trifluoromethyl)phenyl)methanone (110d)  
 
Following TP5 S-(pyridin-2-yl) cyclobutanecarbothioate (108c, 97 mg, 0.50 mmol, 1.0 equiv) was coupled 
with (4-(trifluoromethyl)phenyl)zinc pivalate (109c, 0.95 mmol, 1.9 equiv) prepared according to TP3 from 
the corresponding bromide. The solution was stirred for 4 h and was worked-up as usual.  
Isolated yield: 96 mg, 0.42 mmol, 84% yield, colorless oil. 
Purification: pentane:ethyl acetate = 9:1. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.99 (dt, J = 8.1, 1.0 Hz, 2H), 7.74 – 7.68 (m, 2H), 4.13 – 3.93 (m, 1H), 
2.50 – 2.26 (m, 4H), 2.18 – 2.05 (m, 1H), 1.99 – 1.86 (m, 1H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 199.92, 138.26 , 134.15 (q, J = 32.6 Hz), 128.64 , 125.65 (q, J = 3.8 Hz), 





FT-IR (ATR, cm-1): 𝜈 = 2951, 1674, 1510, 1410, 1322, 1252, 1227, 1212, 1166, 1125, 1108, 1065, 1015, 967, 
949, 922, 893, 856, 842, 783, 774, 762, 731, 684, 671. 
MS (EI, 70 eV): m/z (%) = 227 (1), 174 (8), 173 (11), 173 (100), 145 (25). 




Following TP5 S-(pyridin-2-yl) cyclobutanecarbothioate (109c, 97 mg, 0.50 mmol, 1.0 equiv) was coupled 
with (4-(dimethylamino)phenyl)zinc pivalate (109d, 0.95 mmol, 1.9 equiv) prepared according to TP3 from 
the corresponding bromide. The solution was stirred for 4 h and was worked-up as usual.  
Isolated yield: 97 mg, 0.48 mmol, 95% yield, white solid. 
Purification: pentane:ethyl acetate = 95:5. 
m.p.: 75.2– 77.0 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.82 – 7.71 (m, 2H), 6.67 – 6.57 (m, 2H), 3.88 (pd, J = 8.6, 1.1 Hz, 1H), 
2.98 (s, 6H), 2.42 – 2.27 (m, 2H), 2.18 (dddd, J = 12.4, 10.6, 8.8, 3.9 Hz, 2H), 2.08 – 1.91 (m, 1H), 1.81 
(ddddd, J = 14.6, 9.2, 7.9, 4.0, 1.1 Hz, 1H). 
13C-NMR (100 MHz, CDCl3, ppm): 199.4, 153.0, 130.4, 111.0, 110.9, 41.7, 40.3, 25.3, 18.2. 
FT-IR (ATR, cm-1): 𝜈 = 2959, 1667, 1622, 1478, 1387, 1261, 1195, 1167, 1025, 909, 856, 819. 
MS (EI, 70 eV): m/z (%) = 203 (16), 148 (100), 44 (12), 42 (39). 




Following TP5 S-(pyridin-2-yl) cyclohexanecarbothioate (108a, 111 mg, 0.50 mmol, 1.0 equiv) was coupled 
with (4-fluorophenyl)zinc pivalate (109e, 0.95 mmol, 1.9 equiv) prepared according to TP3 from the 
corresponding bromide. The solution was stirred for 4 h and was worked-up as usual.  
Isolated yield: 62 mg, 0.30 mmol, 60%, colorless oil. 
Purification: pentane:ethyl acetate = 9:1. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.07 – 7.85 (m, 2H), 7.21 – 7.03 (m, 2H), 3.21 (tt, J = 11.4, 3.2 Hz, 1H), 





13C-NMR (100 MHz, CDCl3, ppm): δ = 202.4, 165.7 (d, J = 254.0 Hz), 132.8 (d, J = 3.0 Hz), 131.0 (d, J = 9.2 Hz), 
115.8 (d, J = 21.7 Hz), 45.7, 29.6, 26.1, 26.0.  
FT-IR (ATR, cm-1): 𝜈 = 3068, 2929, 2853, 1678, 1596, 1505, 1463, 1450, 1409, 1371, 1332, 1312, 1295, 
1289, 1249, 1233, 1205, 1176, 1154, 1134, 1102, 1027, 1012, 974, 893, 860, 841, 824, 806, 800, 776, 738, 
675. 
MS (EI, 70 eV): m/z (%) = 206 (9), 151 (21), 138 (9), 124 (8), 123 (100), 95 (8). 




Following TP5 S-(pyridin-2-yl) cyclohexanecarbothioate (108a, 111 mg, 0.50 mmol, 1.0 equiv) was coupled 
with (4-cyano-3-fluorophenyl)zinc pivalate (109f, 0.95 mmol, 1.9 equiv)prepared according to TP4 from 
the corresponding bromide. The solution was stirred for 4 h and was worked-up as usual.  
Isolated yield: 91 mg, 0.39 mmol, 79%, colorless crystals. 
Purification: pentane:ethyl acetate = 9:1. 
m.p.: 54.4 – 56.2 °C 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.85 – 7.68 (m, 3H), 3.16 (tt, J = 11.3, 3.1 Hz, 1H), 1.86 (dp, J = 9.5, 
3.4 Hz, 4H), 1.75 (dddd, J = 11.5, 5.2, 3.3, 1.7 Hz, 1H), 1.58 – 1.16 (m, 5H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 201.2 (d, J = 1.6 Hz), 163.4 (d, J = 261.1 Hz), 142.2 (d, J = 6.1 Hz), 
134.1, 124.3 (d, J = 3.7 Hz), 116.1 (d, J = 20.5 Hz), 113.4, 105.2 (d, J = 15.9 Hz), 46.2, 29.2, 25.9, 25.7. 
FT-IR (ATR, cm-1): 𝜈 = 3076, 2930, 2855, 2239, 1686, 1618, 1567, 1495, 1463, 1450, 1421, 1415, 1373, 
1331, 1313, 1299, 1290, 1274, 1253, 1230, 1192, 1157, 1133, 1120, 1103, 996, 988, 921, 908, 901, 873, 
836, 797, 772, 734, 706. 
MS (EI, 70 eV): m/z (%) = 231 (43), 225 (8), 216 (9), 213 (18), 190 (31), 189 (12), 188 (12), 177 (10), 176 
(100), 165 (7), 164 (26), 163 (26), 158 (7), 148 (86), 121 (59), 129 (10), 105 (24), 100 (21), 83 (16), 77 (9), 
68 (8), 67 (11), 55 (27). 









(Adamantan-1-yl)(3-(trifluoromethyl)phenyl)methanone (110h)  
 
Following TP5 S-(pyridin-2-yl)-adamantane-1-carbothioate (108d, 137 mg, 0.50 mmol, 1.0 equiv) was 
coupled with (3-(trifluoromethyl)phenyl) zinc pivalate (109g, 0.95 mmol, 1.9 equiv) prepared according to 
TP3 from the corresponding bromide. The solution was stirred for 4 h and was worked-up as usual.  
Isolated yield: 94 mg, 0.31 mmol, 61%, white solid. 
Purification: pentane:ethyl acetate = 98:2. 
m.p.: 63.6 – 65.3 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.76 (d, J = 2.0 Hz, 1H), 7.70 (t, J = 8.4 Hz, 2H), 7.52 (t, J = 7.8 Hz, 1H), 
2.09 (q, J = 3.1 Hz, 3H), 1.99 (d, J = 2.9 Hz, 6H), 1.82 – 1.68 (m, 6H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 209.0, 140.3, 131.7 – 129.7 (m), 130.4 (d, J = 1.4 Hz), 128.7, 126.9 (q, 
J = 3.7 Hz), 124.1 (q, J = 3.9 Hz), 123.9 (q, J = 272.5 Hz), 47.1, 39.1, 36.5, 28.1. 
FT-IR (ATR, cm-1): 𝜈 = 2943, 2914, 2854, 1661, 1605, 1453, 1329, 1309, 1261, 1225, 1184, 1162, 1119, 
1102, 1071, 998, 922, 808, 778, 762, 734, 695, 659. 
MS (EI, 70 eV): m/z (%) = 308 (1), 136 (12), 135 (100), 93 (12), 79 (12). 




Following TP5 S-(pyridin-2-yl)-adamantane-1-carbothioate (108d, 137 mg, 0.50 mmol, 1.0 equiv) was 
coupled with (4-cyano-3-fluorophenyl)zinc pivalate (109f, 0.95 mmol, 1.9 equiv) prepared according to 
TP4 from the corresponding bromide. The solution was stirred for 4 h and was worked-up as usual.  
Isolated yield: 114 mg, 0.41 mmol, 81%, colorless crystals. 
Purification: pentane:ethyl acetate = 9:1. 
m.p.: 103.9 -105.8 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.66 (dd, J = 7.9, 6.2 Hz, 1H), 7.31 (ddd, J = 21.5, 8.5, 1.4 Hz, 2H), 2.07 
(q, J = 3.1 Hz, 3H), 1.93 (d, J = 3.0 Hz, 6H), 1.81 – 1.65 (m, 6H). 
13C-NMR (100 MHz, CDCl3, ppm): 207.6 (d, J = 1.4 Hz), 162.6 (d, J = 261.2 Hz), 146.3 (d, J = 6.2 Hz), 133.5, 





FT-IR (ATR, cm-1): 𝜈 = 3053, 2930, 2901, 2858, 2849, 2673, 2652, 2241, 1682, 1620, 1561, 1497, 1451, 
1413, 1344, 1323, 1297, 1276, 1269, 1252, 1225, 1209, 1191, 1179, 1171, 1106, 1099, 1003, 968, 938, 902, 
884, 879, 851, 819, 793, 764, 751, 732, 718, 677, 661. 
MS (EI, 70 eV): m/z (%) = 136 (11), 135 (100), 107 (14), 93 (16), 79 (13). 
HR-MS (EI, 70eV): [C18H18FNO], calcd.: 283.1372; found: 283.1266. 
 
3-(5-(2,5-Dimethylphenoxy)-2,2-dimethylpentanoyl)benzonitrile (110j)  
 
Following TP5 S-(pyridin-2-yl) 5-(2,5-dimethylphenoxy)-2,2-dimethylpentanethioate (108e, 172 mg, 
0.50 mmol, 1.0 equiv) was coupled with (3-cyanophenyl)zinc pivalate (109h, 0.95 mmol, 1.9 equiv) 
prepared according to TP4 from the corresponding iodide. The solution was stirred for 4 h and was 
worked-up as usual.  
Isolated yield: 110 mg, 0.33 mmol, 66%, yellow oil. 
Purification: pentane:ethyl acetate = 95:5. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.97 (d, J = 1.8 Hz, 1H), 7.92 (dt, J = 8.0, 1.5 Hz, 1H), 7.74 (dt, J = 7.7, 
1.4 Hz, 1H), 7.52 (t, J = 7.9 Hz, 1H), 6.99 (d, J = 7.5 Hz, 1H), 6.66 (dd, J = 7.5, 1.5 Hz, 1H), 6.60 – 6.54 (m, 1H), 
3.90 (t, J = 6.0 Hz, 2H), 2.29 (s, 3H), 2.13 (s, 3H), 2.02 – 1.91 (m, 2H), 1.80 – 1.67 (m, 2H), 1.37 (s, 6H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 206.7, 156.8, 139.8, 136.6, 134.2, 131.8, 131.4, 130.4, 129.3, 123.4, 
120.9, 118.2, 112.8, 111.8, 67.5, 47.9, 37.4, 26.0, 25.1, 21.5, 16.0. 
FT-IR (ATR, cm-1): 𝜈 = 2922, 2230, 1677, 1677, 1583, 1508, 1470, 1414, 1388, 1309, 1284, 1262, 1223, 
1156, 1128, 1043, 1017, 999, 844, 803, 752, 683. 
MS (EI, 70 eV): m/z (%) = 335 (4), 214 (100), 144 (13), 130 (26), 122 (17), 102 (10), 83 (12), 55 (15). 
HR-MS (EI, 70eV): [C22H25NO2], calcd.: 335.1885, found: 335.1888. 
 
1-(3-((tert-Butyldimethylsilyl)oxy)phenyl)-5-(2,5-dimethylphenoxy)-2,2-dimethylpentan-1-one (110k)  
 
Following TP5 S-(pyridin-2-yl) 5-(2,5-dimethylphenoxy)-2,2-dimethylpentanethioate (108e, 172 mg, 





0.95 mmol, 1.9 equiv) prepared according to TP3 from the corresponding bromide. The solution was 
stirred for 4 h and was worked-up as usual.  
Isolated yield: 158 mg, 0.36 mmol, 78%, pale yellow oil. 
Purification: pentane:ethyl acetate = 9:1. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.13 – 6.99 (m, 2H), 6.93 (t, J = 2.0 Hz, 1H), 6.79 (d, J = 7.5 Hz, 1H), 
6.73 (ddd, J = 7.8, 2.5, 1.3 Hz, 1H), 6.44 (dd, J = 7.6, 1.5 Hz, 1H), 6.37 (d, J = 1.5 Hz, 1H), 3.68 (t, J = 6.1 Hz, 
2H), 2.09 (s, 3H), 1.94 (s, 3H), 1.79 – 1.68 (m, 2H), 1.59 – 1.48 (m, 2H), 1.14 (s, 6H), 0.78 (s, 9H), 0.00 (s, 
6H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 208.6, 156.9, 155.4, 140.3, 136.4, 130.3, 129.2, 123.5, 122.7, 120.7, 
120.5, 119.3, 111.8, 67.8, 47.7, 37.5, 26.2, 25.7, 25.1, 21.4, 18.2, 15.8, -4.4. 
FT-IR (ATR, cm-1): 𝜈 = 2953, 2927, 1672, 1594, 1576, 1508, 1470, 1421, 1388, 1362, 1251, 1183, 1156, 
1129, 1044, 1000, 913, 834, 800, 779, 759, 685. 
MS (EI, 70 eV): m/z (%) = 320 (23), 319 (100), 235 (32), 83 (8), 73 (14). 
HR-MS (EI, 70eV): [C27H40O3Si], calcd.: 440.2747, found: 440.2751. 
 
Ethyl 4-benzoylbenzoate (110l) 
 
Following TP5 S-(pyridin-2-yl) benzothioate (108f, 108 mg, 0.50 mmol, 1.0 equiv) was coupled with (4-
(ethoxycarbonyl)phenyl)zinc pivalate (109j, 0.95 mmol, 1.9 equiv) prepared according to TP4 at -40 °C 
from the corresponding iodide. The solution was stirred for 4 h and was worked-up as usual. 
Isolated yield: 90 mg, 0.35 mmol, 71% yield, colorless crystals. 
Purification: pentane:ethyl acetate = 95:5. 
m.p.: 93.6 – 95.4 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.20 – 8.11 (m, 2H), 7.82 (ddd, J = 14.6, 7.6, 1.8 Hz, 4H), 7.66 – 7.57 
(m, 1H), 7.50 (dd, J = 8.4, 7.1 Hz, 2H), 4.42 (q, J = 7.1 Hz, 2H), 1.42 (t, J = 7.1 Hz, 3H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 196.2, 166.0, 141.3, 137.1, 133.7, 133.1, 130.3, 129.9, 129.6, 128.6, 
61.6, 14.5. 
FT-IR (ATR, cm-1): 𝜈 = 2979, 1704, 1660, 1604, 1480, 1446, 1399, 1367, 1266, 1179, 1102, 1019, 1004, 937, 
925, 845, 752, 712, 695, 656. 
MS (EI, 70 eV): m/z (%) = 177 (28), 105 (100), 149 (59), 152 (39), 181 (59), 209 (59), 226 (30), 254 (35). 







Following TP5, using TMEDA (10 mol%, 0.05 mmol, 6 mg) as ligand, S-(pyridin-2-yl) benzothioate (108f, 
108 mg, 0.50 mmol, 1.0 equiv) was coupled with (benzo[b]thiophen-2-yl)zinc pivalate (109k, 0.95 mmol, 
1.9 equiv) prepared by directed metalation from benzo[b]thiophen and TMPMgCl (1.0 equiv) at 0 °C for 
3 h, followed by transmetalation with Zn(OPiv)2 (1.0 equiv) The solution was stirred for 4 h and was 
worked-up as usual.  
Isolated yield: 81 mg, 0.34 mmol, 68%, orange oil. 
Purification: pentane:ethyl acetate = 9:1. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.96 – 7.85 (m, 5H), 7.68 – 7.60 (m, 1H), 7.54 (dd, J = 8.3, 6.9 Hz, 2H), 
7.49 (ddd, J = 8.2, 7.0, 1.3 Hz, 1H), 7.42 (ddd, J = 8.1, 7.1, 1.1 Hz, 1H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 189.8, 143.2, 142.8, 139.2, 138.0, 132.6, 132.4, 129.4, 128.7, 127.6, 
126.2, 125.2, 123.1. 
FT-IR (ATR, cm-1): 𝜈 = 1631, 1593, 1576, 1509, 1455, 1444, 1425, 1314, 1285, 1245, 1187, 1175, 1157, 
1114, 1066, 1025, 880, 869, 833, 790, 746, 731, 708, 701, 664. 
MS (EI, 70 eV): m/z (%) = 238 (100), 23 (11), 210 (10), 161 (97), 133 (16), 105 (40), 89 (23), 77 (31). 
HR-MS (EI, 70eV): [C15H10OS], calcd.: 238.0452, found: 238.0454. 
 
(4-Chlorophenyl)(2-fluoro-4-methoxyphenyl)methanone (110n)  
 
Following TP5 S-(pyridin-2-yl) 4-chlorobenzothioate (108g, 125 mg, 0.50 mmol, 1.0 equiv) was coupled 
with (2-fluoro-4-methoxyphenyl)zinc pivalate (109l, 0.95 mmol, 1.9 equiv) prepared according to TP3 from 
the corresponding bromide. The solution was stirred for 4 h and was worked-up as usual.  
Isolated yield:  121 mg, 0.46, 92%, colorless oil. 
Purification: pentane:ethyl acetate = 8:2. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.74 (dd, J = 8.5, 1.6 Hz, 2H), 7.57 (t, J = 8.4 Hz, 1H), 7.46 – 7.40 (m, 





13C-NMR (100 MHz, CDCl3, ppm): δ = 191.5 (d, J = 1.0 Hz), 164.2 (d, J = 11.3 Hz), 163.1, 161.9 (d, 
J = 254.1 Hz), 139.2, 136.7, 132.7 (d, J = 4.4 Hz), 130.9 (d, J = 1.7 Hz), 128.6, 118.9 (d, J = 13.6 Hz), 101.9 (d, 
J = 25.7 Hz), 55.9. 
FT-IR (ATR, cm-1): 𝜈 = 1671, 1588, 1570, 1560, 1544, 1446, 1426, 1340, 1282, 1235, 1218, 1154, 1116, 
1069, 1054, 986, 916, 885, 791, 58, 733, 690. 
MS (EI, 70 eV): m/z (%) = 139 (16), 153 (100), 154 (9), 187 (9), 220 (11), 264 (25), 266 (8). 




Following TP5 S-(pyridin-2-yl) 4-methoxybenzothioate (108h, 123 mg, 0.50 mmol, 1.0 equiv) was coupled 
with (3-(methylthio)phenylzinc pivalate (109m, 0.95 mmol, 1.9 equiv) prepared according to TP3 from the 
corresponding bromide. The solution was stirred for 4 h and was worked-up as usual.  
Isolated yield: 123 mg, 0.48 mmol, 96%, colorless oil. 
Purification: pentane:ethyl acetate = 9:1. 
1H-NMR (400 MHz, CDCl3, ppm): 7.89 – 7.77 (m, 2H), 7.62 (t, J = 1.7 Hz, 1H), 7.55 – 7.30 (m, 3H), 7.05 – 
6.88 (m, 2H), 3.89 (s, 3H), 2.52 (s, 3H). 
13C-NMR (100 MHz, CDCl3, ppm): 195.3, 163.5, 139.3, 139.0, 132.7, 130.1, 129.8, 128.6, 127.1, 126.5, 
113.7, 55.7, 15.8. 
FT-IR (ATR, cm-1): 𝜈 = 2916, 2847, 1650, 1597, 1567, 1507, 1419, 1315, 1282, 1256, 1175, 1154, 1026, 842, 
756, 710. 
MS (EI, 70 eV): m/z (%) = 258 (36), 211 (19), 136 (9) 135 (100), 77 (11). 




Following TP5 S-(pyridin-2-yl) 2-methoxybenzothioate (108h’, 123 mg, 0.50 mmol, 1.0 equiv) was coupled 
with (3-(methylthio)phenylzinc pivalate (109m, 0.95 mmol, 1.9 equiv) prepared according to TP3 from the 
corresponding bromide. The solution was stirred for 4 h and was worked-up as usual.  





Purification: pentane:ethyl acetate = 9:1. 
1H-NMR (400 MHz, CDCl3, ppm): 7.74 (t, J = 1.8 Hz, 1H), 7.54 – 7.40 (m, 3H), 7.39 – 7.29 (m, 2H), 7.04 (td, 
J = 7.4, 0.9 Hz, 1H), 6.99 (dd, J = 8.5, 0.9 Hz, 1H), 3.73 (s, 3H), 2.50 (s, 3H). 
13C-NMR (100 MHz, CDCl3, ppm): 196.2, 157.5, 139.3, 138.5, 132.2, 130.9, 129.8, 128.7, 128.7, 127.0, 
127.0, 120.7, 111.6, 55.7, 15.8. 
FT-IR (ATR, cm-1): 𝜈 = 2920, 2836, 1659, 1597, 1581, 1567, 1486, 1462, 1434, 1413, 1294, 1241, 1180, 
1154, 1111, 1077, 1047, 1020, 994, 973, 959, 949, 936, 889, 809, 750, 716, 672. 
MS (EI, 70 eV): m/z (%) = 258 (32), 211 (43), 138 (23), 135 (100), 121 (58), 79 (26), 77 (38) 




Following TP5 S-(pyridin-2-yl) 4-methoxybenzothioate (108h, 123 mg, 0.50 mmol, 1.0 equiv) was coupled 
with (4-fluorophenyl)zinc pivalate (109e, 0.95 mmol, 1.9 equiv) prepared according to TP3 from the 
corresponding bromide. The solution was stirred for 4 h and was worked-up as usual.  
Isolated yield: 99 mg, 0.43 mmol, 86% yield, white solid. 
Purification: pentane:ethyl acetate = 9:1. 
m.p.: 97.1 – 98.8 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.80 (dt, J = 8.7, 2.7 Hz, 4H), 7.15 (t, J = 8.6 Hz, 2H), 7.03 – 6.92 (m, 
2H), 3.89 (s, 3H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 194.3, 165.2 (d, J = 253.2 Hz), 163.4, 134.6 (d, J = 3.1 Hz), 132.6, 132.4 
(d, J = 9.1 Hz), 130.1, 115.5 (d, J = 21.8 Hz), 113.8, 55.7. 
FT-IR (ATR, cm-1): 𝜈 = 3065, 3019, 2973, 2944, 2916, 2846, 1639, 1628, 1594, 1573, 1504, 1499, 1466, 
1454, 1442, 1416, 1405, 1302, 1296, 1284, 1256, 1224, 1182, 1175, 1148, 1116, 1094, 1064, 1028, 1013, 
967, 959, 949, 928, 856, 842, 828, 815, 789, 763, 682. 
MS (EI, 70 eV): m/z (%) = 231 (7), 230 (43), 199 (13), 136 (9), 135 (100), 123 (16), 77 (9). 









Ferrocenyl-(4-(trifluoromethoxy)phenyl)methanone (110q)  
 
Following TP5 S-(pyridin-2-yl) ferrocenecarbothioate (108i, 162 mg, 0.50 mmol, 1.0 equiv) was coupled 
with 4-(trifluoromethoxy)phenyl)zinc pivalate (109n, 0.95 mmol, 1.9 equiv) prepared according to TP3 
from the corresponding bromide. The solution was stirred for 4 h and was worked-up as usual.  
Isolated yield: 151 mg, 0.40 mmol, 81%, red solid. 
Purification: pentane:ethyl acetate = 9:1. 
m.p.: 38.2 – 40.1 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.03 – 7.91 (m, 2H), 7.30 (d, J = 8.3 Hz, 2H), 4.89 (t, J = 1.9 Hz, 2H), 
4.62 (t, J = 2.0 Hz, 2H), 4.21 (s, 5H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 197.7, 153.8 – 150.2 (m), 138.2, 130.1, 120.5 (q, J = 258.3 Hz), 120.4, 
77.9, 73.0, 71.6, 70.4. 
FT-IR (ATR, cm-1): 𝜈 = 2924, 1627, 1598, 1447, 1251, 1213, 1152, 1104, 1054, 1027, 1014, 1002, 968, 951, 
923, 852, 822, 767, 713. 
MS (EI, 70 eV): m/z (%) = 375 (20), 374 (100), 372 (6), 212 (7), 185 (9), 139 (24). 
HR-MS (EI, 70eV): [C18H13F3FeO2], calcd.: 374.0217, found: 374.0214. 
 
Ferrocenyl-(1-methyl-1H-indol-5-yl)methanone (110r)  
 
Following TP5 S-(pyridin-2-yl) ferrocenecarbothioate (108i, 162 mg, 0.50 mmol, 1.0 equiv) was coupled 
with ((1-methyl-1H-indol-5-yl)zinc pivalate (109b, 0.95 mmol, 1.9 equiv) prepared according to TP3 from 
the corresponding bromide. The solution was stirred for 4 h and was worked-up as usual.  
Isolated yield: 144 mg, 0.42, 84%, red oil. 
Purification: pentane:ethyl acetate = 8:2. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.32 (d, J = 1.8 Hz, 1H), 7.87 (dd, J = 8.6, 1.7 Hz, 1H), 7.38 (d, J = 8.6 Hz, 
1H), 7.14 (d, J = 3.1 Hz, 1H), 6.62 (d, J = 3.1 Hz, 1H), 4.98 (t, J = 2.0 Hz, 2H), 4.56 (t, J = 2.0 Hz, 2H), 4.21 (s, 





13C-NMR (100 MHz, CDCl3, ppm): δ = 199.1, 138.6, 131.6, 130.3, 127.7, 122.7, 122.5, 109.0, 102.7, 79.5, 
72.0, 71.9, 70.3, 33.2. 
FT-IR (ATR, cm-1): 𝜈 = 3093, 2920, 1624, 1597, 1564, 1511, 1489, 1441, 1416, 1373, 1337, 1305, 1286, 
1267, 1242, 1210, 1149, 1135, 1098, 1081, 1044, 1025, 1000, 900, 841, 818, 776, 753, 736, 722. 
MS (EI, 70 eV): m/z (%) = 344 (23), 343 (100), 341 (7), 194 (9), 130 (9). 
HR-MS (EI, 70eV): [C20H17FeNO], calcd.: 343.0660, found: 343.0659. 
 
Quinolin-2-yl(4-(trifluoromethoxy)phenyl)methanone (110s)  
 
Following TP5 S-(pyridin-2-yl) quinoline-2-carbothioate (108j, 133 mg, 0.50 mmol, 1.0 equiv) was coupled 
with 4-(trifluoromethoxy)phenyl)zinc pivalate (109n, 0.95 mmol, 1.9 equiv) prepared according to TP3 
from the corresponding bromide. The solution was stirred for 4 h and was worked-up as usual.  
Isolated yield: 108 mg, 0.34 mmol, 68%, colorless oil. 
Purification: pentane:ethyl acetate = 99:1. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.41 – 8.33 (m, 3H), 8.20 (dq, J = 8.6, 0.9 Hz, 1H), 8.16 (d, J = 8.5 Hz, 
1H), 7.93 (dd, J = 8.2, 1.4 Hz, 1H), 7.81 (ddd, J = 8.4, 6.9, 1.5 Hz, 1H), 7.69 (ddd, J = 8.1, 6.9, 1.2 Hz, 1H), 7.35 
(dq, J = 9.1, 1.1 Hz, 2H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 192.12, 154.22, 152.76, 152.74, 146.79, 137.48, 134.52, 133.72, 
130.65, 130.42, 129.17, 128.85, 127.84, 121.90 – 119.05 (m, 2C) 
FT-IR (ATR, cm-1): 𝜈 = 1662, 1605, 1587, 1508, 1309, 1295, 1202, 1140, 1112, 967, 957, 920, 850, 835, 794, 
769, 743, 669.0 
MS (EI, 70 eV): m/z (%) = 95, (12), 189 (100), 189 (29), 191 (15), 204 (42), 232 (17), 288 (69), 289 (53), 316 
(28), 317 (30). 












tert-Butyl (S)-2-(4-methoxybenzoyl)pyrrolidine-1-carboxylate (110t)  
 
Following TP5 tert-butyl (S)-2-((pyridin-2-ylthio)carbonyl)pyrrolidine-1-carboxylate (108k, 154 mg, 
0.50 mmol, 1.0 equiv) was coupled with ((4-methoxyphenyl)zinc pivalate (72, 0.95 mmol, 1.9 equiv) 
prepared according to TP3 from the corresponding bromide. The solution was stirred for 4 h and was 
worked-up as usual.  
Isolated yield: 110 mg, 0.36 mmol, 72%, pale yellow crystals.  
Purification: pentane:ethyl acetate = 8:2  6:4. 
m.p.: 124.8– 126.9 °C. 
1H-NMR (400 MHz, CDCl3, ppm): (mixture of rotamers) δ = 8.06 – 7.85 (m, 2H), 7.04 – 6.82 (m, 2H), 5.29 
(dd, J = 9.3, 2.9 Hz, 0H), 5.15 (dd, J = 8.8, 3.8 Hz, 1H), 3.87 (s, 2H), 3.85 (s, 1H), 3.71 – 3.58 (m, 1H), 3.54 (dt, 
J = 10.6, 6.6 Hz, 1H), 3.46 (dt, J = 10.3, 7.3 Hz, 0H), 2.41 – 2.18 (m, 1H), 1.91 (ttd, J = 15.0, 7.2, 3.5 Hz, 3H), 
1.46 (s, 3H), 1.25 (s, 5H). 
13C-NMR (100 MHz, CDCl3, ppm): (mixture of rotamers) δ = 197.5, 197.0, 163.7, 163.6, 154.6, 154.0, 130.9, 
130.6, 128.3, 128.1, 114.0, 113.9, 79.8, 79.7, 61.1, 60.9, 55.6, 55.6, 46.9, 46.7, 31.1, 30.1, 28.6, 28.3, 24.3, 
23.7. 
FT-IR (ATR, cm-1): 𝜈 = 2972, 1680, 1597, 1574, 1510, 1477, 1455, 1391, 1363, 1307, 1254, 1228, 1158, 
1115, 1080, 1025, 1010, 988, 918, 880, 838, 809, 771, 688. 
MS (EI, 70 eV): m/z (%) = 170 (34), 125 (81), 114 (89), 77 (13), 70 (100), 57 (67), 41 (14). 
HR-MS (EI, 70eV): [C17H23NO4], calcd.: 305.1627, found: 305.1624. 
Optical rotation: [α]D
20 = -23 (c 1.02, CHCl3). 
Chiral HPLC: 99% ee, OJ-H column, heptane:iPrOH = 95:5, 1.0 mL/min, 30 °C. 
 
tert-Butyl (S)-2-(benzo[d][1,3]dioxole-5-carbonyl)pyrrolidine-1-carboxylate (110u)  
 
Following TP5 tert-butyl 2-((pyridin-2-ylthio)carbonyl)pyrrolidine-1-carboxylate (108k, 154 mg, 





1.9 equiv) prepared according to TP3 from the corresponding bromide. The solution was stirred for 4 h 
and was worked-up as usual.  
Isolated yield: 130 mg, 0.41 mmol, 82%, brown oil. 
Purification: pentane:ethyl acetate = 8:2. 
1H-NMR (400 MHz, DMSO-d6, ppm): (mixture of rotamers) δ = 7.66 (ddd, J = 8.2, 2.8, 1.7 Hz, 1H), 7.49 (t, 
J = 1.9 Hz, 1H), 7.06 (dd, J = 8.1, 0.9 Hz, 1H), 6.15 (s, 2H), 5.25 (ddd, J = 10.8, 9.0, 3.8 Hz, 1H), 3.39 (dddd, 
J = 14.2, 11.8, 7.3, 4.6 Hz, 2H), 2.37 – 2.23 (m, 1H), 1.91 – 1.63 (m, 4H), 1.38 (s, 4H), 1.17 (s, 6H). 
13C-NMR (100 MHz, DMSO-d6, ppm): (mixture of rotamers) δ = 197.3, 196.5, 153.8, 153.4, 152.1, 148.4, 
129.7, 129.5, 125.2, 125.0, 108.7, 108.7, 108.2, 108.0, 102.6, 102.6, 79.0, 78.8, 61.0, 61.0, 47.0, 46.9, 31.0, 
30.1, 28.6, 28.3, 27.5, 24.3, 23.6. 
FT-IR (ATR, cm-1): 𝜈 = 2974, 1682, 1614, 1605, 1505, 1488, 1442, 1392, 1364, 1245, 1160, 1120, 1108, 
1097, 1034, 1000, 973, 927, 910, 884, 856, 807, 772, 740, 718. 
MS (EI, 70 eV): m/z (%) = 319 (4), 246 (11), 170 (48), 149 (100), 121 (18), 70 (75), 58 (23), 57 (48), 43 (53). 
HR-MS (EI, 70eV): [C17H21NO5], calcd.: 319.1420, found: 319.1411. 
Optical rotation: [α]D
20 = -29 (c 0,4 CHCl3). 
Chiral HPLC: >99% ee, OJ-H column, heptane:iPrOH = 99:1, 1.0 mL/min, 30 °C. 
 
(S)-2-(4-Isobutylphenyl)-1-(6-methoxynaphthalen-2-yl)propan-1-one (110v)  
 
Following TP5 S-(pyridin-2-yl) (S)-2-(4-isobutylphenyl)propanethioate (108l, 150 mg, 0.50 mmol, 1.0 equiv) 
was coupled with (6-methoxynaphthalen-2-yl)zinc pivalate (109o, 0.95 mmol, 1.9 equiv) prepared 
according to TP3 from the corresponding bromide. The solution was stirred for 4 h and was worked-up as 
usual.  
Isolated yield: 144 mg, 0.42 mmol, 89%, white solid. 
Purification: pentane:ethyl acetate = 95:5  9:1. 
m.p.: 70.1 – 72.8 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.34 (d, J = 1.7 Hz, 1H), 7.92 (dd, J = 8.7, 1.8 Hz, 1H), 7.70 (d, J = 9.0 Hz, 
1H), 7.61 (d, J = 8.7 Hz, 1H), 7.20 – 7.13 (m, 2H), 7.07 (dd, J = 8.9, 2.5 Hz, 1H), 7.01 (d, J = 2.6 Hz, 1H), 
7.00 – 6.96 (m, 2H), 4.72 (q, J = 6.8 Hz, 1H), 3.83 (s, 3H), 2.31 (d, J = 7.2 Hz, 2H), 1.71 (dp, J = 13.5, 6.7 Hz, 





13C-NMR (100 MHz, CDCl3, ppm): δ = 200.4, 159.8, 140.4, 139.1, 137.2, 132.0, 131.3, 130.4, 129.8, 127.9, 
127.6, 127.1, 125.5, 119.7, 105.7, 77.1, 55.5, 47.4, 5.1, 30.3, 22.5, 22.5, 19.8. 
FT-IR (ATR, cm-1): 𝜈 = 2954, 2923, 1670, 1622, 1508, 1480, 1458, 1438, 1389, 1369, 1337, 1271, 1264, 
1231, 1200, 1167, 1150, 1061, 1024, 945, 911, 901, 893, 864, 856, 849, 830, 817, 801, 776, 770, 762, 738, 
698. 
MS (EI, 70 eV): m/z (%) = 142 (7), 157 (13), 185 (100), 186 (13), 346 (1). 
HR-MS (EI, 70eV): [C24H26O2], calcd.: 346.1933, found: 346.1927. 
Optical rotation: [α]D
20 = -89 (c 1.02, CHCl3). 




Following TP5 S-(pyridin-2-yl) 2-(4-isobutylphenyl)propanethioate (108l, 150 mg, 0.50 mmol, 1.0 equiv) 
was coupled with (3-(methylthio)phenylzinc pivalate (109m, 0.95 mmol, 1.9 equiv) prepared according to 
TP3 from the corresponding bromide. The solution was stirred for 4 h and was worked-up as usual.  
Isolated yield: 110 mg, 0.35 mmol, 71%, colourless oil 
Purification: pentane:ethyl acetate = 98:2 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.80 (t, J = 1.8 Hz, 1H), 7.69 (dt, J = 7.6, 1.4 Hz, 1H), 7.34 (ddd, J = 7.8, 
2.0, 1.1 Hz, 1H), 7.32 – 7.23 (m, 1H), 7.20 – 7.14 (m, 2H), 7.09 – 7.02 (m, 2H), 4.61 (q, J = 6.9 Hz, 1H), 2.45 
(s, 3H), 2.40 (d, J = 7.2 Hz, 2H), 1.80 (dp, J = 13.6, 6.8 Hz, 1H), 1.51 (d, J = 6.9 Hz, 3H), 0.86 (dd, J = 6.6, 
0.8 Hz, 6H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 200.1, 140.4, 139.4, 138.5, 137.1, 130.6, 129.8, 128.7, 127.4, 126.1, 
125.4, 47.7, 45.0, 30.2, 22.4, 22.4, 19.5, 15.6. 
FT-IR (ATR, cm-1): 𝜈 = 2957, 2926, 1682, 1584, 1569, 1509, 1465, 1453, 1415, 1384, 1373, 1333, 1215, 
1080, 1061, 1014, 960, 882, 848, 795, 747, 686, 667. 
MS (EI, 70 eV): m/z (%) = 312 (4), 161 (35), 152 (9), 151 (100), 123 (10). 
HR-MS (EI, 70eV): [C20H24OS], calcd.: 312. 1548, found: 312.2539. 
Optical rotation: [α]D
20 = 107 (c 0.53, CHCl3). 









Following TP5 S-(pyridin-2-yl) (S)-2-methylbutanethioate (108m, 98 mg, 0.50 mmol, 1.0 equiv) was 
coupled with (4-(dimethylcarbamoyl)phenyl)zinc pivalate (109p, 0.95 mmol, 1.9 equiv) prepared according 
to TP4 from the corresponding iodide at 0 °C in 2 h. The solution was stirred for 4 h and was worked-up as 
usual.  
Isolated yield: 80 mg, 0.34 mmol, 69%, yellow oil 
Purification: pentane:ethyl acetate = 6:4, 5% NEt3 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.03 – 7.94 (m, 2H), 7.54 – 7.47 (m, 2H), 3.38 (h, J = 6.7 Hz, 1H), 3.13 
(s, 3H), 2.96 (s, 3H), 1.82 (dqd, J = 13.8, 7.4, 6.3 Hz, 1H), 1.49 (ddd, J = 14.0, 7.6, 6.8 Hz, 1H), 1.19 (d, J = 
6.8 Hz, 3H), 0.91 (t, J = 7.4 Hz, 3H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 203.9, 170.6, 140.4, 137.4, 128.4, 127.3, 42.3, 26.6, 16.6, 11.7. 
FT-IR (ATR, cm-1): 𝜈 = 2963, 2933, 2363, 1684, 1636, 1508, 1458, 1396, 1266, 1219, 1081, 1015, 971, 861, 
839, 709, 699. 
MS (EI, 70 eV): m/z (%) = 233 (7), 189 (5), 177 (11), 176 (100), 120 (6), 104 (11). 
HR-MS (EI, 70eV): [C14H19NO2], calcd.: 233.1416, found: 233.1407. 
Optical rotation: [α]D
20 = 13 (c 0.1, CHCl3). 




Following TP5 S-(pyridin-2-yl) 2-(4-isobutylphenyl)propanethioate (108m, 150 mg, 0.50 mmol, 1.0 equiv) 
was coupled with (3-(dimethylamino)phenyl)zinc pivalate (109q, 0.95 mmol, 1.9 equiv) prepared 
according to TP3 from the corresponding bromide. The solution was stirred for 4 h and was worked-up as 
usual.  
Isolated yield: 110 mg, 0.35 mmol, 71%, colorless oil 





1H-NMR (400 MHz, CDCl3, ppm): δ = 7.35 – 7.15 (m, 3H), 6.86 (ddd, J = 8.0, 2.6, 1.3 Hz, 1H), 3.34 (h, J = 
6.7 Hz, 1H), 2.94 (s, 6H), 1.78 (ddd, J = 13.9, 7.5, 6.5 Hz, 1H), 1.52 – 1.37 (m, 1H), 1.13 (d, J = 6.8 Hz, 3H), 
0.86 (t, J = 7.4 Hz, 3H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 205.3, 150.7, 137.6, 129.1, 116.8, 116.5, 111.5, 42.2, 40.6, 39.4, 35.3, 
26.8, 17.0, 11.9. 
FT-IR (ATR, cm-1): 𝜈 = 2965, 2932, 2874, 1677, 1597, 1574, 1496, 1460, 1434, 1353, 1261, 1213, 1146, 
1062, 986, 943, 865, 773, 7421, 682. 
MS (EI, 70 eV): m/z (%) = 205 (77), 149 (12), 148 (74), 137 (22), 136 (14), 121 (38), 120 (100), 77 (15). 
HR-MS (EI, 70eV): [C13H19NO], calcd.: 205.1467, found: 205.1460. 
Optical rotation: [α]D
20 = 41 (c 1.05, CHCl3). 




KOH (560 mg, 1.0 equiv, 10 mmol) was added to a solution of 4-iodophenol (112, 2.2 g, 10 mmol, 1.0 equiv) 
in EtOH (20 mL) at 0 °C. After 30 min, isopropyl 2-bromo-2-methylpropanoate (113, 2.09 g, 10 mmol, 1.0 
equiv) was added and the mixture was refluxed for 16 h. After solvent evaporation the product was 
subjected to column chromatographical purification with ihexane/EtOAc (98:2) as eluent. Isopropyl 2-(4-
iodophenoxy)-2-methylpropanoate (114) was obtained as a yellow oil (2.44 g, 7 mmol, 70% yield). 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.57 – 7.44 (m, 2H), 6.71 – 6.51 (m, 2H), 5.17 – 4.95 (m, 1H), 1.57 (s, 
7H), 1.21 (d, J = 6.3 Hz, 6H). 
Magnesium turnings (1.2 equiv), dry LiCl (1.2 equiv), Zn(OPiv)2 (1.0 equiv) and dry THF (0.5 M) were added 
to a dry and argon flushed Schlenk-tube equipped with a magnetic stirring bar and a septum. The tube was 
charged with isopropyl 2-(4-iodophenoxy)-2-methylpropanoate (114, 1.0 equiv) at room temperature. To 
monitor the progress of the insertion reaction, reaction aliquots were quenched with iodine and analyzed 
by GC-analysis. The insertion was completed within 4 h and the concentration was determined by titration 
with iodine, yielding (4-((1-isopropoxy-2-methyl-1-oxopropan-2-yl)oxy)phenylzinc pivalate 109r in 72%. 
A dry and argon flushed Schlenk-tube equipped with a magnetic stirring bar and a septum was charged 
with CoCl2 (3.25 mg, 0.025 mmol, 0.10 equiv, dried in vacuo at 400 °C prior to use). Then, the ligand 4,4’-
di-tert-butyl-2,2’-dipyridyl (6.5 mg, 0.25 mmol, 0.10 equiv) and S-(pyridin-2-yl) 4-chlorobenzothioate 





THF (0.5 mL). Then, (4-((1-isopropoxy-2-methyl-1-oxopropan-2-yl)oxy)phenylzinc pivalate (109r, 
0.48 mmol, 1.9 equiv) was added and stirring was continued for 4 h, at 25 °C. Upon consumption of the 
starting material, satured aq. NH4Cl solution (10 mL) was added, the phases were separated and the 
aqueous phase was extracted with EtOAc (3 x 25 mL). The combined organic layers were dried over MgSO4. 
The solvents were evaporated and the residue was subjected to column chromatographical purification. 
Isolated yield: 59 mg, 0.16 mmol, 64% yield, colorless solid. 
Purification: pentane:ethyl acetate = 90:10. 
m.p.:65.6 – 67.4 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.75 – 7.71 (m, 2H), 7.71 – 7.66 (m, 2H), 7.50 – 7.41 (m, 2H), 6.91 – 
6.82 (m, 2H), 5.08 (h, J = 6.3 Hz, 1H), 1.66 (s, 6H), 1.20 (d, J = 6.2 Hz, 6H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 194.3, 173.1, 159.7, 138.4, 136.4, 132.0, 131.2, 130.2, 128.5, 117.2, 
79.4, 69.4, 25.4, 21.5. 
FT-IR (ATR, cm-1): 𝜈 = 2983, 2932, 1728, 1653, 1898, 1496, 1466, 1384, 1285, 1242, 1173, 1143, 4401, 
1090, 1014, 972, 926, 898, 843, 825, 762, 740, 682, 655. 
MS (EI, 70 eV): m/z (%) = 121 (100), 138 (78), 140 26), 197 (70), 232 (66), 234 (21), 273 (65), 275 (26), 360 
(5). 






5. Mild and Regioselective Magnesiation and Functionalization of Aryl Azoles as a 
Powerful Tool for the Synthesis of Pharmaceutically Relevant Targets 
5.1 Preparation of Starting Materials159 
Preparation of Triazoles – General procedure TP1 
A glass flask of suitable size equipped with a magnetic stirring bar, nitrogen inlet tube and a septum cap 
was charged with a commercially available (substituted) azidobenzene solution (approximately 0.5 M in 
MTBE or MeTHF). The flask was immersed in a water bath kept at room temperature. A brisk stream of 
dry nitrogen was bubbled through the solution to evaporate the solvent until the volume of the solution 
approximately halved. Then, acetonitrile was added to restore the original volume of the solution and 
nitrogen was again bubbled until the volume approximately halved. Dilution with MeCN and evaporation 
was repeated twice and finally the volume was reduced so as to obtain a solution of the (substituted) 
azidobenzene having a concentration of approximately 20% (w/V) in acetonitrile. Then, while keeping the 
inert atmosphere, the alkyne (3.0 equiv) and N,N-diisopropylethylamine (DIPEA, 0.5 equiv) were added by 
syringe, followed by the addition of CuI (0.10 equiv). The resulting mixture was stirred at room 
temperature until LC analysis showed complete conversion (12-72 h). 
Finely ground 1,3,5-triazine-2,4,5-trithiol trisodium salt hydrate (Na3TMT, approximately 55% assay, 
100 mg per mmol of azidobenzene) was added and the mixture was stirred at room temperature for at 
least 1 h to precipitate copper in the form of insoluble complexes. The mixture was filtered through a short 
pad of diatomaceous earth, the filter pad washed with MTBE and the combined filtrates were evaporated 










                                                          







The title compound was prepared according to TP1 from commercially available 1‐azido‐4‐chlorobenzene 
solution (0.54 M in MTBE, 10 mL, 5.37 mmol, 1.0 equiv) and ethynyltrimethylsilane (1.58 g, 16.1 mmol, 
3.0 equiv) and was obtained in the form of straw‐colored plates (1.08 g, 4.29 mmol, 80% yield). Spectral 
data were in agreement with the literature.160 
Purification: recrystallization from iPrOH/water (50:50, 20 mL, from reflux temperature to 20 °C). 
1H-NMR (300 MHz, CDCl3, ppm): δ = 7.93 (s, 1H), 7.67–7.73 (m, 2H), 7.46 – 7.53 (m, 2H), 0.38 (m, 9H) 
13C-NMR (75 MHz, CDCl3, ppm): δ = 147.6, 135.5, 134.0, 129.7, 126.9, 121.8, −1.3. 




The title compound was prepared according to TP1 from commercially available 1‐azido‐4‐fluorobenzene 
solution (0.5 M in MTBE, 21.5 mL, 10.8 mmol,1.0 equiv) and ethynyltrimethylsilane (3.18 g, 32.4 mmol, 
3.0 equiv) and was obtained in the form of beige plates (2.34 g, 9.94 mmol, 92% yield). Spectral data were 
in agreement with the literature.162  
Purification: recrystallization from iPrOH/water (50:50, 25 mL, from reflux temperature to –20 °C). 
1H-NMR (300 MHz, CDCl3, ppm): δ = 7.90 (s, 1H), 7.66 – 7.78 (m, 2H), 7.26 – 7.16 (m, 2H), 0.38 (s, 9H) 
19F{1H}-NMR (282 MHz, CDCl3, ppm): δ = −112.7. 
13C-NMR (75 MHz, CDCl3, ppm): δ = 162.3 (d, 1JCF = 248.4 Hz), 147.5, 133.4 (d, 4JCF = 2.3) Hz, 127.3, 122.7 
(d, 3JCF = 8.30 Hz), 116.6 (d, 2JCF = 23.4 Hz), 77.2, −1.2. 
MS (ESI+): m/z (%) = 236.1 [M+H]+. 
                                                          







The title compound was prepared according to TP1 from commercially available azidobenzene solution 
(0.5 M in MeTHF, 10 mL, 5.0 mmol, 1.0 equiv) and ethynyltrimethylsilane (1.47 g, 15 mmol, 3.0 equiv) and 
was obtained in the form of light brown plates (460 mg, 2.12 mmol, 42% yield). Spectral data were in 
agreement with the literature.161 
Purification: recrystallization from iPrOH/water (50:50, 10 mL, from reflux temperature to –20 °C). 
1H-NMR (300 MHz, CDCl3, ppm): δ = 7.95 (s, 1H), 7.75 (d, J = 7.7 Hz, 2H), 7.52 (t, J = 7.7 Hz, 2H), 7.43 (t, 
J = 7.7 Hz, 1H), 0.39 (s, 9H). 
13C-NMR (75 MHz, CDCl3, ppm): δ = 147.3, 137.1, 129.7, 128.5, 127.1, 120.8, −1.2. 




The title compound was prepared according to TP1 from commercially available 4-azidotoluene solution 
(0.5 M in MTBE, 10 mL, 5.0 mmol, 1.0 equiv) and ethynyltrimethylsilane (1.47 g, 15 mmol, 3.0 equiv) and 
was obtained in the form of light brown needles (710 mg, 3.07 mmol, 61% yield). Spectral data were in 
agreement with the literature.160  
Purification: recrystallization from iPrOH/water (50:50, 10 mL, from reflux temperature to −20 °C). 
1H-NMR (300 MHz, CDCl3, ppm): δ = 7.91 (br s, 1H), 7.62 (d, J = 8.4 Hz, 2H), 7.32 (d, J = 8.4 Hz, 2H), 2.43 (s, 
3H), 0.39 (s, 9H). 
13C-NMR (75 MHz, CDCl3, ppm): δ = 138.6, 134.8, 130.2, 127.2, 120.7, 77.2, 21.1, −1.1. 









The title compound was prepared according to TP1 from commercially available 4‐azidoanisole solution 
(0.5 M in MTBE, 10 mL, 5.0 mmol, 1.0 equiv) and ethynyltrimethylsilane (1.47 g, 15 mmol, 3.0 equiv) and 
was obtained as a solid (900 mg, 3.64 mmol, 73% yield). Spectral data were in agreement with the 
literature.161 
Purification: recrystallization from boiling heptane (5 mL, from reflux to room temperature) provided the 
title compound in the form of light brown plates (680 mg, 2.75 mmol, 55%). The mother liquor was 
evaporated to dryness and the residue was purified by flash chromatography on silica gel (eluent: 
hexanes/EtOAc 80:20) to provide a further portion of the target compound in the form of an orange solid 
(220 mg, 0.889 mmol, 18%). 
1H-NMR (300 MHz, CDCl3, ppm): δ = 7.86 (s, 1H), 7.63 (d, J = 9.0 Hz, 2H), 7.03 (d, J = 9.0 Hz, 2H), 3.88 (s, 
3H), 0.39 (s, 9H). 
13C-NMR (75 MHz, CDCl3, ppm): δ = 159.6, 147.0, 130.5, 127.3, 122.4, 114.7, 55.6, −1.1. 




The title compound was prepared according to TP1 from commercially available 3‐azidoanisole solution 
(0.5 M in MTBE, 30 mL, 15.0 mmol, 1.0 equiv) and ethynyltrimethylsilane (4.41 g, 45 mmol, 3.0 equiv) was 
obtained as a brown oil (3.64 g, 14.7 mmol, 98% yield).  
Purification: flash chromatography on silica gel (eluent: hexanes/EtOAc 90:10). 
m.p.: 38.4 – 40.0 °C. 
                                                          





1H-NMR (300 MHz, CDCl3, ppm): δ = 8.01 (s, 1H), 7.30 – 7.37 (m, 2H), 7.28 – 7.22 (m, 1H), 6.86–6.94 (m, 
1H), 3.81 (s, 3H), 0.36 (s, 9H). 
13C-NMR (75 MHz, CDCl3, ppm): δ = 160.2, 146.9, 137.8, 130.1, 127.1, 113.9, 112.3, 106.3, 55.2, −1.4. 
FT-IR (ATR, cm-1): 𝜈 = 295, 1609, 1594, 1500, 1487, 1466, 1440, 1410, 1384, 1314, 1279, 1246, 1235, 1201, 
1179, 1136, 1093, 1049, 1041, 997, 991, 997, 869, 838, 818, 769, 756, 707, 695, 680. 
MS (ESI+): m/z (%) = 248.2 [M+H]+. 
MS (EI, 70 eV): m/z (%) =219 (119, 209 (16), 208 (100), 177 (9). 




The title compound was prepared according to TP1 from commercially available 1‐azido‐2‐fluorobenzene 
solution (0.5 M in MTBE, 30 mL, 15.0 mmol, 1.0 equiv) and ethynyltrimethylsilane (4.41 g, 45 mmol, 
3.0 equiv) and was obtained as a pale yellow oil (3.18 g, 13.5 mmol, 90% yield). Spectral data were in 
agreement with the literature.162 
Purification: flash chromatography on silica gel (eluent: hexanes/EtOAc 9:1). 
1H-NMR (300 MHz, CDCl3, ppm): δ = 7.86 (d, J = 2.8 Hz, 1H), 7.79 – 7.70 (m, 1H), 7.16 – 7.28 (m, 1H), 7.03 
– 7.16 (m, 2H), 0.20 (s, 9H). 
19F{1H}-NMR (282 MHz, CDCl3, ppm): δ = −123.6. 
13C-NMR (75 MHz, CDCl3, ppm): δ = 153.3 (d, 1JCF = 250.7 Hz), 146.8, 129.9 (d, 3JCF = 7.6 Hz), 129.8 (d, 
3JCF = 7.6 Hz), 125.2 (d, 2JCF = 10.6 Hz), 125.04 (d, 4JCF = 3.0 Hz), 125.01, 116.8 (d, 2JCF = 19.6 Hz), −1.3. 






                                                          





5.2 Preparation of Organometallic Reagents and Metalation Optimization 
Directed ortho-metalation (TP2) 
The corresponding substrate was placed in a dry and argon flushed 10 mL Schlenk-tube equipped with a 
magnetic stirring bar and a septum and was suspended in toluene (1.00 M). TMPMgBu (1.0 equiv) was 
added and the mixture was stirred for the appropriate time. To monitor the process of metalation aliquots 
quenched with D2O were analyzed using 1H‐NMR.  
 
(5‐Chloro‐2‐(4‐(trimethylsilyl)‐1H‐1,2,3‐triazol‐1‐yl)phenyl)magnesium reagent (116a) 
 
 
The title compound was prepared according to TP2 from 1‐(4‐chlorophenyl)‐4‐(trimethylsilyl)‐1H‐1,2,3‐
triazole (115a, 126 mg, 0.5 mmol) affording the corresponding magnesium reagent in 81% yield. The yield 
was determined via deuterolysis.  













Optimization of the metalation of 115a: 
 
Table 16: Optimization of the metalation conditions.[a] 
 





(5‐Fluoro‐2‐(4‐(trimethylsilyl)‐1H‐1,2,3‐triazol‐1‐yl)phenyl)magnesium reagent (116b) 
 
The title compound was prepared according to TP2 from 1‐(4‐fluorophenyl)‐4‐(trimethylsilyl)‐1H‐1,2,3‐
triazole (115b, 118 mg, 0.5 mmol) affording the corresponding magnesium reagent in 86% yield. The yield 
was determined via deuterolysis.  
       
 
(2‐(4‐(Trimethylsilyl)‐1H‐1,2,3‐triazol‐1‐yl)phenyl)magnesium reagent (116c) 
 
The title compound was prepared according to TP2 from 1‐phenyl‐4‐(trimethylsilyl)‐1H‐1,2,3‐triazole 
(115c, 109 mg, 0.5 mmol) affording the corresponding magnesium reagent in 72% yield. The yield was 
determined via deuterolysis.  





(5‐Methyl‐2‐(4‐(trimethylsilyl)‐1H‐1,2,3‐triazol‐1‐yl)phenyl)magnesium reagent (116d) 
 
The title compound was prepared according to TP2 from 1‐(para‐tolyl)‐4‐(trimethylsilyl)‐1H‐1,2,3‐triazole 
(115d, 116 mg, 0.5 mmol) affording the corresponding magnesium reagent in 68% yield. The yield was 
determined via deuterolysis.  
       
(5‐Methoxy‐2‐(4‐(trimethylsilyl)‐1H‐1,2,3‐triazol‐1‐yl)phenyl)magnesium reagent (116e) 
 
The title compound was prepared according to TP2 from 1‐(4‐methoxyphenyl)‐4‐(trimethylsilyl)‐1H‐1,2,3‐
triazole (115e, 124 mg, 0.5 mmol) affording the corresponding magnesium reagent in 77% yield. The yield 
was determined via deuterolysis.  





(2‐Methoxy‐6‐(4‐(trimethylsilyl)‐1H‐1,2,3‐triazol‐1‐yl)phenyl)magnesium reagent (116f) 
 
The title compound was prepared according to TP2 from 1‐(3‐methoxyphenyl)‐4‐(trimethylsilyl)‐1H‐1,2,3‐
triazole (115f, 124 mg, 0.5 mmol) affording the corresponding magnesium reagent in 70% yield. The yield 
was determined via deuterolysis.  
      
 
(3‐Fluoro‐2‐(4‐(trimethylsilyl)‐1H‐1,2,3‐triazol‐1‐yl)phenyl)magnesium reagent (116g) 
 
The title compound was prepared according to TP2 from 1‐(2‐fluorophenyl)‐4‐(trimethylsilyl)‐1H‐1,2,3‐
triazole (115g, 118 mg, 0.5 mmol) affording the corresponding magnesium reagent in 80% yield. The yield 
was determined via deuterolysis.  





(5‐Chloro‐2‐(3,5‐dimethyl‐1H‐pyrazol‐1‐yl)phenyl)magnesium reagent (119a) 
 
The title compound was prepared according to TP2 from 1‐(4‐chlorophenyl)‐3,5‐dimethyl‐1H‐pyrazole 
(118a, 104 mg, 0.5 mmol) affording the corresponding magnesium reagent in 82% yield. The yield was 
determined via deuterolysis.  
      
 
(5‐Chloro‐2‐(1H‐pyrazol‐1‐yl)phenyl)magnesium reagent (119b) 
 
The title compound was prepared according to TP2 from 1‐(4‐chlorophenyl)‐1H‐pyrazole (118b, 89 mg, 
0.5 mmol) affording the corresponding magnesium reagent in 78% yield. The yield was determined via 
deuterolysis.  





(2‐(5‐Phenyl‐1,3,4‐oxadiazol‐2‐yl)phenyl)magnesium reagent (119c) 
 
The title compound was prepared according to TP2 from 2,5‐diphenyl‐1,3,4‐oxadiazole (118c, 111 mg, 
0.5 mmol) affording the corresponding magnesium reagent in 76% yield. The yield was determined via 
deuterolysis.  
      
 
(2‐(4,4‐Dimethyl‐4,5‐dihydrooxazol‐2‐yl)phenyl)magnesium reagent (119d) 
 
The title compound was prepared according to TP2 from 4,4‐dimethyl‐2‐phenyl‐4,5‐dihydrooxazole (118d, 
88 mg, 0.5 mmol) affording the corresponding magnesium reagent in 77% yield. The yield was determined 
via deuterolysis.  






yl)magnesium reagent (123) 
 
The title compound was prepared according to TP2 from 1‐(5‐fluoro‐4'‐(trifluoromethoxy)‐[1,1'‐biphenyl]‐
2‐yl)‐4‐(trimethylsilyl)‐1H‐1,2,3‐triazole (117g, 99 mg, 0.5 mmol) affording the corresponding magnesium 
reagent in 80% yield. The yield was determined via deuterolysis. 
      
 
5.3 Unsuccessful Metalation Reactions 
 






5.4 Palladium-Catalyzed Negishi-Cross-Coupling of Arylmagnesium Aryl Azoles with Aryl Bromides 
Optimization of the cross-coupling reaction 
 
 
Palladium-catalyzed Negishi-cross-coupling of arylmagnesium aryl azoles with aryl bromides TP3 
The corresponding arylmagnesium reagent, prepared according to TP1, was transmetalated with a ZnCl2 
solution (1.00 M in THF, 1.0 equiv) and THF (1.0 ml/0.5 mmol) was added. A dry and argon-flushed Schlenk-
tube, equipped with a magnetic stirring bar and a septum was charged with Pd(dppf)Cl2 (1.0 mol%, 
0.005 mmol, 3.7 mg) and the respective aryl bromide (1.00-1.25 mmol, 1.98 – 2.5 equiv). The freshly 
prepared arylzinc reagent was added and the reaction mixture was placed in an oil bath at 55 °C. After 
16 h, saturated aq. NH4Cl solution (5 mL) was added, the phases where separated and the aqueous phase 
was extracted with EtOAc (3 x 25 mL). The combined organic layers were dried over MgSO4. The solvents 
were removed under reduced pressure and the crude product was subjected to column chromatography 




Following TP3 (5‐chloro‐2‐(4‐(trimethylsilyl)‐1H‐1,2,3‐triazol‐1‐yl)phenyl)magnesium reagent (116a, 





Isolated yield:  122 mg, 0.341 mmol, 84%, colorless crystals 
m.p.: 74.1 – 75.6 °C. 
Purification: pentane:ethyl acetate = 95:5 to 9:1. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.56 (d, J = 8.4 Hz, 1H), 7.49 (d, J = 2.3 Hz, 1H), 7.44 (dd, J = 8.4, 2.4 
Hz, 1H), 7.09 (s, 1H), 6.95 – 6.90 (m, 2H), 6.81 – 6.76 (m, 2H), 3.77 (s, 3H), 0.22 (s, 9H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 159.9, 146.6, 138.5, 135.5, 133.8, 131.2, 130.8, 129.7, 128.5, 128.2, 
127.9, 114.3, 55.5, −1.1. 
FT-IR (ATR, cm-1): 𝜈 = 3105, 2956, 1610, 1514, 1490, 1473, 1463, 1455, 1442, 1404, 1288, 1254, 1241, 
1198, 1151, 1124, 1113, 1095, 1037, 1022, 1009, 1000, 982, 906, 819, 775, 762, 755, 724, 711, 680. 
MS (EI, 70 eV): m/z (%) = 330 (26), 328 (65), 314 (65), 283 (69), 279 (86), 271 (34), 139 (63), 73 (100), 43 
(30). 




Following TP3 (2-(4-(trimethylsilyl)-1H-1,2,3-triazol-1-yl)phenyl)magnesium reagent (116c, 0.360 mmol, 
1.00 equiv) was coupled with 2‐(3‐bromophenyl)‐1,3‐dioxolane (0.850 mmol, 195 mg, 2.36 equiv).  
Isolated yield: 103 mg, 0.281 mmol, 78%, colorless oil. 
Purification: pentane:ethyl acetate = 8:2. 
1H-NMR (400 MHz, benzene-d6, ppm): δ = 7.19 (dd, J = 7.7, 1.6 Hz, 1H), 7.07 (dt, J = 7.5, 1.5 Hz, 1H), 7.04 
(t, J = 1.8 Hz, 1H), 6.89 (d, J = 1.5 Hz, 1H), 6.85 – 6.69 (m, 2H), 6.71 – 6.66 (m, 1H), 6.62 (dt, J = 7.7, 1.6 Hz, 
1H), 6.49 (s, 1H), 5.32 (s, 1H), 3.32 (ddd, J = 6.6, 5.1, 2.6 Hz, 2H), 3.21 – 3.13 (m, 2H), 0.00 (s, 9H) 
13C-NMR (100 MHz, benzene-d6, ppm): δ = 145.9, 139.6, 138.0, 137.2, 136.0, 131.2, 131.0, 129.5, 129.4, 
128.6, 128.6, 127.3, 127.0, 126.4, 103.6, 65.2, -1.0. 
FT-IR (ATR, cm-1): 𝜈 = 2956, 2893, 1717, 1504, 1487, 1376, 1248, 1199, 1079, 1054, 1036, 983, 943, 901, 
839, 802, 756, 704, 661. 
MS (EI, 70 eV): m/z (%) = 337 (14), 295 (28), 294 (100), 278 (48), 265 (18), 254 (47), 251 (18), 250 (749, 220 
(17), 218 (15), 204 (85), 192 (16), 174 (13), 152 (11), 75 (15), 73 (16). 








Following TP3 (5‐chloro‐2‐(4‐(trimethylsilyl)‐1H‐1,2,3‐triazol‐1‐yl)phenyl)magnesium reagent (116a, 
0.405 mmol, 1.00 equiv) was coupled with 4‐bromo‐2‐fluorobenzonitrile (0.850 mmol, 170 mg, 2.10 
equiv).  
Isolated yield: 131 mg, 0.353 mmol, 87%, orange crystals. 
Purification: pentane:ethyl acetate = 95:5 to 9:1. 
m.p.: 98.6 – 100.4 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.59 (dd, J = 8.5, 2.1 Hz, 1H), 7.55 (dd, J = 8.6, 0.6 Hz, 1H), 7.54 – 7.49 
(m, 1H), 7.51 (d, J = 2.5 Hz, 1H), 7.29 (s, 1H), 6.95 – 6.92 (m, 1H), 6.92 – 6.89 (m, 1H), 0.27 (s, 9H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 166.0 (d, J = 260.8 Hz), 147.6, 143.6 (d, J = 8.2 Hz), 136.4, 136.2 (d, 
J = 1.9 Hz), 133.7, 133.6, 130.7 (d, J = 10.4 Hz), 130.3, 128.4, 125.0 (d, J = 3.7 Hz), 116.6 (d, J = 20.8 Hz), 
113.4, 101.5 (d, J = 15.4 Hz), −1.1. 
19F NMR (377 MHz, CDCl3, ppm): δ = −105.16 (dd, J = 9.5, 6.5 Hz). 
FT-IR (ATR, cm-1): 𝜈 = 2233, 1619, 1556, 1506, 1421, 1245, 1198, 1186, 1145, 1114, 1029, 993, 982, 923, 
883, 871, 840, 830, 814, 784, 758, 733, 709, 676, 660. 
MS (EI, 70 eV): m/z (%) = 343 (20), 330 (35), 329 (29), 327 (22), 293 (41), 234 (14), 195 (24), 77 (30), 73 
(40), 45 (20), 43 (22). 




Following TP3 (3-fluoro-2-(4-(trimethylsilyl)-1H-1,2,3-triazol-1-yl)phenyl)magnesium reagent (116g, 
0.400 mmol, 1.00 equiv) was coupled with 4‐bromo‐2‐fluorobenzonitrile (0.850 mmol, 170 mg, 2.13 
equiv).  
Isolated yield:  120 mg, 0.339 mmol, 85%, pale yellow oil. 





1H-NMR (400 MHz, CDCl3, ppm): δ = 7.62 (td, J = 8.1, 5.3 Hz, 1H), 7.54 (d, J = 1.1 Hz, 1H), 7.48 (dd, J = 8.0, 
6.6 Hz, 1H), 7.39 (td, J = 8.6, 1.3 Hz, 1H), 7.32 (dt, J = 7.9, 1.2 Hz, 1H), 6.97 – 6.87 (m, 2H), 0.31 (s, 9H).  
13C-NMR (100 MHz, CDCl3, ppm): δ = 162.8 (d, J = 260.2 Hz), 157.2 (d, J = 255.1 Hz), 147.2, 143.84 (dd, 
J = 8.2, 2.6 Hz), 138.2 (d, J = 2.0 Hz), 133.5, 131.8 (d, J = 8.6 Hz), 131.7 (d, J = 1.2 Hz), 126.0 (d, J = 3.6 Hz), 
124.9 (d, J = 3.6 Hz), 123.7 (d, J = 13.7 Hz), 117.4 (d, J = 20.1 Hz), 116.5 (d, J = 20.8 Hz), 113.6, 101.2 (d, J = 
15.5 Hz), −1.1.  
19F NMR (377 MHz, CDCl3, ppm): δ = −105.64 (dd, J = 9.6, 6.6 Hz), −119.96 (dd, J = 9.0, 5.4 Hz). 
FT-IR (ATR, cm-1): 𝜈 = 2234, 1619, 1589, 1561, 1511, 1497, 1470, 1417, 1387, 1265, 1247, 1201, 1170, 
1142, 1125, 1075, 1083, 1034, 999, 985, 958, 835, 797, 763, 744, 721, 711, 701, 665. 
MS (EI, 70 eV): m/z (%) = 326 (55), 312 (61), 311 (45), 311 (45), 311 (45), 311 (62), 311 (64), 311 (65), 310 
(32), 249 (24), 215 (29), 208 (28), 195 (26), 77 (100). 
HR-MS (EI, 70 eV): [C18H16F2N4Si], calcd.: 354.1112; found: 354.1110. 
 
Ethyl 5'-chloro-2'-(4-(trimethylsilyl)-1H-1,2,3-triazol-1-yl)-[1,1'-biphenyl]-3-carboxylate (117e) 
 
Following TP3 (5‐chloro‐2‐(4‐(trimethylsilyl)‐1H‐1,2,3‐triazol‐1‐yl)phenyl)magnesium reagent (116a, 
0.405 mmol, 1.00 equiv) was coupled with ethyl 3‐bromobenzoate (0.850 mmol, 195 mg, 2.10 equiv).  
Isolated yield: 122 mg, 0.305 mmol, 75%, pale yellow solid. 
Purification: pentane:ethyl acetate = 95 :5. 
m.p.: 97.0 – 98.8 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.99 (dt, J = 7.8, 1.4 Hz, 1H), 7.81 (td, J = 1.8, 0.5 Hz, 1H), 7.60 (d, J 
= 8.4 Hz, 1H), 7.55 (d, J = 2.2 Hz, 1H), 7.52 (dd, J = 8.4, 2.3 Hz, 1H), 7.30 (td, J = 7.8, 0.6 Hz, 1H), 7.11 (s, 1H), 
7.10 – 7.07 (m, 1H), 4.36 (q, J = 7.1 Hz, 2H), 1.38 (t, J = 7.1 Hz, 3H), 0.20 (s, 9H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 165.9, 146.8, 137.9, 136.6, 135.8, 133.8, 132.7, 131.3, 131.1, 130.9, 
129.6, 129.1, 128.8, 128.1, 61.4, 14.4, −1.2. 
FT-IR (ATR, cm-1): 𝜈 = 2956, 1715, 1500, 1484, 1490, 1366, 1296, 1285, 1266, 1249, 1236, 1200, 1172, 
1148, 1133, 1124, 1109, 1096, 1049, 1034, 996, 982, 927, 903, 871, 838, 808, 777, 758, 735, 708, 673, 659. 
MS (EI, 70 eV): m/z (%) = 371 (10), 356 (12), 254 (11), 190 (16), 103 (100), 75 (63), 73 (28), 59 (12). 







Following TP3 (5-fluoro-2-(4-(trimethylsilyl)-1H-1,2,3-triazol-1-yl)phenyl)magnesium reagent (116b, 
0.430 mmol, 1.00 equiv) was coupled with 1‐bromonaphthalene (0.850 mmol, 176 mg, 1.98 equiv).  
Isolated yield: 115 mg, 0.318 mmol, 74%, pale yellow oil. 
Purification: pentane:ethyl acetate = 9:1. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.92 – 7.85 (m, 3H), 7.52 – 7.44 (m, 3H), 7.41 – 7.28 (m, 4H), 6.73 (s, 
1H), 0.00 (s, 9H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 162.4 (d, J = 250.6 Hz), 145.8, 137.1 (d, J = 8.6 Hz), 134.2 (d, J = 1.4 Hz), 
133.3, 132.7 (d, J = 3.1 Hz), 131.0, 130.4, 129.1, 128.3, 127.6 (d, J = 9.0 Hz), 127.5, 127.0, 126.4, 125.3, 
124.5, 118.7 (d, J = 23.0 Hz), 116.1 (d, J = 22.7 Hz), −1.5. 
19F NMR (377 MHz, CDCl3, ppm): δ = −111.63 (m). 
FT-IR (ATR, cm-1): 𝜈 = 2956, 1614, 1585, 1502, 1402, 1301, 1248, 1197, 1171, 1146, 1033, 1020, 983, 894, 
878, 838, 798, 775, 757, 731, 709, 696, 688, 667. 
MS (EI, 70 eV): m/z (%) = 334 (24), 333 (100), 332 (62), 320 (20), 319 (93), 318 (57), 318 (57), 318 (57),  
318 (87), 318 (52), 318 (54), 318 (55), 317 (50), 302 (29), 288 (20), 258 (14), 240 (19), 220 (33). 




Following TP3 (5-fluoro-2-(4-(trimethylsilyl)-1H-1,2,3-triazol-1-yl)phenyl)magnesium reagent (116b, 
0.430 mmol, 1.00 equiv) was coupled with 1‐bromo‐4‐(trifluoromethoxy)benzene (0.850 mmol, 205 mg, 
1.98 equiv).  





Large scale-experiment: Following TP3 (5-fluoro-2-(4-(trimethylsilyl)-1H-1,2,3-triazol-1-yl)phenyl)ma-
gnesium reagent (2b, 4.30 mmol, 1.00 equiv) was coupled with 1‐bromo‐4‐(trifluoromethoxy)benzene 
(8.5 mmol, 2.05 g, 1.98 equiv).  
Isolated yield: 1.29 g, 3.262 mmol, 76%, colorless crystals. 
Purification: pentane:ethyl acetate = 9:1. 
m.p.: 74.6 – 76.6 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.60 (ddd, J = 8.3, 5.2, 0.9 Hz, 1H), 7.25 – 7.17 (m, 1H), 7.20 (d, J = 
7.8 Hz, 1H), 7.12 – 7.07 (m, 2H), 7.06 (s, 1H), 7.05 – 7.01 (m, 2H), 0.19 (s, 9H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 162.9 (d, J = 251.2 Hz), 149.4 (q, J = 1.9 Hz), 146.9, 138.4 (d, J = 8.6 Hz), 
135.1 (d, J = 1.6 Hz), 131.5 (d, J = 3.2 Hz), 131.2, 130.0, 128.9 (d, J = 9.2 Hz), 121.3 (q, J = 1.0 Hz), 120.5 (q, 
J = 257.7 Hz), 117.6 (d, J = 23.5 Hz), 116.0 (d, J = 22.7 Hz), −1.3. 
19F NMR (377 MHz, CDCl3, ppm): δ = −58.04 (t, J = 1.1 Hz), −109.19 – −111.70 (m). 
FT-IR (ATR, cm-1): 𝜈 = 1582, 1517, 1501, 1391, 1302, 1263, 1247, 1217, 1198, 1185, 1165, 1147, 1117, 
1104, 1037, 1018, 999, 986, 958, 921, 889, 879, 843, 831, 815, 807, 767, 756, 677, 662. 
MS (EI, 70 eV): m/z (%) = 367 (10), 366 (41), 365 (26), 313 (12), 287 (20), 286 (100), 270 (13), 259 (15), 257 
(65), 224 (11), 222 (18), 190 (10), 77 (22), 73 (11). 




Following TP3 (5-fluoro-2-(4-(trimethylsilyl)-1H-1,2,3-triazol-1-yl)phenyl)magnesium reagent (116b, 
0.430 mmol, 1.00 equiv) was coupled with (4‐bromophenyl)pentafluoro‐ 𝜆6-sulfane (0.850 mmol, 241 mg, 
1.98 equiv).  
Isolated yield: 178 mg, 0.407 mmol, 95%, pale yellow crystals. 
Purification: pentane:ethyl acetate = 9:1. 
m.p.: 84.1 – 85.9 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.65 (ddd, J = 8.3, 2.3, 1.0 Hz, 1H), 7.59 – 7.52 (m, 1H), 7.42 – 7.34 (m, 





13C-NMR (100 MHz, CDCl3, ppm): δ = 163.0 (d, J = 251.8 Hz), 154.0 (p, J = 17.8 Hz), 147.0, 137.96 (d, J = 
8.6 Hz), 137.4 (d, J = 1.6 Hz), 131.6, 131.53 (d, J = 3.3 Hz), 131.0, 129.3, 129.1 (d, J = 9.1 Hz), 125.8 (m) 117.7 
(d, J = 23.7 Hz), 116.4 (d, J = 22.7 Hz), −1.3. 
19F NMR (377 MHz, CDCl3, ppm): δ = 85.25 – 81.34 (m), 62.70 (d, J = 150.3 Hz), −109.90 (td, J = 8.0, 5.1 Hz). 
FT-IR (ATR, cm-1): 𝜈 = 1511, 1486, 1475, 1387, 1281, 1249, 1200, 1192, 1146, 1112, 1035, 983, 923, 915, 
905, 880, 875, 863, 826, 791, 761, 745, 761, 745, 692, 709, 6679, 668. 
MS (EI, 70 eV): m/z (%) = 409 (50), 285 (72), 271 (18), 270 (100), 258 (20), 256 (27), 224 (44), 222 26), 77 
(22). 




Following TP3 (5‐methoxy‐2‐(4‐(trimethylsilyl)‐1H‐1,2,3‐triazol‐1‐yl)phenyl)magnesium reagent (116e, 
0.385 mmol, 1.00 equiv) was coupled with 1‐bromo‐3‐(trifluoromethyl)benzene (0.850 mmol, 191 mg, 
2.21 equiv).  
Isolated yield: 106 mg, 0.271 mmol, 70%, colorless crystals. 
Purification: pentane:ethyl acetate = 9:1 to 85:15. 
m.p.:.98.8 – 100.2 °C 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.31 (d, J = 8.6 Hz, 2H), 7.20 – 7.13 (m, 1H), 7.07 – 7.01 (m, 2H), 6.95 
(s, 1H), 6.87 – 6.79 (m, 2H), 3.70 (s, 3H), 0.00 (s, 9H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 160.5, 146.5, 138.3, 137.5, 131.9 (d, J = 1.5 Hz), 131.3, 131.0 (q, J = 
32.5 Hz), 129.1, 128.4, 128.3, 125.3 – 125.1 (m), 124.7 (q, J = 3.8 Hz), 123.8 (q, J = 272.9 Hz), 116.0, 114.2, 
56.0, −1.22. 
19F NMR (377 MHz, CDCl3, ppm): δ = −62.74 (s). 
FT-IR (ATR, cm-1): 𝜈 = 1606, 1576, 1513, 1486, 1455, 1442, 1332, 1296, 1275, 1249, 1214, 4201, 1164, 
1123, 10075, 1035, 996, 983, 909, 878, 839, 804, 788, 759, 732, 715, 702, 658, 676. 
MS (EI, 70 eV): m/z (%) = 364 (15), 363 (61), 333 (25), 253 (12), 252 (70), 237 (12), 209 (58), 45 (16), 42 
(100). 







Following TP3 (5‐chloro‐2‐(4‐(trimethylsilyl)‐1H‐1,2,3‐triazol‐1‐yl)phenyl)magnesium reagent (116a, 
0.405 mmol, 1.00 equiv) was coupled with 1‐bromo‐2‐fluorobenzene (0.850 mmol, 149 mg, 2.10 equiv).  
Isolated yield: 100 mg, 0.289 mmol, 71%, yellow crystals. 
Purification: pentane:ethyl acetate = 9:1. 
m.p.: 111.0 – 113.2 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.64 (dd, J = 8.2, 0.8 Hz, 1H), 7.56 – 7.48 (m, 2H), 7.32 (dddd, J = 8.2, 
7.3, 5.2, 2.1 Hz, 1H), 7.17 (s, 1H), 7.12 – 6.98 (m, 3H), 0.20 (s, 9H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 159.5 (d, J = 248.2 Hz), 146.5, 135.2, 134.6, 132.4, 131.6 (d, J = 1.6 Hz), 
131.0 (d, J = 2.6 Hz), 130.8 (d, J = 8.1 Hz), 130.3, 129.5, 127.4, 124.6 (d, J = 3.7 Hz), 124.0 (d, J = 15.4 Hz), 
115.9 (d, J = 21.8 Hz), −1.2. 
19F NMR (377 MHz, CDCl3, ppm): δ = −115.51 (ddd, J = 9.9, 7.0, 5.3 Hz). 
FT-IR (ATR, cm-1): 𝜈 = 1507, 1490, 1454, 1447, 1399, 1264, 1249, 1207, 1196, 1154, 1130, 1108, 1041, 984, 
8887, 835, 827, 786, 753, 743, 704, 694, 657. 
MS (EI, 70 eV): m/z (%) = 319 (14), 317 (43), 267 (14), 191 (15), 190 (100), 170 (24), 77 (37), 77 (37), 77 
(56), 77 (56), 77 (56), 73 (18). 




Following TP3 (5‐chloro‐2‐(4‐(trimethylsilyl)‐1H‐1,2,3‐triazol‐1‐yl)phenyl)magnesium reagent (116a, 
0.405 mmol, 1.00 equiv) was coupled with 3‐bromopyridine (0.850 mmol, 134 mg, 2.10 equiv).  
Isolated yield: 112 mg, 0.341 mmol, 84%, colorless crystals. 
Purification: pentane:ethyl acetate = 7:3. 





1H-NMR (400 MHz, CDCl3, ppm): δ = 8.55 (dd, J = 4.8, 1.7 Hz, 1H), 8.44 (dd, J = 2.4, 0.9 Hz, 1H), 7.58 (dd, 
J = 8.2, 0.8 Hz, 1H), 7.56 (d, J = 2.2 Hz, 1H), 7.53 (dd, J = 2.3, 0.9 Hz, 1H), 7.23 (ddd, J = 7.9, 2.3, 1.7 Hz, 1H), 
7.18 (s, 1H), 7.15 (ddd, J = 8.0, 4.8, 0.9 Hz, 1H), 0.22 (s, 9H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 149.7, 149.0, 147.2, 136.1, 135.8, 135.6, 134.1, 132.3, 131.0, 130.9, 
129.6, 128.4, 123.3, −1.1. 
FT-IR (ATR, cm-1): 𝜈 = 1501, 1473, 1411, 1250, 1201, 1154, 1125, 1097, 1042, 1014, 979, 911, 832, 814, 
757, 741, 714, 741, 668. 
MS (EI, 70 eV): m/z (%) = 300 (14), 287 (31), 286 (57), 285 (100), 284 (20), 284 (20), 284 (20), 284 (48), 284 
(49), 255 (11), 73 (15). 




Following TP3 1‐(para‐tolyl)‐4‐(trimethylsilyl)‐1H‐1,2,3‐triazole (116d, 0.340 mmol, 1.00 equiv) was 
coupled with 3‐bromopyridine (0.850 mmol, 134 mg, 2.50 equiv).  
Isolated yield: 72 mg, 0.233 mmol, 69%, yellow solid. 
Purification: pentane:ethyl acetate = 8:2. 
m.p.: 72.2 - 74.0. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.29 (dd, J = 4.8, 1.7 Hz, 1H), 8.24 (dd, J = 2.4, 0.9 Hz, 1H), 7.28 (d, 
J = 8.0 Hz, 1H), 7.14 (ddd, J = 8.1, 2.0, 0.9 Hz, 1H), 7.10 (d, J = 1.9 Hz, 1H), 7.01 – 6.95 (m, 2H), 6.89 (ddd, 
J = 8.0, 4.8, 0.9 Hz, 1H), 2.27 (s, 3H), 0.00 (s, 9H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 149.2, 149.1, 146.7, 140.5, 135.9, 133.8, 133.6, 133.1, 131.4, 131.2, 
130.0, 126.9, 123.1, 21.4, −1.1. 
FT-IR (ATR, cm-1): 𝜈 = 2956, 1512, 1409, 1248, 1205, 1156, 1134, 1039, 102, 997, 981, 832, 816, 755, 714, 
668. 
MS (EI, 70 eV): m/z (%) = 280 (18), 266 (16), 365 (72), 264 (100), 235 (10). 







(5-Methyl-2-(4-(trimethylsilyl)-1H-1,2,3-triazol-1-yl)phenyl)magnesium reagent (117m) 
 
Following TP3 (5‐chloro‐2‐(4‐(trimethylsilyl)‐1H‐1,2,3‐triazol‐1‐yl)phenyl)magnesium reagent (116a, 
0.405 mmol, 1.00 equiv) was coupled with 5‐bromopyrimidine (0.850 mmol, 135 mg, 2.10 equiv).  
Isolated yield: 83 mg, 0.252 mmol, 62%, yellow crystals. 
Purification: pentane:ethyl acetate = 8:2. 
m.p.: 125.8 – 127.4 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 9.15 (s, 1H), 8.44 (s, 2H), 7.60 (dd, J = 8.5, 2.2 Hz, 1H), 7.55 (d, J = 
8.5 Hz, 1H), 7.53 (d, J = 2.2 Hz, 1H), 7.38 (s, 1H), 0.27 (s, 9H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 158.4, 155.9, 147.7, 136.5, 134.0, 132.5, 131.0, 130.7, 130.7, 130.3, 
128.5, −1.1. 
FT-IR (ATR, cm-1): 𝜈 = 3103, 1548, 1507, 1218, 1404, 1386, 1247, 1205, 1185, 1157, 1115, 1037, 1018, 986, 
979, 953, 890, 843, 822, 759, 737, 728, 737, 667. 
MS (EI, 70 eV): m/z (%) = 301 (13), 288 (32), 287 (47), 286 (100), 285 (97), 259 (16), 73 (19). 




Following TP3 (2-methoxy-6-(4-(trimethylsilyl)-1H-1,2,3-triazol-1-yl)phenyl)magnesium (116f, 
0.350 mmol, 1.00 equiv) was coupled with 5‐bromo‐1‐methyl‐1H‐indole (0.850 mmol, 179 mg, 2.43 
equiv).  
Isolated yield: 111 mg, 0.295 mmol, 84%, pale yellow oil. 
Purification: pentane:ethyl acetate = 8:2. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.45 (t, J = 8.1 Hz, 1H), 7.34 (dd, J = 8.1, 1.1 Hz, 1H), 7.27 (dd, J = 1.7, 
0.7 Hz, 1H), 7.19 (dt, J = 8.4, 0.8 Hz, 1H), 7.10 (dd, J = 8.4, 1.1 Hz, 1H), 7.00 (d, J = 3.1 Hz, 1H), 6.87 (dd, J = 





13C-NMR (100 MHz, CDCl3, ppm): δ = 157.7, 145.4, 137.4, 136.2, 131.3, 129.3, 128.6, 128.6, 127.4, 123.8, 
123.4, 122.5, 118.2, 111.7, 109.1, 101.4, 56.3, 32.9, −1.3. 
FT-IR (ATR, cm-1): 𝜈 = 2953, 1598, 1581, 1513, 1488, 1473, 1438, 1422, 1331, 1300, 1246, 4210, 1181, 
1092, 1037, 1014, 989, 839, 803, 792, 778, 760, 735, 719, 697, 667. 
MS (EI, 70 eV): m/z (%) = 348 (25), 347 (34), 334 (25), 333 (100), 319 (11), 318 (42), 301 (7), 290 (6), 73 (7). 




Following TP3 (5‐methoxy‐2‐(4‐(trimethylsilyl)‐1H‐1,2,3‐triazol‐1‐yl)phenyl)magnesium reagent (116e, 
0.385 mmol, 1.00 equiv) was coupled with 5‐bromobenzo[b]thiophene (0.850 mmol, 181 mg, 2.21 equiv).  
Isolated yield: 130 mg, 0.343 mmol, 89%, pale yellow oil. 
Purification: pentane:ethyl acetate = 9:1. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.73 (dt, J = 8.4, 0.7 Hz, 1H), 7.56 (d, J = 8.7 Hz, 1H), 7.48 (dd, J = 1.6, 
0.7 Hz, 1H), 7.44 (d, J = 5.4 Hz, 1H), 7.23 (dd, J = 5.5, 0.8 Hz, 1H), 7.09 (d, J = 2.8 Hz, 1H), 7.05 (s, 1H), 7.04 
– 6.94 (m, 2H), 3.91 (s, 3H), 0.12 (s, 9H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 160.4, 146.2, 139.8, 139.4, 138.8, 133.6, 131.6, 128.7, 128.1, 127.4, 
124.6, 124.0, 123.5, 122.6, 116.2, 113.7, 55.9, −1.2. 
FT-IR (ATR, cm-1): 𝜈 = 2953, 1603, 1575, 1544, 1513, 1500, 1463, 1436, 1412, 1328, 1291, 1247, 1220, 
1199, 1183, 1168, 1154, 1128, 1090, 1055, 1037, 995, 983, 837, 814, 755, 739, 702, 667. 
MS (EI, 70 eV): m/z (%) = 358 (25), 357 (80), 355 (100), 340 (16), 339 (63), 337 (16), 320 (17), 306 (20), 306 
(20), 305 (80), 246 (18), 73 (12). 













Following TP3 (2-(4-(trimethylsilyl)-1H-1,2,3-triazol-1-yl)phenyl)magnesium reagent (116c, 0.360 mmol, 
1.00 equiv) was coupled with 3‐bromothiophene (0.850 mmol, 139 mg, 2.36 equiv).  
Isolated yield:  70 mg, 0.234 mmol, 65%, colorless oil. 
Purification: pentane:ethyl acetate = 9:1. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.60 – 7.56 (m, 2H), 7.50 (m, 2H), 7.24 (s, 1H), 7.20 (dd, J = 5.0, 3.0 Hz, 
1H), 6.96 (dd, J = 3.0, 1.3 Hz, 1H), 6.62 (dd, J = 5.0, 1.3 Hz, 1H), 0.26 (s, 9H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 146.6, 137.6, 135.1, 132.5, 131.2, 130.5, 129.9, 128.5, 127.5, 127.0, 
126.0, 123.6, −1.1. 
FT-IR (ATR, cm-1): 𝜈 = 2956, 1495, 1364, 1248, 1200, 1150, 1112, 1084, 1053, 1036, 983, 838, 792, 756, 
740, 704, 664. 
MS (EI, 70 eV): m/z (%) = 271 (24), 270 (76), 258 89), 257 (20), 256 (100), 255 (26), 239 (21), 225 (15), 166 
(13), 115 (9). 




Following TP3 (5‐chloro‐2‐(4‐(trimethylsilyl)‐1H‐1,2,3‐triazol‐1‐yl)phenyl)magnesium reagent (116a, 
0.405 mmol, 1.00 equiv) was coupled with 3‐bromothiophene (0.850 mmol, 139 mg, 2.10 equiv). 
Isolated yield: 130 mg, 0.389 mmol, 96%, pale yellow crystals 
m.p.: 57.5 – 59.7 °C. 
Purification: pentane:ethyl acetate = 95:5. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.56 (d, J = 2.3 Hz, 1H), 7.52 (d, J = 8.4 Hz, 1H), 7.43 (dd, J = 8.5, 2.4 Hz, 
1H), 7.21 (m, 2H), 6.97 (dd, J = 2.9, 1.3 Hz, 1H), 6.59 (dd, J = 5.0, 1.4 Hz, 1H), 0.25 (s, 9H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 146.8, 136.2, 135.6, 133.9, 133.5, 131.1, 130.3, 128.4, 128.2, 127.2, 





FT-IR (ATR, cm-1): 𝜈 = 3108, 2956, 1533, 1497, 1471, 1247, 1204, 1152, 1126, 1091, 1082, 1041, 1000, 979, 
908, 890, 830, 787, 754, 736, 708, 694, 673. 
MS (EI, 70 eV): m/z (%) = 307 (12), 306 (41), 305 (31), 304 (99), 292 (35), 291 (34), 290 (100), 289 (13), 261 
(11), 256 (14), 255 (42), 240 (29), 208 (11), 73 (23), 44 (11). 
HR-MS (EI, 70 eV): [C15H16ClN3SSi], calcd.: 333.0523; found: 333.0529. 
 
Ethyl 5-(5-chloro-2-(4-(trimethylsilyl)-1H-1,2,3-triazol-1-yl)phenyl)furan-2-carboxylate (117r) 
 
Following TP3 (5‐chloro‐2‐(4‐(trimethylsilyl)‐1H‐1,2,3‐triazol‐1‐yl)phenyl)magnesium reagent (a, 
0.405 mmol, 1.00 equiv) was coupled with ethyl 5‐bromofuran‐2‐carboxylate (0.850 mmol, 186 mg, 2.07 
equiv).  
Isolated yield: 149 mg, 0.381 mmol, 94%, orange crystals. 
Purification: pentane:ethyl acetate = 9:1. 
m.p.: 136.6 – 138.4 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.05 (d, J = 2.3 Hz, 1H), 7.60 (s, 1H), 7.46 (dd, J = 8.4, 2.3 Hz, 1H), 7.36 
(d, J = 8.4 Hz, 1H), 7.00 (d, J = 3.7 Hz, 1H), 5.26 (d, J = 3.7 Hz, 1H), 4.36 (q, J = 7.1 Hz, 2H), 1.37 (t, J = 7.1 Hz, 
3H), 0.36 (s, 9H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 158.4, 150.6, 147.7, 145.0, 136.9, 132.2, 131.0, 129.4, 129.4, 128.4, 
128.2, 119.5, 111.5, 61.4, 14.5, −1.0. 
FT-IR (ATR, cm-1): 𝜈 =1726, 1499, 1468, 1386, 1297, 1148, 1215, 1199, 1158, 1149, 1124, 1114, 1098, 1058, 
1035, 1024, 996, 968, 980, 935, 883, 826, 834, 819, 784, 762, 710, 678, 668.  
MS (EI, 70 eV): m/z (%) = 361 (17), 348 (27), 332 (77), 318 (14), 303 (38), 288 (25), 258 (20), 253 (15), 103 
(45), 75 (100), 73 (83). 












Following TP3 (5-chloro-2-(3,5-dimethyl-1H-pyrazol-1-yl)phenyl)magnesium reagent (119a, 0.410 mmol, 
1.00 equiv) was coupled with 5‐bromobenzo[d][1,3]dioxole (0.850 mmol, 171 mg, 2.07 equiv).  
Isolated yield: 127 mg, 0.389 mmol, 95%, pale yellow oil. 
Purification: pentane:ethyl acetate = 95:5. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.45 (dd, J = 1.8, 1.0 Hz, 1H), 7.40 – 7.33 (m, 2H), 6.72 (d, J = 8.1 Hz, 
1H), 6.59 (dd, J = 8.1, 1.8 Hz, 1H), 6.50 (d, J = 1.8 Hz, 1H), 5.94 (s, 2H), 5.79 (s, 1H), 2.28 (s, 3H), 1.66 (s, 3H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 149.2, 147.9, 147.5, 140.8, 140.4, 136.0, 134.8, 131.2, 130.4, 130.2, 
128.0, 122.4, 108.8, 108.5, 106.0, 101.3, 13.7, 11.3. 
FT-IR (ATR, cm-1): 𝜈 = 2898, 1608, 1594, 1553, 1499, 1483, 1434, 1401, 1364, 1335, 1277, 1251, 1238, 
1220, 1149, 1134, 1105, 1094, 1037, 1023, 1012, 973, 934, 906, 862, 824, 814, 797, 759, 738, 718, 689, 
667. 
MS (EI, 70 eV): m/z (%) = 328 (14), 327 (13), 326 (43), 325 (16), 313 (29), 312 (16), 311 (100), 138 (7). 




Following TP3 (5-chloro-2-(3,5-dimethyl-1H-pyrazol-1-yl)phenyl)magnesium reagent (119a, 0.410 mmol, 
1.00 equiv) was coupled with 3‐bromopyridine (0.850 mmol, 134 mg, 2.07 equiv).  
Isolated yield:  79 mg, 0.277 mmol, 68%, pale yellow oil. 
Purification: pentane:ethyl acetate = 8:2 to 7:3. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.52 (dd, J = 4.8, 1.7 Hz, 1H), 8.39 (dd, J = 2.4, 0.9 Hz, 1H), 7.51 (d, 
J = 2.3 Hz, 1H), 7.48 (dd, J = 8.4, 2.3 Hz, 1H), 7.43 (d, J = 8.3 Hz, 1H), 7.31 (ddd, J = 8.0, 2.4, 1.7 Hz, 1H), 7.18 





13C-NMR (100 MHz, CDCl3, ppm): δ = 149.5, 149.2, 149.1, 140.6, 137.6, 136.4, 135.8, 135.3, 133.2, 130.6, 
130.2, 129.3, 123.4, 106.4, 13.6, 11.3. 
FT-IR (ATR, cm-1): 𝜈 = 1588, 1553, 1499, 1473, 1415, 1393, 1363, 1332, 1292, 1252, 1190, 1131, 1096, 
1028, 1017, 1010, 972, 882, 821, 808, 781, 740, 712, 668, 653. 
MS (EI, 70 eV): m/z (%) = 270 (30), 269 (16), 268 (100), 192 (9). 
HR-MS (EI, 70 eV): [C15H11ClN3+], calcd.: 268.0636; found:268.0633 [M-Me-] 
 
5'-Chloro-2'-(1H-pyrazol-1-yl)-[1,1'-biphenyl]-3-yl 4-methylbenzenesulfonate (120c) 
 
Following TP3 (5‐chloro‐2‐(1H‐pyrazol‐1‐yl)phenyl)magnesium reagent (119b, 0.390 mmol, 1.00 equiv) 
was coupled with 3‐bromophenyl 4‐methylbenzenesulfonate (0.850 mmol, 278 mg, 2.18 equiv).  
Isolated yield: 148 mg, 0.348 mmol, 89%, colorless oil. 
Purification: pentane:ethyl acetate = 85:15. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.66 – 7.56 (m, 2H), 7.53 (d, J = 1.8 Hz, 1H), 7.45 (d, J = 8.5 Hz, 1H), 
7.36 (dd, J = 8.5, 2.4 Hz, 1H), 7.27 (d, J = 8.1 Hz, 2H), 7.15 – 7.06 (m, 2H), 6.96 – 6.86 (m, 2H), 6.77 (dt, J = 
7.8, 1.3 Hz, 1H), 6.68 (t, J = 2.0 Hz, 1H), 6.13 (t, J = 2.1 Hz, 1H), 2.40 (s, 3H),  
13C-NMR (100 MHz, CDCl3, ppm): δ = 149.8, 145.8, 140.9, 139.0, 137.1, 136.6, 134.0, 132.2, 131.2, 130.7, 
130.0, 129.9, 129.0, 128.7, 128.0, 127.2, 122.6, 122.2, 107.1, 21.9. 
FT-IR (ATR, cm-1): 𝜈 = 1596, 1580, 1566, 1517, 1476, 1430, 1371, 1329, 1307, 1293, 1263, 1211, 1192, 
1179, 1147, 1110, 1091, 1042, 1019, 1002, 936, 916, 893, 877, 805, 793, 746, 695, 659. 
MS (EI, 70 eV): m/z (%) = 271 (32), 270 (17), 269 (100), 90 (16), 61 (9), 43 (52), 42 (18). 




Following TP3 (5‐chloro‐2‐(1H‐pyrazol‐1‐yl)phenyl)magnesium reagent (119b, 0.390 mmol, 1.00 equiv) 





Isolated yield: 102 mg, 0.342 mmol, 88%, yellow crystals. 
Purification: pentane:ethyl acetate = 85:15. 
m.p.: 128.8 – 130.4 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.61 (d, J = 1.8 Hz, 1H), 7.57 – 7.49 (m, 3H), 7.45 (dd, J = 1.8, 1.0 Hz, 
1H), 7.20 (d, J = 2.4 Hz, 1H), 6.98 – 6.90 (m, 2H), 6.31 (t, J = 2.1 Hz, 1H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 163.0 (d, J = 259.9 Hz), 144.8 (d, J = 8.4 Hz), 141.3, 137.2, 135.7 (d, 
J = 1.9 Hz), 134.7, 133.6 (d, J = 0.8 Hz), 131.1, 130.5, 130.1, 128.4, 124.9 (d, J = 3.5 Hz), 116.5 (d, J = 20.7 Hz), 
113.7, 107.7, 101.0 (d, J = 15.5 Hz). 
19F NMR (377 MHz, CDCl3, ppm): δ = −105.54 (dd, J = 9.7, 6.6 Hz). 
FT-IR (ATR, cm-1): 𝜈 = 2232, 1622, 1575, 1558, 1550, 1486, 1421, 1392, 1325, 1300, 1259, 1203, 1191, 
1185, 1121, 1111, 1095, 1048, 1041, 1022, 937, 913, 894, 848, 833, 779, 763, 749, 732, 719, 689. 
MS (EI, 70 eV): m/z (%) = 298 (32), 297 (16), 296 (100), 261 (15), 234 (12), 233 (11), 195 (7). 




Following TP3 (2-(5-phenyl-1,3,4-oxadiazol-2-yl)phenyl)magnesium reagent (119c, 0.380 mmol, 
1.00 equiv) was coupled with bromobenzene (0.850 mmol, 133 mg, 2.24 equiv).  
Isolated yield: 91 mg, 0.305 mmol, 80%, pale yellow oil. 
Purification: pentane:ethyl acetate = 9:1. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.19 (dd, J = 7.8, 1.4 Hz, 1H), 7.63 – 7.57 (m, 3H), 7.56 – 7.42 (m, 3H), 
7.42 – 7.34 (m, 5H), 7.34 – 7.29 (m, 2H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 165.2, 164.7, 142.1, 140.9, 131.6, 131.5, 131.1, 130.2, 128.9, 128.8, 
128.3, 127.9, 127.6, 126.7, 123.8, 122.8. 
FT-IR (ATR, cm-1): 𝜈 = 3057, 1607, 1598, 1571, 150, 1488, 1461, 1448, 1437, 1362, 1315, 1292, 1272, 1249, 
1178, 1159, 1116, 1107, 1069, 1043, 1026, 1009, 988, 965, 924, 842, 778, 769, 758, 742, 715, 696, 669. 
MS (EI, 70 eV): m/z (%) = 298 (21), 297 (100), 166 (28), 153 (5), 152 (18). 







Ethyl 2'-(5-phenyl-1,3,4-oxadiazol-2-yl)-[1,1'-biphenyl]-3-carboxylate (120f) 
 
Following TP3 (2-(5-phenyl-1,3,4-oxadiazol-2-yl)phenyl)magnesium reagent (119c, 0.380 mmol, 
1.00 equiv) was coupled with ethyl 3‐bromobenzoate (0.850 mmol, 195 mg, 2.24 equiv).  
Isolated yield: 106 mg, 0.286 mmol, 75%, yellow solid. 
Purification: pentane:ethyl acetate = 9:1. 
m.p.: 121.9 – 123.7 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.24 – 8.18 (m, 1H), 8.12 – 8.05 (m, 2H), 7.65 – 7.52 (m, 4H), 7.51 – 
7.41 (m, 4H), 7.38 (ddt, J = 8.5, 6.8, 1.3 Hz, 2H), 4.35 (q, J = 7.1 Hz, 2H), 1.34 (t, J = 7.1 Hz, 3H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 166.3, 164.7, 164.7, 141.0, 140.8, 133.3, 131.6, 131.5, 131.2, 130.6, 
130.1, 129.9, 128.9, 128.8, 128.3, 126.6, 123.6, 122.7, 61.2, 14.3. 
FT-IR (ATR, cm-1): 𝜈 = 1709, 1597, 1582, 1543, 1496, 1489, 1474, 1448, 1414, 1393, 1367, 1311, 1301, 
1277, 1245, 1168, 1138, 1107, 1072, 1049, 1024, 990, 964, 908, 882, 865, 851, 828, 786, 736, 748, 714, 
702, 691, 656. 
MS (EI, 70 eV): m/z (%) = 370 (29), 369 (100), 152 (7), 151 (7), 105 (19), 77 (12). 




Following TP3 (2‐(4,4‐dimethyl‐4,5‐dihydrooxazol‐2‐yl)phenyl)magnesium reagent (119d, 0.385 mmol, 
1.00 equiv) was coupled with (4‐bromophenyl)pentafluoro‐λ6‐sulfane (0.850 mmol, 241 mg, 2.21 equiv).  
Isolated yield: 90 mg, 0.238 mmol, 62%, pale yellow oil. 
Purification: pentane:ethyl acetate = 8:2. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.81 – 7.72 (m, 3H), 7.52 (td, J = 7.6, 1.5 Hz, 1H), 7.48 – 7.40 (m, 3H), 
7.34 (dd, J = 7.6, 1.3 Hz, 1H), 3.82 (s, 2H), 1.27 (s, 6H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 163.0, 152.9 (p, J = 17.2 Hz), 144.9, 139.7, 130.8, 130.5, 130.2, 128.8, 





19F NMR (377 MHz, CDCl3, ppm): δ = 85.77 – 83.67 (m), 63.13 (d, J = 150.1 Hz). 
FT-IR (ATR, cm-1): 𝜈 = 2967, 1654, 1598, 1784, 1463, 1448, 1399, 1365, 1349, 1310, 1213, 1189, 1100, 
1076, 1061, 1037, 963, 822, 770, 754, 730, 699, 683, 662. 
MS (EI, 70 eV): m/z (%) = 376(100), 322 (22), 291 (75), 250 (23), 220 (29), 183 (60), 180 (23), 179 (19), 178 
(45), 177 (48), 163 (25), 152 (31), 151 (72), 150 (36). 




Following TP3 (2‐(4,4‐dimethyl‐4,5‐dihydrooxazol‐2‐yl)phenyl)magnesium reagent (119d, 0.385 mmol, 
1.00 equiv) was coupled with 5‐bromo‐1‐methyl‐1H‐indole (0.850 mmol, 179 mg, 2.18 equiv).  
Isolated yield: 107 mg, 0.352 mmol, 91%, orange crystals. 
Purification: pentane:ethyl acetate = 8:2. 
m.p.: 154.1 – 155.9 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.72 (dt, J = 7.7, 1.1 Hz, 1H), 7.69 (dd, J = 1.7, 0.8 Hz, 1H), 7.51 – 7.44 
(m, 2H), 7.37 – 7.32 (m, 2H), 7.30 (dd, J = 8.5, 1.7 Hz, 1H), 7.08 (d, J = 3.1 Hz, 1H), 6.49 (dd, J = 3.1, 0.8 Hz, 
1H), 3.82 (s, 3H), 3.74 (s, 2H), 1.31 (s, 6H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 164.6, 142.8, 136.2, 132.6, 130.7, 130.4, 130.3, 129.4, 128.5, 128.3, 
126.4, 122.6, 120.7, 108.8, 101.3, 79.7, 67.4, 33.1, 28.2. 
FT-IR (ATR, cm-1): 𝜈 = 2968, 1658, 1615, 1509, 1470, 1436, 1212, 1365, 1334, 138, 1299, 1246, 1181, 1155, 
1107, 1083, 1066, 1032, 963, 920, 871, 810, 774, 755, 718, 691, 655. 
MS (EI, 70 eV): m/z (%) = 304 (20), 303 (100), 248 (61), 231 (19), 218 (36), 217 (13), 190 (13). 










5.5 Trapping of the Magnesium Reagent 116a with Electrophiles 
1-(4-Chloro-2-iodophenyl)-4-(trimethylsilyl)-1H-1,2,3-triazole (121a) 
 
(5‐Chloro‐2‐(4‐(trimethylsilyl)‐1H‐1,2,3‐triazol‐1‐yl)phenyl)magnesium reagent (116a, 0.405 mmol, 
1.00 equiv) was cooled to 0 °C and quenched with an iodine solution (1.75 mmol, 4.32 equiv) in THF (2 mL). 
The reaction mixture was stirred for 15 min and the remaining iodine was quenched with saturated aq. 
Na2S2O3 solution (15 mL). The mixture was extracted with DCM (3 x 25 mL). The combined organic layers 
were dried over MgSO4. The solvents were removed under reduced pressure and the crude product was 
subjected to column chromatography on silica yielding 1-(4-chloro-2-iodophenyl)-4-(trimethylsilyl)-1H-
1,2,3-triazole. 
Isolated yield: 150 mg, 0.397 mmol, 98%, white crystals. 
Purification: pentane:ethyl acetate = 95:5. 
m.p.: 111.0 – 113.2 °C 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.98 (d, J = 2.2 Hz, 1H), 7.80 (s, 1H), 7.47 (dd, J = 8.4, 2.3 Hz, 1H), 7.35 
(d, J = 8.4 Hz, 1H), 0.38 (s, 9H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 146.8, 139.6, 139.1, 136.5, 130.9, 129.5, 128.4, 94.4, −1.00. 
FT-IR (ATR, cm-1): 𝜈 = 3076, 2957, 1574, 1495, 1473, 1436, 1401, 1372, 1250, 1204, 1160, 1101, 1047, 
1040, 1005, 999, 985, 875, 835, 825, 773, 756, 710, 672, 697. 
MS (EI, 70 eV): m/z (%) = 348 (12), 335 (29), 334 (60), 209 (32), 208 (19), 207 (100), 194 (18), 192 (55), 73 
(19).  















(5‐Chloro‐2‐(4‐(trimethylsilyl)‐1H‐1,2,3‐triazol‐1‐yl)phenyl)magnesium reagent (116a, 0.405 mmol, 
1.00 equiv) was cooled to 0 °C and benzaldehyde (0.10 mL, 1.00 mmol, 2.47 equiv) was added dropwise. 
The reaction was stirred for 1.5 h at this temperature and was then allowed to warm to room temperature. 
Saturated aq. NH4Cl solution (5 mL) was added and the mixture was extracted with EtOAc (3 x 25 mL). The 
combined organic layers were dried over MgSO4. The solvents were removed under reduced pressure and 
the crude product was subjected to column chromatography on silica yielding (5-chloro-2-(4-
(trimethylsilyl)-1H-1,2,3-triazol-1-yl)phenyl)(phenyl)methanol. 
Isolated yield: 125  mg, 0.349 mmol, 86%, pale yellow crystals. 
Purification: pentane:ethyl acetate = 8:2. 
m.p.: 103.8 – 105.7 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.83 (d, J = 2.4 Hz, 1H), 7.35 (dd, J = 8.3, 2.4 Hz, 1H), 7.22 (s, 1H), 7.17 
– 7.08 (m, 4H), 6.97 – 6.89 (m, 2H), 5.87 (d, J = 5.6 Hz, 1H), 4.80 (d, J = 5.7 Hz, 1H), 0.26 (s, 9H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 146.7, 142.4, 141.8, 136.2, 133.4, 131.0, 129.2, 128.4, 128.3, 127.5, 
127.26, 126.5, 71.2, −1.2. 
FT-IR (ATR, cm-1): 𝜈 = 3220, 1493, 1448, 1403, 1345, 1268, 1251, 1235, 1209, 1179, 1157, 1119, 1096, 
1054, 1046, 1027, 1016, 986, 926, 906, 883, 836, 821, 772, 759, 736, 726, 700, 661. 
MS (EI, 70 eV): m/z (%) = 314 (18), 312 (40), 254 (26), 252 (54), 241 (31), 239 (90), 237 (35), 235 (46), 203 
(34), 76 (29), 75 (80), 73 (100). 




(5‐Chloro‐2‐(4‐(trimethylsilyl)‐1H‐1,2,3‐triazol‐1‐yl)phenyl)magnesium reagent (116a, 0.405 mmol, 





The reaction was stirred for 1 h at this temperature and was allowed to warm to room temperature. 
Saturated aq. NH4Cl solution (5 mL) was added and the mixture was extracted with EtOAc (3 x 25 mL). The 
combined organic layers were dried over MgSO4. The solvents were removed under reduced pressure and 
the crude product was subjected to column chromatography on silica yielding 1-(4-chloro-2-
(methylthio)phenyl)-4-(trimethylsilyl)-1H-1,2,3-triazole. 
Isolated yield: 90 mg, 0.302 mmol, 75%, colorless crystals. 
Purification: pentane:ethyl acetate = 95:5. 
m.p.: 84.0 – 85.8 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.84 (s, 1H), 7.34 (d, J = 8.4 Hz, 1H), 7.31 (d, J = 2.2 Hz, 1H), 7.26 – 
7.23 (m, 1H), 2.39 (s, 3H), 0.38 (s, 9H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 146.6, 137.6, 136.2, 133.7, 130.9, 127.9, 126.3, 125.7, 15.7, −0.9. 
FT-IR (ATR, cm-1): 𝜈 = 3077, 1583, 1493, 1472, 1437, 1426, 1400, 1382, 1249, 1204, 1191, 1154, 1096, 
1075, 7039, 1005, 987, 980, 955, 822, 796, 756, 711, 699, 680, 655. 
MS (EI, 70 eV): m/z (%) = 253 (22), 240 (38), 239 (17), 238 (100), 223 (10), 73 (17). 




(5‐Chloro‐2‐(4‐(trimethylsilyl)‐1H‐1,2,3‐triazol‐1‐yl)phenyl)magnesium reagent (116a, 0.405 mmol, 
1.00 equiv) was cooled to ‐40 °C, CuCN·2⋅LiCl solution (1 M in THF, 1.20 mmol, 2.96 equiv) was added and 
the reaction mixture was for 30 min. Benzoyl chloride (0.12 mL, 1.00 mmol, 2.47 equiv) was added 
dropwise and the reaction mixture was allowed to come to room temperature for 16 h. Saturated aq. NH4Cl 
solution (5 mL) was added and the mixture was extracted with EtOAc (3 x 25 mL). The combined organic 
layers were dried over MgSO4. The solvents were removed under reduced pressure and the crude product 
was subjected to column chromatography on silica yielding (5‐chloro‐2‐(4‐(trimethylsilyl)‐1H‐1,2,3‐triazol‐
1‐yl)phenyl)(phenyl)methanone. 
Isolated yield: 89 mg, 0.250 mmol, 62%, colorless crystals. 
Purification: pentane:ethyl acetate = 9:1. 





1H-NMR (400 MHz, CDCl3, ppm): δ = 7.68 – 7.63 (m, 2H), 7.61 – 7.54 (m, 4H), 7.46 (ddt, J = 8.8, 7.0, 1.3 Hz, 
1H), 7.33 – 7.27 (m, 2H), 0.18 (s, 9H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 193.7, 147.4, 135.9, 135.8, 135.5, 133.8, 133.6, 131.7, 130.2, 129.9, 
129.3, 128.6, 126.2, −1.2. 
FT-IR (ATR, cm-1): 𝜈 = 3116, 1656, 1594, 1495, 1448, 1393, 1313, 1244, 1201, 1157, 1112, 1040, 984, 956, 
891, 832, 785, 759, 739, 709, 694, 668, 660. 
MS (EI, 70 eV): m/z (%) = 327 (28), 315 817), 314 (100), 313 (43), 312 (50), 203 (11), 77 (19). 
HR-MS (EI, 70 eV): [C18H18N3Cl2Si], calcd.: 355.0908; found: 355.0898. 
 
Ethyl 2-(5-chloro-2-(4-(trimethylsilyl)-1H-1,2,3-triazol-1-yl)benzyl)acrylate (121e) 
 
(5‐Chloro‐2‐(4‐(trimethylsilyl)‐1H‐1,2,3‐triazol‐1‐yl)phenyl)magnesium reagent (116a, 0.405 mmol, 
1.00 equiv) was cooled to ‐30 °C and CuCN·2 LiCl solution (1 M in THF, 1.20 mmol, 2.96 equiv) was added 
dropwise. The reaction mixture was stirred at this temperature for 30 min and ethyl 2‐
(bromomethyl)acrylate (193 mg, 1.0 mmol, 2.47 equiv) was added. The reaction mixture was allowed to 
come to room temperature for 16 h. Saturated aq. NH4Cl solution (5 mL) was added and the mixture was 
extracted with EtOAc (3 x 25 mL). The combined organic layers were dried over MgSO4. The solvents were 
removed under reduced pressure and the crude product was subjected to column chromatography on 
silica yielding ethyl 2‐(5‐chloro‐2‐(4‐(trimethylsilyl)‐1H‐1,2,3‐triazol‐1‐yl)benzyl)acrylate. 
Isolated yield: 113 mg, 0.311 mmol, 77%, colorless oil. 
Purification: pentane:ethyl acetate = 7:3. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.72 (s, 1H), 7.38 (d, J = 2.3 Hz, 1H), 7.34 (dd, J = 8.4, 2.3 Hz, 1H), 7.26 
(d, J = 8.4 Hz, 1H), 6.18 (d, J = 1.2 Hz, 1H), 5.27 (q, J = 1.3 Hz, 1H), 4.14 (q, J = 7.1 Hz, 2H), 3.52 (s, 2H), 1.24 
(t, J = 7.1 Hz, 3H), 0.36 (s, 9H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 166.2, 146.7, 137.8, 136.9, 135.7, 135.1, 131.1, 130.9, 127.8, 127.8, 
127.8, 61.1, 33.8, 14.3, −1.00. 
FT-IR (ATR, cm-1): 𝜈 = 2956, 1713, 1631, 1598, 1499, 1478, 1407, 1368, 1327, 1300, 1249, 1203, 1186, 





MS (EI, 70 eV): m/z (%) = 306 (15), 263 (23), 261 (55), 249 (24), 248 (28), 215 (25), 190 (23), 189 (33), 75 
(66), 73 (100). 
HR-MS (EI, 70 eV): [C17H22ClN3O2Si], calcd.: 363.1170; found: 363.1156. 
 
5.6 Late-Stage Modifications 
1-(5-fluoro-4'-(trifluoromethoxy)-[1,1'-biphenyl]-2-yl)-1H-1,2,3-triazole (122) 
 
According to the literature163, 1‐(5‐fluoro‐4'‐(trifluoromethoxy)‐[1,1'‐biphenyl]‐2‐yl)‐4‐(trimethylsilyl)‐1H‐
1,2,3‐triazole (117g, 119 mg, 0.3 mmol, 1.00 equiv) was dissolved in THF (0.3 mL) and TBAF (1 M in THF, 
0.45 mmol, 1.50 equiv) was added. The reaction mixture was stirred for 16 h. Saturated aq. NaHCO3 
solution (5 mL) was added and the mixture was extracted with EtOAc (3 x 25 mL). The combined organic 
layers were dried over MgSO4. The solvents were removed under reduced pressure and the crude product 
was subjected to column chromatography on silica yielding the title compound. 
Isolated yield: 88 mg, 0.27 mmol, 91%, colorless oil. 
Purification: pentane:ethyl acetate = 9:1. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.55 (d, J = 1.1 Hz, 1H), 7.52 (dd, J = 8.6, 5.1 Hz, 1H), 7.19 (d, J = 1.1 Hz, 
1H), 7.18 – 7.12 (m, 2H), 7.04 (m, 4H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 163.0 (d, J = 251.7 Hz), 149.4 (q, J = 1.9 Hz), 138.4 (d, J = 8.6 Hz), 134.8 
(d, J = 1.5 Hz), 133.9, 131.3 (d, J = 3.3 Hz), 129.9, 129.1 (d, J = 9.2 Hz), 125.9, 121.2, 120.4 (q, J = 258.0 Hz), 
117.9 (d, J = 23.5 Hz), 116.0 (d, J = 22.6 Hz). 
19F NMR (377 MHz, CDCl3, ppm): δ = −57.81 (s), −109.88 (td, J = 8.3, 5.1 Hz). 
FT-IR (ATR, cm-1): 𝜈 = 1617, 1593, 1580, 1519, 1501, 1474, 1001, 1253, 1206, 1161, 1107, 1089, 1039, 
1026, 1018, 982, 945, 922, 890, 853, 826, 806, 780, 701, 674, 660. 
MS (EI, 70 eV): m/z (%) = 323 (40), 295 (100), 226 (13), 210 (61), 208 (29), 198 (56), 183 (19), 170 (32), 157 
(38). 
HR-MS (EI, 70 eV): [C15H9N3OF4], calcd.: 323.0682; found: 323.0677. 
                                                          









yl)magnesium reagent (123, 0.400 mmol, 1.00 equiv) was coupled with 5‐bromo‐1‐methyl‐1H‐indole 
(0.85 mmol, 179 mg, 2.34 equiv).  
Isolated yield: 184 mg, 0.351 mmol, 88%, pale yellow crystals. 
Purification: pentane:ethyl acetate = 8:2. 
m.p.: 64.9 – 66.6 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.37 (dd, J = 1.7, 0.7 Hz, 1H), 7.33 (dd, J = 8.9, 2.9 Hz, 1H), 7.19 – 7.11 
(m, 4H), 7.10 – 7.04 (m, 3H), 7.03 (d, J = 3.1 Hz, 1H), 6.89 (dd, J = 8.5, 1.7 Hz, 1H), 6.39 (dd, J = 3.2, 0.9 Hz, 
1H), 3.74 (s, 3H), 0.08 (s, 9H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 162.5 (d, J = 251.1 Hz), 149.0 (d, J = 2.0 Hz), 146.1, 144.2 (d, J = 9.2 Hz), 
141.1 (d, J = 9.2 Hz), 136.4, 135.87 (d, J = 1.8 Hz), 132.6, 129.9, 129.7, 128.5, 127.9 (d, J = 1.6 Hz), 121.8, 
121.1, 120.7, 120.5 (q, J = 257.7 Hz), 117.6 (d, J = 22.4 Hz), 115.8 (d, J = 23.3 Hz), 109.2, 101.5, 33.0, -1.3. 
19F NMR (377 MHz, CDCl3, ppm): δ = −57.86 (s), −110.53 (t, J = 8.7 Hz). 
FT-IR (ATR, cm-1): 𝜈 = 2956, 1594, 1511, 1511, 1494, 1463, 1446, 1422, 1325, 1247, 1204, 1160, 1103, 
1080, 1035, 1019, 984, 955, 921, 873, 838, 801, 760, 722, 679. 
MS (EI, 70 eV): m/z (%) = 524 (6), 497 (22), 496 (64), 495 (100), 482 (29), 481 (87), 424 (18), 415 (32), 338 
(23), 337 (24), 335 (59). 















1‐(5‐fluoro‐4'‐(trifluoromethoxy)‐[1,1'‐biphenyl]‐2‐yl)‐4‐(trimethylsilyl)‐1H‐1,2,3‐triazole (117g, 790 mg, 
2.00 mmol, 1.00 equiv) was dissolved in DMF (4 mL) cooled with an icebath to 5 °C and DBDMH (686 mg, 
2.40 mmol, 1.20 equiv) was added and the reaction mixture was stirred for 16 h. After removal of the 
solvent the crude product was subjected to column chromatography on silica yielding the title compound. 
Isolated yield: 769 mg, 1.92 mmol, 93%, pale yellow crystals. 
Purification: pentane:ethyl acetate = 9:1. 
m.p.: 77.8 – 79.5 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.37 (dd, J = 8.6, 5.1 Hz, 1H), 7.08 – 7.00 (m, 3H), 6.99 – 6.94 (m, 2H), 
6.93 – 6.88 (m, 2H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 163.3 (d, J = 252.7 Hz), 149.6 (t, J = 1.9 Hz), 138.6 (d, J = 8.6 Hz), 134.4 
(d, J = 1.5 Hz), 130.8 (d, J = 3.4 Hz), 129.9, 129.1 (d, J = 9.3 Hz), 126.0, 121.4, 120.8, 120.5 (q, J = 258.1 Hz), 
118.1 (d, J = 23.7 Hz), 116.2 (d, J = 22.8 Hz). 
19F NMR (377 MHz, CDCl3, ppm): δ = −57.81 (s), −108.80 (td, J = 7.9, 5.1 Hz). 
FT-IR (ATR, cm-1): 𝜈 = 3158, 1615, 1594, 1580, 1516, 1500, 1478, 1442, 1395, 1278, 1246, 1221, 1205, 
1190, 1164, 1104, 1040, 1034, 1017, 991, 976, 951, 921, 893, 881, 853, 830, 817, 806, 746, 698, 658, 676. 
MS (EI, 70 eV): m/z (%) = 375 (38), 372 (37), 295 (21), 294 (100), 290 (26), 288 (27), 266 (18), 209 (50), 208 
(98), 197 (20), 196 (24), 169 (24), 158 (11), 157 (33). 
















According to the literature164, 4-bromo-1-(5-fluoro-4'-(trifluoromethoxy)-[1,1'-biphenyl]-2-yl)-1H-1,2,3-
triazole was (117g, 99 mg, 0.250 mmol, 1.00 equiv), K2CO3 (69 mg. 0.500 mmol, 2.00 equiv), Pd(PPh3)4 
(29 mg, 0.025 mmol 10 mol%) and (4-chlorophenyl)boronic acid (59 mg, 0.375, 1.5 equiv) were added to 
a flask under argon. Then dioxane (2.25 ml) and water (0.75 ml) were added and the reaction mixture was 
heated for 16 h at 100 °C. Saturated aq. NH4Cl solution (5 mL) was added and the mixture was extracted 
with EtOAc (3 x 25 mL). The combined organic layers were dried over MgSO4. The solvents were removed 
under reduced pressure and the crude product was subjected to column chromatography on silica yielding 
4-(4-chlorophenyl)-1-(5-fluoro-4'-(trifluoromethoxy)-[1,1'-biphenyl]-2-yl)-1H-1,2,3-triazole. 
Isolated yield: 93 mg, 0.22 mmol, 86%, pale orange crystals. 
Purification: pentane:ethyl acetate = 9:1. 
m.p.: 144.7 – 146.3 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.47 – 7.42 (m, 1H), 7.42 – 7.37 (m, 2H), 7.19 (s, 1H), 7.17 – 7.12 (m, 
2H), 7.10 – 7.02 (m, 2H), 6.95 (s, 4H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 163.1 (d, J = 252.0 Hz), 149.5 (d, J = 2.0 Hz), 147.9, 138.3 (d, J = 8.6 Hz), 
134.9 (d, J = 1.5 Hz), 134.4, 131.2 (d, J = 3.2 Hz), 130.0, 129.2, 129.0 (d, J = 9.2 Hz), 128.5, 127.1, 121.8, 
121.4, 120.5 (q, J = 257.9 Hz), 118.0 (d, J = 23.6 Hz), 116.2 (d, J = 22.8 Hz). 
19F NMR (377 MHz, CDCl3, ppm): δ = −58.32 , −110.08 (ddd, J = 8.6, 7.6, 5.1 Hz). 
FT-IR (ATR, cm-1): 𝜈 = 1610, 1519, 1054, 1475, 1426, 2317, 1301, 1279, 1239, 1224, 1206, 1182, 1112, 
1095, 1083, 1035, 1018, 1011, 993, 967, 945, 924, 893, 82, 843, 832, 846, 824, 805, 138, 719, 704, 686, 
675, 662. 
MS (EI, 70 eV): m/z (%) = 407 (32), 406 (30), 405 (100), 370 (32), 369 (52), 318 (11), 286 (11), 285 (44), 272 
(17), 170 (11), 150 (18). 
HR-MS (EI, 70 eV): [C21H12N3O2ClF4], calcd.: 433.0605; found: 433.0600.
                                                          






1. Structure Determination using NMR-Experiments 

















































2. Chiral HPLC Analysis 






























































































































3. Single Crystal X-Ray Diffraction Studies 
1. 2-(4-(1H-Pyrrol-1-yl)cyclohexyl)-5-(trifluoromethyl)pyridine (102ae) 
 
Figure 2: Molecular structure of compound 102ae in the crystal, DIAMOND165 representation; thermal ellipsoids are drawn at 
50 % probability level. The fluorine atoms are disordered over two positions; only one position has been shown for clarity. 
 
 
Table 17: Details for X-ray data collection and structure refinement for compound 102ae.
Empirical formula C16H17F3N2 
Formula mass 294.32 
T[K] 123(2) 
Crystal size [mm] 0.25 × 0.20 × 0.03 
Crystal description colorless block 
Crystal system triclinic 
Space group P-1 
a [Ǻ] 9.3100(9) 
b [Ǻ] 9.3232(11) 
c [Ǻ] 9.3565(9) 
α [°] 66.006(10) 
β [°] 72.336(9) 
γ [°] 76.892(9) 
V [Ǻ3] 701.97(14) 
Z 2 
                                                          
165 DIAMOND, Crystal Impact GbR., Version 3.2i. 
ρcalcd. [g cm-3] 1.392 
μ [mm-1] 0.111 
F(000) 308 
Θ range [°] 2.31 – 25.24 
Index ranges -11 ≤ h ≤ 11 
 -11 ≤ k ≤ 11 
 -11 ≤ l ≤ 10 
Reflns. collected 4530 
Reflns. obsd. 1669 
Reflns. unique 2670 
(Rint = 0.0288) 
R1, wR2 (2σ data) 0.0548, 0.0923 
R1, wR2 (all data) 0.1003, 0.1093 
GOOF on F2 1.028 





2. 5'-Chloro-3-fluoro-2'-(1H-pyrazol-1-yl)-[1,1'-biphenyl]-4-carbonitrile (120d) 
 
Figure 3: Molecular structure of compound 120d in the crystal, DIAMOND165 representation; thermal ellipsoids are drawn at 50 % 
probability level.  
 
Table 18: Details for X-ray data collection and structure refinement for compound 120d.
Empirical formula C16H9ClFN3 
Formula mass 297.71 
T[K] 123(2) 
Crystal size [mm] 0.20 × 0.10 × 0.05 
Crystal description colorless block 
Crystal system monoclinic 
Space group P21/n 
a [Ǻ] 9.6679(4) 
b [Ǻ] 7.3579(2) 
c [Ǻ] 20.1976(8) 
α [°] 90.0 
β [°] 100.596(4) 
γ [°] 90.0 
V [Ǻ3] 1412.27(9) 
Z 4 
ρcalcd. [g cm-3] 1.400 
μ [mm-1] 0.277 
F(000) 608 
Θ range [°] 2.05 – 25.24 
Index ranges -12 ≤ h ≤ 12 
 -9 ≤ k ≤ 9 
 -26 ≤ l ≤ 26 
Reflns. collected 21202 
Reflns. obsd. 2448 
Reflns. unique 3496 
(Rint = 0.0619) 
R1, wR2 (2σ data) 0.0480, 0.0931 
R1, wR2 (all data) 0.0805, 0.1058 
GOOF on F2 1.007 





3. 4,4-Dimethyl-2-(2-(1-methyl-1H-indol-5-yl)phenyl)-4,5-dihydrooxazole (120h) 
 
Figure 4: Molecular structure of compound 120h in the crystal, DIAMOND165 representation; thermal ellipsoids are drawn at 50 % 
probability level.  
 
Table 19: Details for X-ray data collection and structure refinement for compound 120h.
Empirical formula C20H20N2O 
Formula mass 304.38 
T[K] 123(2) 
Crystal size [mm] 0.40 × 0.20 × 0.10 
Crystal description colorless block 
Crystal system orthorhombic 
Space group Pbca 
a [Ǻ] 7.6428(4) 
b [Ǻ] 14.0522(8) 
c [Ǻ] 30.4091(16) 
α [°] 90.0 
β [°] 90.0 
γ [°] 90.0 
V [Ǻ3] 3265.9(3) 
Z 8 
ρcalcd. [g cm-3] 1.238 
μ [mm-1] 0.077 
F(000) 1296 
Θ range [°] 2.98 – 25.24 
Index ranges -10 ≤ h ≤ 6 
 -18 ≤ k ≤ 18 
 -39 ≤ l ≤ 40 
Reflns. collected 29083 
Reflns. obsd. 2866 
Reflns. unique 4040 
(Rint = 0.0607) 
R1, wR2 (2σ data) 0.0500, 0.1126 
R1, wR2 (all data) 0.0768, 0.1280 
GOOF on F2 1.020 





4. (5-Chloro-2-(4-(trimethylsilyl)-1H-1,2,3-triazol-1-yl)phenyl)(phenyl)methanol (121b) 
 
Figure 5: Molecular structure of compound 121b in the crystal, DIAMOND165 representation; thermal ellipsoids are drawn at 50 % 
probability level.  
 
Table 20: Details for X-ray data collection and structure refinement for compound 121b.
Empirical formula C18H20ClN3OSi 
Formula mass 357.91 
T[K] 123(2) 
Crystal size [mm] 0.35 × 0.30 × 0.05 
Crystal description colorless block 
Crystal system monoclinic 
Space group P21/c 
a [Ǻ] 11.6823(5) 
b [Ǻ] 21.2482(6) 
c [Ǻ] 7.8984(3) 
α [°] 90.0 
β [°] 108.644(4) 
γ [°] 90.0 
V [Ǻ3] 1857.72(13) 
Z 4 
ρcalcd. [g cm-3] 1.280 
μ [mm-1] 0.280 
F(000) 752 
Θ range [°] 2.07 – 25.24 
Index ranges -14 ≤ h ≤ 14 
 -25 ≤ k ≤ 26 
 -9 ≤ l ≤ 9 
Reflns. collected 16290 
Reflns. obsd. 2927 
Reflns. unique 3775 
(Rint = 0.0477) 
R1, wR2 (2σ data) 0.0426, 0.1009 
R1, wR2 (all data) 0.0613, 0.1120 
GOOF on F2 1.026 





5. 4-(4-Chlorophenyl)-1-(5-fluoro-4'-(trifluoromethoxy)-[1,1'-biphenyl]-2-yl)-1H-1,2,3-triazole (126) 
 
Figure 6: Molecular structure of compound 126 in the crystal, DIAMOND165 representation; thermal ellipsoids are drawn at 50 % 
probability level.  
 
Table 21: Details for X-ray data collection and structure refinement for compound 126.
Empirical formula C21H12ClF4N3O 
Formula mass 433.79 
T[K] 123(2) 
Crystal size [mm] 0.25 × 0.06 × 0.03 
Crystal description colorless rod 
Crystal system triclinic 
Space group P-1 
a [Ǻ] 5.8604(5) 
b [Ǻ] 10.0154(8) 
c [Ǻ] 16.5065(17) 
α [°] 104.125(8) 
β [°] 98.795(8) 
γ [°] 97.054(7) 
V [Ǻ3] 915.45(15) 
Z 2 
ρcalcd. [g cm-3] 1.574 
μ [mm-1] 0.267 
F(000) 440 
Θ range [°] 2.13 – 25.24 
Index ranges -7 ≤ h ≤ 7 
 -12 ≤ k ≤ 8 
 -16 ≤ l ≤ 20 
Reflns. collected 6200 
Reflns. obsd. 2335 
Reflns. unique 3609 
(Rint = 0.0388) 
R1, wR2 (2σ data) 0.0606, 0.1211 
R1, wR2 (all data) 0.1025, 0.1431 
GOOF on F2 1.022 
Peak/hole [e Ǻ-3] 0.517 / -0.348 
 
